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Abstract	
Painful	diabetic	neuropathy	(PDN)	is	one	microvascular	complication	of	diabetes	mellitus	
(DM)	and	the	focus	of	this	thesis.	PDN	is	a	neuropathic	pain	condition	characterised	by	severe	
burning	pain	in	the	feet	and	sometimes	hands.	It	has	significant	impacts	on	peoples’	mobility,	
sleep	quality	and	overall	quality	of	life.	The	personal	and	societal	burden	associated	with	DM	and	
PDN	is	predicated	to	rise	as	prevalence	rates	increase.	
Pharmacological	management	of	PDN	is	often	less	than	optimal,	and	people	are	left	with	
few	strategies	to	cope.	Multidisciplinary	pain	management	programmes	(PMPs)	use	physical	
activity	and	psychological	coping	strategies	to	help	people	live	better	with	persistent	pain,	yet	
people	with	PDN	are	rarely	referred.	It	is	unknown	whether	these	strategies	would	be	appropriate	
to	help	people	live	with	PDN.		
This	thesis	aimed	to:	1)	locate	and	appraise	all	literature	relating	to	physical	activity	and	
psychological	coping	strategies	in	PDN;	2)	interview	people	with	PDN	and	explore	how	PDN	
impacted	on	their	lives;	3)	explore	the	perspectives	of	patients	and	clinicians	on	the	relevance	of	
PMP	approaches;	and	4)	explore	patients’	treatment	priorities	and	whether	these	might	be	
addressed	by	PMP	strategies.	
To	address	these	aims,	firstly	a	systematic	literature	review	was	conducted.	The	review	
identified	a	paucity	of	studies	investigating	physical	activity	or	psychological	coping	strategies	for	
PDN.	Two	interview	studies	were	conducted,	and	data	were	analysed	using	thematic	analysis	(TA).	
A	study	with	patients	(n=23)	found	the	impacts	of	PDN	were	wide	ranging,	people	had	
experimented	with	many	coping	strategies	unsuccessfully	and	there	was	some	scepticism	that	
PMP	strategies	were	relevant	to	PDN,	though	few	participants	had	direct	experience	of	them.	The	
second	study	interviewed	specialist	diabetes	and	pain	clinicians	and	representatives	from	primary	
care	(n=19).	Clinicians	relied	primarily	on	medication	strategies	and	did	not	have	alternatives	
when	these	failed.	Diabetes	clinicians	highlighted	that	people	with	PDN	were	medically	complex	
patients	and	were	at	risk	of	tissue	damage	from	too	much	physical	activity.	Pain	clinicians	felt	
PMP	strategies	could	be	adapted	to	suit	the	population	with	PDN.	
Informed	by	the	patient	interview	study,	an	Internet	survey	was	developed	to	explore	the	
management	priorities	of	people	with	PDN	(n=63	respondents).	Sleep	disturbance	was	the	top	
priority	in	all	subgroups	analysed.	There	were	six	impacts	most	frequently	prioritised	by	
respondents,	which	did	not	include	pain.	Potential	clinical	management	strategies	for	these	
impacts	have	been	described,	and	suggestions	made	for	future	research.		
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This	thesis	has	shown	a	scarcity	of	existing	evidence	for	non-pharmacological	strategies	in	
the	management	of	PDN.		PMP	strategies	were	not	necessarily	viewed	as	appropriate	by	patient	
participants.	The	impacts	prioritized	by	people	with	PDN	could	however	be	matched	to	
management	strategies	from	other	conditions	where	persistent	pain	is	common.	There	is	no	a	
priori	reason	why	these	strategies	could	not	be	trialled	with	PDN.	Managing	the	impacts	of	PDN	
on	peoples’	lives	remains	a	complex	process.	
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Pain	without	words	
Sculpture	by	Deborah	Ann,	who	lives	with	painful	diabetic	neuropathy,	from	Exhibiting	
Pain.	Reproduced	with	permission.	www.exhibitingpain.wordpress.com	
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Chapter	1	–	Introduction	
This	thesis	explores	the	experience	of	people	who	live	with	painful	diabetic	neuropathy	
(PDN),	a	microvascular	complication	of	diabetes	mellitus	(DM).	It	investigates	how	PDN	impacts	
on	their	lives	and	how	they,	and	clinicians	involved	in	their	healthcare,	currently	manage	these	
impacts.	It	explores	whether	management	strategies	used	with	other	persistent	pain	conditions	
might	be	acceptable	adjuncts	to	management	of	PDN	and	associated	impacts.	Lastly,	the	thesis	
investigates	which	impacts	patients	prioritise	to	manage	more	effectively	and	places	these	in	the	
context	of	existing	evidence.		
This	chapter	will	give	a	background	to	diabetes	as	a	chronic	health	condition	and	highlights	
the	range	of	complications	that	can	occur.	It	will	introduce	PDN	as	one	of	these	complications,	and	
describe	what	is	currently	known	about	the	impact	of	this	condition	on	peoples’	lives.	Lastly,	it	will	
outline	the	aims	of	this	thesis,	the	research	questions,	and	the	thesis	structure.	
1.1	Diabetes	Mellitus	
Diabetes	Mellitus	(DM)	is	an	endocrine	disorder	characterized	by	maintained	
hyperglycaemia	(raised	blood	sugar	level)	due	to	loss	of	insulin	secretion	and/or	impairment	of	
insulin	sensitivity	at	the	target	tissues	(Holt	and	Hanley,	2012a).	In	1999	the	World	Health	
Organisation	(WHO)	revised	the	classification	of	types	of	diabetes;	Type	1	DM	(T1DM)	is	an	
autoimmune	disorder	that	leads	to	the	destruction	of	β-cells	within	the	pancreas;	this	tends	to	be	
diagnosed	in	childhood	or	adolescence.	The	loss	of	β-cells	abolishes	all	insulin	secretion	and	
requires	lifelong	management	with	insulin	replacement	therapy.	Type	2	DM	(T2DM)	is	the	result	
of	depleted	insulin	secretion	by	β-cells	and/or	resistance	to	the	action	of	insulin	at	target	tissues.	
T2DM	tends	to	be	diagnosed	later	in	life.	Other	diagnoses	include	diabetes	secondary	to	other	
endocrine	or	pancreatic	disorders,	specific	genetic	mutations,	or	pregnancy	(Holt	and	Hanley,	
2012b).	
1.1.1	Historical	perspective	
Diabetes	has	been	recognised	as	a	clinical	phenomenon	within	Egyptian	(~1500	BC),	Indian	
(5th	Century	BC)	and	Greek	(2nd	Century	AD)	medical	texts.	The	Persian	physician	Avicenna	(980-
1037	AD)	described	the	altered	appetite,	sweet	tasting	urine,	propensity	for	gangrene	and	
impotence	that	affected	people	with	diabetes.	Diabetes	takes	its	name	from	the	Greek	
diabainein,	meaning	"to	pass	through",	in	relation	to	the	volume	of	urine	people	with	diabetes	
can	produce.	In	the	18th	Century,	the	term	Diabetes	Mellitus	(honey)	was	used	to	differentiate	
patients	with	sweet	tasting	urine,	from	patients	whose	urine	was	tasteless	or	insipid	(Holt	and	
Hanley,	2012a;	Kumar,	Kumar	and	Janardan,	2013).	At	the	end	of	the	19th	Century	the	pivotal	
role	of	the	pancreas	and	specifically	the	β-cells	were	demonstrated.	β-cells,	also	called	Islets	of	
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Langherhans,	are	cells	that	release	insulin	into	the	portal	vein	in	response	to	a	meal.	The	function	
of	insulin	was	discovered	in	1921	by	Sir	Frederick	Banting	and	John	MacLeod	and	its	structure	was	
demonstrated	in	1955	by	Frederic	Sanger.		
The	purification	of	insulin	and	its	emerging	therapeutic	use	in	the	1920s	and	onwards	was	
revolutionary	in	the	treatment	of	T1DM.	Sir	Frederick	Banting	and	Charles	Best	did	not	patent	
their	process	for	the	production	of	insulin	nor	try	to	restrict	the	commercial	application	of	its	use.	
From	a	condition	that	would	lead	to	weight	loss	and	death	within	weeks	to	months,	the	survival	
time	was	increased	to	years	and	then	decades.	Insulin	therapy	has	developed	from	using	bovine	
insulin	in	1923,	to	using	recombinant	DNA	techniques	to	sequence	and	produce	human	analogue	
insulin	in	the	1980s.		
Research	continues	into	the	optimisation	of	insulin	delivery.	This	research	includes	different	
analogues	of	insulin	with	pharmacokinetic	properties	that	mimic	the	physiological	release	profile	
of	functioning	β-cells,	the	development	of	an	external	pancreas	that	can	continually	monitor	
blood	glucose	levels	and	deliver	insulin	appropriately,	and	the	transplantation	of	both	pancreas	
and	β-cells	into	the	patient	with	diabetes	(Holt	and	Hanley,	2012a;	Lawton	et	al.,	2015).	
1.1.2	Functions	of	the	pancreas	and	the	role	of	insulin	
The	pancreas	is	located	in	the	abdomen	and	sits	at	the	outflow	of	the	stomach	at	the	
duodenum.	As	an	exocrine	gland,	it	delivers	digestive	enzymes	directly	into	the	duodenum	to	aid	
with	the	digestion	of	protein,	carbohydrate	and	fat	within	the	food	ingested.	As	an	endocrine	
gland,	it	secretes	hormones	directly	into	the	blood	flow	that	passes	through	its	capillary	bed.	Cell	
subtypes	within	the	pancreas	have	different	roles:	α-cells	secrete	glucagon;	this	hormone	
increases	glucose	concentration	in	the	circulation.	β-cells	secrete	insulin;	this	decreases	the	
circulating	blood	glucose	concentration.	It	is	the	secretion	of	insulin	and	the	subsequent	effect	at	
target	tissues	that	is	of	most	relevance	to	the	pathophysiology	of	diabetes	(Inzucchi	et	al.,	2012).		
The	β-cells	release	insulin	at	a	basal	rate,	which	accounts	for	approximately	50%	of	the	
insulin	released	over	a	24-hour	period.	Immediately	after	a	meal	is	eaten	there	is	an	early	rapid	
insulin	secretion	phase	followed	by	a	sustained	insulin	secretion	phase.	The	insulin	is	released	into	
the	pancreatic	capillary	beds	which	develop	to	form	the	hepatic	portal	vein.	The	hepatic	portal	
vein	transports	the	insulin	directly	into	the	liver	tissue	where	it	has	a	primary	site	of	action	(Kahn,	
Cooper	and	Del	Prato,	2014).	
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Figure	1	-	Regulation	of	blood	glucose	concentration	adapted	from	Holt	&	Hanley	(2012)	(reproduced	with	
permission)	
	
The	actions	of	insulin	are	manifold	and	complex	(partially	summarised	in	Figure	1).	Insulin	
binds	to	a	range	of	different	target	cells	and	has	different	effects	depending	on	cell	type.	Insulin	
impacts	on	carbohydrate	metabolism	by	causing	glucose	to	be	taken	up	from	the	circulation	into	
the	cells;	it	facilitates	glycogen	synthesis	and	inhibits	both	glycogen	breakdown	and	
gluconeogenesis	(creation	of	glucose	from	non-carbohydrate	sources).	Insulin	modulates	the	
metabolism	of	fatty	acids	by	facilitating	the	formation	of	triglycerides	and	cholesterol,	whilst	
inhibiting	their	breakdown.	Insulin	is	also	involved	in	protein	metabolism	by	increasing	the	uptake	
of	amino	acids	and	promoting	protein	synthesis	(Inzucchi	et	al.,	2012).	These	actions	occur	in	all	
cells	in	the	body	although	the	majority	of	these	effects	occur	in	the	liver,	the	concentration	of	
insulin	in	the	blood	stream	leaving	the	liver	can	be	decreased	by	up	to	40%.	The	actions	of	insulin	
are	modified	and	modulated	by	the	synergistic	actions	of	many	other	hormones	including	
glucagon,	adrenalin,	and	glucocorticoids.	It	is	regulated	by	the	relative	neural	activity	of	the	
sympathetic	nervous	system	(SNS)	and	parasympathetic	nervous	systems	(PNS).	Finally,	insulin	
release	is	affected	by	behavioural	and	social	factors	such	as	exercise	(Petersen	and	Pedersen,	
2005)	and	stress	(Lasselin	et	al.,	2012).	
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1.1.3	The	pre-diabetic	state		
The	pathophysiological	processes	of	reduced	release	and	action	of	insulin	can	exist	without	
overt	symptoms	for	many	years.	This	has	been	termed	a	pre-diabetes	state	(Horowitz,	2006).	As	
the	effect	of	insulin	at	target	tissues	declines,	β-cells	increase	the	rate	of	insulin	release	
(hyperinsulinemia)	in	order	to	maintain	blood	glucose	levels	within	a	physiological	range	
(euglycaemia).	With	continued	tolerance	to	insulin	action	a	state	of	hyperinsulinemia	and	
hyperglycaemia	is	reached,	which	eventually	progresses	to	β-cells	depletion	and	a	loss	of	insulin	
secretion	(hypoinsulinemia),	and	maintained	hyperglycaemia	(Donahue	and	Orchard,	1992).	This	
state	can	exist	for	a	prolonged	time	before	possibly	leading	to	signs	and	symptoms	that	would	be	
diagnosed	as	diabetes.	Alberti	and	Zimmet	(2013)	estimated	that	20-25%	of	people	with	T2DM	in	
the	United	Kingdom	(UK)	are	undiagnosed.		
1.1.4	Diagnosis	of	diabetes	
The	diagnosis	of	DM	has	been	informed	by	two	abnormal	plasma	glucose	concentrations,	
following	an	oral	glucose	tolerance	test	or	an	eight-hour	fasting	state	(Bennett,	Guo	and	
Dharmage,	2007).	Fasting	glucose	tests	have	low	sensitivity	(mean	0.25	(Confidence	Interval	(CI)	
0.19	to	0.32))	so	are	prone	to	false-negative	results,	but	high	specificity	(mean	0.94	(CI	0.92	to	
0.96))	(Barry	et	al.,	2017).	Glucose	tolerance	tests	are	relatively	costly	to	administer	and	can	be	
affected	by	technique	and	laboratory	variables	(Bennett,	Guo	and	Dharmage,	2007).	To	account	
for	false	negative	rates,	diagnosis	of	diabetes	was	based	on	a	combination	of	results,	see	Figure	2	
below	(Holt	and	Hanley,	2012a).	
Figure	2	-	World	Health	Organisation	diagnostic	criteria	for	diabetes,	1999	(Holt	and	Hanley,	2012a)	
(reproduced	with	permission)	
	 	 Fasting	plasma	glucose		
	 	 <6.1	mmol/L	 ≥6.1	–	6.9	mmol/l	 ≥7.0	mmol/L	
2h	plasma	
glucose	
following	75g	
oral	glucose	
tolerance	test	
<7.8	mmol/L	 Normal	 Impaired	fasting	
glycaemia	
Diabetes	
≥7.8	–	11.0	
mmol/L	
Impaired	glucose	
tolerance	
Impaired	fasting	
glycaemia	and	
impaired	glucose	
tolerance	
Diabetes	
≥11.1	mmol/L	 Diabetes	 Diabetes	 Diabetes	
The	American	Diabetes	Association	defines	impaired	fasting	glucose	as	5.6-6.9	mmol/L	
Diabetes	may	also	be	diagnosed	if	random	plasma	glucose	is	≥11.1	mmol/L	
	
More	recently	the	diagnostic	process	has	included	measurement	of	glycated	haemoglobin	
levels	(HbA1c)	(Kilpatrick,	Bloomgarden	and	Zimmet,	2009).	Glucose	in	the	blood	plasma	binds	
irreversibly	to	haemoglobin	molecules	until	the	body	reabsorbs	the	erythrocytes.	The	
concentration	of	plasma	HbA1c	increases	proportionally	to	plasma	glucose	so	giving	an	insight	to	
blood	glucose	concentrations	across	2-3	months,	the	lifetime	of	the	erythrocytes	(Bennett,	Guo	
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and	Dharmage,	2007).	The	WHO,	the	International	Expert	Committee	and	the	American	Diabetic	
Association	now	define	HbA1c	of	≥6.5%	(≥48mmol/mol)	as	diagnostic	of	diabetes	and	HbA1c	5.7-
6.4%	(40-47	mmol/mol)	as	indicating	a	raised	risk	of	developing	DM	(Holt	and	Hanley,	2012a;	
Barry	et	al.,	2017).	
There	are	efforts	to	improve	the	early	detection	of	diabetes	and	implement	appropriate	
treatments	so	that	associated	costs	of	the	disease	might	be	mitigated	and	reduced,	for	both	the	
person	and	health	systems.	Current	NHS	cost	estimates	for	diabetes	are	£23.7	billion	and	this	is	
expected	to	rise	toward	£39.8	billion	by	2035-36	(Barry	et	al.,	2017).	A	recent	systematic	review	
evaluated	the	evidence	to	establish	whether	diabetes	pre-screening	programmes	were	useful	for	
identifying	people	who	did	go	onto	develop	DM	(Barry	et	al.,	2017).	The	authors	used	oral	glucose	
tolerance	tests	(fasting	glucose	and	glucose	tolerance	tests	as	described	in	Figure	2	above)	as	gold	
standard	for	diagnosing	pre-diabetes	glycaemic	results	and	compared	HbA1c	data	to	assess	its	
predictive	value.	HbA1c	was	found	to	have	a	sensitivity	of	0.49	(CI	0.40	to	0.58)	and	specificity	of	
0.79	(CI	0.73	to	0.84)	for	diagnosing	prediabetes	in	line	with	oral	glucose	tests	(Barry	et	al.,	2017).	
The	moderate	results	of	specificity	and	sensitivity	mean	people	might	be	reassured	they	do	not	
have	an	increased	risk	for	diabetes	when	they	do	(false	negative),	or	referred	for	treatment	when	
they	do	not	require	it	(false	positive).	
1.1.5	Epidemiology	and	risk	factors	
In	the	UK,	the	population	prevalence	of	diabetes	was	reported	at	6%	(DUK,	2012a),	which	
equated	to	3.2	million	adults.	Data	from	2009	indicated	a	lower	prevalence	of	5.1%,	suggesting	
prevalence	is	increasing		(DUK,	2010).	A	similar	increase	has	been	noted	globally	(Inzucchi	et	al.,	
2012).	The	majority	of	adults	with	diabetes	have	T2DM	(90%),	with	10%	having	T1DM	(NICE,	
2015b).	Of	the	adults	with	T2DM,	56%	are	male	and	44%	female.	The	presence	of	pre-diabetic	
states	means	people	can	have	episodes	of	hyperglycaemia,	without	demonstrating	clinical	
symptoms	that	would	lead	them	to	health	services.	The	majority	of	children	with	diabetes	have	
T1DM,	although	diagnosis	of	children	and	adolescents	with	T2DM	is	increasing	(DUK,	2012a).		
Type	2	DM	has	higher	prevalence	in	Black	and	Minority	Ethnic	groups,	particularly	people	
from	South	Asia	compared	to	rates	in	Caucasians.	Diabetes	prevalence	in	India	and	Bangladesh	
are	8-10%	(Gujral	et	al.,	2013).	People	with	a	South	Asian	background	tend	to	develop	resistance	
to	insulin	action	at	a	younger	age,	and	are	predisposed	to	have	higher	amounts	of	abdominal	and	
visceral	fat	even	for	matched	body	mass	index	than	Caucasian	populations	(Gujral	et	al.,	2013).		
There	are	social	and	demographic	risk	factors	known	to	increase	the	risk	of	developing	
T2DM.	The	balance	between	energy	intake	and	energy	expenditure	has	gradually	changed	in	
recent	decades	in	Western	societies,	as	calories	have	become	cheaper	and	modern	society	
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demands	less	physical	activity.	This	shift	has	led	to	an	increase	in	the	population	percentage	
classed	as	obese	and	heavier.	There	have	been	cultural	shifts	in	diet	toward	pre-packaged	and	
processed	foods	that	often	contain	higher	proportions	of	sugar	and	fat.	A	raised	intake	of	calorie-
dense	food	can	lead	to	an	increase	in	percentage	body	fat	composition.	Episodes	of	life	stress	can	
be	associated	with	less-healthy	choices	of	diet	and	consequent	increases	in	circulating	
inflammatory	markers	(Alford,	2006;	Kiecolt-Glaser,	2010).	The	deposition	of	adipose	tissue	
around	the	abdomen	has	been	linked	to	the	pre-diabetes	state	(Eckel,	Grundy	and	Zimmet,	2005).		
Behavioural	factors	such	as	smoking	and	coffee	consumption	have	been	shown	to	alter	the	
risk	of	developing	diabetes.	Light	smokers	have	a	relative	risk	(RR)	of	1.29	(CI	1.13	to	1.48	and	
heavier	smokers	(≥20	cigarettes/day)	an	RR	1.61	(CI	1.43	to	1.80)	of	developing	T2DM	(Willi	et	al.,	
2007).	In	contrast	to	tobacco,	caffeinated	coffee	consumption	has	been	associated	with	reduced	
risk	of	DM.	Conversely,	high	coffee	consumption	(≥7	cups/day)	had	RR	0.65	(CI	0.54	to	0.78)	when	
compared	to	low	coffee	consumption	(0	to	≤2	cups/day)	(van	Dam	and	Hu,	2005).			
Sedentary	behaviours,	particularly	prolonged	sitting	and	screen	time,	in	childhood	have	
been	associated	with	increased	risk	of	cardiovascular	diseases	and	diabetes	at	30	years	of	age	
(Department	of	Health,	2010a).	National	and	International	guidance	suggest	150	minutes	of	
‘moderate	exercise’	each	week	are	required	to	offset	health	risks	of	sedentary	lifestyles	(Sparling	
et	al.,	2015).	Moderate	intensity	walking	or	cycling	is	defined	by	the	level	of	breathlessness	
caused;	where	conversation	is	limited	to	short	sentences,	this	is	seen	as	‘moderate	exercise’.	
	Social	factors	mediate	the	development	of	diabetes.	Perceptions	of	more	difficult	
childhood	experiences	have	been	associated	with	increased	prevalence	of	diabetes	(Tomasdottir	
et	al.,	2015).	Living	in	a	deprived	urban	area	is	associated	with	increased	risk	of	diabetes	
compared	to	more	affluent	suburbs	that	are	only	a	short	distance	removed	(Steno	Diabetes	
Center/UCL,	2016).	These	social	factors	can	be	considered	as	stressors	on	the	physiological	
system,	which	then	responds	with	a	variety	of	hormonal	cascades	including	adrenaline,	cortisol	
and	pro-inflammatory	biomarkers.	These	agents	all	have	an	impact	on	the	control	of	blood	
glucose	levels	(Tsigos	and	Chrousos,	2002;	Chrousos,	2009).	
In	summary	of	section	1.1.5,	development	of	diabetes	has	been	shown	as	multi-factorial,	
with	development	of	the	disease	state	dependent	upon	a	wide	range	of	factors	including	genetics,	
diet,	activity	levels,	smoking,	life	stress	and	social	environment.		
1.1.6	Impact	of	diabetes	
Diabetes	has	significant	negative	impacts	on	quality	of	life.	A	global	review	of	Disability	
Adjusted	Life	Years	(DALYs)	demonstrated	an	increase	in	diabetes-associated	disability	from	
27,706	DALYs	in	1990	(global	estimate	for	one	year,	all	ages)	to	46,823	in	2010,	an	increase	of	
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69%.	In	1990	diabetes	was	ranked	21st	in	all	diseases	and	had	risen	to	14th	by	2010	(Murray	et	al.,	
2012).	The	increase	in	DALYs	was	due	to	both	rising	prevalence	rates	of	DM	and	improved	
treatment.	Better	treatment	has	reduced	mortality	but	increased	the	number	of	people	living	
long-term	with	the	disease	and	its	consequences		(Alberti	and	Zimmet,	2013).		
Large-scale	studies	have	investigated	the	symptom	burden	of	DM.	Sudore	et	al.	(2012)	
conducted	a	survey	with	people	diagnosed	with	DM	(n=20,188,	62%	response,	n=13,171	cases	
included).	Of	the	sample	(mean	age	60.0	years	(SD9.9),	47%	female,	mixed	ethnic	backgrounds),	
39.7%	experienced	persistent	pain,	23.8%	experienced	sensory	loss	due	to	diabetic	neuropathy,	
24.2%	experienced	sleep	disturbance	and	23.5%	were	depressed	(Patient	Health	Questionnaire-9	
(PHQ-9))	(Sudore	et	al.,	2012).	
Depression	and	anxiety	are	reported	as	more	common	amongst	people	with	DM	than	
matched	controls.	A	postal	survey	of	people	with	T1	and	T2DM	(n=1456,	response	rate	71%)	
found	22.4%	of	respondents	(CI	20.2	to	24.7%)	were	classed	with	mild	to	severe	depression	
(general	population	prevalence	10.4-11.2%)	and	32%	(CI	29.5	to	34.6%)	were	classed	with	mild	to	
severe	anxiety	(general	population	prevalence	15.3%)	(Collins,	Corcoran	and	Perry,	2009).	Anxiety	
has	been	studied	less	frequently	than	depression.	A	retrospective	data	base	study	(total	
n=201,575,	n=20,142	with	DM)	showed	the	lifetime	risk	of	anxiety	to	be	19.5%	in	people	with	DM	
and	10.9%	in	matched	controls	without	DM.	After	adjustment	for	other	sociodemographic	
variables,	the	DM	cohort	were	20%	more	likely	to	be	diagnosed	with	anxiety	(prevalence	ratio	
1.20,	CI	1.12	to	1.30)	(Li	et	al.,	2008).	
There	is	some	evidence	that	DM	has	an	impact	on	cognitive	function	in	later	adulthood	and	
potentially	that	DM	maybe	a	factor	in	the	development	of	Alzheimer’s	disease	(RR	1.5-2.0)	and	
vascular	dementia	(RR	2.0-2.5)	(Biessels,	Deary	and	Ryan,	2008).	Biessels	et	al.	(2008)	
acknowledge	cognitive	performance	declines	with	age	but	highlight	that	episodic	hypoglycaemia	
and	stress	at	crucial	periods	of	life,	especially	early	childhood,	have	been	implicated	in	advanced	
rates	of	cognitive	decline	in	later	life.		
Prolonged	episodes	of	hyperglycaemia	can	lead	to	inflammation	in	the	epithelial	lining	of	
the	vascular	system	and	release	of	free-radicals	(Shakher	and	Stevens,	2011).	With	prolonged	
exposure	to	these	inflammatory	mediators	diabetic	neuropathy	can	develop.	Diabetic	neuropathy	
(without	pain)	is	characterized	by	loss	of	sensory	and	nociceptive	information	(feet	insensate	to	
damage),	a	decline	in	proprioceptive	reactions,	increase	in	standing	balance	sway	and	risk	of	falls	
(van	Schie,	2008).	Presence	of	neuropathy	has	been	associated	with	reduced	physical	mobility	on	
the	Nottingham	Health	Profile	physical	mobility	scale.	The	risk	of	ulceration	and	consequent	
amputation	is	increased	with	neuropathy;	careful	foot	assessment	and	self-care	are	vital	to	
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mitigate	this	risk	(NICE,	2015b).	Clinical	foot	assessment	includes	vibration	sense	test	(128Hz	
tuning	fork),	monofilament	tests	(10g	Semmes-Weinstein)	and	possible	use	of	a	range	of	
screening	questionnaires,	for	example	the	Neuropathy	Symptom	Score	(Lavery,	Armstrong	and	
Boulton,	2004)	or	Leeds	Assessment	of	Neuropathic	Signs	and	Symptoms	(Bennett	et	al.,	2005).	
These	foot	assessment	procedures	are	currently	recommended	by	National	Institute	for	Health	
and	Clinical	Excellence	(NICE)	(NICE,	2015b),	DiabetesUK	(DUK)	(DUK,	2012b)	and	are	part	of	the	
Quality	Outcomes	Framework	(QOF)	for	UK	primary	care	clinicians	(NHS	Employers,	2016).	
Lastly,	diabetes	is	associated	with	increased	incidences	of	common	musculoskeletal	
conditions.	Adhesive	capsulitis	has	an	incidence	of	2-10%	in	the	population	without	diabetes	
rising	to	11-20%	in	the	population	with	diabetes.	Dupuytren’s	contracture,	a	thickening	and	
shortening	of	the	flexor	tendons	in	the	palm	has	an	incidence	of	13%	in	the	population	without	
diabetes	rising	to	20-63%	in	people	with	diabetes	(Smith,	Burnet	and	McNeil,	2003).	
In	summary	of	section	1.1.6,	the	consequences	of	diabetes	are	complex	and	inter-related.	
Depression,	anxiety,	altered	sleep	pattern,	altered	mobility,	altered	circulating	inflammatory	
markers	and	on-going	stress	from	managing	a	long-term	condition	are	not	only	consequences	of	
diabetes,	but	have	the	potential	to	negatively	affect	the	person’s	ability	to	self-manage	their	
condition.		The	following	section	will	detail	the	strategies	that	are	important	for	optimum	
management	of	diabetes,	both	from	the	clinicians	involved	and	from	the	person.	
1.1.7	Management	of	diabetes	
Type	1	DM	involves	autoimmune	destruction	of	β-cells,	which	may	ultimately	lead	to	
complete	abolition	of	insulin	secretion.	Treatment	for	T1DM	involves	insulin	therapy,	in	addition	
to	appropriate	lifestyle	modification	and	dietary	advice,	from	a	much	earlier	point	in	the	
diagnostic	and	management	journey	(Holt	and	Hanley,	2012a).	In	contrast,	T2DM	is	managed	with	
a	combination	of	diet	and	lifestyle	advice,	with	medications	if	required.	This	spectrum	of	clinical	
presentation	ranges	from	early	diagnosis	of	T2DM	being	successfully	managed	by	diet	and	
lifestyle	changes	with	no	need	for	medication,	to	the	other	extreme	where	continual	loss	of	β-
cells,	and	hence	insulin,	may	then	require	insulin	therapy.	
Current	NICE	guidance	focuses	on	five	key	principles	of	DM	management:	(1)	patient	
education,	(2)	dietary	and	activity	advice,	(3)	blood	pressure	management,	(4)	blood	glucose	
management,	and	(5)	appropriate	drug	management	(NICE,	2015b).	Education	is	critical	to	
maximise	patient	engagement	in	self-management	of	diabetes.	Education	is	targeted	at	family	
and	partners	in	addition	to	patients,	because	social	support	networks	have	been	shown	as	
beneficial	in	managing	long-term	conditions	(Strom	and	Egede,	2012).	
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There	are	currently	some	differences	in	the	dietary	advice	given	by	the	National	Health	
Service	(NHS)	and	by	DUK.	They	give	similar	advice	to	eat	regular	meals	(not	skip	meals),	eat	at	
least	five	portions	of	fruit	and	vegetables	daily,	increase	dietary	fibre	intake,	limit	salt	and	alcohol,		
choose	lean	meat,	fish,	eggs	and	pulses	as	sources	of	protein	and	keep	hydrated	with	water	(DUK,	
2017;	NHS,	2017).	The	NHS	advises	eating	plenty	of	complex	carbohydrates	(whole	grain	pasta	
and	bread)	with	low	glycaemic	index;	pure	glucose	has	a	glycaemic	index	of	100	with	low	defined	
as	≤55.	DUK	recommend	‘counting’	carbohydrates	to	ensure	a	closer	monitoring	of	consumption.		
Lifestyle	advice	also	encourages	physical	activity.	The	minimum	recommended	level	of	
activity	(150mins/week,	moderate	intensity)	has	been	discussed	in	section	1.1.5.	This	guidance	is	
for	reducing	the	likelihood	of	developing	a	range	of	health	conditions,	so	not	specific	to	diabetes,	
but	has	been	endorsed	by	diabetes	organisations	(Nagi	and	Gallen,	2010).	This	activity	can	reduce	
the	risk	of	developing	complications	associated	with	diabetes,	such	as	cardiovascular	disease	
(Nagi	and	Gallen,	2010).	
A	systematic	review	included	eight	studies	and	found	improved	diet	and	physical	activity	
levels	reduced	the	relative	risk	of	developing	diabetes	by	37%	(RR	0.63	(CI	0.49	to	0.79)	(Orozco	et	
al.,	2008).	There	were	associated	reductions	in	waist	circumference	(a	measure	of	abdominal	fat	
deposition),	body	weight	and	blood	pressure.	Increasing	physical	activity	has	been	shown	to	have	
association	with	reductions	in	HbA1c	(7.65%	vs.	8.31%,	mean	difference	-0.66%,	p<0.001)	when	
compared	to	control	arms	(Boulé	et	al.,	2001).	Boule	et	al.	(2001)	excluded	studies	including	drug	
interventions	in	order	to	remove	the	confounding	effect	of	medication.	There	was	no	significant	
change	in	body	mass	(83kg	vs.	82.4kg,	mean	difference	0.54,	p=0.76)	between	the	intervention	
and	control	arms	(Boulé	et	al.,	2001).	This	review	highlighted	that	the	physiological	benefits	of	
exercise	can	be	attained	in	the	absence	of	weight	loss.	
NICE	advocate	regular	monitoring	of	blood	pressure	in	people	with	DM	and	the	use	of	anti-
hypertensive	drugs	where	necessary	to	achieve	normotensive	pressure	(NICE	2015).	Uncontrolled	
hypertension	has	an	increased	risk	of	cardiovascular	disease,	cerebrovascular	accidents	and	
nephropathy	(Donahue	and	Orchard,	1992).	Hypertension	within	neural	capillary	beds	also	
predisposes	towards	further	microvascular	damage	and	consequent	neuropathy	and	retinopathy	
(Tooke,	1995).		
Management	of	blood	glucose	levels	is	a	key	principal	of	management.	Hypoglycaemia	(low	
blood	glucose)	will	lead	to	cellular	energy	supplied	by	alternative	biochemical	pathways.	These	
pathways	use	beta-oxidation	releasing	ketone	bodies	that	are	toxic.	Increasing	ketone	
concentrations	lead	to	vomiting,	abdominal	pain,	confusion	and	loss	of	consciousness.	Conversely	
hyperglycaemia	(high	blood	glucose)	leads	to	increased	rates	of	free	radical	release,	epithelial	cell	
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inflammation	and	consequent	microvascular	changes.	Current	guidelines	aim	for	an	optimum	
target	HbA1c	of	48mmol/mol	(6.5%),	or	53mmol/mol	(7%)	if	taking	medication	associated	with	
hypoglycaemia	(NICE,	2015b).	
1.1.8	Complications	of	diabetes	
In	section	1.1.6	the	impacts	of	diabetes	were	outlined.	These	included	higher	rates	of	pain,	
depression,	anxiety,	cardiovascular	diseases	and	declines	in	cognitive	and	balance	functions	when	
compared	to	a	population	without	diabetes.	When	diabetes	is	not	optimally	managed,	a	range	of	
complications	become	more	likely.	These	can	be	divided	into	two	types:	1)	macrovascular	
complications	leading	to	cardiovascular	disease,	both	cardiac	and	peripheral,	and	nephropathy;	
and	2)	microvascular	complications	leading	to	retinopathy	and	neuropathies	(Eckel,	Grundy	and	
Zimmet,	2005).		
It	is	challenging,	if	not	impossible,	to	clearly	differentiate	the	impacts	of	diabetes	from	the	
impacts	of	the	complications,	because	in	many	ways	the	complications	are	extensions	of	the	
disease.	For	example,	rates	of	hypertension	are	higher	in	people	with	diabetes	as	a	direct	
consequence	of	the	disease.	Sustained	hypertension	in	the	large	arteries	can	lead	to	cardiac	
atherosclerosis	and	hence	cardiac	disease.	Hypertension	can	lead	to	increased	inflammation	in	
peripheral	arteries,	plaque	deposition	and	hence	peripheral	vascular	disease	(Inzucchi	et	al.,	
2012).	Increased	blood	pressure	through	the	kidneys	can	lead	to	damage	of	the	vascular	bed	that	
can	significantly	impair	kidney	function.	Diabetes	is	the	most	common	reason	for	developing	end-
stage	kidney	disease	(DUK,	2012a).		
Sustained	hypertension	in	arterioles	and	capillary	beds	can	lead	to	microvascular	
complications.	Epithelial	cell	damage	and	inflammation	within	the	capillary	bed	of	the	retina	
makes	people	with	diabetes	far	more	likely	to	develop	glaucoma,	cataracts	and	retinal	
degeneration	than	the	population	without	diabetes	(Tooke,	1995;	DUK,	2010).	Similar	processes	
in	Aβ	and	A∂	neurones	affect	afferent	sensory	information.	Clinical	signs	of	neuropathy	develop	in	
longer	neurones,	thus	affecting	the	feet	and	lower	extremities	more	often	than	the	upper	limbs	
(Waldman,	2000).	Loss	of	the	protective	nociceptive	information	from	the	feet	can	expose	people	
to	tissue	damage	without	conscious	experience	(Shah	and	Mueller,	2012).	The	reduced	vascularity	
impairs	healing	often	resulting	in	ulceration	and	potential	need	for	amputation	(Holt	and	Hanley,	
2012a).	
Reviews	of	the	impact	of	diabetes	highlight	that	improved	treatment	has	reduced	mortality	
as	a	direct	result	of	the	disease,	but	improved	survival	has	increased	the	time	available	for	
potential	complications	to	develop,	hence	overall	morbidity	due	to	diabetes	has	increased	(Alberti	
and	Zimmet,	2013).	This	is	reflected	in	the	ranking	of	diabetes,	amongst	worldwide	causes	for	
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disability,	rising	over	the	past	20	years	(Murray	et	al.,	2012).	As	well	as	the	difficulty	of	separating	
impacts	from	complications	of	diabetes,	noted	in	the	previous	section,	reviews	have	also	
highlighted	the	difficulty	of	separating	the	person	with	diabetes	from	the	social	situation	in	which	
they	live.	Social	deprivation,	smoking,	alcohol	intake	and	life	stress	have	all	been	associated	with	
the	development	of	cardiovascular	disease,	depression	and	anxiety,	and	stress	related	disorders	
(Chapman,	Tuckett	and	Song,	2008;	Chrousos,	2009;	Yoon,	Kwok	and	Magkidis,	2012;	Steno	
Diabetes	Center/UCL,	2016).		
1.2	Painful	diabetic	neuropathy	
Diabetic	peripheral	neuropathy,	leading	to	sensory	loss,	is	a	common	feature	of	diabetes	
affecting	up	to	50%	of	people	(Lavery,	Armstrong	and	Boulton,	2004;	Boulton	et	al.,	2005).	A	
proportion	of	people	with	neuropathy	progress	to	experience	pain	due	to	neuropathy,	termed	
painful	diabetic	neuropathy	(PDN).	
1.2.1	Pathological	process	
PDN	is	a	significant	complication	of	DM	and	is	caused	by	a	combination	of	processes	which	
occur	in	the	peripheral	sensory	nerves,	at	the	dorsal	horn	of	the	spinal	cord,	and	at	higher	cortical	
centres.		
In	the	peripheral	nerves,	prolonged	hyperglycaemia	leads	to	the	generation	of	reactive	
oxygen	species	(free	radicals)	and	accumulation	of	advanced	glycated	end-products.	Advanced	
glycated	end-products	are	implicated	in	reducing	the	capacity	of	capillary	membranes	to	
vasodilate,	and	in	the	production	and	release	of	pro-inflammatory	cytokines	(Interleukines-1	and	
6,	Tumour	Necrosis	Factor-α)	and	nerve	growth	factors	(Insulin-like	growth	factor	and	platelet-
derived	growth	factor).	The	consequences	of	these	multiple	mechanisms	are	microvascular	
ischaemia,	disruption	to	the	mitochondrial	energy	supply	for	epithelial	cells	and	damage	to	
epithelial	capillary	linings	(Tesfaye	et	al.,	2010;	Shakher	and	Stevens,	2011).		
These	processes,	initiated	by	hyperglycaemia,	are	specific	to	diabetes,	but	similar	changes	
in	peripheral	nerves	have	been	shown	to	contribute	to	neuropathic	pain	symptoms	following	
chemotherapy	(Wolf	et	al.,	2008),	radiotherapy	(Johansson,	Svensson	and	Denekamp,	2000),	
excess	alcohol	consumption	(Chopra	and	Tiwari,	2012)	and	anti-retroviral	treatments	for	human	
immunodeficiency	virus/acquired	immunodeficiency	syndrome	(Schütz	and	Robinson-Papp,	
2013).		
The	pathophysiological	changes	described	above	lead	to	structural	epithelial	cell	damage,	
myelin	sheath	breakdown	in	A∂-fibres	and	increased	insertion	of	ion	channels	into	the	axolemma.	
An	increased	population	of	ion	channels	allows	the	axon	to	initiate	ectopic	(spontaneous)	
production	of	action	potentials	along	afferent	c-	and	A∂-fibres,	into	the	dorsal	horn	of	the	spinal	
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cord,	hence	increasing	nociception	(Woolf	and	Mannion,	1999;	Baron,	2006).	Charles	Sherrington,	
who	first	described	c-fibres,	defined	nociception	as	neural	activity	in	response	to	the	presence	of	
noxious	stimuli	acting	on	receptors	in	peripheral	tissues.	The	noxious	stimuli,	extremes	of	
temperature,	inflammatory	mediators	or	mechanical	force,	would	damage	tissues	if	they	
continued	to	act	(Woolf	and	Ma,	2007).	It	is	important	to	be	clear	at	this	point	that	nociception	is	
not	the	same	as	pain.	These	multiple	processes	contribute	to	peripheral	sensitisation	(Butler,	
2000;	O’Leary	et	al.,	2016).	
At	the	dorsal	horn	of	the	spinal	cord,	persistent	high	levels	of	afferent	nociception	lead	to	a	
cascade	of	events	termed	central	sensitisation.	These	events	include:	increased	AMPA	(alpha-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate)	receptor	activity;	activation	of	NMDA	(N-
methyl-D-aspartic	acid)	receptors,	which	have	slower	kinetics	so	allowing	more	sodium	ions	to	
pass	across	the	neuronal	membrane;	phenotypic	changes	in	the	neural	cells	to	increase	the	
production	of	AMPA	receptors;	and	altered	activity	of	glial	cells	(astrocytes).	This	cascade	of	
activity	leads	to		both	reduced	removal	of	excitatory	neurotransmitters,	and	increased	release	of	
pro-inflammatory	neurotransmitters	into	the	local	dorsal	horn	synapses	and	systemically	
(Latremoliere	and	Woolf,	2009;	Allen	and	Barres,	2009).		
As	well	as	an	increased	excitatory	drive,	there	is	loss	of	inhibitory	control	from	local	
interneurons	and	descending	inhibitory	control	systems	originating	in	higher	cortical	centres	
(Millan,	2002).	The	imbalance	between	excitation	and	inhibition	creates	an	amplification	of	the	
transmission	of	action	potentials	from	peripheral	sensory	neurones	to	ascending	second	order	
neurones.	These	multiple	processes	contribute	to	central	sensitisation	(Latremoliere	and	Woolf,	
2009)	and	underpin	the	clinical	presentations	of	allodynia	(pain	as	a	result	of	innocuous	stimuli)	
and	spontaneous	pain	that	are	particularly	common,	with	neuropathic	pain	states.	
Similar	processes	of	increased	neuronal	excitation	and	reduced	inhibition	at	higher	cortical	
centres	are	thought	to	lead	to	the	conscious	experience	of	pain	(Tracey	&	Mantyh	2007;	Tracey	&	
Bushnell	2009;	Moseley	&	Vlaeyen	2015),	although	the	exact	processes	leading	to	conscious	
perception	are	far	from	being	fully	elucidated	(Thacker,	2015).	
This	story	is	one	that	builds	from	physics	of	molecular	interaction,	through	biochemistry	to	
biology	and	finally	to	the	person.	The	person	experiences	a	perception	of	pain	and	will	interact	
with	their	social	world	in	a	variety	of	ways	because	of	that	perception,	equally	their	social	world	
has	an	effect	on	their	perception	of	threat	and	pain	(Engel,	1978).	
1.2.2	PDN	presentation	and	diagnosis	
The	multiple	physiological	processes	lead	to	the	development	of	burning	pain	in	a	‘glove	
and	stocking’	distribution	that	is	usually	constant,	daily	and	moderate	to	severe	intensity	(Gore	et	
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al.,	2006;	Hoffman	et	al.,	2010;	Koroschetz	et	al.,	2011).	The	pain	is	often	not	related	to	physical	
activity	but	spontaneous	and	unpredictable;	it	is	often	worse	at	night	leading	to	disturbed	and	
inadequate	sleep	(Zelman,	Brandenburg	and	Gore,	2006).	PDN	is	associated	with	significant	
impact	on	physical	function	and	mobility	(Bair	et	al.,	2010)	as	well	as	poor	mood	state	and	quality	
of	life,	over	and	above	the	impact	of	diabetes	alone	(Zelman	et	al.,	2005).		
Clinicians	need	to	consider	differential	diagnoses	including	neuropathy	related	to	alcohol,	
vitamin	B12	deficiency,	neurotoxic	medications	(chemotherapies	and	anti-retroviral	medications)	
or	other	musculoskeletal	(nerve	root	pain)	and	vascular	causes	for	pain	(Doupis	et	al.,	2009;	
Hartemann	et	al.,	2011).	Clinical	examination	considers	the	function	of	small	diameter	
(temperature	and	light	touch)	and	large	diameter	(10g	monofilament	test	and	128Hz	tuning	fork)	
nerve	fibers.	Large	diameter	nerve	function	and	nerve	conduction	studies	can	be	normal	in	people	
with	PDN	(Hartemann	et	al.,	2011).	
1.2.3	PDN	prevalence	
PDN	affects	16-23%	of	people	with	DM	(Daousi	et	al.,	2004;	Veves,	Backonja	and	Malik,	
2008;	Hartemann	et	al.,	2011),	that	is,	approximately	600,000	people	in	the	UK.	The	prevalence	is	
higher	for	people	with	T2DM	(18%),	than	T1DM	(6%)	(Hartemann	et	al.,	2011).	There	is	concern,	
particularly	for	the	population	who	have	T2DM,	that	increasing	prevalence	of	DM	and	earlier	
development	of	prediabetes	states,	leads	to	longer	periods	of	time	for	the	person	to	develop	
microvascular	complications	because	of	hyperglycemic	physiological	consequences	(Alberti	and	
Zimmet,	2013).	
1.2.4	The	impact	of	PDN	
1.2.4.1	Severity	of	pain	
In	cross	sectional	studies	15-20%	of	participants	rated	their	pain	as	‘mild’,	47-57%	as	
‘moderate’	and	25-33%	as	‘severe’	(Davies	et	al.,	2006;	Tölle,	Xu	and	Sadosky,	2006).	A	survey	of	
patients	with	PDN	(n=255)	found	‘average	pain’	was	rated	as	mean	5.0	(SD2.5)/10,	and	‘worst	
pain’	rated	as	mean	5.6	(SD2.6)/10	(Gore	et	al.,	2006).	A	further	cross-sectional	study	found	
12.5%	of	those	with	PDN	had	never	disclosed	their	symptoms	to	a	clinician,	and	39.3%	had	never	
received	treatment	for	their	symptoms	(Daousi	et	al.,	2004).	This	suggests	that	PDN	may	have	
been	a	hidden	problem	when	this	study	was	conducted.	A	recent	audit	of	UK	pain	clinic	data	
found	neuropathic	pain	under-represented,	which	suggests	this	may	still	be	the	case	(BPS,	2012).		
1.2.4.2	Impact	on	mood	
Diabetes	is	associated	with	increased	prevalence	of	depression	and	anxiety	when	compared	
to	people	without	diabetes	(Collins,	Corcoran	and	Perry,	2009),	please	see	section	1.1.6	above.	
Persistent	pain	of	all	causes	is	associated	with	higher	prevalence	of	depression	(Campbell,	Clauw	
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and	Keefe,	2003)	and	anxiety	(McCracken	et	al.,	1999).	It	is	perhaps	not	surprising	that	the	
coexistence	of	both	DM	and	pain	is	positively	associated	with	depression	and	anxiety.		
Data	for	rates	of	anxiety	and	depression	from	a	PDN	study	(Gore	et	al.,	2006)	are	presented		
in	Table	1,	in	comparison	to	data	from	a	postal	survey	establishing	the	normative	data	for	the	
Hospital	Anxiety	and	Depression	Scale	(HADS)	outcome	measure	(Breeman	et	al.,	2015).	Both	
mood	states	are	notably	worse	in	the	PDN	cohort.	
Table	1	-	Comparative	Hospital	Anxiety	and	Depression	Scale	data	for	PDN	and	healthy	controls	
HADS	category	 %	Anxiety	 %	Depression	
	 PDN1	n=265	 HC2	n=6189	 PDN1	 HC2	
Normal	 38.0	 66.7	 48.2	 83.7	
Mild	 25.1	 17.0	 22.4	 9.5	
Moderate/Severe	 35.3	 16.1	 28.2	 6.9	
HADS	–	Hospital	Anxiety	and	Depression	Scale.	HC	–	Healthy	controls.	PDN	–	Painful	diabetic	
neuropathy.	1	Gore	et	al.	(2006),	2	Breeman	et	al.	(2015)	
	
1.2.4.3	Impact	on	function	
Studies	have	quantified	the	impact	of	PDN	on	function	using	a	range	of	outcome	measures.	
The	EuroQol	(EQ5D)	measure	of	health	status	asks	five	questions,	including	a	pain	rating	question,	
to	calculate	a	life	utility	score	between	0.0	(equates	to	death)	and	1.0	(equates	to	perfect	life	
utility).	Study	participants	rated	their	life	utility	as	0.59-0.63	(mild	pain),	0.43-0.52	(moderate	
pain)	and	0.2-0.25	(severe	pain)	(Currie	et	al.,	2006;	Tölle,	Xu	and	Sadosky,	2006).		
Other	studies	have	used	the	Brief	Pain	Inventory	(BPI)	as	an	indicator	of	function;	scores	
toward	10,	represent	a	greater	interference	of	pain	on	function.	The	results	of	three	studies	are	
detailed	in	Table	2.	Two	studies	are	presented	as	representative	of	PDN	research	(Galer,	Gianas	
and	Jensen,	2000;	Hoffman	et	al.,	2010),	and	a	third	comparison	study	that	used	the	BPI	with	
people	experiencing	low	back	pain	(LBP)	(Song	et	al.,	2016).	All	aspects	of	function	measured	by	
the	BPI	are	notably	worse	with	PDN	than	LBP.	The	domains	for	activity,	walking	and	sleep	quality	
have	been	consistently	rated	as	impaired	by	the	experience	of	PDN.	
Chapter	1	–	Introduction	
Page	-	15	
Table	2	-	PDN	impact	on	function	
BPI	subscales	 PDN	 LBP	
	 Galer,	Ginas	and	
Jensen	(2000)	n=105	
Mean	(SD)	
Hoffman	et	al.	(2010)	
n=400	
Mean	(SD)	
Song	et	al.	(2016)	
n=271	
Mean	(SD)	
General	activity	 4.33	(3.15)	 5.5	(2.5)	 2.03	(2.34)	
Mood	 4.04	(3.02)	 5.5	(2.7)	 3.25	(2.66)	
Walking	ability	 4.63	(3.13)	 5.6	(2.7)	 3.32	(2.61)	
Normal	work	 4.70	(3.21)	 5.1	(2.8)	 3.50	(2.77)	
Relationships	 3.13	(2.90)	 4.3	(2.8)	 1.76	(2.26)	
Sleep	 5.38	(3.25)	 5.5	(2.9)	 2.80	(2.88)	
Enjoyment	of	life	 5.00	(2.89)	 5.1	(2.8)	 2.69	(2.66)	
BPI	–	Brief	pain	inventory,	PDN	–	Painful	diabetic	neuropathy,	LBP	–	Low	back	pain	
	
The	SF36	outcome	measure	can	be	presented	as	physical	and	mental	composite	summary	
scores.	Scores	nearer	to	100	represent	higher	levels	of	function.	A	study	comparing	people	with	
PDN	(n=290)	to	matched	cases	with	diabetes	but	without	PDN	(n=1,037)	found	no	difference	in	
the	mental	composite	scores	(50.51	(PDN)	to	50.98	(DM),	p=0.24).	People	with	PDN	however,	
scored	significantly	lower	on	the	physical	composite	scale	(41.58	to	46.07,	p=0.0001)	
(DiBonaventura,	Cappelleri	and	Joshi,	2011).	
1.2.4.4	Impact	on	sleep	
Studies	investigating	sleep	found	PDN	was	associated	with	disturbed	sleep,	as	measured	by	
the	Sleep	Problems	Index,	and	with	reduced	sleep	quantity	and	adequacy.	The	impact	on	sleep	
was	significantly	greater	than	the	comparison	data	for	both	the	US	population	generally	(all	
p<0.001),	and	for	a	sample	with	chronic	pain	(all	p<0.001)	(Zelman,	Brandenburg	and	Gore,	2006).	
These	data	highlight	the	specific	impact	neuropathic	pain	appears	to	have	on	measures	of	sleep.	A	
recent	study	examined	the	associations	between	sleep	quality	(Medical	Outcome	Study	Scale	
(MOS))	and	mood	(HADS).	There	was	a	positive	association	between	sleep	disturbance	and	pain	
(r=0.40,	p<0.001)	and	between	sleep	disturbance	and	depression	(r=0.30,	p<0.001)	(Hughes	et	al.,	
2016).	
1.2.4.5	Impact	on	work	
People	with	PDN	are	no	more	likely	to	be	off	work	(absenteeism)	than	people	with	diabetes	
alone	(4.74%	to	3.49%,	p=0.28),	but	are	more	likely	to	self-evaluate	being	at	work,	but	unable	to	
fully	complete	their	job	role	(presenteeism)	(17.84%	to	13.52%,	p=0.022),	and	to	rate	themselves	
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as	having	overall	work	impairment	(19.77%	to	13.75%,	p=0.028)	(DiBonaventura,	Cappelleri	and	
Joshi,	2011).	
1.2.4.6	Impact	on	healthcare	systems	
A	number	of	studies	have	investigated	healthcare	costs	associated	with	PDN.	Data	have	
demonstrated	that	routine	and	emergency	medical	appointments,	and	the	cost	of	medication	
increase	in	line	with	pain	symptom	severity	(Alleman	et	al.,	2015).	Using	data	from	Tölle	et	al.	
(2006)	and	converting	to	2013	costs,	Alleman	et	al.	(2015)	demonstrated	yearly	healthcare	costs	
rising	from	€2,375	(mild	pain)	to	€3,795	(severe	pain).		
Using	2006-2008	data	from	Insurance	databases	in	the	USA,	DiBonaventura	et	al.	(2011)	
calculated	the	total	direct	(hospital/primary	care	visits)	and	indirect	costs	(lost	income	from	
absenteeism	and	presenteeism)	associated	with	PDN	to	be	$28,428	across	two	years,	($17,440	
diabetic	control	cases,	$15,981	healthy	control	cases).		
1.3	Current	management	for	PDN	
The	most	logical	strategy	for	preventing	PDN	would	be	to	reduce	neuropathy	from	
developing	in	the	first	place.	Research	investigating	enhanced	glucose	control	for	prevention	and	
treatment	of	neuropathy	have	been	systematically	studied	(Callaghan	et	al.,	2012).	Seven	studies	
investigated	T1DM.	The	homogeneity	of	two	high-quality	studies	allowed	the	conduct	of	meta-
analysis	(n=1,228),	the	results	of	which	showed	the	annualised	risk	difference	to	be	-1.84%	(CI	-
1.11	to	-2.56)	for	developing	clinical	neuropathy,	in	participants	using	enhanced	glucose	control	
approaches.	Eight	studies	focussed	on	T2DM,	four	studies	were	sufficiently	homogeneous	to	
allow	meta-analysis	(n=6,669),	demonstrating	a	risk	difference	of	-0.58%	(CI	0.01	to	-1.17),	
indicating	no	significant	difference	between	enhanced	glucose	control	and	usual	care.	The	
authors	recorded	secondary	outcome	data	of	adverse	events	rates.	Participants	in	the	enhanced	
glucose	control	intervention	arms	experienced	higher	rates	of	hypoglycaemic	episodes	(62	
episodes	requiring	assistance	per	100-patient	years,	compared	with	19	in	the	control	arms,	
p<0.001).	The	review	concluded	that	enhanced	control	appears	to	protect	against	the	
development	of	PDN		for	T1DM	more	so	than	T2DM,	but	the	increased	risk	of	hypoglycaemia	
needs	to	be	considered	(Callaghan	et	al.,	2012).		
When	PDN	has	been	diagnosed,	a	range	of	medication	options	are	recommended	(Bril	et	
al.,	2011;	NICE,	2010,	2013a;	NHS	BNSSG,	2012).	In	the	UK,	NICE	guidance	(NICE	2010)	for	PDN	
recommended	Duloxetine	as	first-line	therapy,	or	Amitriptyline	if	Duloxetine	was	contraindicated.	
Second-line	therapy	recommendations	were	to	switch	to	Amitriptyline	or	combine	with	
Pregabalin	if	Duloxetine	was	the	first-line	drug;	or	switch	to,	or	combine	with	Pregabalin	if	
Amitriptyline	was	the	first-line	drug.	If	suitable	pain	relief	was	not	achieved	with	second-line	
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drugs,	then	referral	to	specialist	units,	and	consideration	of	short-term	Tramadol	as	a	third-line	
drug	was	suggested.	Stronger	opiates	such	as	morphine	were	not	advised.		
The	American	Academy	of	Neurology	guidance	differed	slightly	to	that	from	NICE.	
Pregabalin	was	recommended	with	Level	A	evidence	(established	as	effective	in	at	least	two	Class	
1	studies	(high	quality	randomised	controlled	study	design))	and	Gabapentin,	Duloxetine	and	
Amitriptyline	with	Level	B	evidence	(probably	effective	in	at	least	one	Class	1	study	or	two	
consistent	Class	2	studies	(moderate	quality	randomised	controlled	study	design))	(Bril	et	al.,	
2011).		
For	the	UK	reader,	it	is	important	to	note	the	guidance	for	medication	had	evolved	between	
NICE	2010	and	NICE	2013	to	become	less	certain	and	prescriptive	(NICE,	2013a).	This	was	partly	
due	to	economic	reasons.	The	license	for	Pregabalin	ended	in	2014	thus	allowing	generic	
manufacture	and	so	a	reduced	cost.	In	addition,	Finnerup	et	al.	(2015)	in	a	comprehensive	meta-
analysis	found	the	‘number	needed	to	treat’	(NNT)	for	the	four	main	neuropathic	pain	
medications	ranged	from	3.6	(Amitriptyline)	to	7.7	(Pregabalin).	Furthermore	when	data	were	
examined	by	individual	case,	rather	than	by	population	average,	patients	were	found	to	either	
‘respond’	or	‘not	respond’	to	a	class	of	medication	(Moore,	Derry	and	Eccleston,	2013).	Response	
to	medication	does	not	follow	a	typical	bell-shaped	Gaussian	distribution	(Moore,	Derry	and	
Eccleston,	2013).	
The	current	guidance	from	NICE	(NICE	2013)	suggests	there	is	no	preferable	first	line	
therapy,	rather	clinicians	select	from	Amitriptyline,	Duloxetine,	Pregabalin	and	Gabapentin	
depending	on	contra-indications,	effectiveness	on	subsequent	patient	review	and	patient	
reported	side-effects.	There	are	a	sizeable	proportion	of	patients	with	PDN	who	do	not	
experience	adequate	management	of	pain	symptoms,	or	the	consequent	impacts,	with	these	
drugs	(Moore,	Derry	and	Eccleston,	2013;	Finnerup	et	al.,	2015).	
If	successful	management	of	pain	symptoms,	and	its	impacts,	is	not	achieved	with	the	
recommended	drugs,	NICE	recommend	referral	on	to	specialist	pain	services.		
1.3.1	Current	research	programmes	for	PDN	treatment	
There	are	research	programmes	currently	underway,	investigating	novel	approaches	to	
PDN	management.	Spinal	cord	stimulation	has	been	explored	in	a	multi-centre	randomised	trial	
(de	Vos	et	al.,	2014).	Sixty	patients	with	PDN	were	randomised	2:1	into	the	stimulation	arm	or	the	
control	arm.	These	arms	were	similar	for	social	and	clinical	variables	at	baseline	but	potential	
participants	with	depression	were	excluded.	Studies	have	found	half	the	population	(52%)	with	
PDN	were	rated	depressed	to	some	degree,	and	28%	as	moderate	to	severely	depressed	(Gore	et	
al.,	2006).	This	exclusion	criterion	raises	the	possibility	that	the	study	participants	do	not	
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accurately	represent	the	population	with	PDN.	At	six-month	follow	up	there	had	been	no	
significant	change	in	control	arm	pain	scores	(Visual	Analogue	Scale	(VAS)	mean	67(SD18)	to	
67(SD21),	non-significant)	but	a	significant	decrease	in	the	intervention	arm	(mean	73(SD16)	to	
31(SD28),	p<0.001).	In	the	intervention	arm,	25/40	(60%)	participants	experienced	>50%	pain	
reduction.		
A	randomised,	placebo	controlled	study	investigated	the	efficacy	of	inhaled	cannabis	for	
PDN	(Wallace	et	al.,	2015).	Using	tetrahydrocannabinol	(THC)	of	different	strengths	(1%,	4%	and	
7%)	delivered	by	aerosol,	the	study	found	reductions	in	spontaneous	pain	of	63.8%	(SD37.0)	(1%,	
non-significant),	64.8%	(SD36.0)	(4%,	p<0.10)	and	69.0%	(SD32.0)	(7%,	p<0.05),	when	compared	
to	placebo	inhalant	(52.8%	(SD40.0).	The	study	was	small	(n=16)	and	participants	were	
randomised	between	THC	and	placebo	arms.	The	study	had	a	short	follow	up,	measuring	effects	
to	three	hours	from	first	dose.	The	participants	who	were	delivered	the	7%	THC	dose	performed	
least	well	on	three	neurocognitive	tasks.		
Two	studies	investigating	Botulinum	toxin-A	(BTX-A)	efficacy	for	PDN	were	included	in	a	
recent	meta-analysis	(Lakhan,	Velasco	and	Tepper,	2015).	Both	studies	injected	BTX-A	into	12	
sites	in	a	grid	pattern	on	the	dorsum	of	the	participants’	feet.	The	toxin	is	absorbed	by	the	
afferent	neurones	and	transported	to	the	synapse	in	the	dorsal	horn.	BTX-A	inhibits	the	release	of	
various	neurotransmitters	at	the	dorsal	horn	synapse,	notably	the	excitatory	amino	acid	
glutamate.	The	two	studies	were	double	blinded,	with	one	a	crossover	design	(Yuan,	Sheu	and	Yu,	
2009)	and	the	second	a	placebo-controlled	design	(Ghasemi,	Ansari	and	Basiri,	2014).	Participant	
numbers	were	small	(n=18	and	n=20).	The	meta-analysis	showed	that	BTX-A	resulted	in	reduced	
pain	on	a	VAS	by	-1.96	points	(CI	-3.09	to	-0.84,	p<0.001)	at	the	four-week	follow	up.	There	was	
one	adverse	event	reported	of	an	injection	site	infection.	
A	systematic	review	of	psychological	therapies	for	neuropathic	pain	in	adults,	found	nine	
studies	listed	in	trials	registers	as	currently	underway	but	results	were	not	yet	available	
(Eccleston,	Hearn	and	Williams,	2015).	
1.4	Current	concepts	and	models	for	pain	–	A	short	history	
This	thesis	will	explore	the	lived	experience	of	physical	pain	in	people	with	PDN.	Pain	is	a	
complex	experience	that	goes	to	the	heart	of	our	understandings	of	perception	and	
consciousness.	There	have	been	key	stages	of	development	to	our	present	knowledge	of	pain	
mechanisms	that	will	be	outlined.	The	description	of	these	developments	will	allow	an	
appreciation	for	the	state	of	the	art	in	pain	research,	and	also	highlight	the	interdependence	
between	clinical	and	basic	science	research.			
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The	word	pain	can	be	traced	to	the	French	peine,	and	further	to	the	Latin	poena,	which	
translates	as	penalty	or	punishment.	Prior	to	the	Middle	ages,	little	was	known	about	the	
physiology	of	pain,	but	the	experience	of	pain	was	considered	as	a	punishment	from	God,	for	sins	
committed	(Lewis,	1940).	
Introductions	to	pain	often	start	with	the	French	philosopher	and	mathematician	René	
Descartes	(1596-1650).	In	Treatise	of	Man	(1664),	Descartes	described	a	pathway	between	
peripheral	stimuli	to	the	body	and	the	pineal	gland	in	the	brain,	where	he	proposed	all	conscious	
thought	and	experience	resided	(see	Figure	3	below).	The	division	between	body	and	brain,	
Cartesian	Dualism,	allowed	scientists	to	research	these	pathways	in	greater	detail	while	allowing	
the	Church	to	retain	ownership	of	the	soul	(Sullivan,	2008).	Although	350	years	old,	Dualism	can	
still	be	seen	in	both	academic	and	popular	science	writing	about	pain.	It	is	common	to	see	
diagrams	labelled	with	pain	receptors,	pain	nerve	fibres,	and	pain	centres	in	the	brain.	These	
diagrams	have	the	implication	that	pain	is	external	to	the	corporeal	body,	sensed	by	pain	
receptors	and	then	transmitted	into	the	brain	along	pain-specific	nerve	pathways.	
Figure	3	-	Rene	Descartes	model	of	pain	-	Treatise	of	Man	(1664)	(copyright	permission	not	required).		
A	significant	development	came	in	1965	with	Melzack	and	Wall	publishing	the	Gate	Control	
Theory	of	Pain	(Melzack,	1999).	The	Gate	Control	Theory	(Figure	4)	demonstrated	how	
descending	neural	messages	from	higher	limbic	brain	centres	(L),	were	able	to	excite	spinal	gate	
neurones	(SG).	An	increased	discharge	from	SG	neurones,	would	lead	to	inhibition	of	the	
incoming	sensory	(S)	information	at	the	synapses	in	the	spinal	cord.	This	model	highlighted	that	
the	experience	of	pain	was	not	solely	dependent	on	peripheral	stimuli,	but	that	higher	centres	of	
the	brain	had	the	capacity	to	attenuate	the	peripheral	stimuli,	both	in	an	inhibitory	or	facilitatory	
manner.	Wall	argued	that	this	explained	many	of	the	inconsistencies	between	pain	and	injury	
observed	in	clinical	practice	(Wall,	1999).		
Although	the	Gate	Control	Theory	was	significant	in	moving	pain	science	forward	by	giving	
the	brain	more	than	a	role	as	passive	receiver	of	pain,	Melzack	was	clear	the	theory	was	not	
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sufficient	to	explain	all	clinical	pain	presentations	(Melzack,	1990,	1999,	2005).	He	highlighted	
that	this	model	did	not	account	for	the	pain	people	experienced	after	a	stroke	or	the	phantom	
pain	that	could	exist	even	in	congenital	missing	limbs.	
Figure	4	-	Melzack	and	Wall,	Gate	Control	Theory	1965	(Melzack	1999)	(reproduced	with	permission)	
L	–	Limbic	system,	S	–	sensory	system,	SG	–	Spinal	gate	neurone,	T	–	Thalamic	relay	neurone,	+	-	
excitation,	-	inhibition.	
1.4.1	The	Mature	Organism	Model		
The	next	phase	in	the	development	of	comprehensive	models	for	pain	came	from	Louis	
Gifford,	with	the	publication	of	the	Mature	Organism	Model	(MOM)	(Gifford,	1998a)	and	from	
Melzack,	with	the	publication	of	the	Pain	Neuromatrix	model	(Melzack,	2001).		
Gifford’s	MOM	(see	Figure	5	below)	contains	an	input	arm,	where	the	organism	(person)	is	
continually	sampling	from	itself	(tissues)	and	from	the	environment.	The	sampled	information	is	
then	scrutinised	by	the	brain	and	given	weight	dependent	on	that	person’s	life	experience	-	how	
dangerous	is	this	situation?	Is	there	tissue	damage	present?	What	strategies	have/have	not	
worked	in	the	past?	This	central	decision-making	process	leads	to	a	variety	of	outputs	that	include	
pain	experience,	motor	system,	cognitive	system,	stress	system	and	behavioural	changes	that	are	
deemed	most	appropriate	for	survival	and	the	restoration	of	homeostasis.	Gifford	described	this	
as	a	‘Mature’	organism	model,	because	the	persons’	life	experiences	sculpt	the	scrutinising	and	
weighting	process	toward,	or	away	from,	a	range	of	behaviours.	The	selected	behaviours	give	
feedback	into	the	process	of	scrutiny.	In	clinical	practice	this	means	the	person’s	pain	experience	
and	other	system	outputs	cannot	be	divorced	from	the	narrative	of	their	life.		
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Figure	5	-	Mature	Organism	Model	(Gifford	1998)	(reproduced	with	permission).	
	
1.4.2	The	Neuromatrix	Theory	
Melzack	published	the	Neuromatrix	theory	at	a	similar	time	to	Gifford’s	MOM	(Melzack,	
1999).	The	Neuromatrix	(see	Figure	6	below)	includes	input	from	the	body	(cutaneous,	visual,	and	
vestibular	inputs),	other	physiological	systems	(immune	system	and	stress	system)	and	from	the	
person’s	life	(culture,	past	experiences).	This	information	is	processed	in	the	central	part	of	the	
model,	and	from	this	processing	emerges	a	range	of	outputs.	These	outputs	include	the	
experience	of	pain	with	its	sensory,	cognitive	and	affective	components.	These	outputs	include	
motor	action	programmes	(behaviours)	and	adaptations	within	the	immune	and	stress	regulatory	
systems.		
The	Neuromatrix	is	abstract	and	conceptual;	Melzack	did	not	suggest	precise	anatomical	
locations.	The	Neuromatrix	should	not	be	conflated	with	an	anatomically	located	Pain	Matrix	
(Tracey	and	Johns,	2010).	While	regions	of	the	brain	have	been	implicated	in	the	processing	of	
threat	and	pain	(Tracey	and	Mantyh,	2007;	Tracey	and	Bushnell,	2009),	these	same	regions	are	
also	implicated	in	the	processing	of	pleasure	(Leknes	and	Tracey,	2008).	
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Figure	6	-	The	Neuromatrix	Theory	(Melzack	2001)	(reproduced	with	permission)	
A	–	affective	processing,	C	–	cognitive	processing,	S	–	sensory	processing	
Although	with	different	textual	descriptions	and	schematic	diagrams,	the	MOM	and	the	
Neuromatrix	theory	display	similar	ideas	about	the	complexity	of	pain.	An	important	distinction	to	
previous	models	is	they	place	pain	as	an	output,	rather	an	input.	Said	in	another	way,	pain	is	
created	by	the	synchronous	activity	of	multiple	immune	and	neural	systems,	and	is	experienced	
by	the	person	(Thacker	and	Moseley,	2012).	These	models	both	identify	that	pain	perception	does	
not	occur	in	isolation,	but	as	part	of	a	response	that	includes	other	systems.	This	symphony	of	
responses	is	dependent	on	the	situational	context,	the	salience	and	meaning	the	person	
subconsciously	gives	to	that	situation	(Iannetti	and	Mouraux,	2010;	Moseley	and	Flor,	2012).	
Further,	these	responses	are	sculpted	by	the	success	and	failures	that	we	all	experience	through	
life.		
The	recursive	nature	of	these	models	can	explain	why	some	output	responses	may	become	
inappropriate	for	the	context	of	the	person	in	pain.	These	responses	may	have	been	adaptive	in	
the	short	term	around	the	time	of	an	injury,	but	have	become	maladaptive	in	the	long	term	when	
that	tissue	injury	has	healed	(Moseley,	2007;	Chapman,	Tuckett	and	Song,	2008).	These	models	
and	theories	add	support	to	the	biopsychosocial	approach	to	persistent	pain	(Engel,	1978).	
1.5	Pain	management	programmes		
Integrated	biopsychosocial	models	such	as	the	MOM	and	Neuromatrix	are	helpful	when	
treatments	aimed	at	pain	reduction	are	unsuccessful.	Pain	management	programmes	(PMPs)	aim	
to	help	individuals	live	well	with	pain	and	typically	involve	multidisciplinary	clinical	teams	of	
medics,	psychologists,	physiotherapists,	occupational	therapists	and	nurses	(BPS,	2013).	The	
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specific	team	mix	varies	dependent	on	the	PMP	provider.	Despite	their	name,	programmes	tend	
to	focus	on	quality	of	life,	rather	pain	reduction	(Moseley	and	Butler,	2015).	
A	recent	systematic	review	of	multidisciplinary	PMPs	for	LBP	included	41	studies	(n=6,858	
participants)	(Kamper	et	al.,	2015).	All	included	studies	compared	multidisciplinary	PMPs	against	
non-multidisciplinary	approaches.	The	authors	concluded	PMPs	reduce	pain	by	a	standardised	
mean	difference	(SMD)	of	-0.21	(CI	-0.04	to	-0.37,	p=0.01),	this	was	calculated	as	equivalent	to	a	
0.5-point	reduction	on	a	10-point	scale	for	pain.	The	PMPs	also	reduced	disability	by	a	SMD	-0.23	
(CI	-0.06	to	-0.40,	0=0.007).	They	found	evidence	that	attending	a	PMP	increased	the	likelihood	of	
being	in	work	at	one	year	by	odds	ratio	1.87	(CI	1.39	to	2.53,	p<0.001).		
The	British	Pain	Society	(BPS,	2013)	recommend	multidisciplinary	teams	of	clinicians	are	the	
“treatment	of	choice	for	people	who	experience	persistent	pain	that	is	adversely	affecting	their	
quality	of	life	and	where	there	is	significant	impact	on	physical,	psychological	and	social	function”	
(Executive	summary	1.2-1.2).	This	recommendation	was	based	on	evidence	from	high	quality	
randomised	trials	and	systematic	reviews	of	pain	management	research,	including	meta-analysis	
of	outcome	data,	graded	1++	in	the	Scottish	Intercollegiate	Guideline	Network	level	of	evidence.	
The	British	Pain	Society	recommends	that	the	content	of	the	PMP	should	include	education	
on	pain	mechanisms,	general	health	and	self-management	strategies,	guided	practice	of	exercise	
and	challenge	to	unhelpful	beliefs,	behaviours	and	habits	that	may	contribute	to	disability	(BPS,	
2013).	The	key	recommended	interventions	are	physical	rehabilitation	and	psychologically	
focussed	treatment	-	these	will	be	examined	in	more	detail	in	the	following	sections	(section	1.5.1	
and	1.5.2).	Other	topics	within	PMPs	can	include	sleep	strategies,	stress	management	strategies	
and	communication	skills	training.	The	curriculum	of	PMPs	are	often	based	on	the	particular	
interests	of	clinicians	involved	in	their	inception	and	delivery	(Ehde,	Dillworth	and	Turner,	2014).	
The	British	Pain	Society	acknowledges	that	a	variety	of	course	content,	intensity	and	delivery	
formats	have	been	implemented	and	researched.	
1.5.1	Physical	activity	in	PMPs	
Central	tenets	of	PMPs	are	strategies	of	graded	physical	activity	or	exercise.	The	physical	
approach	aims	to	promote	cardiovascular	fitness	and	functional	capacity	that	will	allow	a	person	
to	achieve	goals	and	valued	life	activity.	This	may	be	a	graded	increase	in	day-to-day	activity,	or	a	
structured	exercise	program.	Exercise	may	include	hydrotherapy,	Tai	Chi-type	movement,	
cardiovascular	exercise	or	resistance	strength	training.	There	is	uncertainty	about	what	type	of	
exercise	is	optimal	for	pain.	A	recent	systematic	review	of	muscle	stabilisation	exercises	for	the	
management	of	LBP	found	this	specific	approach	to	be	effective	for	reducing	pain	(VAS)	when	
compared	to	alternative,	non-physical	exercise	treatments	(pain	reduction	(0-100	scale)	mean	-
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6.39	(CI	-10.14	to	-2.65)).	When	stabilisation	exercises	were	compared	with	other	exercise	
approaches,	the	reduction	in	pain	was	non-significant	(pain	reduction	mean	-3.06	(CI	-6.74	to	
0.63))	(Smith,	Littlewood	and	May,	2014).	Although	statistically	significant	the	absolute	reduction	
in	pain	did	not	approach	the	minimal	clinically	important	difference	for	pain	(reduction	of	24-40	
on	0-100	scale)	(Smith,	Littlewood	and	May,	2014).	
A	Cochrane	overview	of	physical	activity	and	exercise	for	chronic	pain	of	all	causes	was	
recently	published	(Geneen	et	al.,	2017).	Twenty-one	reviews	(381	studies)	were	pooled	covering	
a	range	of	pathologies	associated	with	persistent	pain,	which	included	rheumatoid	arthritis,	
osteoarthritis	and	spinal	disorders	amongst	others.	PDN	was	not	a	specific	pathology	but	
neuropathic	pain	was	represented	by	the	inclusion	of	fibromyalgia	syndrome	(FMS),	post-polio	
syndrome	and	spinal	cord	injury.	The	authors	included	any	form	of	physical	exercise,	and	specified	
reported	pain	severity	as	the	primary	outcome	with	physical	and	psychological	function	and	
quality	of	life	as	secondary	outcomes.	The	included	primary	studies	were	often	small,	with	
223/264	(84%)	having	<50	participants	per	study	arm.	It	has	been	suggested	that	studies	should	
aim	to	recruit	more	than	50	participants	(100	in	total	in	a	2-arm	study)	to	minimise	bias	from	
regression	to	the	mean	(Moore	et	al.,	2010).	Most	studies	also	lacked	long-term	follow	up	beyond	
six-months.		
Most	of	the	included	reviews	demonstrated	beneficial	effects	of	exercise	on	pain	severity,	
but	these	results	have	inconsistencies	between	the	exercise	interventions,	participant	pathology	
and	follow-up	time	points.	Other	than	transient	soreness	after	exercise,	no	reviews	reported	
worsening	of	pain	following	exercise	protocols.	There	were	more	consistent	improvements	in	
measures	of	physical	function	and	health-related	quality	of	life.	Fourteen	of	the	21	reviews	found	
statistically	significant	improvements	in	physical	function	and	these	had	small	to	moderate	effect	
sizes	(Geneen	et	al.,	2017).	The	conclusion	was	that	physical	exercise	appears	to	benefit	function	
and	quality	of	life	for	those	with	persistent	pain,	and	may	improve	pain	severity.		
1.5.2	Psychological	treatment	in	PMPs	
An	equally	important	central	tenet	of	PMPs	is	strategies	to	help	people	deal	with	the	
psychological	distress	that	can	occur	alongside	on-going	pain.	This	distress	can	include	stress,	
anger,	guilt,	depression,	anxiety	or	a	combination	of	the	above.	Distress	can	manifest	in	
maladaptive	behaviours,	such	as	avoidance	and	social	withdrawal,	which	may	further	reduce	
physical	fitness,	mood	state	and	social	contact	(Vlaeyen	and	Linton,	2000).	Psychological	coping	
strategies	aim	to	help	people	develop	psychological	and	behavioural	techniques	to	mitigate	these	
manifestations	of	distress,	and	so	improve	their	pain	experience	and	overall	quality	of	life	(BPS,	
2013).	Clinical	practice	and	research	are	most	often	based	on	principles	of	Cognitive	Behavioural	
Therapy	(CBT)	and	Acceptance	and	Commitment	Therapy	(ACT).	
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The	goals	of	CBT	have	been	described	as	“to	reduce	pain	and	psychological	distress	and	to	
improve	physical	and	role	function	by	helping	individuals	decrease	maladaptive	behaviours,	
increase	adaptive	behaviours,	identify	and	correct	maladaptive	thoughts	and	beliefs,	and	increase	
self-efficacy	for	pain	management”	(Ehde,	Dillworth	and	Turner,	2014).	A	recent	Cochrane	review	
for	psychological	therapies	for	chronic	pain	found	42	eligible	studies	(Williams,	Eccleston	and	
Morley,	2012).	These	randomised	trials	were	with	adults	and	had	used	recognised	psychological	
frameworks	or	models	in	their	intervention	arm.	The	review	found	CBT	had	a	small	effect	on	pain	
reduction	when	compared	to	treatment-as-usual	at	the	end	of	the	treatment	course	(SMD)	-0.21	
(CI	-0.37	to	-0.05,	p<0.05)).	This	effect	was	not	significant	at	longer-term	follow	up.	The	authors	
found	CBT	had	a	beneficial	effect	on	mood	at	the	end	of	treatment	(SMD	-0.38	(CI	-0.57	to	-0.18,	
p<0.01))	though	this	effect	became	non-significant	at	long	term	follow	up	(SMD	-0.26	(CI	-0.51	to	
0.00,	p=0.05)).	Lastly,	they	found	CBT	reduced	disability	(SMD	-0.19	(CI	-0.33	to	-0.05,	p<0.01),	
and	although	this	effect	was	reduced	at	longer	term	follow	up	it	remained	significant	(SMD	-0.15	
(CI	-0.28	to	-0.02,	p<0.05).	There	was	no	effect	when	active	treatment	(for	example,	exercise	
programme	or	pain	related	education)	was	the	comparator	arm.		
Williams,	Eccleston	and	Morley	(2012)	concluded	that	CBT	demonstrated	small	benefits	on	
pain,	mood	and	disability	immediately	post-treatment	when	compared	against	treatment	as	
usual.	They	suggested	future	research	should	not	examine	outcome	changes	at	the	group	level,	
but	focus	on	trying	to	establish	what	features	of	CBT	are	effective	for	which	patient	groups,	and	
on	which	outcome	domains.	
The	other	psychological	approaches	used	in	PMPs	are	ACT	which	has	developed	from	CBT,	
and	Mindfulness-based	stress	reduction	(MBSR)	(Morley	and	Williams,	2015).	ACT	focuses	on	
accepting	pain	and	related	cognitions,	rather	than	trying	to	challenge	and	reappraise	these,	as	
with	CBT	(Veehof	et	al.,	2011;	McCracken	and	Vowles,	2014).	ACT	aims	to	help	people	use	their	
resources	(time,	energy,	motivation)	in	living	towards	important	life	values,	and	to	reduce	
behaviours	that	try	to	change	the	unchangeable.	Values	differ	from	goals	in	being	unobtainable	
yet	central	to	the	person’s	core	sense	of	self	(for	example,	being	a	perfect	parent	is	unobtainable)	
(McCracken	and	Yang,	2006).	MBSR	has	origins	in	Buddhist	teachings.	Similar	to	ACT,	MBSR	
emphasises	being	present	with	pain,	rather	than	fighting	the	experience.		
A	systematic	review	included	19	eligible	studies	investigating	ACT	and	MBSR	in	the	
management	of	chronic	pain	(Veehof	et	al.,	2011).	Ten	controlled	studies	(randomised	and	non-
randomised	methods)	were	included	in	meta-analyses.	The	interventions	were	compared	against	
waitlist,	treatment	as	usual	or	educational	interventions.	For	pain	severity,	the	results	showed	a	
moderate	effect	size	of	SMD	0.37	(CI	0.20	to	0.53,	p<0.01)	favouring	the	intervention	arms.	The	
effect	on	overall	quality	of	life	(n=6	studies)	was	found	to	have	SMD	0.41	(CI	0.16	to	0.65,	p<0.01)	
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favouring	the	intervention	arms.	Key	researchers	in	the	field	suggest	the	literature	relating	to	CBT	
and	ACT	approaches	to	pain	are	reaching	a	level	of	maturity	(McCracken	and	Thompson,	2011).	
Rather	than	future	studies	comparing	active	treatment	to	placebo	or	treatment	as	usual,	to	
investigate	whether	the	individual	approach	is	effective,	studies	should	focus	on	elucidating	which	
approach	works	for	whom	(Vlaeyen	and	Morley,	2015).	
The	Cochrane	review	(Williams,	Eccleston	and	Morley,	2012)	described	above,	included	
pain	of	many	causes	and	pathologies.	This	breadth	of	presentations	and	pathologies	may	cause	
meaningful	changes	within	some	participant	sub-groups	to	be	obscured.	Authors	have	suggested	
that	considering	all	chronic	pain	as	homogenous	is	an	important	error	and	that	efforts	should	
focus	on	understanding	how	different	people,	or	different	underlying	pathologies	may	react	
differently	to	the	same	intervention	(Turk	and	Okifuji,	2003;	Turk,	2005).	This	would	allow	more	
patient-specific	delivery	of	treatments.		
1.5.3	Should	people	with	neuropathic	pain	be	considered	a	distinct	subgroup?	
It	could	be	appropriate	to	consider	neuropathic	pain	as	a	distinct	subgroup	for	a	number	of	
reasons.	Neuropathic	pain	has	associations	with	defined	disease	processes,	for	example,	multiple	
sclerosis	(MS),	alcoholic	neuropathy	and	PDN;	or,	as	a	side-effect	of	specific	treatments,	for	
example,	radiotherapy-induced	neuropathy,	chemotherapy-induced	neuropathy	and	neuropathy	
due	to	anti-retroviral	treatments	for	human	immunodeficiency	virus.	This	specificity	is	in	contrast	
to	non-specific	diagnostic	labels	used	for	LBP,	whiplash	associated	disorder	and	FMS	(Daniel	and	
Van	der	Merwe,	2006).	Neuropathic	pain	has	different	symptom	profiles	(unpredictable,	burning	
quality,	often	worse	at	night),	than	either	nociceptive	pain	mechanisms	(predictable	provocation,	
dull	ache,	lack	of	sleep	disturbance)	or	central	pain	mechanisms	(diffuse	non-anatomical	
locations,	pain	disproportionate	to	nature	and	extent	of	tissue	dysfunctions,	strong	association	
with	maladaptive	psychosocial	factors)	(Smart	et	al.,	2012a,	2012c,	2012b).	The	series	of	studies	
by	Smart	et	al.	(2012a,	b	and	c)	used	Delphi	survey	techniques	to	reach	consensus	from	clinical	
experts	on	the	presenting	patterns	for	these	pain	mechanisms.	The	authors	were	clear	to	
highlight	that	patients	do	not	present	with	pain	purely	from	one	mechanistic	process,	but	they	
were	on	a	continuum	from	mostly	tissue	based	(very	acute	injury	pain)	to	mostly	central	process	
based	(post-stroke	pain)	(Smart	et	al.,	2010).			
Differences	have	been	demonstrated	between	patient	presentations	of	neuropathic	and	
nociceptive	pain.	A	study	compared	the	profile	of	people	with	mechanical	LBP	(n=57),	considered	
a	model	of	nociceptive	pain,	against	post-herpetic	neuralgia	(PHN)	as	a	model	of	neuropathic	pain	
(n=49)	(Daniel	et	al.,	2007).	Logistic	regression	showed	that	having	pain	aggravated	by	touch	and	
air	movement	were	predictive	of	belonging	to	the	PHN	group.	Allodynia	(pain	on	light	tough)	was	
experienced	by	32%	of	the	PHN	group	but	none	of	the	LBP	group.	Pacing,	a	standard	approach	to	
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the	management	of	LBP,	had	not	been	found	useful	by	any	respondents	with	PHN.	The	PHN	group	
were	significantly	more	likely	to	describe	the	cause	of	their	pain	as	‘nerve	damage’,	whereas	the	
LBP	group	were	more	ambiguous	in	their	answers,	or	stated	they	did	not	know	the	cause.		
Martin	et	al.	(2014)	researched	the	issues	of	patient	belief	about	pain.	Using	Q-
methodology	they	explored	how	patients	with	neuropathic	pain	conceived	of	the	causes	and	
impacts	of	their	pain	and	outlined	three	factors	of	shared	subjective	experience	relevant	to	this	
thesis.	Participants	in	factor	1	conceived	neuropathic	pain	as	due	to	nervous	system	dysfunction,	
stated	that	psychology	had	an	impact	on	the	experience	and	were	open	to	psychologically	
directed	treatments.	Participants	in	factor	2	conceived	neuropathic	pain	as	due	to	nervous	system	
dysfunction,	rejected	psychological	factors	as	relevant	to	their	pain	experience	and	were	neutral	
to	psychologically	directed	treatments.	Participants	in	factor	3	felt	nerve	damage	was	irreparable,	
reported	psychological	factors	were	relevant	to	their	pain,	but	rejected	psychologically	directed	
treatments	as	relevant.	People	with	PDN	have	a	diagnostic	label	for	the	cause	of	their	pain,	and	it	
is	of	interest	to	explore	openness	(or	lack	of)	to	psychological	approaches.		
It	is	accepted	that	neuropathic	pain	presents	differently	to	musculoskeletal	pain	(Haanpää	
et	al.,	2011).	Despite	this,	previous	Cochrane	reviews	of	psychological	therapy	included	pain	of	all	
causes,	except	headaches	(Williams,	Eccleston	and	Morley,	2012).	Eccleston,	Hearn	and	Williams,	
(2015)	therefore	conducted	a	systematic	review	specifically	investigating	psychological	therapy	
for	neuropathic	pain	conditions.	Two	studies	were	included	in	the	review,	each	with	a	high	degree	
of	bias,	resulting	in	no	recommendations	for	treatment	(Eccleston,	Hearn	and	Williams,	2015).		
The	modest	treatment	effect	sizes	found	across	pain,	mood	and	disability	outcomes	could	
be	considered	a	reason	to	abandon	psychological	therapies	for	pain.	Leading	authors	in	the	field	
suggest	future	research	should	measure	how	credible	participants	deem	the	intervention	to	be	as	
well	as	their	expectations	of	the	intervention	(Vlaeyen	and	Morley,	2015).	The	modest	treatment	
effects	observed	might	be	partially	due	to	some	participants	having	a	low	expectation	of	the	
intervention	and	not	considering	it	credible	or	related	to	the	problems	they	experience.		
There	is	evidence	that	neuropathic	pain	is	different	in	its	clinical	presentation,	particularly	
considering	nocturnal	pain	and	spontaneous	flare.	People	with	primary	neuropathic	pain	are	not	
frequently	referred	to	PMPs	(Daniel	et	al.,	2015)	and	the	clinical	experience	of	the	researcher	and	
others,	suggests	not	all	standard	PMP	strategies	are	appropriate	for	neuropathic	pain	problems.	
People	with	neuropathic	pain	hold	a	range	of	beliefs	regarding	pain	and	whether	psychological	
state	is	relevant	to	the	problems	they	experience	(Martin,	Daniel	and	Williams,	2014).	This	range	
of	beliefs	will	affect	whether	psychological	interventions	are	deemed	credible	and	acceptable.	It	is	
therefore	appropriate	to	explore	these	issues	with	people	who	experience	PDN.	
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1.6	Purpose	of	the	thesis	
1.6.1	Thesis	rationale	
There	are	evidenced	guidelines	for	the	pharmacological	management	of	neuropathic	pain	
(NICE,	2010,	2013a)	and	PDN	specifically	(Bril	et	al.,	2011).	These	guidelines	do	not	fully	concur	
resulting	in	clinical	uncertainty	(Spallone,	2012).	Previous	research	has	shown	that	patients	with	
PDN	are	frequently	taking	analgesia	not	recommended	within	these	guidelines	(over	the	counter	
anti-inflammatories),	and	even	when	they	are	taking	recommended	medication	their	ratings	for	
satisfaction	and	effectiveness	are	low	(Gore	et	al.,	2006).		
Although	PMPs	have	been	shown	to	be	clinically	and	cost	effective	for	the	management	of	
musculoskeletal	persistent	pain	(Gatchel	and	Okifuji,	2006;	Williams,	Eccleston	and	Morley,	2012),	
it	is	unclear	whether	the	strategies	contained	within	them	are	appropriate	for	the	person	with	
PDN	or,	if	the	person	with	PDN	would	be	inclined	to	attend	such	a	programme.	Clinicians	involved	
with	PMPs	identify	that	people	with	PDN	are	infrequently	referred	and	strategies	may	not	be	
appropriate	to	neuropathic	pain	(Daniel	et	al.,	2015).	Beyond	medication,	physical	exercise	and	
psychological	coping	strategies,	there	are	limited	evidenced	therapeutic	options	for	persistent	
pain	and	associated	impacts,	so	the	strategies	available	need	to	be	as	tailored	and	specific	as	
possible.	
1.6.2	Thesis	aims	
1) To	conduct	a	systematic	literature	review	of	the	evidence	investigating	physical	activity	
and	psychological	coping	strategies,	in	the	management	of	PDN.		
2) To	explore	peoples’	experiences	of	living	with	and	self-managing	PDN,	and	their	
perspectives	on	physical	activity	and	psychological	coping	strategies	for	PDN	
management.	
3) To	explore	specialist	clinicians’	current	strategies	for	management	of	PDN	(as	one	form	of	
diabetic	complication),	and	their	perspectives	on	physical	activity	and	psychological	
coping	strategies	for	PDN	management.	
4) To	explore	which	impacts	of	PDN	people	prioritise	for	improved,	or	alternative,	
management	strategies.	
1.6.3	Thesis	objectives	
1) To	source	and	critically	appraise	the	current	research	that	investigates	physical	activity	
and	psychological	coping	strategies	in	the	management	of	PDN	(Chapter	2).	
2) To	conduct	semi-structured	interviews	with	people	who	experience	PDN	finding	out	how	
PDN	impacts	on	their	lives	and	how	they	currently	manage	(Chapters	3	and	4).	
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3) To	explore	within	those	interviews	the	participant	perspectives	on	physical	activity	and	
psychological	coping	strategies	for	the	management	of	PDN	(Chapters	3	and	4).	
4) To	explore	using	semi-structured	interviews	how	clinicians	currently	view	management	
strategies	for	PDN,	and	to	explore	their	perspectives	on	activity	and	pain	coping	strategies	
for	the	management	of	PDN	(Chapters	3	and	5).	
5) To	conduct	an	Internet	survey	investigating	which	of	the	impacts	of	PDN,	generated	by	
the	patient	interview	study,	respondents	would	prioritise	for	better	management	
(Chapter	6).	
1.7	Researcher	perspective	
1.7.1	Prior	Knowledge	
The	researcher	had	been	a	full-time	clinical	physiotherapist	in	the	NHS	for	twelve	years.	The	
majority	of	this	time	has	been	spent	in	musculoskeletal	outpatients,	specialising	in	management	
of	people	with	persistent	pain.	The	researcher	has	been	involved	in	delivering	multidisciplinary	
PMPs	and	physiotherapy-led	pain	coping	skills	courses.	The	pain	coping	skills	courses	do	not	have	
the	expertise	of	a	clinical	psychologist	involved	and	the	eligibility	criteria	include	mild	to	moderate	
depression	and	anxiety,	alongside	the	pain	problem,	rather	than	more	severe	mood	states,	where	
clinical	psychology	support	is	more	appropriate.	The	researcher	had	basic	knowledge	of	DM	at	the	
outset	of	the	doctorate	and	was	grateful	to	learn	more	about	DM	and	PDN	by	spending	time	in	
tertiary	medical	clinics	for	PDN.		
1.7.2	Thesis	worldview	
This	thesis	focuses	on	the	clinical	problem	of	managing	PDN	and	whether	strategies	from	
PMPs	would	enhance	this	management.	This	research	takes	a	pragmatic	stance;	the	focus	is	on	
the	clinical	utility	of	the	outcome	rather	than	the	methods	involved	(Creswell	and	Plano	Clark,	
2011).	As	Chapter	3	will	outline	in	more	detail,	the	overall	ontology	is	constructivist;	the	
researcher	will	assume	that	the	reality	of	the	person’s	experience	of	PDN	is	contingent	on	social	
meaning	and	internal	interpretation,	and	this	experience	does	not	lend	itself	to	simple	
quantification.	There	are	a	variety	of	qualitative	research	methods	that	arise	from	this	stance.	The	
Internet	survey	(Chapter	6)	however,	used	a	quantitative	approach	to	explore	and	establish	
patient	priorities	for	management.	The	approach	taken	for	each	study,	from	research	questions	to	
study	methods	and	analysis,	was	focussed	toward	improving	clinical	service	provision.		
1.8	Thesis	structure	
Chapter	1	outlined	the	background	to	diabetes	and	PDN,	including	its	current	management.	
It	also	outlined	the	content	and	approach	of	multidisciplinary	PMPs	for	a	range	of	persistent	pain	
conditions.	Chapter	2	presents	a	systematic	review	exploring	what	is	currently	known	about	
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physical	activity	and	psychological	coping	strategies	for	PDN.	Chapter	3	describes	the	
methodological	considerations	for	two	interview	studies,	firstly	with	people	who	experience	PDN,	
and	secondly	with	clinicians	who	are	involved	in	helping	them	manage	PDN.	Chapters	4	and	5	
present	the	detailed	results	and	discussions	for	each	interview	study.	Chapter	6	presents	an	
Internet	survey	that	further	explored	the	impact	of	PDN	and	the	priorities	people	with	PDN	had	
for	improved	management.	Chapter	7	discusses	whether	the	patient	priorities	identified	can	be	
mapped	to	existing	evidence	based	treatment	strategies	and	where	further	research	is	required.	
Chapter	8	summarises	the	new	knowledge	developed	by	this	thesis.		
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Chapter	2	–	A	systematic	review	of	the	literature	investigating	physical	activity	
and	psychological	coping	strategies	
The	previous	chapter	outlined	the	impact	of	PDN	and	the	guidance	for	management,	
primarily	through	pharmacology.	It	introduced	the	components	of	PMPs	–	strategies	for	physical	
rehabilitation	and	for	coping	psychologically	with	persistent	pain.	In	this	chapter,	a	systematic	
review	of	the	literature	to	establish	the	evidence	for	these	strategies	specifically	for	people	with	
PDN	is	presented.	
A	previous	version	of	this	study	was	published	in	Physiotherapy	(Davies	et	al.,	2015)	and	
subsequently	updated	for	this	thesis	(see	Appendix	1).	
2.1	Introduction	
Multidisciplinary	PMPs	incorporate	various	physical	activity	approaches	and	a	range	of	
psychological	models,	for	example	CBT	or	ACT,	but	have	physical	reactivation	and	psychological	
coping	as	their	key	tenets	(BPS,	2013).	Multidisciplinary	PMPs	have	a	good	evidence	base	for	
management	of	non-neuropathic,	persistent	pain	conditions	(Main	et	al.,	2012;	NICE,	2009;	
Williams,	Eccleston	and	Morley,	2012).	
In	the	context	of	chronic	pain	management,	physical	activity	is	not	aimed	at	curing	the	pain	
problem	but	increasing	the	person’s	ability	to	function	(BPS,	2013).	The	physical	aspect	aims	to	
help	people	establish	a	baseline	for	functional	activity	and	use	principles	of	graded	exposure	
(Boersma	et	al.,	2004)	to	gradually	increase	physical	capacity.	In	a	recent	study	(Schneider	et	al.,	
2014)	of	people	with	PDN	(n=2576)	the	interference	that	PDN	caused	to	‘general	activity’	and	
‘walking	ability’	were	identified	as	important	functions	to	be	improved	through	treatment	for	
their	PDN.	These	functions	are	appear	appropriate	for	PMPs,	but	there	is	a	lack	of	evidence	for	
any	specific	form	of	physical	activity	in	the	management	of	PDN	and	it	is	not	clear	whether	
activity	would	alter	either	pain	or	function	in	this	condition.	
Psychological	coping	includes	the	use	of	cognitive	and	behavioural	interventions	to	help	
people	live	with	a	persistent	pain	problem.	The	authors	of	a	systematic	review	exploring	cognitive	
and	behavioural	approaches	for	neuropathic	pain	highlighted	in	their	introduction	that	
neuropathic	pain	is	often	described	by	the	underlying	pathology	(for	example,	PDN),	rather	than	
as	an	entity	in	itself	(van	de	Wetering	et	al.,	2010).	They	aimed	to	devise	a	search	that	would	
accommodate	all	these	pathologies,	yet	PDN	was	omitted	from	the	published	search	strategy.	The	
methodology	was	subsequently	criticised	for	its	heterogeneity	in	relation	to	conditions	and	
interventions.	Further	critique	related	to	the	absence	of	a	control	arm	in	11	of	the	14	included	
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studies	and	small	sample	sizes	in	some	studies	(Eccleston	et	al.,	2010).	Due	to	these	deficiencies,	
the	review	by	van	Wetering	et	al.	(2010)	was	not	considered	as	a	definitive	state	of	the	literature	
into	psychological	coping	strategies	for	neuropathic	pain	(Eccleston	et	al.,	2010).			
Pain,	irrespective	of	cause,	is	an	interfering	experience,	and	reduction	in	pain	severity	a	
common	priority	of	both	patients	and	clinicians	(Sanderson	et	al.,	2010;	Moore,	Derry	and	
Eccleston,	2013).	In	recent	guidance	for	management	of	neuropathic	pain,	NICE	note	that	
neuropathic	pain	has	disproportionate	effect	on	physical	and	mental	health	than	other	pain	
mechanisms,	even	when	adjusted	for	pain	severity	(NICE,	2013a).	When	pain	cannot	be	reduced,	
a	shift	of	clinical	focus	to	maximisation	of	quality	of	life	can	be	appropriate	(Smith	et	al.,	2013).	
For	this	systematic	review,	it	was	appropriate	to	set	pain	severity	as	the	primary	outcome	
as	this	aligned	with	patient	priorities	and	studies	of	medication	commonly	use	this	outcome.	
Selecting	pain	severity	would	potentially	allow	results	data	from	studies	investigating	physical	
activity	or	psychological	coping	to	be	compared	against	treatment	effect	sizes	for	medication.	
Outcomes	measuring	quality	of	life	were	included	as	secondary	outcomes	when	available	in	the	
primary	research.		
2.2	Objectives	
This	systematic	review	had	three	objectives:	to	establish	the	effect	of	1)	physical	activity	in	
the	management	of	PDN,	2)	psychological	coping	strategies	in	the	management	of	PDN;	and	3)	
identify	gaps	in	the	evidence	to	inform	future	research	priorities	for	PDN.	
2.3	Methods	
2.3.1	Protocol	and	registration	
The	original	protocol	was	registered	with	The	International	prospective	register	of	
systematic	reviews	(PROSPERO)	(CRD42013006365),	and	the	study	was	reported	in	accordance	
with	the	Preferred	Reporting	Items	for	Systematic	Review	recommendations	(PRISMA)	(Moher	et	
al.,	2009).	
2.3.2	Eligibility	criteria	
Studies	were	required	to	meet	the	following	inclusion	criteria:		
1. A	study	population	with	a	clear	diagnosis	of	painful	neuropathy,	secondary	to	diabetes	
and	results	reported	specifically	for	people	with	PDN	where	individuals	with	other	
neuropathic	pain	pathologies	were	included	in	the	trial.	
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2. Human	adult	participants.	PDN	becomes	more	common	with	longer	duration	of	
diabetes;	childhood	onset	is	very	rare.	Basic	science	studies	were	inappropriate	for	
investigating	utility	of	clinical	interventions.		
3. Include	an	intervention	that	was	either	a)	physical	exercise	or	activity,	and/or	b)	used	
recognised	psychological	approaches	that	aimed	to	help	participants	cope	with	pain.	
Studies	investigating	an	intervention	that	included	a	combined	approach	were	also	
included.			
4. Patient	reported	pain	as	a	primary	outcome	measure.	
5. To	assess	the	efficacy	of	the	intervention,	only	studies	using	randomised	controlled	
designs	were	included.	The	lack	of	control	comparison	groups	in	case	series	and	cohort	
designs	mean	changes	in	outcome	measures	cannot	be	assigned	to	the	intervention	
with	any	certainty.			
6. No	exclusion	was	made	based	upon	language	or	date	of	publication.	
2.3.3	Information	sources	
Ten	electronic	databases	covering	medical,	allied	health	and	psychology	subjects	were	
searched.	The	Cochrane	Library	indexes	high	quality	trials	and	systematic	reviews	conducted	in	
healthcare.	Physiotherapy	Evidence	Database	(PEDro),	Medline/PubMed,	Cumulative	Index	to	
Nursing	and	Allied	Health	Literature	(CINAHL),	Allied	and	Complementary	Medicine	(AMED),	
Embase,	SportDiscus,	Web	of	Science	and	BioMed	Central	index	studies	of	all	methodological	
designs	in	healthcare	including	basic	biological	sciences	and	clinical	interventions.	PsychINFO	
indexes	psychology	studies.		
2.3.4	Search	
Symptoms	of	PDN	have	a	range	of	clinical	diagnostic	labels	(painful	sensory	neuropathy,	
painful	distal	diabetic	neuropathy)	and	usage	of	these	terms	can	vary	between	American	and	
European	authors	and	between	pain,	diabetes	and	neurology	related	journals.	Search	lines	1-3	in	
Figure	7	(below)	were	felt	inclusive	to	ensure	any	study	relating	to	PDN	would	be	retrieved	for	
consideration.		
Existing	Cochrane	reviews	that	investigated	the	effect	of	physical	activity	in	cancer	(Cramp	
and	Byron-Daniel,	2012)	and	rheumatoid	arthritis	(Cramp	et	al.,	2013)	were	used	as	a	basis	for	
this	search	concept.	All	approaches	to	physical	training	-	endurance,	strength,	flexibility	and	high-
intensity	interval	training,	were	included	(Figure	7,	lines	34-41).	These	terms	were	further	
developed	using	wild	card	characters	to	ensure	alternate	spellings	were	not	omitted.	The	search	
aimed	to	include	physical	activity,	rather	than	solely	structured	exercise,	and	exercise	approaches	
such	as	Tai	Chi	or	movement	therapy,	that	do	not	precisely	fit	any	category.	The	strategy	was	
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developed	(Figure	7,	lines	42-44)	to	include	search	terms	for	Neurodynamics	(Shacklock,	2007),	a	
manual	therapy	that	mobilizes	neural	tissue,	as	this	form	of	activity	may	have	direct	relevance	to	
the	population	with	PDN	(Boyd,	2008;	Boyd	et	al.,	2010),	and	can	be	delivered	by	clinicians	or	
through	patient	self-mobilization.		
For	psychological	interventions,	existing	systematic	reviews	of	cognitive	behavioural	and	
acceptance	based	interventions	were	used	as	a	basis	for	keyword	searches	(Veehof	et	al.,	2011;	
Williams,	Eccleston	and	Morley,	2012).	This	included	established	CBT,	ACT	and	MBSR	approaches	
(Morley	and	Williams,	2015)	(Figure	7,	lines	5-32).	
This	search	was	applied	via	EBSCO	to	Medline,	AMED,	EMBASE,	CINAHL,	SportDiscus	and	
PsychINFO.	A	simplified	search	strategy	was	used	for	PEDro,	Cochrane	Library,	BioMed	Central	
and	Web	of	Science.	These	searches	were	conducted	by	the	research	student	in	the	week	
beginning	18	November	2013	and	repeated	2	July	2014	but	limited	to	studies	published	in	2013/4	
to	ensure	the	results	were	up-to-date	to	submit	for	publication	(Davies	et	al.,	2015).	To	update	
the	review	for	this	thesis,	librarian	staff	at	the	Royal	United	Hospitals,	Bath,	repeated	the	search	
in	September	2016	limiting	dates	from	2014	to	September	2016.	
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Figure	7	-	Systematic	literature	review	search	strategy	
1. PAIN	explode	all	trees	(MeSH)		
2. DIABETES	explode	all	trees	(MeSH)		
3. Neuropath*	or	Polyneuropath*		
4. 1	AND	2	AND	3		
5. PSYCHOTHERAPY	explode	tree1	(MeSH)		
6. COGNITIVE	THERAPY	single	term	(MeSH)		
7. BEHAVIOUR	THERAPY	explode	tree	1	(MeSH)		
8. BIOFEEDBACK	(PSYCHOLOGY)	single	term	(MeSH)		
9. ((behaviour*	next	therapy)	or	(behaviour*	next	therapies))		
10. ((cognitive	next	therapy)	or	(cognitive	next	therapies))		
11. (relax*	near	technique*)		
12. ((relax*	near	therapy)	or	(relax*	near	therapies))		
13. meditat*		
14. psychotherap*		
15. (psychological	next	treatment)		
16. ((psychological	next	therapy)	or	(psychological	next	therapies))		
17. (group	next	therapy)		
18. (self-regulation	next	training)		
19. (coping	next	skill*)		
20. (pain-related	next	thought*)		
21. (behavior*	near	rehabilitat*)		
22. (psychoeducation*	next	group)		
23. (psychoeducation*	next	groups)		
24. (psycho-education*	next	group)		
25. (psycho-education*	next	groups)		
26. (mind	and	(body	next	relaxation	next	technique*))		
27. MIND-BODY	AND	RELAXATION	TECHNIQUES	explode	tree	1	(MeSH)		
28. mindfulness		
29. mindfulness-based	stress	reduction	or	MBSR		
30. mindfulness-based	cognitive	therapy	or	MBCT		
31. Acceptance-based	or	acceptance	based		
32. Acceptance	and	commitment		
33.	 5	OR	6	through	32 
34. ((exercise*	or	resistance	or	strength	or	flexibility	or	endurance)	near	(train*	or	
program*))		
35. ((resistance	or	aerobic*	or	endurance*)	near	exercise*)		
36. (interval	training	or	sport*	or	movement	therap*)		
37. stretching.mp		
38. (dance	therap*	or	exercise*	or	“Tai	Ji”	or	“Tai	Chi”	or	“Tai-Ji”	or	“Tai-Chi”	or	walking	
or	yoga)		
39. graded	near	(activit*	or	exercise*	or	program*)		
40. physical*	near	(active*	or	therap*	or	exercise*)	
41. exp	kinesiotherapy/		
42. (nerve	or	neural)	near	(glid*	or	slid*)		
43. (nerve	or	neural)	near	(exercise*	or	therap*	or	treatment*	or	mobilization*)		
44. (nerve	or	neural)	near	(tension	or	mechanic*	or	dynamic*)		
45. 34	OR	35	through	44	
46. 5	AND	(33	OR	45)	
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2.3.5	Study	selection	
From	the	studies	retrieved,	duplicates	were	removed	and	the	titles	judged	against	the	
eligibility	criteria.	Studies	that	clearly	did	not	meet	eligibility	criteria	were	excluded.	Abstracts	for	
all	remaining	studies	were	then	reviewed	and	judged	against	the	eligibility	criteria.	The	full	texts	
of	studies	that	could	not	be	clearly	excluded	were	obtained.	These	full	texts	were	judged	against	
eligibility	criteria	to	select	the	final	included	studies.	In	the	case	of	uncertainty,	a	study	was	taken	
forward	to	the	next	stage	until	it	was	clear	it	did,	or	did	not	meet	the	criteria.	The	research	
student	carried	out	this	process.		
This	process	was	repeated	for	the	search	update	conducted	in	September	2016.		
2.3.6	Data	collection	process	and	data	items	
The	principal	data	extracted	from	the	selected	studies	included:	evidence	of	diagnostic	
criteria	for	PDN,	nature	of	intervention	(type	of	physical	activity,	type	of	psychological	therapy),	
demographics	and	numbers	of	the	control	and	intervention	arm,	duration	of	follow	up	periods,	
outcome	measures	of	pain,	results,	attrition	rates	and	noted	adverse	effects.	Studies	were	
checked	for	quality	of	life	outcome	measures;	if	present,	appropriate	data	were	extracted	at	this	
point.	The	research	student	conducted	the	data	extraction	using	a	specific	form	designed	in	
collaboration	with	doctoral	supervisors	(Appendix	2	–	Data	extraction	table).	To	ensure	accuracy	
Professor	Fiona	Cramp	repeated	the	data	extraction	for	physical	activity	studies,	and	Dr	Jeremy	
Gauntlett-Gilbert	for	psychological	coping	studies.	
2.3.7	Critical	appraisal	and	risk	of	bias	in	individual	studies	
Risk	of	bias	was	assessed	using	the	Cochrane	Collaboration	tool	(Higgins	et	al.,	2011)	and	
methodological	quality	assessed	using	the	NICE	critical	appraisal	tool	for	randomised	studies	
(NICE,	2006).	Although	there	is	overlap	in	the	quality	domains	of	the	Cochrane	and	NICE	
checklists,	both	were	used	to	inform	an	in-depth	critical	appraisal	of	the	included	studies.	The	
Cochrane	checklist	requires	consideration	of	seven	domains	where	bias	can	be	introduced	to	a	
study.	Each	domain	considers	whether	the	research	process	described	by	the	study	authors	
represents	high	risk,	low	risk,	or	uncertain	source	of	bias.	The	Cochrane	tool	does	not	use	scoring	
scales	to	quantify	the	process	of	critical	appraisal.	
The	NICE	checklist	guides	the	reviewer	through	a	series	of	questions	relating	to	the	quality	
of	the	methods	as	well	as	the	results,	including	their	ability	to	address	the	study	aim(s).	The	
research	student	reviewed	all	studies,	extracted	the	necessary	information	to	the	data	extraction	
form,	and	critically	appraised	the	studies.	Doctoral	supervisors	critically	appraised	the	included	
studies,	blind	to	the	opinion	of	the	research	student.	Professor	Cramp	performed	the	second	
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review	for	studies	involving	physical	activity	and	Dr	Gauntlett-Gilbert	for	studies	involving	
psychological	interventions.	The	individual	appraisals	were	compared	and	discussed	in	the	event	
of	disagreement.	A	third	independent	reviewer	(Professor	McCabe)	was	available	if	consensus	
could	not	be	reached.	
2.4	Results	
2.4.1	Study	selection	
After	duplicates	were	removed,	1306	potential	studies	remained.	After	excluding	studies	
based	on	titles,	179	abstracts	were	reviewed.	Reviewing	these	abstracts	against	the	eligibility	
criteria	left	23	studies	for	full	text	review.	After	final	consideration	against	the	eligibility	criteria	
four	articles	were	retained	for	inclusion	in	the	full	review,	two	studies	focused	on	physical	activity	
and	two	focused	on	psychological	interventions.		
Following	the	search	update	in	September	2016,	120	articles	were	retrieved	following	
removal	of	duplicates.	All	were	excluded	based	on	title	or	abstract.	The	outline	of	the	screening	
process	is	summarised	in	Figure	8.	
2.4.2	Study	characteristics	(Table	3	-	Synopsis	of	selected	studies)	
One	quasi-experimental	trial	of	Tai	Chi	(Ahn	and	Song,	2012)	and	one	randomised	
controlled	trial	investigating	aerobic	physical	exercise	(Dixit,	Maiya	and	Shastry,	2014)	were	
included.	There	were	two	randomised	controlled	trials	of	psychological	interventions	(CBT	and	
mindfulness	relaxation)	(Otis	et	al.,	2013;	Teixeira,	2010).	All	participants	were	diagnosed	with	
either	Type	1	or	Type	2	diabetes,	although	the	majority	had	Type	2.	Sample	size	ranged	from	19-
87,	with	only	two	studies	reporting	a	sample	size	calculation	(Ahn	and	Song,	2012;	Teixeira,	2010).	
The	intervention	arms	were	compared	with	treatment	as	usual	(Ahn	and	Song,	2012;	Dixit,	Maiya	
and	Shastry,	2014;	Otis	et	al.,	2013)	or	a	control	arm	of	diabetes	self-care	education	that	received	
the	equivalent	health	professional	contact	time	as	the	intervention	arm	(Teixeira,	2010).	
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Figure	8	-	Process	of	study	selection	
	
	
Articles	generated	by	search	strategy	(n=1306,	after	removal	of	duplicates)	
Abstracts	reviewed	for	relevance	(n=179)	
Articles	excluded	at	title	review	(n=1127)	
Articles	excluded	at	abstract	review	(n=156)		
Full	text	articles	relevant	to	physical	
activity	(n=18)	
Full	text	articles	relevant	to	psychological	
therapy	(n=5)	
Search	strategy	developed	and	applied	to	Medline,	AMED,	EMBASE,	CINHAL,	
SportsDISCUS,	PsychINFO,	Cochrane,	PEDro,	BioMed	and	Web	of	Science	
Full	text	articles	excluded	due	to:	no	
pain	outcome	measure	(n=11),	non-
controlled	design	(n=5),	PDN	an	
exclusion	criteria	(n=1)	
Physical	activity	final	articles	(n=2)		 Psychological	coping	final	articles,	(n=2)	
Full	text	articles	excluded	due	to:	no	pain	
outcome	measure	(n=2),	non-controlled	
design	(n=1)	
Search	repeated	for	2013/14.	Two	further	articles	found	for	physical	activity,	one	
excluded	as	subgroup	PDN	data	unavailable	
Search	repeated	for	2014	to	Sept	2016	retrieved	n=120	articles	
Articles	excluded	at	title	or	abstract	review	(n=120)	
Final	article	selection	(Physical	activity	n=2	and	psychological	coping	n=2)		
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Table	3	-	Synopsis	of	selected	studies	
Authors	 Ahn	&	Song	(2012)	 Dixit,	Maiya	and	Shastry	
(2014)	
Otis	et	al.	(2013)	 Teixeira	(2010)	
Research	objective	 Physical	activity		 Physical	activity	 Psychological	coping	 Psychological	coping	
Study	design	 Quasi-experimental	controlled	
trial	
Single	blind,	RCT	 Single	blind,	RCT	 Single	blind,	RCT	
Participant	characteristics	
Mean	age	(standard	
deviation)		
Gender	
Type	of	diabetes		
Duration	of	diabetes	
Duration	of	PDN		
Location	of	treatment	
Intervention	(n=20):	66	(6.4)	
years,	12	male,	all	Type	2,	DM	
duration	12	(8.8)	years.	PDN	
duration	not	stated.		
Control	(n=19):	62.7	(7.5)	
years,	8	male,	all	Type	2,	DM	
duration	-13	(10)	years.	PDN	
duration	not	stated.		
Korean	University	Hospital	
outpatient	clinic.	
Intervention	(n=40):	54.4	
(1.2)	years,	22	male,	all	Type	2	
DM	type,	DM	duration	
65.5(1.9)	months,	PDN	
duration	not	stated.	
Control	(n=47):	59.4(1.1)	
years,	31	male,	all	Type	2	DM,	
DM	duration	82.1(1.6)	
months,	PDN	duration	not	
stated.	
Tertiary	care	centre,	India.	
Intervention:	(n=12):	62	(11)	
years,	all	male,	all	type	2	DM,	
DM	and	PDN	duration	not	
stated.		
Control:	(n=8):	63	(11.6)	years,	
all	male,	all	type	2,	DM	and	PDN	
duration	not	stated.		
USA	veterans	medical	centre.	
All	participants	(n=20):	74	(10.8)	
years,	5	male,	all	type	2,	DM	
duration	12.6	(9.4)	years,	PDN	
duration	7.7	(6.6)	years.	Community	
medical	practice	and	retirement	
communities,	USA.	
Sample	size	 n=39	 n=87	 n=19	 n=20	
PDN	diagnostic	criteria	 10g	monofilament	
assessment,	Neuropathy	total	
symptom	score	(TSS)	
Physician	assessment,	
Michigan	Diabetic	Neuropathy	
Score	>7.		
Other	causes	for	neuropathy	
excluded	
Medical	records	screened	for	
primary	compliant	of	
neuropathic	pain	in	hands	or	
feet		
Self-referred,	no	medical	screening	
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Authors	 Ahn	&	Song	(2012)	 Dixit,	Maiya	and	Shastry	
(2014)	
Otis	et	al.	(2013)	 Teixeira	(2010)	
Intervention	 Tai	Chi,	2x1	hour	per	week,	12	
weeks,	plus	routine	education	
on	diabetes	management	
Aerobic	exercise	at	40-60%	of	
Heart	Rate	Reserve,	5-6	days	
per	week,	accumulating	150-
360	mins/week	exercise,	at	
Rate	Perceived	Exertion	6-20.	
8	weeks.	
Advice	on	foot	care	and	
hypoglycaemia	
	
	
Individual	CBT,	1-hour	session,	
x11	sessions.	
mindfulness	based	relaxation	(MR),	1	
hour	session	then	audio	CD	for	home	
practice.	
Control	arm	 Routine	education	on	diabetes	
management	
Weekly	physician	appointments	
with	diet	and	foot	care	advice	
Treatment	as	usual,	offered	CBT	
after	completion	of	4	month	follow	
up.	
Nutritional	advice	(1hour)	and	asked	to	
keep	a	food	diary	for	4	weeks	
Outcomes	 NTSS	
SF36	(Korean)	
MDNS	
NeuroQoL	
WHYMPI	
BDI	
NPS	
NeuroQoL	
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Authors	 Ahn	&	Song	(2012)	 Dixit,	Maiya	and	Shastry	
(2014)	
Otis	et	al.	(2013)	 Teixeira	(2010)	
Main	statistically	significant	
findings	
NTSS:	worsened	in	both	arms	but	
less	worse	in	Tai	Chi	arm	
(p=0.042).		
	
SF36:	Tai	Chi	arm	improved	
compared	to	baseline	-		Physical	
function	(p=0.028),	bodily	pain	
(not	neuropathy	specific)	
(p=0.009),	physical	role	limitation	
(p=0.006)	emotional	role	
limitation	(p=0.002)	and	social	
function	(p=0.001).		
MDNS	total	score	improved	in	
exercise	arm	12.57(1.74)	(CI	
13.11-12.03)	to	7.03(1.86)	(CI	
7.61	–	6.45),	control	arm	
13.55(1.75)	(CI	14.05	–	13.05)	to	
14.57(1.5)	(CI	15	-	14.09),	
p<0.001.	
	
NeuroQOL	total	score	improved	
in	exercise	arm,	32.85(1.32)	(CI	
33.28	–	32.42)	to	24.14(1.12)	(CI	
24.82	–	24),	control	arm	
33.55(1.37)	(CI	33.95	–	33.15)	to	
34.16(1.37)	(CI	34.61	–	33.71),	
p<0.001.		
	
NeuroQOL	Pain	subscale	exercise	
arm	1.6(1.76)	(CI	2.12	–	1.08)	to	
1.61(1.29)	(CI	2.08	–	1.14),	
control	arm	1.65(1.75)	(CI	2.17	–	
1.14)	to	1.73(1.69)	(CI	2.28	–	
1.18),	p=0.03.	
HLM:	CBT	arm	declined	in	pain	
severity	(B=-0.54)	and	pain	
interference	(B=-0.77).	TAU	arm	
was	not	significantly	different.	No	
change	in	BDI	either	arm.				
	
Pre-post	(4/12)	for	CBT	arm:	pain	
interference	decline	t(7)=3.15,	
p<0.5,	pain	severity	declined	
t(7)=3.87,	p<0.1.		2/8	CBT	arm	50%	
reduction	in	pain,	3/8	at	least	20%	
reduction	in	pain.		
	
Between	arm	pre-post	(4/12):	pain	
severity	decreased	1.08	(sd	0.79),	
TAU	unchanged,	p<0.1,	Pain	
interference	CBT	declined	1.35	(SD	
1.22),	TAU	increased	0.22	(SD	0.73)	
p<0.5	
Hypothesis	1	(MR	leads	to	QoL	
improvement):	no	significant	difference	
in	overall	QoL,	symptom	related	QoL,	
pain	QoL	or	emotional	QoL.		
	
Hypothesis	2	(MR	leads	to	decreased	
pain):	no	significant	difference	in	pain	
intensity	or	pain	unpleasantness.		
	
Adverse	effects/events	 None	noted	 Not	reported	 Not	reported	 Not	reported	
BDI	–	Beck	depression	inventory,	CBT	–	Cognitive	behavioural	therapy,	DM	–	Diabetes	mellitus,	HLM	–	Hierarchical	linear	modelling,	HRR	–	Heart	rate	reserve,	MR	–	mindfulness	
relaxation,	MDNS	–	Michigan	diabetic	neuropathy	scale,	NPS	-	Neuropathic	pain	scale,	NTSS	-	Neuropathy	total	symptom	score,	PDN	–	Painful	diabetic	neuropathy,	QoL	–	quality	of	life,	
RCT	–	randomised	controlled	trial,	RPE	–	rate	of	perceived	exertion,	SF36	–	Shortform	36	health	survey,	TAU	–	treatment	as	usual,	WHYMPI	-	West	Haven	Yale	Multidimensional	Pain	
Inventory	
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2.4.3	Risk	of	bias	and	quality	appraisal	
The	summary	of	the	Cochrane	and	NICE	appraisal	checklist	can	be	found	in	Table	4	and	
Table	5	respectively.	The	relevant	methodological	issues	in	each	study	will	be	reviewed	in	turn.		
Table	4	-	Cochrane	Risk	of	bias	assessment	(Higgins	et	al.,	2011)	
	 Ahn	&	Song	
(2012)	
Dixit,	Maiya	
and	Shastry	
(2014)	
Otis	et	al.	
(2013)	
Teixeira	(2010)	
Random	sequence	allocation		 +	 -	 -	 -	
Allocation	concealment		 +	 +	 +	 ?	
Blinding	of	participants	and	
personnel		 +	 +	 ?	 +	
Blinding	of	outcome	assessment		 ?	 -	 ?	 ?	
Incomplete	outcome	data	
	 +	 +	 +	 ?	
Selective	reporting	
	 -	 -	 ?	 -	
Other	bias	
	 ?	
+	
Low	
recruitment	%	
?	 ?	
+	High	risk	of	bias,	-	low	risk	of	bias,	?	risk	of	bias	cannot	be	ascertained	
	
Table	5	-	Assessment	of	methodological	quality	checklist	1.1	–	2.3	(NICE,	2005)	
	 Ahn	&	Song	
(2012)	
Dixit,	Maiya	and	
Shastry	(2014)	
Otis	et	al.	(2013)	 Teixeira	(2010)	
Clear	research	
question	
Adequately	
addressed	
Well	covered		 Well	covered		 Well	covered		
Randomization	process	 Poorly	addressed	 Well	covered		 Well	covered		 Well	covered		
Adequate	concealment	 Not	applicable	 Not	addressed	 Not	addressed	 Not	addressed	
Subjects	and	
investigators	‘blind’	
Not	addressed	 Poorly	addressed		 Not	reported	 Poorly	addressed	
Similar	pre-trial	
intervention	and	
control	arms		
Well	covered		 Well	covered		 Adequately	
addressed	
Not	addressed	
Intervention	is	only	
difference	between	
arms	
Well	covered		 Well	covered		 Well	covered		 Adequately	
addressed	
Valid	and	reliable	
outcome	measures	
Adequately	
addressed	
Well	covered		 Well	covered		 Well	covered		
Dropout	rates	prior	to	
completion	
Well	covered		 Well	covered		 Well	covered		 Well	covered		
Intention	to	treat	
analysis	performed	
Not	addressed	 Not	addressed	 Not	addressed	 Not	addressed	
Comparable	between	
sites	
Not	applicable	 Not	applicable	 Not	applicable	 Not	applicable	
How	well	does	method	
minimise	bias?	
-	(Not	
randomized	or	
blinded)	
+	(Lost	data	from	
those	whose	pain	
increased,	lost	
motivation,	other	
reasons)	
+	(Not	blinded,	
lost	data	from	
drop	outs)		
-	(Not	blinded,	did	
not	achieve	sample	
size)	
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	 Ahn	&	Song	
(2012)	
Dixit,	Maiya	and	
Shastry	(2014)	
Otis	et	al.	(2013)	 Teixeira	(2010)	
If	biased,	in	which	
direction?	
Likely	
overestimate	the	
benefit	of	
intervention	
Likely	
overestimate	the	
benefit	of	
intervention	
Likely	
overestimate	the	
benefit	of	
intervention	
Likely	overestimate	
the	benefit	of	
intervention	
Considering	clinical	
aspects,	method	and	
statistics,	is	the	overall	
effect	due	to	
intervention?	
Moderately	 Uncertain,	
intervention	arm	
unchanged	
clinically,	control	
arm	worsened,	
leading	to	the	
statistical	
significance	
Moderately	 Uncertain	
	
Ahn	&	Song	(2012)	conducted	a	quasi-experimental	study	investigating	the	effects	of	Tai	
Chi.	The	first	thirty	participants	consented	were	allocated	Tai	Chi,	and	their	outcomes	compared	
to	the	next	block	of	twenty-nine	control	participants.	A	sample	size	calculation	was	conducted	
based	on	the	ability	to	detect	change	in	HbA1c,	and	the	target	sample	was	recruited.	Although	
not	true	randomisation	there	were	no	significant	differences	between	study	arms	at	baseline	for	
the	sociodemographic	and	clinical	variables	recorded.	The	authors	used	a	robust	range	of	
outcome	measures	but	they	do	not	state	clearly	if	these	were	completed	by	researchers	blind	to	
treatment	allocation.	The	study	suffered	from	a	high	drop-out	rate	(~30%)	in	both	study	arms	and	
the	management	of	missing	data	was	not	discussed,	so	the	results	are	at	risk	of	attrition	bias.		
Dixit,	Maiya	and	Shastry	(2014)	investigated	structured	aerobic	exercise.	They	stratified	the	
severity	of	the	neuropathy	using	the	Michigan	Diabetic	Neuropathy	Score	and	then	randomised	
participants	into	study	arms	accounting	for	equal	severity	of	the	neuropathy.	There	were	clear	
protocols	for	minimising	allocation	and	detection	bias,	through	blinding	of	researchers	to	the	trial	
arm	of	participants.	Anthropometrics	were	shown	to	be	similar	between	trial	arms	at	baseline,	
but	other	characteristics	were	not	analysed.	Clear	details	of	the	intervention	were	provided,	and	
the	comparison	arm	received	weekly	physician	appointments.	Such	frequency	may	not	represent	
true	‘treatment	as	usual’.	No	sample	size	calculation	was	conducted,	however	the	researchers	
assessed	n=335	potential	participants	and	recruited	n=87,	highlighting	difficulties	in	recruitment	
from	their	population.	There	was	significant	loss	to	follow	up	(~22%)	in	both	arms	of	the	trial	and	
no	details	were	provided	of	how	missing	data	were	managed	so	the	results	are	again	at	risk	of	
attrition	bias.		
Teixeira	studied	the	effect	of	mindfulness	relaxation	on	PDN	(Teixeira,	2010).	They	used	
random	number	draw	to	allocate	participants	to	trial	arm	and	used	outcome	measures	for	quality	
of	life	(NeuroQoL)	and	pain	(Neuropathic	Pain	Scale)	that	have	been	validated	for	neuropathic	
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pain.	Previous	studies	informed	a	sample	size	calculation,	however	the	target	was	not	achieved	
allowing	the	possibility	of	type	II	error.	Further,	it	is	not	clear	that	the	arms	were	equitable	at	the	
start	of	the	trial	or	that	researchers	were	fully	blind	to	the	treatment	arm,	allowing	for	potential	
detection	bias.	There	was	minimal	loss	to	follow	up	but	it	is	not	clear	how	the	missing	data	were	
handled.	
Otis	et	al.	(2013)	conducted	a	pilot	trial	of	CBT	in	a	US	military	veteran	population.	
Participants	were	randomised	to	trial	arm	and	these	were	demonstrated	to	be	comparable	at	
baseline	for	the	sociodemographic	variables	recorded.	The	CBT	intervention	was	clearly	outlined.	
The	study	used	the	WHYMPI	as	their	primary	outcome	measure,	which	has	not	been	validated	for	
neuropathic	pain.	It	was	not	clear	that	researchers	responsible	for	outcome	measures	were	fully	
blind	to	the	treatment	arm.	Outcomes	were	reported	for	three	time	points	(pre-,	post-course	and	
at	three	months),	and	appropriate	statistical	analysis	was	used	to	account	for	repeated	measures,	
but	caution	should	be	applied	due	to	the	small	sample	size	(n=19)	and	significant	attrition	in	the	
treatment	arm	(3	of	11,	27%).	
Overall,	few	studies	were	located	and	each	of	the	studies	investigated	a	different	form	of	
physical	exercise	or	psychological	coping.	These	studies	defined	their	participant	eligibility	criteria,	
used	appropriate	outcome	measures	for	pain	or	quality	of	life	in	persistent	pain	states,	and	
described	the	interventions	clearly.	These	studies	were	all	of	small	sample	size;	either	not	stating	
a	sample	size	calculation,	or	not	retaining	the	sample	size	to	the	end	of	the	study.	Studies	
experienced	difficulty	in	recruiting	participants	to,	or	retaining	participants	within	the	studies.	In	
general,	appropriate	steps	had	been	taken	to	blind	researchers,	but	for	the	interventions	studied	
it	was	impossible	to	achieve	true	blinding	of	participants.	The	main	concerns	with	all	the	
identified	studies	were	high	attrition	rates	and	the	lack	of	clear	intention	to	treat	analysis;	this	
allows	results	potentially	to	be	inflated	in	favour	of	the	interventions.	
2.4.4	Results	of	individual	studies	
Detailed	results	can	be	found	in	Table	3	-	Synopsis	of	selected	studies.		
2.4.4.1	Primary	outcome	measure	
Ahn	&	Song	(2012)	used	the	SF36	and	Neuropathy	Symptom	Score	outcome	measures.	The	
SF36	bodily	pain	subscale	improved	in	the	intervention	arm	from	pre-	to	post-intervention	by	
mean	difference	11.87	(SD26.74)	and	worsened	in	the	control	arm	by	mean	difference	-11.34	
(SD6.17)	(post-intervention	between	arm	comparison	p=0.009).	The	Neuropathy	Symptom	Score	
contained	questions	related	to	pain	and	function	but	the	individual	pain	data	were	not	specified	
in	the	results.	Overall	the	Neuropathy	Symptom	Score	improved	slightly	in	the	intervention	arm	
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(mean	difference	0.21	(SD1.44))	and	worsened	in	the	control	arm	(mean	difference	-1.64	
(SD3.61)),	post-intervention	between	arm	comparison	p=0.042.	The	sample	size	calculation	was	
based	on	ability	to	detect	changes	in	HbA1c,	not	changes	in	pain,	and	therefore	it	is	unknown	
whether	the	study	was	powered	appropriately	when	considering	results	related	to	pain	
experience.	
Dixit,	Maiya	and	Shastry	(2014)	used	the	NeuroQOL	measure	that	contains	a	specific	pain	
subscale.	They	demonstrated	minimal	change	in	the	intervention	arm	(mean	1.60	(SD1.76)	to	1.61	
(SD1.29))	and	worsening	pain	in	the	control	arm	(mean	1.65	(SD1.75)	to	1.73	(SD1.69)),	post-
intervention	between	arm	comparison	(p=0.03).	
Otis	et	al.	(2013)	used	the	WHYMPI	as	the	pain	outcome	measure.	Hierarchical	linear	
modelling	was	used	to	analyse	the	data	and	account	for	repeated	measures.	Analysis	showed	the	
CBT	group	decreased	in	pain	severity	(B=-0.54)	and	pain	interference	(B=-0.77).	There	were	no	
significant	changes	in	the	treatment-as-usual	arm.	From	pre-intervention	to	4	month	follow	up	
pain	severity	decreased	in	the	CBT	arm	and	did	not	alter	significantly	in	the	treatment-as-usual	
arm	(p<0.01).	Pain	interference	also	decreased	in	the	CBT	group	compared	to	the	treatment-as-
usual	arm	(p<0.05).	
Teixeira	(2010)	proposed	two	hypotheses	within	their	study:	1)	mindfulness	relaxation	
leads	to	quality	of	life	improvement	and	2)	mindfulness	relaxation	leads	to	decreased	pain.	The	
results	demonstrated	no	difference	between	intervention	and	control	arms	for	either	hypothesis.		
Only	Ahn	&	Song	(2012)	specifically	reported	on	monitoring	for	adverse	effects	with	no	
events	in	either	arm.	No	other	included	study	specifically	stated	the	occurrence	of	adverse	events.		
2.4.4.2	Secondary	outcome	measures	
The	SF36	questionnaire	used	by	Ahn	&	Song	(2012)	includes	subscales	for	physical	role	and	
emotional	role,	amongst	others.	Table	6	summarizes	selected	results.	For	the	intervention	arm	
there	were	improvements	in	several	quality	of	life	subscales,	but	there	were	deteriorations	in	
these	measures	for	the	control	arm.		
Table	6	-	Selected	results	SF36	(Ahn	&	Song	2012)	
	 Tai	Chi	–	pre-post	mean	
difference	(SD),	n=20	
Control	–	pre-post	mean	
difference	(SD),	n=19	
p=	
Physical	function	 4.75(16.58)	 -5.78(11.69)	 0.028	
Role	physical	 17.25(28.64)	 -4.02(14.20)	 0.006	
Role	emotional	 17.5(24.78)	 -7.36(20.73)	 0.002	
Social	function	 10.89(30.29)	 -18.28(18.85)	 0.001	
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The	NeuroQoL	measure	used	by	Dixit,	Maiya	and	Shastry	(2014)	included	the	overall	pain	
score,	reported	earlier,	and	subscales	for	quality	of	life.	Selected	data	were	presented	in	Table	7.	
As	with	the	results	in	the	previous	paragraph,	while	the	intervention	arm	had	improved	for	a	
number	of	quality	of	life	subscales,	this	was	accompanied	by	reduction	in	these	scores	for	the	
control	arm.	
Table	7	-	Selected	results	NeuroQoL	(Dixit,	Maiya	and	Shastry,	2014)	
	 Aerobic	exercise	
(absolute	%	change),	
n=29	
Control	(absolute	%	
change),	n=37	
p=	
Restricted	activity	daily	life	 23.21	 -4.14	 0.03	
Disruptions	in	social	
relationships	
21.73	 -28	 0.02	
Emotional	distress	 11.31	 -14.82	 0.10	
Specific	impact	on	QoL	 16.67	 -1.67	 <0.001	
Overall	QoL	score	 19.64	 -14.26	 <0.001	
QoL	–	quality	of	life	
	
In	the	remaining	studies,	Otis	et	al.	(2013)	used	the	WHYMPI	measure,	which	comprises	12	
subscales	but	they	only	consider	the	Pain	Interference	and	Pain	Severity	subscales	in	their	
analysis,	and	did	not	present	other	subscale	data.	Teixeira	(2010)	used	the	NeuroQoL	measure,	
but	did	not	present	the	subscales	in	a	manner	that	allowed	interpretation.		
2.4.5	Synthesis	of	results	
Physical	activity	appeared	to	benefit	general	quality	of	life,	as	rated	by	SF36	and	NeuroQoL	
measures,	rather	than	pain	specifically.	Where	there	were	statistically	significant	effects	on	pain,	
it	appeared	that	pain	increased	in	control	arms,	rather	than	pain	improving	in	the	intervention	
arms.	There	appeared	to	be	significant	barriers	to	recruitment	and	retention	in	physical	activity	
studies.	CBT	appeared	to	benefit	participants,	but	dropouts	occurred	early	in	the	intervention.	
These	results	need	to	be	considered	with	some	caution	given	the	small	sample	size	and	high	
attrition	rates	in	most	studies.		
2.5	Discussion	
This	systematic	review	aimed	to	examine	the	evidence	for	physical	activity	and	
psychological	coping	strategies	in	the	management	of	PDN.	Two	studies	of	physical	activity	and	
two	studies	of	psychological	therapy	were	identified.	The	identified	studies	were	heterogeneous	
with	methodological	limitations.	The	findings	suggest	that	physical	activity	has	the	potential	to	
improve	overall	physical	and	mental	wellbeing,	and	possibly	to	arrest	an	increase	in	pain	
compared	to	control	arms.	In	the	one	study	that	reported	adverse	effects	(Ahn	and	Song,	2012),	
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none	were	noted	beyond	transient	pain	increases	or	hypoglycaemia.	Mindfulness	relaxation	did	
not	have	a	significant	effect	on	pain	or	quality	of	life,	though	the	intervention	studied	involved	
very	little	actual	contact	time	with	a	professional.	CBT	was	shown	to	improve	pain	and	quality	of	
life	in	a	single	study,	but	this	was	a	small	pilot	study	that	was	significantly	affected	by	participant	
dropout.	
2.5.1	Physical	activity	for	PDN	and	DM	
From	the	studies	that	investigated	physical	activity,	Ahn	&	Song	(2012)	demonstrated	
improvements	in	SF36	subscales	in	the	intervention	arm,	though	this	might	be	due	to	
improvement	in	general	physical	and	emotional	health,	as	much	as	impact	on	PDN	specifically.	
There	was	inconclusive	evidence	regarding	the	impact	on	pain;	in	fact	it	appeared	the	significant	
findings	in	Ahn	&	Song	(2012)	and	Dixit,	Maiya	and	Shastry	(2014)	were	due	to	control	arms	
worsening	rather	than	intervention	arms	improving.	It	maybe	that	people	with	PDN	need	to	be	
more	active	(physically)	in	order	to	stand	still	(in	terms	of	pain).		
There	are	known	methodological	difficulties	using	pain	self-report	measures	to	objectify	a	
subjective	experience	(Moore,	2013).	Attention	toward	an	experience,	in	order	to	rate	it,	can	
often	increase	the	pain	severity	(McCabe	et	al.,	2005;	van	Damme	et	al.,	2009).	This	attention	can	
lead	to	bias	in	the	reporting	of	pain	experience	both	at	the	pre-	and	post-intervention	stages	of	an	
intervention	trial.	However,	these	rating	scales,	whether	VAS	or	NRS,	have	been	used	in	the	
majority	of	pain	research	to	represent	an	outcome	of	importance	to	patients	with	PDN	(Schneider	
et	al.,	2014).		
The	eligibility	criteria	for	this	review	specified	the	inclusion	of	pain	severity	as	an	outcome	
within	the	included	studies.	Other	measures	of	function	or	quality	of	life	were	included	as	
secondary	outcomes	of	the	review	where	reported.	This	study	was	not	designed	to	locate	all	
studies	that	investigated	the	effect	of	physical	activity	on	quality	of	life	in	PDN.	Although	the	
results	presented	here	do	suggest	engagement	in	physical	activity	may	have	positive	effects	on	
PDN-related	quality	of	life,	this	cannot	be	made	with	certainty	at	this	point.	The	review	results	
were	broadly	congruent	with	a	recent	Cochrane	overview	of	physical	activity	for	chronic	pain,	
which	found	inconsistent	results	for	changes	in	pain	severity	but	more	consistent	improvements	
in	measures	of	physical	function	(Geneen	et	al.,	2017).	
Considering	diabetes	more	generally,	public	health	research	clearly	demonstrate	that	
increasingly	sedentary	behaviours	and	changing	diets	are	contributing	to	the	rising	prevalence	of	
the	condition	(Department	of	Health,	2010a;	Alberti	and	Zimmet,	2013).	There	are	few	extrinsic	
barriers	to	most	adults	achieving	the	recommended	levels	of	physical	activity	(Department	of	
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Health,	2010a,	2011);	rather	internal	motivation	to	increase	and	sustain	activity	levels	is	shown	to	
be	a	limiting	factor	(Sørensen,	Skovgaard	and	Puggaard,	2006).	Irrespective	of	whether	physical	
activity	has	benefits	to	PDN	for	pain	reduction	or	quality	of	life	increase,	physical	activity	has	
positive	benefits	for	managing	diabetes.		
The	DARE	(Diabetes	Aerobic	and	Resistance	Exercise)	trial	evaluated	the	effectiveness	of	
aerobic	and/or	resistance	exercise	compared	to	a	control	arm,	for	improving	glycaemic	control	
and	so	reducing	the	risk	of	macrovascular	and	microvascular	complications	of	DM	(Sigal	et	al.,	
2007).	The	study	(n=251	adults	with	T2DM)	found	combined	exercise	(n=64,	aerobic	and	
resistance,	3x/week,	22	weeks)	reduced	HbA1c	by	-0.51%	(CI	-0.87	to	-0.14)	compared	to	the	
control	arm	(n=63,	p-0.007	between	group	comparison).	Aerobic	and	resistance	exercise	were	
also	beneficial	compared	to	control	arm,	but	less	so	than	a	combination	of	both.	A	later	health	
economic	evaluation	also	found	the	increased	investment	in	delivering	the	combined	exercise	
programme	(Canadian	$40,050,	control	$31,075)	cost	effective	for	increasing	quality	adjusted	life	
years	(QALYs)	(Combined	exercise	$4792/QALYs,	control	$37,872/QALYs)	(Coyle	et	al.,	2012).	Such	
research	highlights	that	strategies	to	increase	physical	activity	in	people	with	diabetes	have	health	
benefits	for	other	aspects	of	DM,	if	not	yet	demonstrated	for	PDN.		
The	low	recruitment	and	high	attrition	rates	within	the	studies	included	in	this	review	
suggest	recruitment	and	retention	to	physical	activity	programmes	needs	further	research	to	
inform	the	development	of	clinical	services.	Further	research	is	required	to	understand	the	
patients’	perceptions	of	physical	activity,	what	potential	benefits	they	consider	and	what	barriers	
maybe	present	to	them	accessing	physical	activity.	
2.5.2	Psychological	interventions	for	PDN	
The	psychological	coping	interventions	studied	were	CBT	(Otis	et	al.,	2013)	and	mindfulness	
relaxation	(Teixeira,	2010).	There	was	insufficient	evidence	from	these	studies	to	make	
recommendations	on	these	approaches	for	PDN.	While	the	results	from	Otis	et	al.	(2013)	appear	
encouraging,	the	high	dropout	rate	limits	the	findings.	The	authors	note	the	dropouts	occurred	by	
session	three	of	eleven.	One	possible	explanation	is	lack	of	‘buy-in’	to	CBT	lead	to	early	dropout.	
Guidance	from	the	British	Pain	Society	stresses	that	engagement	with	PMPs	cannot	be	coerced	
(BPS,	2013)	and	assessment	must	be	made	of	the	person’s	readiness	to	adopt	alternative	physical	
and	psychological	behaviours.	It	is	possible	the	participants	who	dropped	out	from	CBT	conceive	
their	pain	as	due	to	nerve	damage	or	disease	related	processes,	and	view	psychological	treatment	
as	irrelevant	to	their	pain	experience	(Martin,	Daniel	and	Williams,	2014).	
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As	noted	in	section	2.1,	the	only	existing	systematic	review	for	psychological	interventions	
in	neuropathic	pain,	van	de	Wetering	et	al.	(2010),	had	been	heavily	criticized	(Eccleston	et	al.,	
2010).	In	order	to	address	these	criticisms,	the	Cochrane	Collaboration	conducted	a	systematic	
review	for	psychological	therapies	in	neuropathic	pain	(Eccleston,	Hearn	and	Williams,	2015).	
Eccleston,	Hearn	and	Williams,	(2015)	only	included	studies	of	randomised	and	controlled	design;	
the	intervention	had	to	be	based	on	recognised	psychological	approaches	and	retain	a	minimum	
20	participants	in	each	arm	at	follow-up.	Trials	with	small	sample	sizes	are	at	risk	of	over-
estimating	the	effects	of	treatment	because	of	regression	to	the	mean,	amongst	other	sources	of	
bias	(Moore	et	al.,	2010).	The	review	identified	two	studies	for	inclusion:	CBT	for	pain	in	spinal	
cord	injury	(Heutink	et	al.,	2012)	and	psychotherapy	in	‘Burning	mouth	syndrome’	(Miziara	et	al.,	
2009),	neither	of	which	demonstrated	beneficial	effects.	The	two	psychological	intervention	
studies	included	in	this	current	review	would	have	been	excluded	on	the	criterion	of	insufficient	
sample	size.	At	the	time	of	developing	the	search	protocol	used	for	this	chapter	(2013),	the	
Cochrane	review	had	not	been	published;	the	aim	of	this	chapter	was	to	find	all	published	
research	specific	to	PDN,	so	no	lower	sample	size	limit	was	set.	Since	both	these	reviews	found	
little	published	evidence,	it	is	clear	there	is	currently	a	scarcity	of	research	into	management	of	
the	impact	of	neuropathic	pain	by	psychologically	directed	interventions.		
2.5.3	Further	research	
The	population	who	experience	DM	and	PDN	is	increasing	(Alberti	and	Zimmet,	2013).	PDN	
impacts	on	many	day-to-day	functions	such	as	activity	and	walking,	and	is	distressing	(Alleman	et	
al.,	2015).	The	available	analgesics	are	not	sufficient	to	ameliorate	these	impacts	(Finnerup	et	al.,	
2015),	and	there	is	a	lack	of	concordance	between	the	range	of	impacts	and	the	current	
management	approaches	for	PDN.	As	health	services	reconfigure	to	deal	with	the	increasing	
burden	of	chronic	diseases	such	as	diabetes,	pain	management	services	may	come	under	
increasing	pressure	to	help	manage	this	condition.	Currently	the	evidence	base	for	the	two	key	
pillars	of	PMPs	is	scarce	and	of	low	quality.		
NICE	highlight	that	neuropathic	pain	has	greater	effect	on	quality	of	life	than	other	pain	
conditions	even	when	pain	severity	is	controlled	for,	and	it	is	unclear	what	other	factors	are	
responsible	for	mediating	quality	of	life	(NICE,	2013a).	NICE	(2013a)	recommended	in-depth	
qualitative	research	with	people	who	experience	neuropathic	pain	to	elucidate	factors	deemed	
important	to	improve	their	quality	of	life.		
Research	trials	into	physical	activity	had	difficulty	recruiting	and	retaining	participants.	It	
would	be	profitable	to	explore	peoples’	opinions	of	physical	activity,	to	understand	issues	of	
engagement	and	motivation	for	physical	approaches.	Similarly,	the	one	study	with	CBT	had	
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significant	participant	drop	out,	early	in	the	intervention.	(Otis	et	al.	2013).	It	would	be	beneficial	
to	understand	whether	people	with	PDN	view	psychological	interventions	as	appropriate	and	
relevant	to	the	problems	they	have	to	manage.		
The	perspective	of	clinicians	to	these	strategies	was	also	considered	important	to	explore.	
The	clinical	opinion	diabetes	clinicians	have	for	PMP	strategies	would	affect	the	likelihood	of	them	
endorsing	and	referring	their	patients	with	PDN	to	pain	services	for	management.	The	perspective	
of	pain	clinicians	was	also	important,	to	understand	whether	they	felt	people	with	PDN	could	fit	
into	existing	pain	services,	or,	if	necessary,	what	alterations	might	be	required.		
The	explorative	nature	of	these	questions	best	suits	qualitative	approaches	(Petty,	
Thomson	and	Stew,	2012a).	The	methodology	and	methods	used	for	both	these	qualitative	
studies	are	described	in	the	following	Chapter	3,	with	results	for	patients	detailed	in	Chapter	4,	
and	clinicians	detailed	in	Chapter	5.		
2.6	Conclusions	
A	central	tenet	of	PMPs	aims	to	assist	people	to	improve	their	physical	capacity.	The	two	
studies	investigating	physical	activity	contain	significant	methodological	bias,	notably	high	
participant	attrition	rate	lost	to	follow	up.		
The	other	tenet	of	PMPs	is	psychological	coping,	yet	the	paucity	of	the	studies	retrieved	
does	not	allow	firm	conclusions	to	be	made	on	the	best	psychological	strategies	to	help	people	to	
cope	with	their	persistent	pain.	
	
The	next	chapter	will	detail	the	methodological	considerations	for	two	interview	studies,	
with	people	who	experience	PDN	and	with	clinicians	who	are	involved	in	its	management.	The	
chapter	will	detail	the	philosophical	approach	with	the	inherent	assumptions	that	are	then	
present,	and	will	detail	the	methods	used	for	these	studies.		
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Chapter	3	–	Methodology	and	methods:	patient	and	clinician	interviews	
This	chapter	opens	by	considering	what	attributes	are	necessary	for	quality	and	rigour	in	
qualitative	research.	The	philosophical	position	and	methodological	considerations	for	the	
interview	studies	are	then	examined.	The	nature	of	the	experience	being	investigated	(living	with	
PDN),	the	rationale	for	using	specific	research	methods	(one	to	one	interviews)	and	the	analytical	
framework	used	(thematic	analysis)	are	then	considered.	The	methods	used	to	recruit	participants	
and	collect	the	data	are	subsequently	provided.	Justification	is	also	provided	for	the	research	
methods	with	consideration	of	the	strengths	and	limitations	of	the	approach.	
3.1	What	constitutes	high	quality	qualitative	research?	
The	products	of	research	should	not	be	accepted	blindly,	but	rather,	considered	critically.	
This	means	considering	whether	the	research	process	is	likely	to	have	produced	results	and	
conclusions	that	can	be	considered	‘true’.	The	standards	for	critical	appraisal	depend	on	the	
ontological	and	epistemological	perspectives	of	the	research	(Mays	and	Pope,	2000;	Pope	and	
Mays,	2006).	These	standards	need	to	be	considered	by	the	researcher	when	designing	the	
research	study	and	collecting	data,	as	well	as	when	producing	dissemination	reports.	These	
standards	must	also	be	considered	by	research	consumers	who	will	critically	appraise	the	
research	produced,	in	order	to	consider	the	implications	for	their	clinical	practice	(Katrak	et	al.,	
2004).		
Research	produced	within	a	quantitative	framework	should	provide	results	that	are	valid	
and	reliable.	This	means	valid	results	accurately	reflect	the	reality	of	the	phenomena	being	
investigated.	Reliable	results	are	those	shown	to	be	repeatable	and	so	generalizable	from	the	
study	sample,	to	the	wider	population.		
The	application	of	terms,	such	as	validity	and	reliability,	to	qualitative	research	has	been	
disputed.	Authors	contend	that	attempts	to	use	these	terms	for	quality	appraisal	in	a	qualitative	
framework,	force	this	type	of	research	to	be	measured	against	inappropriate	goal	posts	(Yardley,	
2000;	Sandelowski	and	Barroso,	2002;	Rolfe,	2006).	The	underlying	philosophical	positions	of	
qualitative	research	are	that	phenomena,	particularly	social	and	personal	experience,	are	
dependent	on	a	variety	of	factors,	and	there	is	not	one	universal	‘truth’.	It	is	inappropriate	to	ask	
whether	a	qualitative	research	study	has	‘valid’	conclusions,	since	there	is	no	assumption	that	a	
‘true’	result	exists.	Equally,	it	is	not	appropriate	to	expect	to	obtain	similar	results	by	repeating	a	
qualitative	research	study,	as	the	small	sample	group	and	differing	sociocultural	factors	involved	
would	inevitably	mean	conclusions	could	differ	(Yardley,	2000;	Rolfe,	2006).	
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This	does	not	mean	qualitative	research	is	not	worthwhile	per	se,	rather	the	consumer	of	
the	research	must	consider	if	the	research	context	is	applicable	to	their	clinical	area.	For	clinical	
health	research	this	means	considering	whether	the	social	and	cultural	variables	in	the	research	
population	mirror	those	variables	in	the	clinical	population	in	which	the	research	consumer	
works.	When	considering	the	quality	of	qualitative	research,	it	is	important	to	have	transparency	
of	the	contextual	and	situational	settings,	as	well	as	the	clinical	profile	of	the	participants.	
Research	consumers	must	also	consider	whether	the	study	methods	used,	are	an	appropriate	
match	between	research	questions	and	the	stated	conclusions	(Pope,	Ziebland	and	Mays,	2000).		
In	the	following	sections	the	methodological	considerations	for	each	interview	study	will	be	
considered	separately	or	together,	as	needed	for	clarity.	Strategies	that	were	used	to	develop	and	
maintain	quality	research	will	be	outlined	in	appropriate	sections.	
3.1.1	How	is	research	quality	appraised?	
The	strategies	used	to	assure	research	quality	in	qualitative	studies	has	been	the	subject	of	
a	review	(Reynolds	et	al.,	2011).	Reynolds	et	al.	(2011)	highlight	two	narratives	in	the	literature:	
that	quality	appears	to	be	demonstrated	either	by	reflection	on	the	research	process	over	the	
lifespan	of	the	project	–	Process	orientated	quality	assurance,	or	at	the	point	of	research	
dissemination	–	Output	orientated	quality	assurance.		
The	process-orientated	option	relies	on	transparency	at	key	decision	points	on	the	project	
journey,	reflections	on	interpretation	throughout	the	analysis	and	a	demonstration	of	researcher	
engagement	with	these	processes.	The	following	methodological	sections	will	describe	these	
decisions	and	the	procedures	in	place	to	ensure	research	quality	through	data	gathering	and	
subsequent	analysis.		
It	is	the	author’s	responsibility	to	include	sufficient	detail	of	the	sample	demographics,	
recruitment	and	analytic	assumptions	amongst	other	details,	so	that	the	research	consumer	can	
evaluate	trustworthiness.	Within	quantitative	research,	checklists	have	been	established	to	help	
the	consumer	consider	quality	-	NICE	and	the	Scottish	Intercollegiate	Guidelines	Network	are	two	
cited	examples.	A	systematic	review	of	existing	checklists	for	qualitative	research	found	22	in	
existence,	suggesting	uncertainty	regarding	quality	appraisal	of	qualitative	research	(Tong,	
Sainsbury	and	Craig,	2007).	
The	review	by	Tong,	Sainsbury	and	Craig	(2007)	led	to	the	Consolidated	criteria	for	
Reporting	Qualitative	research	(COREQ),	a	32-item	checklist	that	was	created	using	expert	
consensus	to	combine	existing	checklists	and	consolidate	them	into	three	domains:	Domain	1	–	
research	team	and	reflexivity,	Domain	2	–	study	design	and	Domain	3	–	analysis	and	findings.	The	
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COREQ	checklist	aims	to	help	the	consumer	critically	evaluate	the	presented	research,	in	order	to	
evaluate	the	methodological	strength	and	the	utility	of	the	results	in	their	clinical	work.	This	
checklist	has	been	used	when	writing	Chapters	3,	4	and	5	to	ensure	that	the	studies	were	
presented	with	sufficient	detail	to	allow	full	critical	appraisal.	Importantly,	as	with	checklists	for	
quantitative	research,	the	COREQ	checklist	does	not	rate	the	quality	of	the	research	directly,	but	
provides	a	critical	framework	for	use	by	the	research	consumer	to	decide	upon	the	quality	and	
applicability.	
3.2	Introduction	to	patient	study	
Currently	the	management	of	PDN	is	nearly	entirely	pharmacological	(Bril	et	al.,	2011;	NICE,	
2013a),	yet	patient	satisfaction	with	the	effectiveness	of	these	medication	strategies	has	been	low	
(Gore	et	al.,	2006;	Sadosky,	Hopper	and	Parsons,	2014).	
While	PMPs	have	been	shown	to	be	clinically	effective	(Williams,	Eccleston	and	Morley,	
2012;	Phillips	et	al.,	2008),	the	effectiveness	cannot	be	assumed	to	transfer	to	other	populations	
with	distinct	pathologies	(Turk	and	Okifuji,	2001).	PMPs	are	delivered	to	people	who	have	
persistent	pain	of	any	cause,	yet	because	of	the	differences	in	neuropathic	pain	outlined	in	
Section	1.5.3,	it	may	be	appropriate	to	refine	the	content	of	PMPs	specifically	for	neuropathic	
pain	problems.			
No	research	to	date	has	asked	people	with	PDN	how	they	currently	manage	impacts	with	
the	potential	that	personal	experience	may	hold	useful	information	to	inform	coping	strategies.	It	
is	unknown	whether	people	with	PDN	would	find	adjunctive	pain	management	strategies,	
particularly	physical	and	psychological	approaches,	to	be	acceptable	or	appropriate	for	the	
impacts	of	PDN.		
3.2.1	Patient	study	aims	
The	patient	interview	aimed	to	explore:	1)	how	PDN	impacts	on	participants’	lives,	2)	the	
strategies	participants	have	developed	to	manage	these	impacts,	3)	the	participants’	perspectives	
on	the	potential	utility	of	PMP	strategies	for	coping	with	persistent	pain.	
3.2.2	Patient	study	objectives	
The	objective	of	this	study	was	to	conduct	one-to-one	interviews,	either	in	person	or	by	
telephone,	with	people	who	experience	PDN.		
3.2.3	Patient	study	research	questions	
1) What	are	the	impacts	of	PDN	on	the	participant’s	life?		
2) What	strategies	do	participants	employ	to	manage	the	impact	of	PDN	on	their	lives?		
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3) What	are	their	views	on	physical	activity	strategies	to	manage	the	impact	of	PDN?	
4) What	are	their	views	on	pain	coping	strategies	to	manage	the	impact	of	PDN?		
5) How	do	people	who	may	have	multiple	diabetic	co-morbidities	prioritise	the	management	
of	their	health	issues?	
3.3	Introduction	to	clinician	study	
The	symptoms	of	PDN	and	consequent	functional	limitations,	are	under-reported	by	
patients	and	not	routinely	inquired	about	by	health	care	professionals	(HCP)	(Sadosky,	Hopper	
and	Parsons,	2014).	General	Practitioners	(GPs)	and	diabetic	specialist	nurses	(DSN)	have	the	
principal	responsibility	for	managing	diabetes	in	primary	care	(Department	of	Health,	2010b);	only	
patients	with	more	complex	medical	requirements	should	be	referred	on	and	managed	in	
secondary	care	clinics	(Department	of	Health,	2010b;	NHS	BNSSG,	2012).	Diabetes	can	lead	to	a	
range	of	secondary	complications	which	means	a	person	could	be	under	the	care	of	many	
different	specialities	concurrently	for	example:	renal,	cardiovascular,	vascular,	and	ophthalmology	
clinics.	
In	England,	the	QOF	directs	primary	care	management	of	diabetes.	It	stipulates	the	need	to	
gather	specific	data	from	patients	and	provide	specific	clinical	services	to	improve	care.	There	are	
financial	incentives	for	primary	care	practices	that	comply	with	this	guidance.	The	QOF	system	for	
2016/17	included	targets	for	management	of	glycaemic	control,	hypertension,	regular	foot	
assessment	and	enhancing	self-management.	Foot	assessment	was	retained,	aiming	to	identify	
patients	at	risk	of	diabetic	ulcers	and	potential	amputations.	There	were	no	QOF	indicators	for	the	
management	of	pain	related	to	diabetes	(NHS	Employers,	2016)	resulting	in	a	lack	of	external	
incentive	for	clinicians	to	ask	about	this	type	of	pain.		
Discrepancies	have	been	identified	between	patient	and	HCP	experiences	of	PDN	
assessment.	Daousi	et	al.	(2004)	found	13%	of	their	population	with	PDN	had	never	reported	their	
pain	symptoms	to	a	HCP	and	39%	had	never	received	any	form	of	treatment.	More	recently,	
Sadosky,	Hopper	and	Parsons	(2014)	found	83%	of	the	patient	population	reported	pain	
consistent	with	PDN,	but	only	41%	had	received	an	official	diagnosis,	suggesting	that	PDN	may	
remain	under	diagnosed	and	managed.	When	symptoms	were	raised,	72%	of	patients	felt	their	
pain	was	only	discussed	‘in	passing’,	yet	45%	of	HCP	felt	these	discussions	were	‘in	detail’	
(Sadosky,	Hopper	and	Parsons,	2014).	Potential	barriers	to	communication	included	difficulty	for	
patients	in	describing	their	symptoms	and	the	perception	that	the	presence	of	pain	indicated	
poor	diabetes	management	(Sadosky,	Hopper	and	Parsons,	2014).	Taylor-Stokes	et	al.	(2011)	
found	HCPs	underestimated	pain	intensity	compared	to	patient	reports	in	nearly	half	of	cases.		
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When	pain	is	raised,	the	recommended	management	is	entirely	based	on	medication,	see	
Chapter	1,	section	1.3	for	details.	These	medication	strategies	have	NNT	between	four	and	eight,	
which	leaves	many	people	with	sub-optimally	managed	pain	and	related	distress.	A	recent	survey	
of	500	clinicians	who	treated	people	with	PDN	(50%	GPs,	30%	specialist	physicians	including	
diabetologists	and	pain	clinicians,	20%	nurses)	found	87%	wanted	more	information	on	non-
pharmacological	strategies	they	could	employ	or	recommend	to	their	patients	with	PDN	(Sadosky,	
Hopper	and	Parsons,	2014).	This	suggests	that	clinicians	are	mindful	that	medication	lacks	efficacy	
and	have	identified	a	need	for	adjunctive	strategies.		
If	adequate	pain	control	cannot	be	achieved	with	medication,	the	guidance	documents	
suggest	onward	referral	to	secondary	pain	services.	An	audit	of	UK	national	pain	services	found	
patients	with	pain	classified	as	neuropathic	accounted	for	856	of	9528	(9%)	patient	contacts	(BPS,	
2012).	Examination	of	the	ICD-10	classification	(International	Statistical	Classification	of	Diseases	
and	Related	Health	Problems,	World	Health	Organisation)	assigned	by	clinicians	to	their	patient	
cases,	found	musculoskeletal	pain	accounted	for	67%	of	classifications	and	codes	related	to	PDN	
were	not	present	in	the	top-25	frequently	used	codes	(BPS,	2012).	The	British	Pain	Society	report	
specifically	highlighted	that	neuropathic	pain	appears	under-represented	in	pain	clinics.	
Patients	are	usually	referred	to	PMPs	from	pain	clinics,	rather	than	direct	access;	therefore,	
if	neuropathic	pain	were	under-represented	in	pain	clinic,	it	is	likely	under-represented	in	PMPs.	
The	experience	of	pain	clinicians	who	have	treated	people	with	neuropathic	pain	in	PMPs,	suggest	
these	patients	appear	to	require	adapted	packages	of	PMP	components,	rather	than	those	
traditionally	delivered	for	musculoskeletal	pain	(Daniel	et	al.,	2015).	They	suggest	the	differences	
in	the	symptom	profile	and	impact	between	musculoskeletal	pain	and	neuropathic	pain	make	
certain	common	approaches	to	pain,	such	as	pacing,	unsuccessful	or	irrelevant	to	patients	with	
neuropathic	pain	(Daniel	and	Van	der	Merwe,	2006;	Daniel	et	al.,	2007).	Research	has	highlighted	
the	range	of	opinions	held	by	patients	with	neuropathic	pain	when	considering	the	interaction	of	
psychology	and	pain,	and	whether	psychological	therapy	was	considered	appropriate	(Martin,	
Daniel	and	Williams,	2014).	These	were	discussed	in	detail	in	Chapter	1,	section	1.5.3.		
Section	1.6	highlighted	that	the	patient	perspectives	on	PMP	strategies	were	largely	
unknown.	The	perspectives	of	clinicians	involved	in	diabetes	and	pain	management	to	using	pain	
management	strategies	with	neuropathic	pain,	were	also	unknown.	Diabetes	clinicians	play	a	
central	role	in	managing	PDN	and	potentially	referring	onto	other	services	to	help	their	patients	
manage	PDN.	Pain	clinicians	have	experience	of	applying	PMP	strategies	with	a	variety	of	pain	
conditions	and	may	have	valuable	clinical	insight.				
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3.3.1	Clinician	study	aims	
The	clinician	interview	study	aimed	to	understand	clinicians’	approaches	to	the	
management	of	PDN	and	their	views	on	whether	physical	activity	and	psychological	coping	
strategies	might	be	appropriate	for	this	population.	It	used	their	experience	of	diabetes,	PDN	and	
pain	management	to	understand	how	the	content	and	delivery	of	PMPs	may	need	to	be	tailored	
to	this	patient	group.	
3.3.2	Clinician	study	objectives	
The	objective	was	to	conduct	one-to-one	interviews	with	a	range	of	clinicians	who	were	
primary	care	generalists,	or	specialist	in	managing	diabetes	or	pain.		
3.3.3	Clinician	study	research	questions	
1) How	do	clinicians	involved	in	diabetes	management,	currently	help	patients	to	manage	
PDN?		
2) What	are	clinician’s	perspectives	on	the	usefulness	of	physical	activity	as	a	means	to	
manage	PDN?		
3) What	are	clinician’s	perspectives	on	the	usefulness	of	psychologically	based	pain	coping	
strategies	as	a	means	to	manage	PDN?	
3.4	Research	methodology	
3.4.1	Patient	study	–	Ontology	
Ontology	is	the	philosophical	study	into,	and	questions	about	the	reality	of	nature	and	
existence.	It	asks	questions	about	Truth	and	Being,	that	is,	what	can	be	said	to	exist	(Petty,	
Thomson	and	Stew,	2012a).	
There	are	two	opposed	views	on	the	nature	of	truth	–	the	positivist	paradigm	proposes	
there	is	truth	present	in	the	world,	which	can	be	discovered	with	hypothesis	generation	and	
tested	with	objective	experimental	research	designs.	These	designs	provide	numerical	data	that	
will	either	support	or	refute	the	hypothesis.	Post-positivism,	in	contrast	with	Positivism,	accept	
empirical	data	have	an	element	of	error	and	so	the	absolute	truth	of	reality	may	not	be	described	
by	experimentation.	The	Interpretivist	paradigm	posits	that	some	truths,	such	as	personal	
experience,	are	not	quantifiable,	so	these	experiences	cannot	be	reduced	to	numerical	data	
because	the	personal	experience	is	effected	by	social	context,	personal	beliefs	and	psychological	
variables	(Cutcliffe	and	McKenna,	2002;	Petty,	Thomson	and	Stew,	2012a,	2012b).	The	experience	
of	pain	could	be	investigated	under	both	paradigms,	so	the	appropriate	method	must	be	selected	
to	answer	the	specific	research	questions.		
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The	personal	subjective	experience	of	‘pain’	is	an	emergent	neurocognitive	event	that	
arises	from	the	interactions	of	multiple	body	systems	including	the	peripheral	nervous	system,	
spinal	cord,	multiple	brain	areas,	the	immune	and	endocrine	systems	(Thacker	and	Moseley,	
2012;	Quintner	et	al.,	2008;	Thacker,	2015).	In	this	context,	the	term	‘emergent’	highlights	that	
the	experience	of	pain	-	what	it	is	like	for	that	person	-	is	not	a	linear	process	located	in	pain	
pathways	and	pain	centres	as	suggested	by	René	Descartes	(Cohen	et	al.,	2011),	but	a	dynamic	
process	dependent	upon	many	variables	(Chi	et	al.,	2012).	Conceptual	models	such	as	the	MOM	
(Gifford,	1998a)	and	the	Neuromatrix	Theory	(Melzack,	1999,	2001)	highlight	the	breadth	of	
factors	that	must	be	considered	to	begin	to	understand	pain.	Psychological	factors	such	as	fear	of	
(re)injury	(Vlaeyen	and	Linton,	2000),	raised	worry	about	pain	severity	(catastrophization)	or	
potential	futures	with	pain	(Turner,	Jensen	and	Romano,	2000),	and	emotional	distress	(Campbell,	
Clauw	and	Keefe,	2003)	have	been	demonstrated	to	affect	the	impact	any	structural	pathology	
may	have	on	a	person’s	experience.	In	addition,	the	social	environment	a	person	lives	in	and	their	
social	support	networks	have	been	demonstrated	to	affect	the	perceived	impact	of	pain	(Kendal,	
Linton	and	Main,	1997).	The	social	environment	also	has	an	effect	on	management	of	diabetes,	
with	greater	social	support	associated	with	improved	outcomes	and	positive	changes	in	lifestyle	
(Strom	and	Egede,	2012).		
The	patient	study	aimed	to	explore	the	impact	of	PDN	on	the	person	and	how	they	
managed	that	impact	-	the	experience	or	phenomenon	of	living	with	and	managing	PDN.	Due	to	
the	wide	range	of	psychological	and	other	variables	described	earlier,	research	methods	that	used	
an	Interpretivist	ontological	paradigm	were	most	appropriate	to	answer	the	research	questions.	
These	questions	do	not	have	a	predetermined	expectation	of	what	might	be	found.	There	is	no	
stated	hypothesis;	rather,	they	aim	to	explore	the	personal	experience	of	participants.	Such	
exploratory	questions	demand	a	qualitative	approach	(Smith,	Bekker	and	Cheater,	2011).	It	would	
not	be	appropriate	to	use	post-positivist	research	methods	such	as	questionnaires	with	closed-
ended	questions.	The	construction	of	a	questionnaire	by	researchers	who	have	no	experience	of	
the	problem	and	imperfect	knowledge	of	the	condition	would	limit	the	participant’s	potential	
responses.	Questionnaires	could	have	been	constructed	with	open-ended	questions	which	would	
have	allowed	participants	to	report	discursively	about	their	experiences	(Yardley,	2000).	This	
approach	would	however	have	prevented	the	interviewer	from	interacting	with	the	participant	to	
ensure	as	clear	an	understanding	as	possible,	of	their	responses.		
3.4.2	Patient	study	–	Epistemology	
Epistemology	is	the	philosophical	perspective	on	ways	by	which	we	can	acquire	knowledge.	
There	must	be	concordance	between	ontology	and	epistemology	for	any	research	programme	to	
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be	coherent	(Carter	and	Little,	2007).	Since	the	ontological	perspective	is	Interpretivist	–	the	
subjective	experience	of	the	participants	is	created	by	their	interpretation	of	many	variables	–	it	
would	not	be	concordant	to	take	objective	measures	such	as	walking	speed	or	body	temperature	
to	be	an	accurate	representation	of	their	experience.	This	research	programme	accepts	the	
experience	of	participants	is	constructed	by	their	thoughts,	beliefs,	and	social	world	–	a	social	
constructionist	epistemological	position.	People	with	PDN	are	best	placed	to	relate	that	
phenomenon	within	the	research	process	through	their	spoken	words.	It	is	important	that	no	
judgement	is	made	about	the	impacts	people	describe	or	management	strategies	they	may	have	
tried.		
To	explore	a	phenomenon	-	the	experience	of	living	with	PDN	-	a	number	of	research	
methods	are	possible,	most	commonly	the	use	of	one-to-one	interviews	or	focus	groups	(Taylor	
and	Francis,	2013).	The	research	questions	in	this	study	seek	to	understand	the	personal	
experience	and	viewpoint	of	each	participant.	The	epistemological	position	of	this	research	
accepts	the	participant	experience	can	be	made	meaningful	by	spoken	words,	and	the	researcher	
will	interpret	these	words	with	sufficient	accuracy	to	reflect	the	participant’s	experience	
(Darlaston-Jones,	2007).	If	the	research	questions	were	seeking	reasons	for	the	impact,	or	a	group	
consensus	of	perspectives	on	physical	activity	and	psychological	coping,	focus	groups	could	have	
been	used.	Focus	groups	can	be	used	to	understand	why	certain	viewpoints	and	perspectives	are	
held	by	participants	(Bryman,	2012).	The	process	of	group	discussion	can	give	insight	to	the	
elements	of	agreement	and/or	disagreement	about	a	topic,	allowing	the	researcher	insight	into	
the	differing	perspectives	held.	Focus	groups	can	be	a	method	for	reaching	consensus	on	a	topic,	
but	a	limitation	in	this	context	is	that	strong	personalities	can	dominate.	Less	forthcoming	
personalities	may	acquiesce	to	the	consensus	without	agreement	(Bryman,	2012).		
Other	forms	of	non-verbal	communication,	such	as	photographs	or	artwork	have	been	used	
to	explore	the	meaning	and	experience	of	pain.	Studies	have	used	photo	essays	with	adults	who	
had	persistent	pain	to	document	their	experiences	of	living	with	pain	(Baker	and	Wang,	2006),	or	
in-depth	interviews	exploring	how	the	engagement	in	art	supports	well-being,	despite	persistent	
pain	(Reynolds	and	Prior,	2003).	These	methods	did	not	fit	the	pragmatic	nature	of	the	research	
questions.	For	these	reasons	one-to-one	interviews	were	considered	the	most	appropriate	data	
collection	method	(Kvale,	1996;	Doody	and	Noonan,	2013).	
3.4.3	Clinician	study	–	Ontology	
This	study	asked	clinicians	about	their	management	of	PDN	and	their	perspectives	on	PMP	
strategies	based	upon	routine	clinical	practice.	Medical	decisions	are	often	effected	by	subtle	
nuances	of	clinical	presentation,	making	no	two	patients	the	same	(Butler,	2000;	Croskerry,	2000).	
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Although	the	drive	is	towards	evidence-based	health	care,	specific	clinical	guidelines	do	not	exist	
for	the	patient	who	presents	with	a	range	of	health	co-morbidities	(Greenhalgh,	Howick	and	
Maskrey,	2014).	Indeed,	for	patients	who	have	multiple	concurrent	co-morbidities,	clinical	
guidelines	can	actively	contradict	one	another.	A	further	consideration	is	that	evidence-based	
medicine	puts	empirical	studies	as	the	highest	level	of	evidence.	There	is	a	challenge	to	
interpreting	population	data	in	relation	to	the	single	case	study	patient	who	sits	in	front	of	a	
clinician	(Anjum,	Kerry	and	Mumford,	2015;	Eriksen	et	al.,	2013).	This	leaves	clinicians	to	act	as	
much	as	artists	as	scientists,	needing	to	make	decisions	based	on	interpretation	of	the	patient	
narrative	and	their	intuition,	as	well	as	objective	medical	data	(Buckingham	and	Adams,	2000;	
Greenhalgh,	2002;	Edwards	et	al.,	2004).	An	Interpretivist	ontological	paradigm	was	appropriate	
for	this	study	also.		
3.4.3	Clinician	study	–	Epistemology	
The	perspective	of	a	clinician	is	unique,	developed	through	life	experiences,	professional	
training,	and	clinical	experience.	This	study	aimed	to	explore	the	perspectives	of	a	range	of	
clinicians	on	PDN	management	using	a	social	constructionist	epistemological	position.	It	did	not	
set	out	to	confirm	whether	PMP	strategies	were,	or	were	not,	appropriate.	A	focus	group	method	
was	felt	to	be	problematic	for	a	number	of	reasons;	firstly,	opinions	from	a	range	of	professionals	
were	required	and	perceived	medical	hierarchy	may	inhibit	participants	from	giving	their	true	
perspectives.	Secondly,	the	perspective	of	primary	care	practice	nurses	would	likely	differ	from	
secondary	care	medical	consultants	and	so	consensus	of	opinion,	which	was	not	the	aim	of	the	
study,	would	also	be	unlikely.	Similarly,	the	perspective	of	the	diabetes	multidisciplinary	team	
would	likely	differ	from	the	pain	management	multidisciplinary	team.	Lastly,	potential	
participants	were	likely	to	have	work	commitments	across	multiple	sites	and	work	diaries	that	
would	make	the	practicalities	of	scheduling	a	focus	group	challenging.	For	an	exploratory	study,	
one-to-one	interviews	were	felt	the	most	suitable	method	by	which	to	discuss	these	issues	with	
clinicians	because	it	would	allow	them	to	give	their	individual	perspective	and	opinion	in	
confidence.	
3.5	Selection	and	recruitment	of	participants	
3.5.1	Issues	of	sample	size	
There	is	debate	in	the	research	literature	about	specification	of	appropriate	sample	size	
within	Interpretivist	research	studies	(Higginbottom,	2004;	Marshall,	1996;	Sandelowski,	2000a).	
Sample	size	is	critical	in	post-positivist	research	because	statistical	calculations	depend	on	
sufficient	sample	population	to	account	for	variety	within	other	variables.	Qualitative	
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Interpretivist	studies	are	based	within	an	exploratory	context	and	are	not	driven	by	any	
predetermined	hypothesis.		
When	all	the	variables	that	can	impact	on	pain	are	considered	including	ethnicity,	culture,	
age	and	social	factors,	it	would	be	improbable	to	recruit	a	sample	that	reflected	the	range	of	
potential	variables	and	experience	(Baker	and	Edwards,	2012).	However,	a	claim	may	be	made	to	
support	the	results	of	a	study	if	data	saturation	can	be	demonstrated.	Saturation	has	been	
defined	as	“when	no	new	information	or	themes	are	observed	in	the	data”	(Mack	et	al.,	2005;	
Guest,	2006).	It	has	been	further	suggested	that	good	practice	is	to	specify	an	initial	sample	size	
and	then	further	specify	how	many	further	interviews	will	be	conducted,	without	new	themes	
emerging	(stopping	criterion)	(Francis	et	al.,	2010).	Other	authors	contend	that	this	description	of	
sample	adequacy	can	be	taken	to	mean	simply	counting	thematic	codes.	This	empirical	approach	
to	qualitative	data	is	potentially	at	odds	with	the	philosophical	position	of	these	research	studies	
(Morse,	1995).	Cutcliffe	and	McKenna	(2002)	suggest	a	claim	for	sufficient	data	acquisition	should	
be	based	on	the	richness	and	depth	of	the	data	analysis	produced.	
For	both	interview	studies,	no	statement	of	target	sample	size	was	made.	Rather	it	was	
hoped	to	recruit	patient	participants	who	would	represent	a	spread	of	clinical	severity	and	a	
breadth	of	social	and	cultural	backgrounds.	It	was	necessary	to	exclude	potential	participants	who	
did	not	have	a	suitable	level	of	conversational	English.	This	will	be	further	discussed	in	Inclusion	
and	exclusion	criteria,	below.		
For	the	clinician	study,	it	was	planned	to	recruit	two	representatives	of	the	main	
professions	involved	in	managing	pain	and	diabetes.	The	choice	of	two	participants	could	be	
considered	arbitrary	as	there	is	no	reason	why	two	members	from	a	profession	should	give	a	
representative	voice	on	pain	management	strategies.	A	minimum	of	two	clinicians	was	however	
considered	feasible	and	pragmatic.	
3.5.2	Patient	study	
3.5.2.1	Sample	population	
This	study	required	people	with	a	confirmed	diagnosis	of	PDN.	The	study	was	exploratory;	
thus,	specification	of	sample	size	was	not	set.	Rather,	it	was	hoped	to	achieve	a	wide	range	of	
views	on	PDN	by	recruiting	a	variety	of	age,	sex,	ethnicity	and	duration	of	diabetes	and	PDN.	
3.5.2.2	Inclusion	and	exclusion	criteria	
The	participants	were	required	to	have	painful	neuropathy	secondary	to	diabetes	(Coyne,	
1997;	Higginbottom,	2004),	and	be	able	to	communicate	in	conversational	English.	In	order	to	
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limit	issues	with	translation	of	meaning	between	languages	in	spoken	conversations,	it	was	felt	
appropriate	to	limit	participants	to	those	who	could	engage	in	conversation	without	the	need	of	
an	interpreter	(Temple	and	Young,	2004).	This	does	mean	the	results	and	conclusions	of	this	study	
may	not	apply	to	non-English	speakers.	This	decision	also	implicitly	excluded	people	who	
communicate	by	non-verbal	means.	Sign	language	translates	internal	monologue	to	physical	
gesture	(Temple	and	Young,	2004),	the	production	of	sign	language	could	be	considered	a	further	
layer	of	interpretation,	even	before	the	interpretation	of	a	translator	who	would	be	required	to	
work	with	the	researcher	and	participant.	Such	issues	are	not	complete	barriers	to	qualitative	
research	across	language	divides,	but	the	strategies	for	dealing	with	these	issues	should	be	
transparent.	Other	exclusion	criteria	were	kept	to	a	minimum	-	no	exclusion	was	made	based	on	
sex,	age,	ethnicity	or	type	of	diabetes	–	these	criteria	aimed	to	allow	the	maximum	variety	of	PDN	
experience	and	management	to	be	reflected	by	the	study	participants.	Participants	were	not	
excluded	if	they	had	other	persistent	pain	problems	(for	example,	LBP)	but	it	was	made	clear	that	
the	interview	related	to	impacts	that	they	associated	with	the	PDN	they	experienced,	rather	than	
other	pain	problems.	
3.5.2.3	Recruitment	process	
There	were	two	strategies	for	recruitment,	locally	through	NHS	diabetes	and	PDN	specialist	
clinics,	and	nationwide	by	advertisement	in	Balance,	the	peer-support	magazine	of	DUK.	
For	the	local	NHS	clinics,	patients	who	had	a	confirmed	diagnosis	of	PDN	were	given	a	study	
participant	information	sheet	(PIS)	by	their	clinician	in	clinic,	see	Appendix	3.	The	PIS	included	the	
study	aims,	the	mind-map	of	strategies	used	in	PMPs	and	the	diabetes	complication	
questionnaire.	The	mind-map	and	diabetes	complication	document	are	further	detailed	in	Section	
3.6.	If	they	had	further	questions	or	were	interested	in	being	involved,	the	PIS	had	contact	details	
for	the	researcher.	On	contacting	the	researcher,	further	questions	about	the	study	were	
answered	and	eligibility	confirmed.	A	face-to-face	or	telephone	interview	was	subsequently	
scheduled	for	a	mutually	convenient	date	and	time.		
DUK	supported	this	study	with	an	advert	in	Balance	magazine,	which	had	a	national	
distribution	in	the	UK	of	approximately	146,000	people	with	diabetes	or	family	members.	DUK	
membership	has	an	equal	sex	balance	(50%	female,	47%	male,	3%	unknown),	is	nationwide	and	
representative	of	the	UK	population	geographically	(membership	3%	Northern	Ireland,	5%	Wales,	
7%	Scotland,	and	85%	England)	and	represents	all	age	groups	(31%	<60	years,	44%	60-79	years,	
17%	>80	years,	15%	unknown).	DUK	do	not	have	membership	ethnicity	data,	however	they	do	
have	a	stated	policy	to	actively	engage	ethnic	minorities	in	diabetes	awareness	programmes	that	
include	research	studies	(DUK,	2015).	The	advert	included	brief	study	information,	as	well	as	an	e-
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mail	address	and	telephone	contact	details	for	the	researcher.	People	who	contacted	the	
researcher	and	fulfilled	the	eligibility	criteria	were	sent	the	PIS	pack	for	further	information	on	the	
study.	If	they	were	subsequently	interested	in	participating,	they	contacted	the	researcher	and	a	
mutually	convenient	date	and	time	was	scheduled	for	an	interview.		
3.5.3	Clinician	study	
3.5.3.1	Sample	population	
The	sample	population	was	staff	involved	in	the	medical	care	of	patients	with	diabetes	and	
PDN,	and	staff	involved	in	PMPs.	Management	of	diabetes	and	pain	differs	between	primary	and	
secondary	care,	so	appropriate	representation	from	all	areas	was	sought.		
As	with	the	patient	study,	there	were	also	communication	issues	to	consider	with	the	
clinician	study.	Medical	language	has	evolved	to	be	specific	and	unambiguous.	Diagnostic	labels	
convey	much	information	between	HCPs	who	can	assume	a	large	volume	of	innate	information	
from	a	short	piece	of	medical	terminology.	These	specific	meanings	should	facilitate	quick	and	
accurate	communication	between	clinicians.	As	a	physiotherapist	with	experience	of	working	with	
consultant	anaesthetists	and	psychologists,	as	well	as	other	physiotherapists,	the	researcher	
could	be	considered	to	have	insider	status	with	regard	to	the	interview	participants	(Petty,	
Thomson	and	Stew,	2012a;	Mack	et	al.,	2005;	Finlay,	2002a).	Insider	status	implies	a	different	
dynamic	of	power	and	status	than	existed	within	patient	interviews.	Shared	terminology	may	
facilitate	more	rapid	communication,	but	could	also	hide	specific	meanings	if	subconscious	
acceptance	of	these	terms	was	not	considered.	A	non-clinical	researcher	would	need	to	ask	
further	questions	to	clarify	meaning	of	unfamiliar	terminology	that,	whilst	increasing	the	duration	
of	the	interview,	would	ensure	the	full	implication	of	the	clinicians’	perspectives	were	recorded.	
When	forced	to	slow	down	and	consider	the	words	used,	it	is	not	unusual	to	find	that	the	topic	
has	to	be	considered	more	carefully	than	when	using	terminology.	
The	researcher	is	an	active	clinician,	so	it	is	prudent	to	reflect	on	the	potential	for	some	
aspects	of	the	clinician	interviews	to	have	elements	of	assumption	and	prejudice	from	the	outset.	
These	limitations	will	be	considered	in	greater	detail	in	Chapter	4.2.	
3.5.3.2	Inclusion	and	exclusion	criteria	
The	sample	was	purposive,	with	the	aim	to	include	at	least	two	members	of	the	main	
professions	involved	in	managing	diabetes	and/or	pain:	diabetes	medical	clinicians,	pain	clinicians,	
DSNs,	practice	nurses,	psychologists,	physiotherapists,	podiatrists	and	GPs.	Having	no	clinical	role	
in	either	diabetes	or	pain	management	was	the	only	exclusion	criterion.	
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3.5.3.3	Recruitment	process	
In	order	to	recruit	the	variety	of	staff	required,	clinicians	from	two	secondary	care	and	one	
primary	care	NHS	organisation	were	approached	to	participate.	Clinicians	in	secondary	care	were	
identified	directly	from	diabetes	and	pain	services	Internet	pages	and	emailed	a	PIS	by	the	
researcher	(Appendix	4).	As	with	the	patient	study,	this	included	the	mind-map	of	pain	coping	
strategies	(Appendix	6).	Clinicians	were	required	to	contact	the	researcher	if	they	wanted	further	
information	about	the	study.	If	they	were	eligible	and	able	to	participate	a	mutually	convenient	
appointment	time	was	arranged	to	conduct	a	face-to-face	interview.		
In	order	to	recruit	from	primary	care,	where	clinicians	do	not	usually	have	a	clinical	
speciality,	recruitment	was	via	the	Primary	Care	Research	Network.	The	Primary	Care	Research	
Network	send	regular	updates	of	active	research	projects	to	all	primary	care	clinicians,	this	
allowed	clinicians	with	an	interest	in	the	study	to	contact	the	researcher	for	further	information.	
As	with	recruitment	of	secondary	care	clinicians,	if	they	met	the	eligibility	criteria	and	were	able	
to	participate,	a	face-to-face	interview	appointment	was	scheduled.		
3.6	Materials	included	with	the	PIS	
3.6.1	Patient	study	
The	PIS	can	be	found	in	full	in	Appendix	3.	People	with	diabetes	can	develop	a	wide	range	
of	potential	complications	all	stemming	from	the	abnormal	levels	of	hyperglycaemia.	
Microvascular	complications	include	PDN,	retinopathy	and	autonomic	neuropathy	(Tooke,	1995;	
Holt	and	Hanley,	2012a).	Macrovascular	complications	include	nephropathy,	cardiovascular	
disease	and	peripheral	arterial	disease	including	ulceration	due	to	poor	healing	(Donahue	and	
Orchard,	1992;	Holt	and	Hanley,	2012a).	People	with	diabetes	can	experience	greater	levels	of	
depression	and	anxiety	than	the	population	without	a	chronic	condition	(Biessels,	Deary	and	
Ryan,	2008;	Bair	et	al.,	2010).	Managing	diabetes	and	its	complications	is	known	to	be	challenging	
(Hinder	and	Greenhalgh,	2012).	Please	refer	back	to	Chapter	1	for	more	details	on	complications	
related	to	DM.	PDN	is	only	one	of	these	potential	complications	and	the	patient	study	sought	to	
understand	the	wider	medical	complications	that	interview	participants	were	experiencing,	and	
how	much	these	complications	interfered	with	their	lives.		
Potential	participants	were	sent	a	study	questionnaire	that	had	sixteen	common	
complications	arranged	in	no	specific	order	(Appendix	5).	The	layout	aimed	to	give	no	precedence	
to	any	specific	complication.	It	had	free	space	to	add	any	additional	complication	associated	with	
diabetes	the	participant	experienced.	Participants	were	asked	to	rank	the	complications	they	
experienced	on	a	scale	as	follows:	1=most	interfering	problem,	2=next	most	interfering	problem,	
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and	so	on.	Participants	were	asked	to	complete	this	questionnaire	once	they	had	agreed	to	the	
interview.	It	was	collected	in	person	for	face-to-face	interviews,	or	completed	verbally	for	
telephone	interviews.	
3.6.2	Patient	and	clinician	studies	
Participants	in	both	interview	studies	were	asked	how	relevant	they	felt	strategies	taught	
by	PMPs	might	be	to	PDN.	It	could	not	be	assumed	however,	that	either	patient	or	clinician	
participants	would	be	familiar	with	the	strategies	that	are	taught	within	PMPs.	
To	address	this	issue	a	mind-map	was	produced	based	on	British	Pain	Society	guidance	and	
other	high	quality	sources	of	evidence	(BPS,	2013;	Geneen	et	al.,	2014;	Karjalainen	et	al.,	2009;	
Williams,	Eccleston	and	Morley,	2012),	see	Appendix	6	–	Pain	management	programme	mind-
map.	The	programme	manuals	of	two	secondary	care	PMPs	(Yeovil	District	Hospitals	NHS	
Foundation	Trust	and	Calderdale	and	Huddersfield	NHS	Foundation	Trust)	were	consulted	to	
ensure	that	active	clinical	programmes	reflected	the	guidance	and	were	not	using	any	other	
strategies.		
Participants	in	both	the	patient	and	clinician	studies	received	this	mind-map.	The	mind-map	
outlined	the	strategies	that	comprise	a	PMP,	arranged	in	a	circle	so	as	not	to	imply	any	one	
strategy	was	superordinate	to	another.	There	were	no	descriptions	of	what	these	strategies	were	
in	practice,	but	it	provided	a	basis	for	discussion	about	how	appropriate	these	strategies	
appeared	to	participants	for	the	management	of	PDN.	The	mind-map	also	incorporated	a	“??”	
box,	this	allowed	the	insertion	and	discussion	of	any	potentially	useful	management	strategies	
from	the	participant’s	experience.	The	researcher	carried	out	the	interviews	and	was	conscious	of	
the	manner	in	which	the	strategies	were	described	would	not	bias	participants	or	suggest	
particular	benefits.	
3.7	Method	for	data	collection	
3.7.1	Patient	study	
An	interview	method	was	considered	appropriate,	as	opposed	to	a	focus	group,	to	allow	
participants	to	describe	the	impact	of	PDN	in	their	own	words.	An	interview	would	allow	them	to	
describe	any	form	of	management	strategies	they	had	tried	and	would	allow	them	to	give	their	
perspective	on	PMP	strategies	in	confidence.	Interviews	can	be	conducted	in	a	structured	format,	
where	a	series	of	questions	is	followed	in	the	same	order	for	each	participant,	through	to	an	un-
structured	format	where	the	interview	is	completely	free	flowing,	with	no	specific	questions	to	
cover.	For	these	research	questions,	a	semi-structured	interview	was	planned	using	a	topic	guide	
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to	ensure	all	key	topics	were	covered.	The	development	of	this	guide	is	covered	in	section	3.9	
Interview	content	and	approach.	
Participants	were	interviewed	either	face-to-face	interview	on	University	of	the	West	of	
England	(UWE)	premises	or	at	their	own	home.	The	University	‘Safety	for	social	researchers’	
guidance	on	lone	working	was	followed	for	interviews	conducted	at	the	participant’s	home.	Or	
interviews	were	conducted	over	the	telephone	as	they	preferred	or	locality	dictated.	This	decision	
was	pragmatic,	but	potential	differences	between	face-to-face	and	telephone	interviews	should	
be	considered.	Face-to-face	meetings	are	more	personal	and	rapport	can	be	developed	more	
readily.	Telephone	interviews,	however,	can	allow	the	participant	to	be	more	open	with	their	
answers	and	perhaps	more	confident	to	talk	about	contentious	issues,	which	they	may	not	be	in	a	
face-to-face	interview	(Novick,	2008).	There	are	differences	in	non-verbal	communication	and	
cues	between	face-to-face	and	telephone	interviews.	In	interviews	conducted	away	from	the	
participant’s	home	(on	University	premises	or	by	telephone),	the	interviewer	has	no	knowledge	of	
the	home	and	local	environment	in	which	the	interviewee	lives.	During	telephone	interviews	
there	are	no	clues	to	the	interviewee’s	apparent	fitness,	body	mass	index	or	other	cues	about	
personal	life	–	information	that	has	been	described	as	‘ethnographic’	(Holt,	2010).	Similarly,	the	
interviewee	also	had	no	knowledge	of	the	interviewer,	other	than	tone	of	voice,	which	may	
provide	cues	to	social	grouping.	Existing	research	that	required	widening	recruitment	for	similar	
pragmatic	reasons	found	no	differences	in	data	quality	between	the	different	modes	of	contact	
for	interviews	(Sturges	and	Hanrahan,	2004).	
3.7.2	Clinician	study	
All	interviews	for	this	study	were	conducted	face-to-face	at	the	place	of	work	for	each	
participant.	This	option	presented	least	disturbance	to	their	work	pattern.	Similar	to	the	patient	
study	an	interview	guide	was	used	to	ensure	no	key	topics	were	omitted	from	the	interview,	
please	see	section	3.9	Interview	content	and	approach,	for	the	development	of	this	topic	guide.		
3.8	Process	for	informed	consent	
3.8.1	Patient	study	
In	order	to	provide	informed	consent,	potential	participants	must	understand	the	possible	
risks	and	benefits	of	taking	part	in	a	study	(Orb,	Eisenhauer	and	Wynaden,	2001;	Department	of	
Health,	2005).	Participants	had	the	opportunity	to	ask	questions	when	initially	contacting	the	
researcher	and	a	further	opportunity	was	provided	prior	to	the	start	of	the	scheduled	interview.	
The	aims	of	the	study,	the	process	of	making	recordings	anonymous,	their	right	to	withdraw	at	
any	point	and	the	background	of	the	interviewer	as	a	clinical	physiotherapist	were	reiterated	prior	
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to	commencing	the	interview.	If	participants	were	happy	to	proceed	with	the	interview,	informed	
consent	was	taken.	For	face-to-face	interviews,	participants	signed	a	consent	form,	and	for	
telephone	interviews	they	were	asked	to	make	an	affirmative	statement	of	consent	as	the	first	
section	of	the	recorded	interview	(Appendix	7).	
3.8.2	Clinician	study	
Prior	to	commencing	the	interview	the	aims	of	the	study,	the	process	of	making	recordings	
anonymous,	the	participant’s	right	to	withdraw	at	any	point	and	the	background	of	the	
interviewer	as	a	clinical	physiotherapist	were	reiterated.	If	participants	were	happy	to	proceed	
with	the	interview,	then	informed	consent	was	taken	and	participants	signed	a	consent	form.	
3.9	Interview	content	and	approach	
3.9.1	Patient	study	
Once	informed	consent	was	obtained,	the	initial	section	of	the	interview	covered	
demographic	questions:	age,	ethnicity,	type	of	diabetes,	duration	of	diabetes	and	PDN,	any	
current	analgesia	and	current	work	status.	The	demographic	data	form	can	be	found	in	Appendix	
8.	
The	interviews	were	semi-structured	based	on	an	interview	schedule,	please	see	Appendix	
9	for	the	root	questions.	This	schedule	was	developed	to	ensure	that	the	main	areas	of	interest	
(PDN	impact,	participant	management	and	participants’	views	on	both	physical	activity	and	
psychological	coping)	were	covered	by	the	interview.	These	root	questions	and	potential	follow	
up	questions	were	based	upon	the	existing	literature,	the	research	questions	and	the	experience	
of	the	research	student	and	supervisory	team.	They	were	also	discussed	with	an	Expert	Patient	
Research	Partner	(EPRP),	to	ensure	the	questions	made	sense	and	were	appropriately	worded.	
The	participant	discourse	led	the	exact	order	of	the	interview	topics,	but	the	schedule	ensured	no	
key	topics	were	omitted.	
There	was	the	potential	risk	that	talking	about	the	experience	and	impact	of	PDN,	could	
distress	participants.	There	were	arrangements	in	place	for	Professor	Candy	McCabe	to	call	any	
participant	who	became	distressed,	with	their	agreement,	to	discuss	the	issues	raised,	and	plan	
any	appropriate	intervention.	Professor	McCabe	was	Director	of	Studies	for	the	researcher	and	
has	extensive	clinical	and	research	experience	with	persistent	pain	states	(Rheumatoid	arthritis,	
Complex	Regional	Pain	Syndrome,	Breast	radiotherapy	injuries).	Some	of	these	clinical	services	
are	national	centres	and	one	aspect	of	her	role	is	arranging	for	appropriate	clinical	services	to	be	
provided	near	the	person’s	home.	This	experience	of	advocacy	would	be	useful	were	interview	
participants	to	have	become	distressed.		
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3.9.2	Clinician	study	
The	initial	structured	section	of	the	interview	gathered	the	participant’s	profession,	their	
experience	and	role	in	managing	diabetes	and	PDN,	or	their	involvement	in	delivering	PMPs.	The	
subsequent	semi-structured	section	was	guided	by	an	interview	schedule	developed	from	the	
existing	literature	on	PMPs	and	PDN,	and	the	clinical	experience	of	the	researcher	and	supervisory	
team	(please	see	Appendix	9b).	The	interview	explored	the	options	participants	considered	for	
helping	people	with	PDN	manage	this	condition.	It	then	explored	the	clinicians’	views	of	physical	
activity	and	psychological	coping	strategies	for	managing	PDN.	Finally,	it	asked	about	any	practical	
issues	that	should	be	considered	for	potential	PDN	management	interventions.	
3.10	Data	preparation	–	patient	and	clinician	studies	
An	MP3	device	was	used	to	digitally	record	all	interviews	to	electronic	media.	In	face-to-
face	interviews	an	external	microphone	was	placed	between	the	interviewer	and	participant,	and	
in	telephone	interviews	the	MP3	recorder	was	connected	to	the	phone	line	by	an	adaptor.	
Once	the	interview	was	concluded,	the	MP3	files	were	transferred	for	secure	storage	to	
password	protected	UWE	servers	and	the	original	MP3	files	deleted	from	the	device.	The	
researcher	transcribed	the	first	four	patient	interviews	to	Microsoft	Word	(Microsoft	Corporation,	
USA),	and	all	other	interviews	were	transcribed	by	a	professional	secretarial	service	(Essential	
Secretaries).	The	MP3	file	was	uploaded	by	secure	file	transfer	and	returned	as	a	Microsoft	Word	
document.	These	documents	were	then	stored	on	UWE	secure	servers.	The	Word	documents	
were	anonymised	by	replacing	the	participant’s	name	with	a	pseudonym.	Any	other	identifying	
details,	such	as	specific	UK	locations,	place	names,	NHS	Trust	names,	or	clinicians	were	also	
removed	(for	example,	“I	was	treated	at	[NHS	Trust]…”).	The	transcripts	were	imported	to	NVivo	
v10	(QSR	International,	Doncaster,	Australia)	for	data	management	and	subsequent	analysis.	The	
original	MP3	files,	the	transcribed	interview	documents	and	the	NVivo	files	were	all	stored	on	
secure	UWE	servers.		University	policies	on	data	management	were	adhered	to	throughout	these	
studies.	
3.11	Interview	data	analysis	
There	are	numerous	methods	by	which	qualitative	data	can	be	analysed,	depending	on	the	
philosophical	perspective	of	the	research	project	and	the	research	questions	(Pope	and	Mays,	
2006).	Authors	have	highlighted	that	reporting	the	philosophical	assumptions	present	in	the	
analytical	process	of	qualitative	research,	often	lack	clarity	and	explicit	detail	(Caelli,	Ray	and	Mill,	
2008;	Braun	and	Clarke,	2006;	Sandelowski	and	Barroso,	2002).	Caelli,	Ray	and	Mill	(2008)	suggest	
four	key	areas	that	research	reports	should	make	explicit:	1)	theoretical	position	of	the	
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researcher,	2)	congruence	between	methodology	and	methods,	3)	strategies	for	demonstrating	
rigour	and	4)	the	‘analytic	lens’	through	which	the	analysis	is	carried	out.	Congruence	between	
methodology	and	methods,	and	the	analytic	lens	are	the	focus	of	the	following	section.	Strategies	
for	research	rigour	have	been	considered	in	the	introductory	section	3.1.1,	and	are	described	in	
detail	throughout	this	chapter.	
There	were	a	number	of	analytic	frameworks	that	needed	consideration,	and	the	analysis	
should	match	the	research	questions	as	well	as	the	methods	employed	to	gather	data.		
3.11.1	Patient	study	
The	research	questions	explored	the	participants’	experiences	of	PDN.	Communication	of	
experiences	can	take	many	forms,	but	the	most	common	is	spoken	word.	Analysis	of	the	spoken	
word	can	be	at	the	semantic	level	–	the	words	are	taken	at	their	face	value	meaning,	or	at	a	latent	
level	–	where	attention	is	paid	to	the	mode	and	manner	of	their	delivery	(Pope	and	Mays,	2006;	
Braun	and	Clarke,	2013b).	
To	explore	the	experiences	of	PDN	management	and	potential	utility	of	PMP	strategies,	it	
was	necessary	to	look	for	patterns	across	the	data	set	(all	interviews).	The	eventual	results	and	
conclusions	needed	to	reflect	the	sample	population	with	PDN,	not	the	individuals	who	
contributed	to	the	data.	An	analytic	framework	such	as	Interpretive	Phenomenological	Analysis	
(IPA)	is	focussed	on	the	personal	experience	of	a	phenomenon	in	detail,	and	so	results	only	claim	
to	be	true	from	the	perspective	of	those	few	individuals	interviewed	(de	Witt	and	Ploeg,	2006).	
IPA	has	been	used	in	high	quality	research	into	peoples’	experiences	of	pain.	For	instance,	
Reynolds	and	Prior	(2003)	used	IPA	to	examine	in	detail	how	people	used	artistic	means	to	
maximise	their	sense	of	wellbeing.	The	results	outline	the	wide	range	of	benefits	described	by	the	
participants,	but	these	cannot	be	generalised	to	all	people	with	persistent	pain.	IPA	has	also	been	
used	to	explore	the	impact	of	persistent	pain	(Smith	and	Osborn,	2007).	In-depth	interviews	with	
six	participants	were	analysed	using	IPA;	the	results	highlighted	the	negative	impact	persistent	
pain	had	on	self-identity,	and	the	further	impact	that	context	of	social	and	public	engagement	had	
on	self-image.	These	results	are	reported	in	detail	for	each	theme	with	supporting	quotes	from	
the	participants.	Clinicians	who	read	this	research	could	become	more	attentive	to	the	
psychosocial	impact	of	pain	on	the	lives	of	patients	they	work	with,	but	this	research	was	not	
designed	to	identify	therapeutic	treatment	options.	
Thematic	Analysis	(TA)	is	considered	a	philosophically	flexible	approach	which	allows	it	to	
be	used	in	a	diverse	range	of	qualitative	studies.	Braun	and	Clarke	(2014)	make	a	distinction	
between	“Big	Q	Qualitative”	research	which	is	ontologically	coherent	with	an	Interpretivist	
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perspective,	and	“Small	q	qualitative”	research	which	is	coherent	with	a	post-positivist	
perspective	(Braun	and	Clarke,	2014).	To	say	this	in	another	way	-	Qualitative	research	could	use	
TA	to	explore	the	themes	that	relate	to	the	experience	of	living	with	PDN;	and	qualitative	
research	could	use	TA	to	count	the	occurrence	of	themes	and	link	frequency	to	relative	
importance.	This	second	approach	is	consistent	with	post-positivism	as	it	implies	that	the	‘truth’	
about	PDN	impacts	can	be	deduced	from	the	frequency	counts	of	the	codes.	
Another	common	analytic	approach	to	qualitative	data	is	Grounded	Theory	(Petty,	
Thomson	and	Stew,	2012b),	which	aims	to	develop	new	theories	of	social	processes.	Grounded	
theory	starts	with	no	a	priori	hypotheses	or	models	to	fit	data	to,	rather	it	focuses	solely	on	data	
gathered	from	participants	who	have	had	experience	of	the	phenomenon	in	question.	From	being	
grounded	in	this	data,	new	theories	of	the	social	process	in	question	can	be	built.	The	research	
questions	asked	in	this	study	did	not	aim	to	define	theories	for	why	participants	experienced	the	
impact	from	PDN	that	they	described,	or	to	define	theories	as	to	whether	or	not	strategies	from	
PMP	were	deemed	acceptable.	There	are	comprehensive	existing	theories	that	consider	the	
multitude	of	variables	affecting	the	likelihood	of	pain,	as	well	as	clearly	identifying	that	the	
experience	of	pain	is	not	only	subjective,	but	has	psychological	and	social	ramifications	(Engel,	
1978;	Melzack,	2001,	2005).	There	were	no	reasons	to	suppose	that	the	presentation	of	PDN	
would	not	fit	with	these	existing	models.	
To	summarise	at	this	point,	and	address	the	issue	of	congruence	from	research	questions	to	
methods	(Holloway	and	Todres,	2003;	Darlaston-Jones,	2007;	Caelli,	Ray	and	Mill,	2008);	this	
research	study	asked	questions	of	personal	experience	and	perspective	(Interpretivist	ontology),	
these	topics	were	spoken	about	either	face-to-face	or	over	a	telephone	(interview	methods	
within	a	social	constructionist	epistemology),	and	other	ethnographic	information	did	not	form	
part	of	the	analysis.	The	results	and	conclusions	drawn	from	the	acquired	data	needed	to	be	
representative	of	the	population	interviewed,	although	not	necessarily	generalizable	beyond	that	
sample,	rather	than	focussed	at	the	individual	level	(interview	method).	The	most	appropriate	
analytic	framework	to	use	was	therefore	TA	(Braun	and	Clarke,	2006;	Braun	and	Clarke,	2012).		
TA	could	be	conducted	with	initial	theories	about	what	kinds	of	themes	may	be	produced	
from	the	data	–	a	deductive	approach.	The	data	could	have	been	sifted	and	the	participants’	
impacts	located	within	the	biological,	psychological	and	social	domains	of	the	biopsychosocial	
model	(Engel,	1978).	An	alternative	approach,	and	that	taken,	was	to	use	an	inductive	approach,	
where	no	assumptions	are	made	prior	to	the	interview	process.	The	interview	process	could	be	
considered	a	blank	slate	upon	which	participants	were	able	to	freely	discuss	their	experiences	of	
PDN,	their	strategies	for	managing	PDN	and	their	views	of	pain	management	strategies.	
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	The	philosophical	flexibility	of	TA	has	been	one	of	its	main	criticisms;	that	is,	lacking	
allegiance	to	any	specified	philosophy	degrades	the	approach	to	one	of	a	generic	coding	
technique,	rather	than	an	approach	in	its	own	right	(Holloway	and	Todres,	2003;	Holloway	and	
Todres,	2007).	This	is	challenged	by	Braun	and	Clarke	(2014),	as	well	as	other	researchers	in	the	
wider	debate	around	transparency	in	the	reporting	of	qualitative	research	(Yardley,	2000;	Rolfe,	
2006;	Caelli,	Ray	and	Mill,	2008;	Braun	and	Clarke,	2013b).	The	collected	responses	of	these	
authors	are	that	there	must	be	clarity	and	transparency	in	the	reporting	of	why	critical	decisions	
are	made	in	designing	a	research	study.		
Having	described	the	ontological	and	epistemological	positions	within	this	research,	the	
‘analytical	lens’	used	to	survey	the	data	needs	to	be	explained.	This	needs	to	come	full	circle	to	
address	the	research	questions,	otherwise	qualitative	research	risks	becoming	focussed	on	
methodology	rather	than	research	product	(Sandelowski,	2000b).	By	exploring	the	experiences	of	
people	with	PDN	and	their	perspective	on	the	utility	of	PMP	strategies,	the	analysis	needed	to	be	
equally	pragmatic	(Feilzer,	2010;	Smith,	Bekker	and	Cheater,	2011).	In	practice	this	meant	there	
were	two	possible	extremes	when	analysing	the	results	–	at	one	extreme	all	participants	would	
value	all	PMP	strategies	and	feel	they	are	totally	suitable	to	their	experience	of	PDN.	The	other	
extreme	was	that	all	participants	would	fully	reject	the	suitability	of	all	PMP	strategies	for	helping	
them	to	manage	PDN.	The	reality	was	likely	to	be	somewhere	between	these	extremes	and	it	
would	be	for	the	researcher	to	consider	how	to	use	the	resulting	analyses,	by	considering:	were	
there	any	indications	of	potential	pragmatic	practical	treatment	options	for	people	with	PDN	
present	in	the	analysis?		
These	considerations	were	important	for	the	current	studies	and	when	considering	
potential	future	research.	For	instance,	if	there	were	mixed	participant	perspectives	on	a	certain	
pain	management	strategy,	criteria	would	be	required	to	include	or	exclude	it	from	a	possible	
PDN	intervention.	
3.11.2	Clinician	study	
Much	of	the	justification	for	using	TA	within	the	patient	study	was	also	applicable	to	the	
clinician	study.	It	could	not	be	taken	for	granted	that	all	clinicians	interviewed	would	have	a	
thorough	understanding	of	the	strategies	taught	within	PMPs.	Since	nothing	was	known	about	
the	clinicians’	perspectives,	there	was	the	potential	for	positive,	negative	and	ambivalent	
viewpoints	on	PMP	strategies.	This	exploration	suited	an	inductive	TA	approach,	as	no	
assumptions	were	made	regarding	the	perspectives	clinicians	might	hold.		
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There	were	some	differences	in	the	research	questions	between	the	patient	and	clinician	
study.	The	clinician	study	was	not	asking	about	the	clinicians’	experience	of	pain,	but	rather	their	
professional	perspectives	on	the	management	of	PDN	and	the	potential	utility	of	PMP	strategies.	
There	was	no	phenomenon	to	be	explored.	There	were	still	internal	clinical	reasoning	processes	
and	pragmatic	perspectives	on	PMP	strategies	that	were	best	explored	through	a	spoken	
conversation.	
3.11.3	The	process	of	analysis	
There	are	seven	stages	to	TA;	1)	transcription	of	interview	data;	2)	repeat	reading	and	
familiarization	with	the	dataset;	3)	complete	coding	across	the	dataset;	4)	searching	for	themes;	
5)	reviewing	the	themes	produced;	6)	defining	and	naming	themes;	and	7)	writing	the	
dissemination	report	(Braun	and	Clarke,	2013a).		
Recruitment	and	interviews	for	the	two	interview	studies	took	place	concurrently.	The	early	
processes	for	coding	and	identification	of	themes	also	occurred	concurrently.	The	supervisory	
team	identified	issues	with	both	coding	and	theme	production	by	the	quality	assurance	processes	
that	were	in	place.	These	issues	would	have	led	to	researcher	bias	in	the	results.	The	steps	taken	
to	mitigate	this	potential	bias	are	described.	
1)	Interview	transcription	
The	researcher	transcribed	the	first	four	patient	interviews	verbatim.	This	allowed	an	
immersion	in	these	interview	texts	and	led	to	an	appreciation	of	how	dis-jointed	both	interviewer	
questions	and	interviewee	answers	can	be	when	transcribed.	Due	to	the	significant	time	
commitment	required,	later	patient	interviews	and	all	clinician	interviews	were	transcribed	by	
professional	secretarial	services.	When	transcripts	were	returned	in	Word	format,	they	were	read	
alongside	the	audio	MP3	file,	to	check	for	accuracy.	Secretarial	services	used	a	system	of	
highlights	where	unfamiliar	words	had	been	spelt	phonetically,	where	participant	and	interviewer	
spoke	over	one	another,	or	where	sections	were	inaudible	(MacLean,	Meyer	and	Estable,	2004).	
By	re-reading	and	re-listening	to	the	interview	recordings,	the	transcripts	could	be	edited	to	
produce	an	accurate	reflection	of	the	discourse.		
There	are	academic	discussions	over	the	merit	and	necessity	of	verbatim	transcription	
(Halcomb	and	Davidson,	2006;	Davidson,	2009).	The	arguments	centre	on	the	difficulty	of	turning	
spoken	word,	with	all	the	nuances	of	intonation	and	inflection,	to	written	text.	This	research	was	
not	using	an	in-depth	linguistic	analysis	such	as	conversation	analysis,	where	it	is	necessary	to	
code	each	utterance	and	pause	in	the	transcription	(Irvine,	Drew	and	Sainsbury,	2012).	While	
these	research	studies	do	not	require	a	complex	notation	system	to	code	such	pauses,	they	do	
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require	verbatim	transcription	because	these	words	are	the	only	mode	by	which	the	participants	
were	asked	to	convey	their	experiences	of	PDN.	These	interviews	were	required	to	be	as	faithful	
as	possible,	as	they	formed	the	data	on	which	analysis	was	based.	
Along	with	the	transcribed	verbatim	interviews,	two	forms	of	supplementary	notes	were	
kept.	Most	interviews	were	reflected	on	for	their	conduct	and	process.	These	field	notes	
contained	initial	thoughts	or	unexpected	topics	that	had	arisen	in	the	interview	and	reflections	on	
the	conduct	of	the	interview.	A	reflexive	diary	was	also	kept	using	Evernote,	a	cloud	based	note	
storage	application	that	can	be	updated	from	laptop,	desk	PC	or	smart	phone.	This	diary	was	used	
to	keep	a	record	of	important	conversations,	emails	with	supervisors,	and	insights	that	occurred.	
The	data	from	field	notes	and	the	reflexive	diary	were	not	part	of	the	data	set	used	for	the	
analysis.	They	were	used	as	part	of	the	quality	management	process	that	will	be	described	in	the	
subsequent	sections	on	the	process	of	analysis.	
These	multiple	processes:	recording	notes	on	conduct	of	the	interviews,	maintaining	a	
reflexive	diary	and	the	actual	transcribed	data	from	the	interview,	provide	a	triangulation	of	
sources	that	can	be	returned	to	in	the	next	phase	of	analysis.	This	triangulation	allows	the	
researcher	to	revisit	the	context	of	the	interview	in	audio,	as	well	as	typed	form,	to	check	the	
meaning	has	not	been	misunderstood	(Halcomb	and	Davidson,	2006).	These	processes	were	
appropriate	to	the	needs	of	the	research	methodology	and	research	questions	being	asked.		
2)	Familiarisation	with	the	data	
Historically,	becoming	familiar	or	immersed	with	qualitative	data	required	hardcopy	
printouts	of	interview	transcripts.	These	were	read	repeatedly	and	important	sections,	at	least	in	
the	opinion	of	the	researcher,	were	highlighted.	These	approaches	encouraged	physical	
immersion	with	the	data,	but	were	not	amenable	to	quick	cross-referencing	large	volumes	of	data	
or	finding	participant	quotes.		
Computer	Assisted	Qualitative	Data	Analysis	Software	(CAQDAS)	packages	have	been	
developed	and	refined	over	the	past	20	years	(Johnson,	Dunlap	and	Benoit,	2010).	Prior	to	
starting	the	analysis,	the	researcher	attended	a	two-day	NVivo	training	course.	A	key	message	
was	that	such	software	provides	a	platform	for	the	analysis	by	storing	and	managing	the	data	–	it	
does	not	perform	the	analysis	(Johnson,	Dunlap	and	Benoit,	2010;	Johnston,	2006).	Further,	the	
use	of	computer-assisted	strategies	does	not	guarantee	that	research	produced	would	be	of	
greater	quality	than	research	using	manual	strategies	(Paulus	et	al.,	2015).	The	use	of	NVivo	has	
potential	risks	and	benefits	that	must	be	understood	by	the	researcher,	preferably,	prior	to	
investing	significant	time	in	becoming	familiar	with	the	software.	
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A	risk	for	this	research	was	that	NVivo	software	features,	such	as	searches	for	particular	
words	and	their	resulting	frequency	counts,	might	be	confused	with	relative	importance	in	later	
analysis.	The	topics	that	participants	were	likely	to	discuss	could	have	a	plethora	of	synonyms.	For	
instance,	a	search	for	“Pain”	across	all	interviews	would	not	capture	the	participants	describing	
their	symptoms	as	throbbing,	aching,	or	nagging.	A	search	for	“my	sleep	is	disturbed”	would	miss	
reference	made	by	participants	to	“my	sleep	is	rubbish”	or	“I	hardly	get	any	sleep	at	all”.	Paulus	et	
al.	(2015)	describe	these	analytical	approaches	as	software-driven,	where	software	technical	
capabilities	have	excess	influence	on	the	conduct	of	the	analysis.	The	use	of	such	CAQDAS	
features	is	not	wrong	per	se,	but	would	not	be	complementary	to	the	philosophical	position	of	
these	research	studies.	The	analysis	of	these	research	studies	had	to	be	built	from	the	interview	
data	the	participants	had	given	and	software	techniques	would	not	facilitate	that	process.	
This	researcher	used	NVivo	(v10,	QSR	International)	at	a	basic	level.	NVivo	allowed	
interview	transcripts	to	be	stored	as	sources,	and	then	accessed	for	coding.	NVivo	allowed	nodes	
to	be	created;	these	nodes	were	a	collection	of	references	extracted	from	the	interview	sources	
that	related	to	a	specific	topic	contained	in	the	interviews.	This	use	of	CAQDAS	was	method-drive,	
where	the	functions	of	the	software	were	subservient	to	the	analytical	approach	being	used	
(Paulus	et	al.,	2015).	As	new	topics	were	raised	in	the	interview,	new	nodes	were	created	as	
required.	For	clarity,	and	for	consistency	with	the	approach	of	thematic	analysis,	the	term	code	
will	be	used	from	here,	in	place	of	node.	These	basic	functions	and	the	ability	to	access	the	
dataset	from	multiple	work	places,	were	felt	to	outweigh	any	philosophical	or	tangible	distance	
from	the	data	that	CAQDAS	software	may	create	(Bringer,	Johnston	and	Brackenridge,	2004;	
Hutchison,	Johnston	and	Breckon,	2010).	The	specific	use	of	NVivo	through	the	analysis	will	be	
described	in	each	following	section	for	transparency	(Paulus	et	al.,	2015;	Woods	et	al.,	2016).	
The	anonymised	Word	transcripts	were	imported	to	NVivo	for	re-reading	and	later	analysis.	
The	transcripts	were	read	a	number	of	times	to	embed	the	conversations,	and	the	main	topics	
and	issues	discussed.	
3)	Complete	coding	across	the	dataset	
The	data	within	each	individual	interview	were	coded;	this	means	small	units	of	text	were	
highlighted	and	assigned	codes	that	captured	the	essence	of	what	had	been	stated	by	the	
participant.	New	codes	were	created	as	required	by	the	data.		
A	code	has	been	described	metaphorically	as	a	brick	in	a	wall,	or	as	a	piece	of	fabric	in	a	
patchwork	(Braun	and	Clarke,	2013b).	It	is	the	smallest	unit	of	data;	each	code	should	contain	
reference	to	only	one	specific	topic.	The	data	were	coded	to	include	the	surrounding	text	that	
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provided	contextual	background.	In	the	example	below	(Figure	9)	the	text	included	as	‘Effect	on	
family’,	also	included	text	that	became	coded	as	‘Delays	in	treatment’.	The	language	was	
impossible	to	separate	without	losing	all	sense	of	what	was	being	spoken	about.		
The	example	below	uses	a	pseudonym	to	provide	anonymity	to	the	participant,	and	has	
removed	a	self-reference	to	their	given	name.		
Figure	9	-	Example	of	interview	coding.	
	
The	analytic	process	cycles	between	the	codes	and	the	data,	creating	new	codes	as	
required.	Often	an	existing	code	would	be	close	to	the	issue	of	the	new	text	requiring	coding,	but	
not	sufficiently	close	to	allow	the	existing	code	to	be	used.	In	these	cases	a	new,	precise	code	was	
created	to	maintain	an	accuracy	and	richness	to	the	data	(Lambert	and	Loiselle,	2008).	Richness	of	
data	refers	to	deeper,	rather	than	superficial,	engagement	with	the	interview	text.	To	engage	in	
superficial	coding	requires	a	level	of	interpretation	on	the	part	of	the	researcher,	moving	from	
interview	text	to	code.	Such	superficial	coding	maybe	appropriate	for	some	research	studies,	but	
this	study	was	exploratory	and	there	was	uncertainty	regarding	the	issues	that	would	be	raised.	If	
INTERVIEWER:	
you	mentioned	three	obvious	areas	of	impact	the	pain	itself	and	how	it	
impacts	on	your	mobility	on	your	sleep	and	you	said	it	was	bringing	you	down		
MARY:	
Yes,	so	emotionally	it	was	just	like,	so	I	suppose,	I	just	got	very	depressed	I	
think	even	to	people	I	was	still	smiley	[personal	name].	I	knew	I	had	stopped	
really	eating	properly,	you	almost	give	up	because	nobody	else	is	like	taking	
notice	at	home.	My	husband	and	both	my	sons	everybody	could	see	that	it	
was	making	me	ill	just	purely	because	I	wasn't	getting	the	answers	that	I	
wanted,	and	the	treatment	I	wanted	it	was	making	me	ill	as	well	as	sort	of…	
Coded	as:		 	 Emotional	depression	
	 	 	 Nobody	is	listening	
	 	 	 Effect	on	family	
	 	 	 Delays	in	treatment	
	 	 	 Can’t	face	food	
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researcher	interpretation	is	allowed	too	early	in	the	process	it	risks	introducing	bias	to	all	future	
layers	of	analysis	(Pope,	Ziebland	and	Mays,	2000).		
3.11.4	Process	orientated	quality	assurance	–	coding	the	data	
The	supervisory	team	have	extensive	experience	of	qualitative	research	and	were	
instrumental	in	developing	the	research	student’s	understanding	and	conduct	of	the	research	
studies	by	a	rigorous	review	process	and	both	verbal	and	written	feedback.		
The	researcher’s	experience	as	a	clinician	includes	training	in	motivational	interview	and	
empathic	listening	skills.	It	became	clear	that	while	useful	in	the	clinical	interview,	some	of	these	
skills	became	leading	questions	in	a	research	interview.	The	reflective	listening	skill	of	
summarizing	a	section	of	clinical	interview,	for	instance	“That	situation	sounds	very	distressing”,	
can	lead	a	patient	to	divulge	further	information	that	is	useful	for	developing	a	clinical	
management	plan.	In	a	research	interview	this	phrase	may	put	the	idea	of	distress	into	the	words	
of	the	participant.		
Interviewers	must	maintain	a	neutrality	and	impartiality	or	be	at	risk	of	introducing	
researcher	bias	into	the	data	(Cohen	and	Crabtree,	2008).	To	address	this	issue	a	series	of	
coached	role-play	sessions	were	established	with	Professor	McCabe	and	an	experienced	research	
nurse,	this	coaching	allowed	the	interview	wording	to	be	analysed	and	immediately	critiqued.	A	
key	development	in	the	researcher	was	to	accept	a	topic	like	sleep	quality,	although	frequently	
referenced	in	the	PDN	literature,	might	not	be	raised	by	the	interviewee.	If	this	topic	were	not	
raised,	it	would	be	inappropriate	to	direct	a	question	towards	their	experience	of	sleep,	as	this	
leads	the	interview	by	the	researchers’	expectations,	not	the	subjective	experience	of	the	
participant.		
For	patient	and	clinician	studies,	researcher	bias	was	identified	in	the	early	phase	of	the	
coding	process.	The	first	phase	of	coding	was	conducted	between	October	2013	and	September	
2014,	when	coding	of	early	interviews	was	happening	concurrently	with	recruitment	and	conduct	
of	later	interviews.	When	the	supervisory	team	reviewed	the	early	codes,	it	was	clear	the	names	
of	the	codes	were	being	created	with	the	research	questions	in	mind.	For	instance,	PDN	impact	-	
mood,	PDN	impact	-	sleep	and	PDN	impact	-	family	suggest	that,	based	on	the	existing	PDN	
literature,	there	was	an	expectation	of	certain	impacts	participants	would	experience.	It	was	not	
possible	to	satisfactorily	address	this	issue	by	re-coding	the	data	within	the	existing	NVivo	project,	
so	this	project	was	closed.	A	new	NVivo	project	was	established	and	all	patient	and	clinician	
interviews	were	re-coded	between	November	2014	and	March	2015.		
4)	Searching	for	themes	
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Once	all	interviews	within	each	study	had	been	fully	coded,	the	codes	created	were	
grouped	together	to	form	higher-order	themes.	Themes	can	be	considered	as	having	a	central	
organising	concept	that	unites	the	codes	within	them	(Braun	and	Clarke,	2013b).	Metaphorically,	
the	themes	are	the	patchwork	quilt	created	with	pieces	of	fabric,	or	the	house	built	with	bricks.	A	
theme	should	be	internally	consistent	and	coherent	from	the	codes	it	contains,	and	each	theme	
should	be	exclusive.	
Where	there	are	a	large	number	of	codes,	managing	the	data	on-screen	through	NVivo	
becomes	difficult.	Hard	copies	of	the	codes	were	therefore	created	then	cut	up	into	individual	
codes	and	brought	together	into	groups	that	appeared	similar.	For	example,	any	code	related	to	
sleep	could	be	grouped,	whether	it	related	to	getting	to	sleep,	staying	asleep	or	sleeping	through	
the	day.		
The	process	of	drawing	themes	together	allows	the	consistency	of	coding	to	be	checked	
and	has	been	termed	‘constant	comparison’	(Mays	and	Pope,	2000;	Pope,	Ziebland	and	Mays,	
2000).	NVivo	facilitated	this	process	of	constant	comparison	because	it	allowed	immediate	access	
back	to	the	source	data.	For	example,	there	were	two	codes	that	related	to	‘sleep	disturbance’	
and	‘difficulty	getting	to	sleep’.	The	data	within	these	codes	could	be	checked	to	establish	
whether	these	two	codes	were	appropriate	to	merge	because	they	have	coded	the	same	issue,	or	
whether	PDN	actually	causes	two	distinct	impacts	on	getting	to	sleep	(sleep	initiation)	and	staying	
asleep	(sleep	maintenance).	The	title	of	the	code	could	also	be	checked	to	ensure	that	it	
accurately	portrayed	the	data	it	contained.	This	process	facilitates	the	consideration	of	whether	
two	unique	issues	about	sleep	are	contained	within	the	dataset,	so	developing	an	“analytic	
richness”	(Bringer,	Johnston	and	Brackenridge,	2004).		
Although	all	the	interview	dataset	had	been	initially	coded,	the	process	of	returning	to	the	
data	and	the	codes	produced	(constant	comparison),	refined	the	codes	into	unique	entities	and	
allowed	the	produced	themes	to	be	constantly	refined.	
3.11.5	Process	orientated	quality	assurance	–	producing	themes	
As	the	codes	were	analysed	to	create	themes,	the	supervisory	team	examined	these	
outputs.	The	issue	of	researcher	bias,	identified	earlier,	was	again	identified.	The	first	phase	of	
codes	that	had	been	created	were	used	to	form	themes	that	were	focussed	on	the	research	
questions.	Themes	were	developed	that	related	to	the	impact	of	PDN	and	participant	views	of	
management.	These	themes	were	devised	with	the	research	question	as	the	primary	focus,	not	
the	data	elicited	from	the	interviews.	This	was	a	process	of	deductive	analysis,	taking	an	initial	
hypothesis	or	model	and	examining	the	data	to	see	whether	it	can	be	supported.	A	deductive	
Chapter	3	–	Methodology	and	methods:	patient	and	clinician	interviews	
Page	-	77	
	
approach	is	compatible	with	qualitative	research	as	research	from	Dures	et	al.	(2012)	highlight,	
but	it	does	not	sit	congruently	with	the	research	questions	or	the	philosophic	position	of	these	
research	studies	(Holloway	and	Todres,	2003).	The	decision	had	been	taken	to	re-code	all	data,	
and	hence	the	first	phase	of	analysis	was	also	stopped.	Once	the	re-coding	was	complete,	the	
development	of	themes	and	super-ordinate	themes	was	re-started,	using	inductive	principles	as	
described.		
These	quality	assurance	processes	at	coding	and	theme	production	were	circular	not	linear,	
as	there	were	overlaps	between	the	phases	of	data	gathering,	coding	and	analysis.	These	
processes	were	not	aimed	at	ensuring	that	there	were	high	levels	of	agreement	between	
researcher	and	supervisory	team,	this	could	be	considered	an	inter-rater	reliability	score	for	the	
analytic	process	and	would	be	appropriate	to	research	sited	in	a	post-positivist	paradigm	(Morse	
et	al.,	2002).	Rather,	they	were	used	to	ensure	that	the	researcher’s	approach	to	the	process	of	
data	acquisition	and	analysis	was	neutral	and	appropriate	for	the	nature	of	these	studies.	These	
studies	were	situated	in	an	Interpretivist	framework,	where	the	interpretation	of	the	researcher	
would	be	slightly	different	than	that	of	the	supervisory	team.	This	remains	appropriate	because	it	
was	the	researcher	who	had	the	deep	and	prolonged	engagement	with	the	data,	rather	than	the	
supervisory	team.		
5)	Reviewing	the	themes	
The	development	of	a	theme	structure	requires	consideration	of	whether	themes	naturally	
coalesce	into	a	higher	level	of	pattern.	These	superordinate	themes	should	still	have	a	central	
concept	they	embody,	but	they	will	encompass	different	facets	of	that	concept	within	the	themes	
they	contain.	It	is	only	at	this	point	when	the	patterns	of	codes,	themes	and	superordinate	
themes	have	been	developed,	that	these	patterns	can	be	examined	in	relation	to	the	research	
questions	asked.		
3.12	Expert	Patient	Research	Partner	involvement	
Exploratory	qualitative	research	has	certain	pre-judgements	inherent	from	the	start,	most	
notably	the	life	experiences	and	prejudices,	both	positive	and	negative,	present	in	the	researcher	
(Finlay,	2002b;	Le	Gallais,	2008;	Johnson,	Long	and	White,	2001).	Is	it	possible	for	a	researcher	
with	no	experience	of	persistent	pain	or	diabetes	to	know	what	questions	to	ask?	The	
involvement	of	patients	in	research	design	and	conduct	is	increasingly	recognised	as	good	
practice	(www.invo.org.uk).	The	patient	perspective	on	the	impact	of	disease	has	highlighted	that	
clinician	researchers	are	not	necessarily	best	placed	to	independently	decide	the	direction	of	
future	research	(Gooberman-Hill,	2012;	Dures	et	al.,	2016;	Hewlett	et	al.,	2005).		
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In	order	to	recruit	an	EPRP	to	this	project,	a	recruitment	letter	was	sent	to	all	patients	who	
had	been	assessed	at	a	specialist	tertiary	clinic	for	PDN	between	2010	and	2013	(n=53).	This	
aimed	to	recruit	one	or	two	people	who	had	an	interest	in	the	research	process	and	felt	they	
could	contribute	their	experience.	Only	one	person	responded	to	this	letter.	They	have	played	a	
role	in	this	research	in	a	number	of	ways.	Firstly,	by	contributing	to	research	design	and	
collaborating	in	developing	the	interview	schedule	for	the	patient	study.	The	EPRP	also	helped	
develop	and	revise	the	PIS	for	the	study	recruitment	and	discussed	the	emerging	coding	and	
themes	of	the	analysis	with	the	researcher.	
Although	the	patient	experience	is	becoming	more	common	in	health	research,	it	is	not	
universal.	Some	researchers	feel	that	EPRPs	do	not	bring	an	un-biased	perspective	to	the	research	
and	do	not	have	sufficient	academic	experience	of	the	research	process	(Staniszewska	et	al.,	
2007).	It	is	therefore	important	these	relationships	are	managed	carefully,	appropriate	training	is	
provided	and	the	contribution	of	EPRPs	is	clearly	recognised	in	the	outputs	of	the	research	(Brett	
et	al.,	2014;	Elberse,	Caron-Flinterman	and	Broerse,	2011).	The	supervisory	team	all	have	
extensive	experience	of	patient	engagement	and	involvement	with	other	research	studies	and	
facilitated	training	sessions	with	the	EPRP	on	research	methodology.		
3.13	Interview	ethical	considerations	and	approvals	
Health	researchers,	working	with	people	who	have	a	variety	of	physical	and/or	mental	
health	conditions,	need	to	be	aware	these	conditions	can	make	people	feel	vulnerable	and	
exposed	to	potential	exploitation.	Exploitation	can	occur	due	to	the	asymmetric	relationship	of	
power	between	patient/participant	and	clinician/researcher	(Townsend,	Cox	and	Li,	2010).	
Exploitation	can	include	the	participant	not	understanding	they	are	part	of	a	research	study,	by	
giving	an	intervention	against	someone’s	will,	by	withholding	an	intervention	that	is	indicated	or	
by	using	someone’s	personal	experience	to	produce	qualitative	research	reports	without	
acknowledging	their	contribution.		
Ethical	considerations	for	research	involving	people	as	participants,	are	based	on	
autonomy,	beneficence	and	justice	(Orb,	Eisenhauer	and	Wynaden,	2001).	The	considerations	aim	
to	ensure	that	potential	participants	understand	the	nature	of	the	research,	actively	choose	to	be	
part	of	that	research	and	are	dealt	with	fairly	throughout	the	research	process.				
During	interview	research,	it	is	important	that	the	participant	can	lead	the	interview	
discourse.	The	interviewer	should	keep	the	interview	schedule	in	mind,	but	there	is	no	need	for	
the	interview	to	follow	the	same	order	for	each	participant.	Open-ended	questions	such	as	“How	
does	painful	diabetic	neuropathy	affect	you?”	could	be	used	to	allow	the	participant	to	discuss	
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the	issues	they	felt	had	the	greatest	priority.	This	approach	is	the	opposite	of	an	interviewer-led	
structured	interview	and	supports	the	participant’s	autonomy.	The	PIS	designed	for	these	studies	
also	aimed	specifically	to	facilitate	autonomy.	
Beneficence	means	maximising	potential	benefits	to	participants	and	doing	no	harm	to	
them	(Orb,	Eisenhauer	and	Wynaden,	2001).	Being	a	participant	in	an	interview	study	has	no	
immediate	benefits	to	the	participants,	and	has	the	potential	to	be	physically	and	emotionally	
distressing.	Physical	distress	might	have	occurred	due	to	prolonged	sitting	for	the	interview.	One	
interview	was	split	into	two	sessions	because	the	participant	needed	to	take	a	break.	Emotional	
distress	may	occur	when	talking	about	the	range	of	impacts	that	PDN	has	had	on	their	lives.	It	is	
also	important	participants	do	not	feel	judged	by	the	interviewer.	Having	chronic	health	
conditions,	which	have	led	to	physical	health	and	mental	health	problems,	should	not	be	judged	
either	explicitly	or	implicitly	through	the	course	of	the	interview	(Townsend,	Cox	and	Li,	2010).	To	
manage	potential	distress	in	a	clinical	consultation	requires	empathic	communication	skills	
developed	through	clinical	experience.	Arrangements	were	in	place	for	Professor	McCabe	to	
contact	participants	were	they	to	have	become	distressed	in	a	manner	that	could	not	be	managed	
in	the	moment.		
For	participants	to	have	confidence	to	share	personal	information,	it	was	vital	they	could	
not	be	identified	in	any	way.	Any	information	that	could	identify	a	participant	was	removed;	this	
included	their	name	by	using	pseudonyms	in	the	transcription,	removal	of	any	specific	home	
locality,	NHS	or	other	health	organisations	and	to	specific	clinicians	involved	in	their	care.	This	last	
point	is	important	for	the	clinicians	who	are	involved	in	the	patient	participants’	care,	as	
participants’	views	may	reflect	negatively	on	the	care	received	by	these	clinicians.	Anonymity	was	
also	important	for	clinician	participants	to	feel	confident	in	talking	freely	about	their	clinical	
practice	and	approach	to	the	management	of	PDN.		
Personal	data	from	interview	participants	must	be	protected.	Interview	transcripts,	quotes	
used	in	poster	presentations,	thesis	chapters	and	academic	papers	have	had	all	personal	
information	removed.	The	participant	data	including	full	names,	addresses	and	phone	numbers,	
sociodemographic	and	clinical	details	were	kept	in	an	electronic	study	spreadsheet.	This	file	was	
password	protected	and	kept	on	UWE	servers	that	required	further	password	security	measures	
to	access.	UWE	have	data	management	policies	on	the	storage	of	electronic	patient	sensitive	data	
that	were	adhered	to	fully	throughout	the	research	process.	These	data	will	be	destroyed	after	
nine	years,	in	accordance	with	these	guidelines.		
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All	participants	were	made	aware	that	the	researcher	was	also	a	practicing	physiotherapist,	
experienced	in	managing	persistent	pain.	This	was	made	explicit	in	the	PIS	and	in	the	opening	of	
the	interview.	It	was	the	opinion	of	the	researcher	that	it	would	have	been	disingenuous	to	
conceal	this	fact	from	participants.	This	decision	did	however	create	the	dual	role	of	clinician-
researcher	and	the	potential	for	conflict	between	these	roles	(Houghton	et	al.,	2010).	Patient	
participants	occasionally	asked	for	clinical	advice	during	the	process	of	the	interview.	It	was	not	
the	role	of	the	researcher	to	give	advice	or	to	suggest	treatment	interventions	the	person	had	not	
been	given	the	opportunity	to	trial.	With	experience	the	researcher	became	more	adept	at	
bracketing	such	questions,	and	then	returning	to	them	at	the	conclusion	of	the	interview.	This	
allowed	the	interview	to	focus	on	the	research	topics,	but	also	gave	due	time	to	the	patients’	
requests.	In	answering	these	questions,	it	was	always	stressed	that	the	researcher,	despite	being	
a	clinician,	was	not	acting	in	a	capacity	to	alter	treatment	or	suggest	other	interventions.	
3.13.1	Patient	study	-	Approvals	
Ethical	approval	for	this	study	was	obtained	from	the	UWE	Health	and	Applied	Sciences	
Faculty	ethics	committee,	from	the	NHS	National	Research	Ethics	Committee	(Frenchay)	(Study	
identifier	13/SW/0125)	and	from	University	Hospitals	Bristol	NHS	Foundation	Trust	(UHBristol)	
Research	and	Innovation	department	(Study	identifier	ME/2013/4345).	The	relevant	permissions	
letters	can	be	found	in	Appendices	11-13.		
In	order	to	widen	recruitment	a	national	advert	was	placed	through	Balance	the	DUK	
membership	publication.	A	substantial	amendment	was	submitted	for	approval	and	granted	by	
Frenchay	NREC,	please	see	Appendix	13	–	REC	substantial	amendment.	
3.13.2	Clinician	study	-	Approvals	
Ethical	approval	for	this	study	was	obtained	from	the	UWE	Health	and	Applied	Sciences	
Faculty	ethics	committee.	To	approach	clinicians	in	secondary	care,	proportionate	review	
approval	was	secured	from	the	Research	and	Innovation	departments	of	University	Hospitals	
Bristol	NHS	Foundation	Trust	(Study	identifier	ME/2013/4340)	and	North	Bristol	NHS	Trust	(Study	
identifier	3164).	To	approach	clinicians	in	primary	care,	a	letter	of	access	was	secured	from	Bristol	
Community	Health.	The	relevant	permissions	letters	can	be	found	in	Appendix	14	–	Clinician	
permission	letters.	
	
This	chapter	has	outlined	the	decisions	made	in	conducting	two	interview	studies.	Starting	
from	the	research	questions	it	has	detailed	the	philosophical	perspectives	these	studies	were	
located	within.	It	has	detailed	the	methods	used	to	sample	and	recruit	participants	to	these	
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studies,	how	the	interview	topics	were	formulated	and	how	the	interviews	were	conducted.	The	
analytical	process	has	been	clearly	described	and	shown	to	be	congruent	to	the	research	
questions.	Processes	for	quality	assurance	of	these	research	studies	have	been	described.		
The	following	two	chapters	will	present	the	results	of	these	studies.	Each	chapter	will	
contain	individual	discussion	and	conclusions.		
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Chapter	4	–	Results	from	the	patient	interview	study	
The	preceding	chapter	outlined	the	methodological	considerations	relevant	to	the	planned	
interview	studies.	It	described	the	decisions	taken	to	provide	a	coherent	approach	from	research	
questions	to	analytic	framework.	Chapter	3	also	described	specific	methods	that	were	followed	in	
the	conduct	of	these	two	studies.	The	following	chapter	will	present	the	detailed	results	and	
discussions	for	the	study	with	people	who	experience	PDN.	Further	reference	in	this	chapter	to	
‘participants’	relates	only	to	patients	who	were	interviewed.	The	results	from	the	interviews	with	
clinicians	are	presented	in	Chapter	5.	
4.1	Interview	participant	characteristics	
All	potential	participants	who	contacted	the	researcher	having	received	the	study	
information	were	interviewed,	except	one,	who	did	not	meet	the	inclusion	criteria	as	they	had	
neuropathy	but	no	pain.	Twenty-three	participants	were	recruited	with	a	mean	age	of	62	years	
(range	24-86	years);	12	were	women.	All	except	one	participant	identified	themselves	as	White	
British.	Ten	participants	had	Type	1	diabetes.	Participants	self-reported	being	diagnosed	with	
diabetes	for	a	mean	of	23	years	(range	7-50	years)	and	having	experienced	PDN	for	a	mean	of	10	
years	(range	1-24	years).	A	summary	of	participant	characteristics	is	presented	in	Table	8,	further	
interviewee	details	can	be	found	in	Appendix	15.	The	interviews	lasted	between	30	and	120	
minutes.		
Table	8	-	Participant	characteristics	
Characteristic	 N	 Mean	(range)	
Participants	 23	 	
Gender	
Female	
Male	
	
12	
11	
	
Age	years	 	 62.5	(24-86)	
Ethnicity		
White	British	
West	Indian	
	
22	
1	
	
Type	1	diabetes	
Type	2	diabetes	
10	
13	
	
Duration	with	Diabetes	(years)	 	 23.5	(7-50)	
Duration	with	PDN	(years)	 	 10.3	(1-24)	
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Characteristic	 N	 Mean	(range)	
Current	analgesia	
Anti-epileptics	
Amitriptyline	
Strong	opioids	
Paracetamol	
Duloxetine	
Co-codamol	
Capsaicin	cream	
Nil	analgesia	
	
9	
8	
7	
5	
3	
2	
1	
5	
2	(0-4)	
Current	employment	
Retired		
Full	time	
Other	
	
20	
2	
1	
	
	
4.2	Results	of	participant	diabetes	complication	questionnaire	
To	be	eligible	for	this	study,	participants	all	experienced	PDN	as	a	complication	of	their	
diabetes.	In	addition,	they	experienced	a	range	of	other	complications	related	to	their	diabetes,	
please	see	Chapter	3,	section	3.6.1	for	details	of	the	complication	questionnaire.	Table	9	shows	
the	occurrence	of	complications.	Although	the	study	eligibility	criteria	required	participants	to	
have	PDN,	not	all	participants	scored	this	complication.	This	may	have	been	due	to	the	
questionnaire	lacking	clarity	whether	it	was	asking	about	all	complications	of	diabetes,	or	only	
those	experienced	in	addition	to	PDN.	In	the	free	text	options	participants	did	not	identify	any	
further	complications	they	experienced,	which	were	not	already	part	of	the	questionnaire	form.		
Table	9	-	Participant	complications	associated	with	diabetes	
Issues	participants	associated	with	diabetes	 N	 %	
Painful	neuropathy	
Glycaemic	control	issues	
Sensory	loss	
Retinopathy	
Mood	issues	
Weight	management	
Nephropathy	
Sex	life	
Hypertension	
Cardiovascular	disease	
Bladder	issues	
Bowel	issues	
Foot	ulcers	
Memory	loss	
Liver	disease	
Frozen	shoulder	
17	
13	
11	
10	
9	
8	
7	
7	
7	
6	
6	
6	
5	
5	
3	
3	
74	
56	
47	
43	
39	
35	
31	
31	
31	
26	
26	
26	
22	
22	
16	
16	
	
Chapter	4	–	Results	from	the	patient	interview	study	
Page	-	84	
	
Table	10	Shows	how	participants	considered	these	complications	interfered	with	their	lives.	
There	was	variation	in	how	participants	completed	the	questionnaire.	Participants	did	not	always	
rate	the	complications	in	a	strict	sequential	order	of	interference	(where	1=greatest	interference,	
to	X	as	required).		
PDN	was	the	most	frequent	complication	identified	(74%).	As	noted	earlier,	not	all	
participants	rated	PDN	for	the	interference	it	had	on	their	lives.	PDN	had	the	highest	interference	
score	for	impacting	on	participants’	lives	(median	1,	(interquartile	range	(IQR)	0)).		
Thirty-nine	per	cent	of	the	cohort	identified	mood	problems	as	an	issue	but	these	moods,	
when	present,	were	rated	the	second	most	interfering	aspect	of	diabetes	(2(0)).		
The	third	ranking	complications	for	interference	included	glycaemic	control	(3(2)),	foot	
ulceration	(3(1)),	cardiovascular	disease	(3(2))	and	nephropathy	(3(1)).	Although	these	
complications	have	similar	ratings	for	interference,	control	of	blood	sugars	was	endorsed	by	56%	
of	the	participants,	whereas	the	others	were	endorsed	by	20-30%	of	the	participants.		
Table	10	-	Participant	interference	rating	for	complications		
Complication	 Participant	count	(n)	 Interference	rating	(median,	(IQR))	
Painful	neuropathy	 17	 1	(0)	
Mood	issues	 9	 2	(0)	
Retinopathy	 10	 2	(1.5)	
Sensory	loss	 11	 2	(1.5)	
Weight	management	 8	 2.5	(1.5)	
Glycaemic	control	
issues	
13	 3	(2)	
Foot	ulcers	 5	 3	(1)	
Cardiovascular	disease		 6	 3	(2)	
Nephropathy	 7	 3	(1)	
Bowel	issues	 6	 3.5	(1)	
Liver	disease	 3	 4	(0.5)	
Hypertension	 7	 4	(3)	
Memory	loss	 5	 4	(4)	
Sex	life		 7	 4	(3)	
Bladder	issues	 6	 4.5	(3.25)	
Frozen	shoulder	 3	 5	(1)	
Interference	rating	anchored	with	1=most	interfering	complication	of	DM	
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4.3	An	overview	of	the	thematic	structure	of	patient	interviews	
The	interview	data	were	coded	using	the	principles	of	TA	(Braun	and	Clarke,	2012).	Each	
code	created	referred	to	a	unique	issue	raised	by	participants.	These	codes	were	grouped	into	
organising	themes	that	contained	a	central	concept.	Themes	were	then	further	brought	together	
as	superordinate	themes	where	appropriate.	Full	details	of	this	approach	can	be	found	in	Chapter	
3,	section	3.11.	
The	first	attempt	at	interview	coding	was	started	once	the	first	three	interviews	had	been	
conducted	and	continued	concurrently	with	on-going	recruitment	and	interviews.	This	first	
attempt	at	coding	was	discarded,	(see	Chapter	3,	sections	3.11.4	and	5)	due	to	potential	
researcher	bias.	The	second	attempt	at	coding,	presented	here,	was	completed	when	recruitment	
had	stopped	and	all	interviews	conducted.	The	history	of	code	creation	showed	that	no	new	
codes	were	created	beyond	interview	13.	It	would	have	been	unethical	to	discard	interview	
transcripts	simply	because	the	creation	of	new	codes	appeared	not	to	be	required.	Participants	
had	given	their	time	to	be	interviewed	and	consented	to	be	involved	with	the	expectation	that	
their	contribution	would	be	used.	It	was	appropriate	to	give	due	respect	to	the	data	that	had	
been	provided	by	all	participants	interviewed.		
Quotes	from	participants	have	been	used	to	illustrate	codes	or	themes	as	required,	and	
these	are	identified	by	pseudonym,	sex	(M/F)	and	age.		
The	superordinate	themes	(Figure	10)	were:	Medical	care	for	PDN	-	all	participants	had	
tried	a	variety	of	medication	strategies	to	alleviate	pain	and	subsequent	impacts.	This	
superordinate	theme	provided	the	context	of	treatment	recommendations	participants	had	
received,	against	which	they	had	explored	other	strategies	to	manage	their	PDN.	The	impact	of	
PDN	presented	the	range	of	impacts	PDN	had	on	participants’	lives,	these	ranged	across	all	
manner	of	day-to-day	activities.	Participant	management	of	PDN,	included	all	non-medication	
strategies	that	participants	had	experienced.	Two	superordinate	themes	explored	the	
participants’	perspectives	on	PMP	strategies:	Perspectives	on	physical	activity	and	Perspectives	on	
talking	therapy.	
Chapter	4	–	Results	from	the	patient	interview	study	
Page	-	86	
	
Figure	10	-	Superordinate	theme	overview	for	patient	interviews	
	
4.4	Superordinate	theme:	Medical	care	for	PDN	
Before	exploring	the	impacts	of	PDN	described	by	participants,	and	the	strategies	they	had	
developed	or	experimented	with	for	managing	this,	it	is	important	to	outline	their	experience	of	
PDN	management	from	the	clinical	teams	they	have	contact	with,	both	secondary	care	
Consultants	and	primary	care	GPs	(Figure	11).	These	issues	were	not	the	focus	of	the	thesis,	but	
were	important	to	provide	the	context	within	which	patients	sought	to	improve	their	own	
management	of	PDN	and	its’	impacts.	Participants	spoke	at	length	about	their	journey	to	PDN	
diagnosis	and	how	their	clinical	team	currently	managed	PDN	and	the	associated	impacts.	This	
superordinate	theme	contained	three	themes	-	NHS	time	to	hear	the	patient,	Forming	treatment	
plans	and	Managing	the	medication.		
Figure	11	-	Medical	care	for	PDN	-	themes	and	subthemes	
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4.4.1	Theme:	NHS	Time	to	hear	the	patient		
Participants	had	experienced	a	variety	of	clinical	pathways	from	their	first	experience	of	
PDN-like	symptoms	to	diagnosis	and	treatment.	Some	participants	described	their	GP	identifying	
the	likely	pathology	almost	immediately.		
“I	went	to	the	general	GP	and	said	look	I’ve	got	these	burning,	burning	in	my	feet	
and	he	just	said	it’ll	be	neuropathy…”	Philip,	M57.	
Others	described	many	consultations	and	test	procedures	over	several	years	before	a	
diagnosis	was	established	and	treatment	initiated.		
“I	believe	the	nerve	damage	that	I	have	got	has	been	caused	because	I	had	it	for	
such	a	long	time	before	my	GP	referred	me	to	[secondary	care	specialist].”	Joan,	
F57.	
Participants	had	a	variety	of	experiences	of	clinical	consultations.	Some	described	being	
moved	through	clinic	appointments,	without	feeling	involved	in	the	process:	
“I	would	say	this	conveyer	belt	of	you	know	line	up,	go	in	one	by	one,	blood	
pressure,	blood	sample,	urine	sample,	go	through	the	motions	of	it,	oh	you’re	
overweight	yeah,	okay	I	know	[laughing]	um,	and,	and	our	practice	is	very	
professional,	I	get	er	a	printed	sheet	and	goals	at	the	bottom,	sometimes	I	wonder	if	
we’ve	been	at	the	same	meeting”	Jane,	F68.	
When	describing	their	experience	of	clinical	consultations	participants	described	feeling	
that	clinicians	had	set	formats	to	their	consultation	that	did	not	often	include	enquiry	about	pain.		
“…	you	go	and	the	talk	is	how	your	kidneys	are,	how	your	liver	is,	how	your	blood	is,	
how	your	eyesight	is,	you	know,	all	these	different	categories,	your	blood	sugars,	
your	blood	pressure,	your	cholesterol,	your	fine,	goes	through	the	whole,	but	there	
doesn’t	seem	to	be	any,	anything	automatic	for	nerve	pain.”	Lisa,	F69.	
Closely	linked	to	this	issue,	was	the	feeling	of	not	being	heard	by	the	clinician,	even	when	
they	were	able	to	talk	about	the	problems	they	experienced	related	to	PDN.	
“so	you	almost	in	a	way	give	up	and	think	nobody	is	listening	to	me	I’ll	just	be	quiet	
I’ll	just	almost	shut	up.”	Mary,	F44.	
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The	lack	of	being	heard	created	a	sense	their	problems	were	being	dismissed	or	they	were	
in	the	wrong	place	to	raise	them.	Other	participants	however,	described	their	problems	were	
heard	and	acknowledged,	and	then	some	form	of	treatment	was	forthcoming.	
“He	said	there	are	tablets	out	there	you	know	and	he	was	really	the	first	person	I	
thought	‘no,	he’s	listened	to	me’,	he	sounds	like	he	understands	how	disabling	it’s	
become	for	me”	Mary	F44.		
“The	pain	management	people	came	up	and	they	were	very	good,	they	listened	to	
everything	and	they	prescribed	all	the	tablets.”	Barbara,	F80.	
These	descriptions	suggest	that	getting	clinicians	in	the	health	service	to	attend	to	and	
understand	the	nature	of	the	persons’	problems	could	present	a	challenge.	Patients	described	
feeling	disempowered	from	raising	the	key	issues	they	wanted	to	discuss	with	clinicians.		
4.4.2	Theme:	Forming	treatment	plans	
This	theme	contained	two	subthemes:	Delays	in	Treatment	and	Starting	treatment.	Delays	
in	Treatment	(4.4.2.1)	-	participants	described	the	process	of	reaching	some	form	of	treatment	for	
PDN,	this	journey	may	have	been	delayed	by	clinical	inertia	or	lack	of	diagnostic	certainty.	Starting	
treatment	(4.4.2.2)	-	once	treatment	was	started	this	was	usually	the	prescription	of	medication,	
and	advice	to	focus	on	overall	diabetes	management.			
4.4.2.1	Subtheme:	Delays	in	treatment	
Participants	had	experienced	delays	both	in	diagnosis	or,	once	the	diagnosis	was	confirmed,	
delays	to	starting	any	form	of	treatment.	For	some	this	was	due	to	seeing	different	GPs	in	primary	
care,	which	they	reported	had	led	to	a	lack	of	co-ordinated	care	planning.	For	others,	they	had	no	
real	explanation	for	why	these	delays	occurred.	
	“There	was	a	big	period	of	time	between	first	it	occurring	and	actually	getting	
somebody	to	deal,	properly	deal	with	it.”	Sam,	M53.	
“we’re	talking	from	seven	years	from	having	the	symptoms	to	only	about	three	
years	ago,	so	it	took	a	good	four	years	to	get	to	the	point	where	actually	some	
treatment	was	started	and	then	it	took	another	two	years	no	three	years	to	get	to	
the	point	of	seeing	a	professor	that	was	interested	in	diabetic	painful	neuropathy	
and	being	told	‘Well	actually	you	still	haven’t	been	put	on	the	NICE	guidelines	of	
what	they	say	the	cocktail	of	drugs	are’	as	a	starting	point,	so	we	still	hadn’t	got	to	
that	point	six	years	on.”	Mary,	F44.	
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4.4.2.2	Subtheme:	Starting	treatment	
Participants	described	the	process	of	reaching	and	initiating	agreed	treatment	plans	with	
their	clinical	teams.	Some	participants	described	a	palpable	sense	of	relief	that	something	was	
being	done.	The	treatment	plans	participants	experienced	were	centred	on	prescription	of	
analgesic	medication	and	close	management	of	blood	sugar	levels.	
“Yeah,	I	think	medication	came	up	pretty	quickly,	and	it	was,	like,	the	obvious,	it	was	
almost	like	a	no-brainer.	You’ve	got	neuropathy;	well,	you’d	better	try	some	
medication.”	Sally,	F48.	
“to	start	to	try	some	drugs	to	see	how	we	go	even	if	it	took	for	the	next	two	three	
years	messing	about	with	drugs,	upping	them,	but	to	get	on	that	ladder	if	you	like	to	
start	was	a	big	relief	to	me	that	we	were	going	to	do	that.”	Mary,	F44.	
Clinicians	encouraged	patients	to	manage	their	blood	sugar	levels	closely	within	the	
recommended	parameters.		
“…it’s	a	matter	of	keeping	your	blood	sugar	levels	correct…”	Daniel,	M67.	
“…he	[GP]	just	said	to	carry	on	taking	the	Paracetamol	and	just	see	how	things	
went,	to	keep	my	blood	sugars	as	tight	as	possible.”	Mary,	F44.	
However,	with	different	clinicians	involved	at	different	times,	participants	described	
receiving	contradictory	advice	as	to	how	closely	monitored	and	managed	their	HbA1c	should	be.	
“we’re	trying	to	get	it	between	five	and	eight	or	five	and	seven	[%HbA1c].	Everybody	
has	a	different	thing,	every	Doctor	has	a	different	opinion	and	[one]	says	‘no	I’m	
quite	happy	if	it’s	ten,	I’m	quite	happy	if	it’s	nine’,	some	will	go,	‘I’m	not	happy,	it’s	
too	high	that	now	and	you	know	we	need	it	at	seven’.	Do	you	see	what	I	mean?”	
Philip,	M57.	
4.4.3	Theme:	Managing	the	medication	
All	participants	had	some	experience	of	medication	trials	from	primary	care,	secondary	care	
or	both.	Three	subthemes	have	been	constructed	from	these	experiences:	Medications	do	help	
(4.4.3.1),	Medications	can	fail	(4.4.3.2)	and	Choices	of	Medication	(4.4.3.3).	
4.4.3.1	Subtheme:	Medications	do	help	
Participants	reported	some	benefits	from	the	medications	they	had	been	prescribed.	The	
benefits	included	allowing	the	individual	to	be	more	active	in	daily	life,	to	sleep	better	and	to	feel	
some	sense	of	control	over	the	interference	caused	by	PDN.	
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“I’d	say	it’s	probably	better	now	since	having	this	cocktail	of	drugs	that	I’m	on”	
Mary,	F44.	
“I	um,	but	the	Gabapentin	is	always	there	because,	sometimes	I’ll,	I’ll	take	a	couple	
before	I	play	golf.”	Mike,	M65.	
“I’ve	found	that	the	one	Amitriptyline	at	night	usually	controls	the	worst	of	any	pain	
that	I	do	get.”	Barbara,	F80.	
Some	participants	had	come	to	arrangements	with	their	clinicians	to	find	a	balance	of	
medication,	others	had	self-titrated	the	dose	to	manage	any	side	effects.	Medications	had	
reduced	but	not	eliminated	the	pain.	Participants	described	uncertainty	about	their	analgesic	
effect	but	were	worried	that	stopping	them	may	lead	to	the	impacts	of	PDN	becoming	more	
intrusive.	
“…	if	I	stop	taking	it	[medication],	it	[pain]	might	be	permanent	[…]	because	I’ve	sort	
of	got	used	to	it,	I	kind	of	think	‘well	it	must	be	working	in	some	respects	because	I	
only	get	it,	probably	now	I	only	get	it	about	once	every	three	weeks’	or	something	
like.	So	I’m	of	the	opinion	that	the	tablet	must	be	doing	something	and	I	don’t	want	
to	stop.”	Sam,	M53.	
4.4.3.2	Subtheme:	Medications	can	fail	
Some	participants	had	tried	medications	but	found	they	were	ineffective	at	reducing	pain.	
“Just	take	it,	you	know	[…]	three	times	a	day,	I	don’t	think	it’s	any	good.”	Aaron	
M75.		
“Yeah	and	because	it	wasn’t	doing	anything	to	help	the	pain	I	thought,	‘This	is	
silly.’”	Anne,	F52.	
Some	participants	stated	clinicians	would	only	prescribe	the	cheaper	drugs,	and	this	was	
unfair,	having	paid	into	the	system	for	all	their	working	lives	better	medical	care	should	be	
available.	
“Then	she	[GP]	says	‘right,	I	didn’t	really	want	to	give	you	this	one’,	because	I	think	
she	was	trying	the	cheaper	versions	first,	you	know,	you	know	what	doctors	are	like	
in	the	surgery.”	Mike,	M65.	
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“I	could	go	to	the	Doctor	and	say	right,	look,	money’s	no	object,	I’ll	pay	for	these	
and	I’m	sure	there’d	be	a	Doctor	out	there,	going	yeah	you	can	have	these.”	Philip,	
M57.	
As	all	medications	can	have	side	effects,	some	participants	found	these	were	less	tolerable	
than	the	PDN.	Descriptions	of	tiredness,	nausea	and	feeling	like	a	zombie	were	common.	Tension	
existed	between	symptom	management	and	being	able	to	live	an	active,	engaged	life.		
	“…I	slept	all	day	and	all	night,	and	I	felt	as	if	I	hadn’t	even	got	...	I	didn’t	even	know	
whether	I’d	got	legs	or	feet.	So,	yes,	they	did	work,	but	it,	it	just	addled	my	brain.”	
Heather,	F57.	
“…	I	was	a	zombie	and	of	course	when	I	went	back	to	see	him	and	told	him,	I	said	
they	shut	everything	down,	I	couldn’t,	you	know	they	didn’t	do	nought	and	he	went	
‘well	I	suppose	you’ll	have	to	go	back	on	the	Morphine	then’.”	Philip,	M57.	
4.4.3.3	Subtheme:	Choices	of	medication	
Participants	had	a	number	of	points	where	they	described	making	choices	about	
medication.	The	options	for	different	medications	were	sometimes	taken	in	collaboration	with	
their	clinician,	but	some	participants	described	medication	as	an	imposition	and	presented	as	the	
only	treatment	on	offer.	Participants	described	situations	where	clinicians’	choices	were	limited	
by	other	co-morbidities,	such	as	nephropathy.	
“That’s	right	I	can’t	remember	their	names	and	I	know	we	talked	about	them,	but	I	
think	that	was	partly	because	of	my	kidney	impairment,	that	they	were	felt	to	be	
inappropriate.”	Lisa,	F69.	
Other	times	participants	chose	to	refuse,	reduce	or	stop	medications	that	were	prescribed	
for	them.	
“If	you	hit	the	slightest	nag	they	want	to	increase	your	medication	for	whatever,	
and	um	as	far	as	I	can,	I	steadfastly	refuse	to	be	drawn	into	this	taking	more	and	
more	tablets.”	Jane,	F68.	
4.5	Superordinate	theme:	The	impact	of	PDN	
A	schematic	diagram	demonstrating	the	diversity	of	impacts	can	be	seen	in	Figure	12.		
The	participants	described	a	wide	variety	of	impacts	due	to	PDN.	For	the	majority	of	
participants,	most	facets	of	everyday	life	were	effected	in	some	way.	The	quote	from	Joan	was	
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indicative	of	the	problems	people	faced;	it	is	not	representative	of	any	code	at	this	point	but	is	
used	by	way	of	introduction:	
“As	soon	as	it	started,	it	made,	it	affected	every	aspect	of	my	life,	its,	…	you	know	
from	going	shopping	to	going	out.	It	has	made	it,	…	a	bit,	I	don’t	know	it’s	hard	to	
put	into	words,	it	rules	my	life.”	Joan,	F57.	
This	superordinate	theme	contained	four	themes.	Firstly,	The	experience	of	living	with	PDN	
(4.5.1)	described	the	subjective	experience	of	PDN.	Affects	those	around	me	(4.5.2)	described	the	
impact	PDN	had	on	the	participant’s	wider	social	network.	A	range	of	negative	emotions	(4.5.3)	
described	the	impact	on	mood	state.	Lastly,	Life	is	a	constant	challenge	(4.5.4)	outlined	the	day-
to-day	impact	of	PDN.	
Figure	12	-	The	impact	of	PDN	-	themes	and	subthemes	
	
4.5.1	Theme:	The	experience	of	living	with	PDN		
Participants	spoke	about	the	challenge	of	living	with	PDN	from	two	perspectives.	They	
described	the	personal	experience	of	PDN.	This	first-person	description	was	captured	in	
subtheme:	An	Internal	experience	(4.5.1.1).	The	second	subtheme,	A	very	personal	problem	
(4.5.1.2),	was	created	to	capture	how	participants’	felt	viewed	by	others	and	how	their	sense	of	
self	or	identity	may	have	changed	due	to	PDN.	A	third	subtheme	Making	the	most	of	life	(4.5.1.3)	
captured	a	counter	perspective	to	the	first	two	as	some	participants	were	able	to	carry	on	with	
daily	activities	despite	PDN.	They	had	a	positive	approach	toward	PDN,	viewing	it	as	a	challenge	to	
overcome.		
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4.5.1.1	Subtheme:	An	internal	experience		
There	were	evocative	descriptions	of	experiencing	PDN	from	a	first-person	perspective.	Bob	
equated	his	experience	of	PDN	to	“Templar	Torture”	as	there	were	depictions	from	the	Middle	
Ages	of	Templar	Knights	having	boiling	oil	poured	over	their	feet	in	order	to	extract	confessions.		
	“…I	couldn’t	walk	at	all	in	my	job	and	you	know	it	used	to	bring	tears	to	your	eyes	
believe	me.”	Philip,	M57.	
“I	went	to	the	general	GP	and	said	look	I’ve	got	these	burning,	burning	in	my	feet	…”	
Philip,	M57.	
“my	husband	touches	my	foot,	and	then	I	feel	like	killing	him.	[…]	I	say	it’s	like	
walking	on	hot	sand.”	Heather,	F57.	
There	were	some	close	associations	with	symptoms	that	participants	described	as	‘restless	
legs’.	
“Can’t	keep	my	legs	still	and	then	they	start	burning,	itching;	oh	you	don’t	know	
where	to	put	your	feet.”	John,	M69.	
One	participant’s	pain	experience	affected	his	self-image	and	led	him	to	remove	all	mirrors	
from	his	house.	
“I	got	rid	of	them	all	[mirrors],	I	cannot	stand	to	look	at	myself.”	Bob,	M63.	
Participants	described	the	contradiction	of	having	numb	feet,	thereby	not	feeling	the	
appropriate	warning	pain	from	tissue	damage,	while	simultaneously	having	an	experience	of	
burning	pain	that	served	no	purpose.	
“…you	get	that	numbness	and	then	on	the	other	hand	the	extreme	pain.”	Bob,	M63.	
There	was	a	similar	contradiction	for	patients,	between	their	feet	looking	normal	and	their	
experience	of	pain	perception.	
“You	know	what	I	mean,	they’re	not	gnarled	and	knotty,	they	look	quite	ordinary	
feet	and	yet	they’ve	got	this	most	incredible	pains.”	Lisa,	F69.	
There	were	descriptions	of	symptoms	associated	with	the	experience	of	PDN	such	as	
headaches;	these	were	more	common	after	a	stressful	day	due	to	PDN.		
“I	do	find	I	am	really	tired,	quite	stressed,	always	have	a	headache.	Then	I	find,	you	
know,	I	have	problems	then	going	to	sleep.”	Mary,	F44.	
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One	participant	held	their	breath	whilst	trying	to	do	a	physical	activity,	which	led	to	a	sense	
of	breathlessness.		
“I	find	I	get	breathless,	it’s	like	I	cannot	breathe	out	or	I’m	making	a	cup	of	tea,	I	find	
I	tend	to	speed	up	things.	I	don’t	know	why,	there’s	no	reason	to	speed	up.”	Bob,	
M63.	
4.5.1.2	Subtheme:	A	very	personal	problem		
This	subtheme	described	how	participant’s	felt	viewed	by	other	people	in	society.	
Participants	described	the	invisible	nature	of	PDN,	where	other	people	could	not	understand	
what	they	were	experiencing,	or	what	they	had	to	endure.		
There	were	parallels	drawn	with	common	colds	or	injuries	that	other	people	had	likely	
experienced;	these	shared	experience	allowed	empathy	and	understanding.	There	were	clear	
descriptions	from	participants	that	they	kept	the	experience	of	PDN	to	themselves,	because	only	
someone	else	with	PDN	could	understand.	
“I’d	never	met	anybody	else	with	it	[PDN],	so	...	whereas,	if	you’ve	got	a	cold,	or	a	
shoulder	pain,	or	something,	you	know,	most	people	know	what	that’s	like.	And,	
actually,	I	feel	that	sort	of	thing,	people	are	more	understanding,	simply	because	
they	know	what	it’s	like,	and	they’ve	got	empathy.”	Sally,	F48.	
“I	don’t	think	people	take	it	seriously,	they	think	well	it’s	an	itchy	foot,	get	over	it,	it	
doesn’t	work	that	way.”	Bob,	M63.	
Participants	described	feeling	that	other	people	had	negative	perceptions	of	them	because	
there	was	nothing	to	‘see’	that	would	explain	the	pain.	If	falls	had	been	experienced,	participants	
were	concerned	that	people	thought	they	were	drunk	or	on	drugs.	
	“I	have	fallen	over	a	few	times	when	I	have	been	out	on	my	own	and	people	just	
ignored	it,	I	think	they	think	I’m	just	drunk.	[…]	I’ve	been	laying	on	the	floor	for	half	
an	hour	and	things	like	that	and	people	have	just	ignored	me,	I	think	they	think	I’m	
drunk	or	on	drugs	or	something,	I’ve	never	had	anybody	help.”	Kate,	F58.	
From	this	potential	lack	of	understanding	participants	had	stopped	talking	about	the	
problem.	Instead,	they	chose	to	keep	the	problems	they	experienced	to	themselves.	
“I	would	say	“oh	no	it	been	an	ok	day”	when	actually	it’s	been	an	awful	day.”	Mary,	
F44.	
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“Whereas	this,	well,	it’s	just,	well,	you	know,	nobody	really	gets	it,	and	therefore	I	
don’t	really	talk	about	it	very	much,	because	I	don’t	really	see	the	point.”	Sally,	F48.	
4.5.1.3	Subtheme:	Making	the	most	of	life		
There	were	participants	for	whom	PDN	did	not	overly	affect	their	ability	to	live	their	lives.	
PDN	caused	minimal	interruption	to	their	lives.		
“I	mean	to	say	I	do	keep	active,	I	do	my	own	gardening	all	of	it.	I	used	to	do	all	the	
decorating	here,	I	don’t	do	that	nowadays	I	must	admit	now,	I	am	nearly	80.	But	as	I	
say	I	walk	my	dogs	so	I	keep	active	and	I	think	that	helps	because	I	think	if	you	stop	
doing	something	you	lose	the	ability	to	do	that.”	Barbara,	F80.	
“I	tend	to	ignore	them	[PDN	symptoms],	um.	I	just	get	on	with	life,	I	fish.	I	put	my	
waders	on.	I	lay	floor	slabs.	I	paint	and	I	just	get	on	with	it	and	it’s	just	part	of	
life…well	it	really	doesn’t	impact	on	me	very	much.	I	mean,	er,	I’m	tending	almost	to	
ignore	it.”	Roger,	M86.	
In	order	to	cope,	and	make	the	most	of	life,	some	participants	viewed	PDN	as	a	challenge	to	
conquer.	This	required	being	optimistic	and	making	the	most	of	their	lives	by	setting	and	
achieving	a	goal,	or	doing	something	nice	each	day.		
	“Yeah,	I	had	that	sort	of	where	I’d	done	something	you	know,	I	felt	like	I’ve	
achieved	something	because	also	the	feeling	of	not	having	achieved	anything,	
wasted	a	day	just	sat	down	watching	TV	you	think	what	a	waste	of	a	day	you	
know.”	Bob,	M63.	
“I	do	like	a	cup	of	coffee,	and	I	find,	sometimes,	if	it’s	getting	me	down	a	bit	[…]	it,	
sort	of,	lifts	your	mood	a	little	bit…or	whatever.	And	I	thought,	that’s	my	one	
pleasure,	is	a	cup	of	coffee,	and	I’m	having	a	decent	cup	of	coffee.”	Ellen,	F63.	
For	Anne,	this	approach	included	not	wasting	emotional	energy	on	something	she	had	little	
control	over.	
“What	you	don't	do	is	waste	it,	just	um	feeling	sorry	for	yourself	basically,	I’m	in	
pain	again,	blah,	blah,	blah,	that’s	no	good.	You’ve	got	to	feed	that	emotion	into	
something	else.”	Anne,	F52.	
4.5.2	Theme:	Affects	those	around	me		
Participants	described	how	PDN	had	an	impact	on	people	who	were	close	to	them.	It	could	
affect	their	relationships	with	partners	and	family.		
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“That's	all	it	was,	and	I	know	the	type	of	person	he	[Mary’s	husband]	is,	if	he	feels	
hopeless	that	he	can’t	actually	physically	or	mentally	do	something	he	gets	very	
worked	up	and	so	that	makes	the	whole	situation	ten	times	worse	you	know”	Mary,	
F44.	
“I	might	bite	Ian’s	head	off	[…]	and	when	you’re	a	couple	and	somebody	has	got	
neuropathy	pain,	to	my	way	of	thinking	there’s	always	somebody	that	loses.”	Anne,	
F52.	
“...	back	to,	to	the	eighties	and	early	nineties,	it	[PDN]	caused	a,	it	caused	the	
divorce	between	me	and	my	wife	–	she	couldn’t	handle	it	anymore	–	and	we	had	a	
divorce.”	Mark,	M62.	
It	could	affect	their	communication	and	make	them	less	tolerant	to	family	and	friends	
around	them.	Participants	demonstrated	this	reduced	tolerance	by	being	more	easily	irritated	in	
conversation	or	by	other	peoples’	actions.	Participants	actively	removed	themselves	from	the	
family	environment	or	social	situations,	choosing	instead	to	be	on	their	own.	
	“It’s	like	I	said,	it	tends	–	the	pain	–	it,	sort	of,	takes	over,	um,	and	you	might,	sort	
of,	turn	around	and	say	something,	but	you’ve	said	it,	and	you	don’t	realise	you,	
you’ve	spoken	sharply	[...]	because	sometimes	Keith	will	say	afterwards,	‘you	don’t	
need	to	say	it	quite	like	that’.”	Ellen,	F63.	
“I	think	there’s	just	really,	if	my	wife	comes	and	talks	to	me,	I	say	to	her,	‘look,	I’m	
sorry	I	can’t,	I	can’t	answer	you,	I	don’t	want	to	talk	to	you.’”	Aaron,	M75.	
4.5.3	Theme:	A	range	of	negative	emotions	
Participants	gave	clear	examples	of	negative	emotions	such	as	feeling	angry	with	
themselves	or	their	feet,	suicidal	because	of	the	pain,	embarrassed	because	of	social	restrictions	
and	depressed	because	of	the	on-going	problems	they	had	to	cope	with.		
“you	know	I	do	get	bad	tempered	and	I	think	why	me,	you	know	‘why	bloody	me?’	
you	know.	I	used	to	like	hate	your	feet	in	a	way.”	Philip,	M57.	
“…but	it	must	be	somehow	because	I	just	get	too	down	and	I	have,	erm,	tried	to	
take	my	own	life	three	or	four	times.	[…]	Because	they	[medications]	have	to	be	
locked	away	because	I	have	taken	lots	of	them	[…]	Well	I,	I	don’t,	I	suppose	by	trying	
to	take	overdoses	and	things,	I’m	not	coping	with	it.”	Kate,	F58.	
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“I	had	to	go	out	in	the	garden	and	I	had	to	make	out	that	I	felt	sick	because	I	was	
too	embarrassed	to	say	about	these	pains	in	my	leg	because	there	was	nothing	
there,	there	was	nothing	to	show	and	our	son	came	and	picked	us	up	and	we	went	
home.”	Joan,	F57.	
	“Yeah,	yeah,	it	makes	me	aggressive	and	depressed	sometimes,	and	there	are	times	
when	I	go	into	this	low	mood	and	it	takes	me	hours	or	days	to	come	out	of	it.”	
Aaron,	M75.	
There	were	clear	examples	of	worry	about	specific	issues	such	as	money	and	health,	but	
often	participants	were	generally	concerned	about	the	future,	the	unknown	and	how	they	may	be	
in	the	months	and	years	to	come.		
	“And	the	biggest	[issue]	probably,	anxious	problems	about	the	future.”	Daniel,	
M67.	
Participants	gave	examples	of	frustration	due	to	simple	tasks	being	made	more	difficult	or	
even	impossible	because	of	the	symptoms	they	experienced.	
“I	try	and	bite	my	lip	and	think	right	carry	on	for	another	half	hour,	and	the	pains	
that	great	I’m	having	to	stop	every	couple	of	minutes,	or	say	to	them	look	I’ve	got	to	
sit	down,	I	can’t	walk	and	I	get	frustrated	because	they’re	way	ahead	of	me	and	
then,	oh,	hang	on,	wait	for	our	lad.”	Philip,	M57.	
This	sense	of	frustration	linked	to	the	next	theme:	Life	is	a	constant	challenge.	
4.5.4	Theme:	Life	is	a	constant	challenge		
This	was	a	large	theme	that	contained	five	subthemes:	Increasingly	on	my	own	(4.5.4.1),	A	
shrinking	world	(4.5.4.2),	Sleep	and	fatigue	(4.5.4.3),	Harder	to	remain	at	work	(4.5.4.4),	and	Day	
to	day	life	is	a	struggle	(4.5.4.5).	
4.5.4.1	Subtheme:	Increasingly	on	my	own		
This	subtheme	presented	the	participants’	reflections	on	their	own	feelings	of	isolation.	
Participants	described	social	isolation	due	to	cancelling	arrangements	or	limiting	their	social	life	
because	PDN	was	too	intrusive:	
“I	found	I	was	cancelling	appointments,	I	didn’t	want	to	see	people.	I	didn’t	want	to	
speak	to	people,	um	because	I	thought	I	was	going	around	with	this	tattoo	on	my	
head	that	I‘m	in	this	severe	pain	and,	um,	don't	speak	to	me	because	I’ll	probably	
bite	your	head	off.”	Anne,	F52.	
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“It	makes	you	a	hermit	…”	Bob,	M63.	
Some	participants	had	lost	confidence	to	go	out	by	themselves:	
“…	I	just	don’t	go	out,	I	just	don’t	want	to	go	out,	I	can’t	go	out.	If	I	get	out	and	then	
I	can’t	get	back	because	of	the	pain	I	just	don’t	bother,	whereas	if	he’s	[partner]	
with	me	he	can	always	help	me	and	I’m	not	on	my	own,	but	to	be	on	my	own	
outside	environment	just	frightens	me.”	Kate,	F58.	
“It’s	like	I	say	we	have	got	no	social	life	whatsoever	because	I	never	know	from	one	
day	to	the	next	whether	I	am	going	to	be	alright	to	go	out	or	not	and	it	becomes	…	
embarrassing	and	I	would	rather	just	stay	in.”	Joan,	F57.	
4.5.4.2	Subtheme:	A	shrinking	world		
This	subtheme	described	the	reduced	scope	of	the	participant’s	world.	Participants	
disclosed	that	their	lives	had	become	confined	by	PDN,	by	reducing	physical	activity	and	hobbies:	
“I	think	I	have	really	taken	a	massive	step	back	from	physical,	anything	physical,	
yeah	I	can’t	walk	a	long	distance.”	Mary,	F44.	
They	described	pain	had	reduced	their	walking	capacity	and	tolerance:	
	“…	but	unfortunately	the	pain	got	greater	and	greater	to	where	I	couldn’t	walk.	It	
gave	you	the	impression	that	you’re	walking	on	broken	glass.”	Philip,	M57.	
As	well	pain	experienced	when	walking,	participants	described	that	reduced	sensory	
information	from	their	feet	further	impacted	on	their	confidence	to	go	out.	Numbness	due	to	
neuropathy	reduces	the	joint	position	sense	required	for	walking	and	this	is	associated	with	
balance	issues,	loss	of	confidence	and	potential	falls.	
“I	do	fall	down	quite	a	few	times,	but	I’m	indoors	or	in	the	garden,	that’s	not	a	
problem,	but	when	I	go	out	I	use	my	walking	sticks	too,	for	security	because	I	don’t	
really	want	to	go	face	down	in	the	street	or	anything.”	Kate,	F57.		
As	well	as	reduced	walking,	participants	experienced	pain	and	reduced	confidence	for	using	
the	pedals	when	driving.	
“It’s	the	same	with	driving,	sometimes	when	I	used	to	drive	my	pick-up,	if	you	go	on	
a	long	journey	you’d	be	in	that	car	and	some	days	your	feet	would	burn	that	much	
just	by	keeping	it	on	the	throttle.”	Philip,	M57.	
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The	combination	of	restrictions	in	both	walking	and	driving,	led	people	to	describe	losing	
independence,	and	that	life	had	become	increasingly	narrow.	
“I	don’t	know	if	it	is	because	I	don’t	drive,	but	in	the	situation	I	am	now	I	do	feel	like	
my	independence	has	kind	of	been,	well	not	been	taken	away	but	I	don’t	have	as	
much	independence	as	maybe	I	used	to	have	because	I	can’t	walk	as	far.”	Sarah,	
F24.	
“You	feel	to	be,	sort	of	entering	this	funnel	where	the	choice	is,	life	choices	are	
getting	smaller	and	smaller	because	of	the	restrictions,	you	know,	um,	you’ll	learn	
what	not	to	do.”	Jane,	F68.	
4.5.4.3	Subtheme:	Sleep	and	Fatigue		
Participants	described	their	experiences	of	frequent	sleep	disturbance.	This	included	
difficulty	getting	off	to	sleep	and,	or,	remaining	asleep.		
“I	found	that	I	would	stay	up	a	little	bit	longer	because	the	pain	or	the	tablets	hadn’t	
kicked	in	or	I’d	get	into	bed,	I’d	go	off	and	I’d	be	up	at	twelve	and	I’d	be	up	for	an	
hour,	then	it	would	be	two	hours.	I	don't	think	I’ve	slept	for	more	than	two	to	two	
and	a	half	hours	in	over	two	years.”	Anne,	F52.		
“It	tends	to	just	appear	at	night-time	when	I’m	lying	down,	which	means	that	it	
disturbs	my	sleep,	which	is	the	biggest	impact	of	the	lot.”	Sam,	M53	
A	common	complaint	was	the	weight	of	bedclothes	on	participants’	feet.	There	were	
descriptions	of	how	uncomfortable	the	lightest	sheet	could	be.		
“Even	in	bed	at	night,	the	sheet	is	too	heavy	on	my	feet.	You	feel	as	if	you’d	like	a	
cradle.”	Ellen,	F63.	
“I	sleep	in	the	sun	lounging	chair	because	I	can’t	lay	down	because	if	I	lay	down	flat	
it	makes	it	even	worse,	I	can’t	stand	any	quilts	or	blankets	or	anything	on	my	legs”	
Joan,	F57.	
The	need	to	get	up	and	walk	around	helped	with	pain	for	one	participant,	but	was	not	
conducive	to	achieving	a	restful	night’s	sleep.	
“I	can’t	sleep	because	I	can’t	keep	my	legs	still	and	the	only	way	I	can	get	any	relief	
is	to	either	stand	up	or	walk	around	and	even	then,	it	doesn’t	relieve	it,	it’s	just	not	
the	centre	of	everything	in	your	brain.”	Joan,	F57.	
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The	loss	of	sleep	quality	was	a	key	factor	when	describing	the	impact	PDN	had	on	their	
lives.	Some	participants	however	did	not	experience	night	pain	or	sleep	disturbance	due	to	PDN.		
“I	have	no	problem	with	sleep,	no.”	Mike,	M65.	
	Following	on	from	sleep	issues,	participants	talked	further	about	the	consequent	tiredness	
they	experienced	during	the	day.		
“It’s	really,	really	bad	and	I’m	just	tired	all	the	time,	exhausted,	I’ve	totally	forgotten	
about	tiredness.”	Anne,	F52.	
4.5.4.4	Subtheme:	Harder	to	remain	at	work		
Although	most	participants	were	retired,	some	were	working.	For	those,	remaining	at	work	
was	a	struggle	due	to	a	mixture	of	pain,	concentration	issues	due	to	pain	interference,	and	fatigue	
from	frequent	disturbed	sleep.		
“So,	sometimes	I	feel	a	bit,	because	I’m	so	conscious	of	my	tongue	feeling	odd,	that	I	
do	feel	a	little	bit	tongue-tied.	And	I,	I	probably	don’t	come	across	that	way	–	er,	it’s	
probably	just	in	my	head	that	I’m	experiencing,	since	I’m	feeling	very	odd	–	but	that	
does	worry	me,	you	know,	particularly,	perhaps	really	for	my	work.”	Sally,	F48.	
“When	it	got	to	the	stage	where	I	couldn’t	walk	to	work	and	I	can’t	go	to	work	
because	I	can’t	write,	and	I	can’t	type,	peeling	potatoes	at	home	has	become	a	
struggle,	that’s	when	I’ve	realised	that	you	know	this	has	got	to	be	sorted	out.”	
Sarah,	F24.	
Participants	described	how	important	work	was	in	providing	and	maintaining	a	sense	of	
self.	They	described	no	inherent	inability	to	do	their	job	role,	yet	they	had	been	unable	to	
continue	in	work	because	of	the	impacts	PDN	had	on	their	ability	to	cope	with	work	demands.	
“I	think	it	was	also	thinking	work	are	sort	of	seeing	it	like	‘oh	you’re	not	coping	
you’re	not	managing’	and	when	you’re	so	used	to	being	in	control	of	things	it’s	very	
hard	to	then	have	people	saying	‘[name]	we	think	you	should	cut	your	hours	in	half’	
or	‘we	think	dropping	down	a	band	so	you	haven’t	got	that	responsibility’.”	Mary,	
F44.	
“I	haven’t	got	to	get	up	and	get	down	for	work	for	seven	o’clock	in	the	morning,	no,	
so	it’s	you	know,	you	can	sort	of	cope	across	with	that.”	Lisa,	F69.	
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As	a	counter	point,	there	were	participants	who	were	employed,	and	did	not	find	PDN	
affected	their	ability	to	perform	their	role.		
“I’ve	never,	pretty	much	ninety-nine	per	cent	of	the	time,	never	suffered	with	it	
when	I’ve	been	at	work	or	volunteering…”	Sam,	M53.	
4.5.4.5	Subtheme:	Day	to	day	life	is	a	struggle	
This	subtheme	was	constructed	from	participants’	descriptions	about	unique	impacts	of	
PDN.	These	were	separate	and	distinct	from	impacts	outlined	in	subthemes	so	far.	This	subtheme	
demonstrates	the	breadth	of	impact	PDN	had	on	everyday	activity.	
	The	impacts	include	the	physical	difficulty	of	getting	up	in	the	morning	after	a	night	in	bed:	
“Then	as	soon	as	you	get	up	in	the	morning,	as	soon	as	you	put	your	feet	down	on	
that	ground	it	kicks	off.”	Philip,	M57.	
The	affect	PDN	had	on	memory	and	concentration:	
“Well	I’d	say	my	memory	is	awful.	I	can	remember	things	quite	away	back,	but	
things	I’ve	done	a	couple	of	days	ago	just	go,	they	just	don’t	stay	in	my	head.”	Kate,	
F57.	
The	difficulty	participants	experienced	simply	sitting	still	-	they	were	unable	to	sit	through	a	
film	or	dinner	with	friends,	without	needing	to	get	up	and	move.	
“I	am	sat	down	now	in	a	chair	and	that	is	my	worst	part	is	sitting	down	…”	Clive,	
M86.	
They	described	how	the	experience	of	PDN	could	make	them	feel	nausea	so	affecting	their	
appetite	for	food.	This	had	a	subsequent	impact	on	diabetes	dietary	management.		
“…	I’d	feel	physically	sick	with	the	pain,	I	wouldn’t	be	able	to	eat	which	obviously	
then	in	turn	affected	my	blood	sugars,	it	wasn’t	very	productive	for	my	diabetes	to	
be	feeling	that	way.”	Sarah,	F24.	
Participants	disclosed	their	intimate	relationships	with	partners	had	diminished	or	ceased	
because	of	PDN.		
“Definitely	because	I	get	it	up	in	the	groin	and	when	it’s	in	the	groin	it’s	like	having	a	
gnawing	toothache,	so	I	think	there’s	probably	a	lot	of	people	that	wouldn’t	want	to	
say,	“I	don't	have	a	sex	drive,	I	don't	feel	sexy	anymore.	The	desire’s	just	…”	I	mean	I	
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love	my	husband	desperately	and	we’ve	got	a	great	relationship,	um,	but	I	miss	the	
closeness	because	there’s	something	about	that	final	closeness	that	you	share	that	
is	just	between	you	two	that	you	don't	get	anywhere	else.”	Anne,	F52.	
Because	of	sensory	loss,	participants	were	aware	of	the	need	for	foot	care	and	surveillance.	
Closely	allied	to	this,	some	had	problems	buying	appropriate	fitting	footwear.		
“Not	really,	I	mean	I,	I	am	very	aware	of	my	feet	as	a	diabetic	anyway,	so	I	do	wash	
them	daily	and	check	them	regularly	and	I	do	get	my	husband	to	look	at	them	
underneath,	the	bits	that	I	can’t	see	to	make	sure	they’re	alright	and	I	do	wear	sort	
of	clean	socks	or	tights	every	day.”	Lisa,	F69.	
“Um	that	you	can	send	off	for	it	[shoe	insoles],	it	saves	you	going	looking	round	
shops	and	they	make	these	shoes,	you	know	like	the	idea	of	a	mattress,	that	moulds	
to	your	body.”	Jane,	F68.	
Participants	reflected	how	life	had	altered	since	they	developed	symptoms	of	PDN;	they	
particularly	focused	on	lost	independence	and	how	their	personality	may	have	changed.		
“I	used	to	be	the	life	and	soul	of	the	party,	feisty,	bolshie,	er,	confident	but	now	I’m	
just	you	know	basically	a	shadow	of	what	I	was	before.”	Bob,	M63.	
“I	used	to	love	walking,	um,	and	standing	because	I’ve	always	done	baking	and	I’ve	
always	been	an	active	person	in	respect	I’m	always	on	my	feet.”	Anne,	F52.	
Participants	spoke	generally	about	the	restrictions	to	daily	activity	they	faced	without	being	
specific;	the	implication	being	that	all	aspects	of	life	were	affected	by	PDN.		
“Well,	it	stops	us	just	doing	day-to-day	things	[…]	So	I,	basically	all	the	things	I	used	
to	do,	I	don’t	do.”	Neil,	M66.	
“You	try	and	get	across	what	this	pain	does	to	you,	it’s	a	depravity,	is	that	the	
word?”	Anne,	F52.	
“I’ve	had	to	have	treatment	for	my	eyes,	for	retinopathy	and	things	like	that,	
kidneys	are	okay,	but	it’s,	I	guess	it’s	the	neuropathy	that	is	so	intrusive	and	painful	
at	times.”	Dawn,	F68.	
As	Dawn	suggested	in	the	last	quote,	although	she	experienced	other	complications	due	to	
her	diabetes,	it	was	the	PDN	that	had	the	greatest	impact	on	her	life.	
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4.6	Superordinate	theme:	The	patient	management	of	PDN	
The	participants	in	this	study	described	a	wide	variety	of	management	strategies	they	had	
tried.	Any	strategy,	whether	successful	or	not,	was	grouped	into	the	following	themes	(Figure	13).	
These	strategies	were	in	addition	to	the	advice	for	PDN	management	that	they	had	received	
through	the	NHS	services	that	were	described	in	section	4.4.		
This	superordinate	theme	contained	two	themes:	Seeking	Help	and	Advice	(4.6.1),	this	
described	the	sources	of	information	that	PDN	participants	had	accessed.	The	theme	Pragmatic	
approach	to	management	(4.6.2)	described	the	variety	of	strategies	participants	had	
experimented	with	to	manage	the	impacts	they	experienced.	
Figure	13	-	Patient	management	of	PDN	-	themes	and	subthemes	
	
4.6.1	Theme:	Seeking	help	and	advice		
There	were	very	few	instances	when	participants	described	specific	points	of	information	
and	help	they	sought	regarding	PDN.	No	participant	was	explicit	about	an	issue	or	topic	they	had	
researched	rather,	when	this	issue	was	raised,	participants	wanted	general	information.	
“As	much,	as	much	information	as	possible.”	Ellen,	F63.	
Participants	had	often	used	the	Internet	to	seek	information.	There	was	scepticism	about	
the	accuracy	and	veracity	of	Internet	pages.	Participants	were	cautious	about	any	site	that	
claimed	‘miracle’	benefits	or	charged	for	supplements.		
“I	Googled	it,	there	was	a	company	in	North	America	that	was	selling	these	vitamin	
B,	extra	strength	vitamin	B,	and	I	took	that	for	a	while,	which	I	suppose	did	help,	I	
don’t	know	if	it	really	helped	that	much	or	not.”	Dawn,	F68.	
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“you	can	never	be	sure	that	you	are	getting	what	you	are	paying	for	and	you	don’t	
know	what	is	in	it,	and	you	know	they	always	say	you	know	the	best	person	to	
prescribe	your	medicines	is	your	GP.”	Joan,	F57.	
The	Internet	had	led	some	participants	to	peer-support	forums.	There	were	both	positive	
and	negative	experiences	of	accessing	these	forums.	Participants	found	reading	the	experiences	
of	others	with	PDN	created	some	validation	of	their	own	experiences.	They	described	feeling	less	
alone	and	isolated	and	benefited	by	hearing	how	other	people	were	coping.		
“I	think	I	was	looking	for	somebody	else	with	the	same	sort	of	problems	I	was	
having,	it	just	felt	good	to	know	that	actually	even	though	you’re	here,	and	there	
isn’t	anybody	else	I	know	close	to	me	with	diabetes,	with	the	same	problems	[…]	
they’re	all	around	the	country	and	they’re	all	experiencing	really	a	mirrored	image	
of	what	I’m	going	through.”	Mary,	F44.	
Some	forum	users	were	less	helpful	though,	posting	replies	that	implied	development	of	
PDN	was	due	to	poor	diabetes	management	and	suggesting	that	it	was	the	individual’s	fault.	
“…you’d	only	get	the	odd	few	who	that	would	say	‘well	actually	I	don't	know,	you’ve	
done	something	wrong’	and	you	think	‘well	why	post	that	on	there?’”.	Mary,	F44.	
There	were	two	characteristics	for	the	sources	of	information	that	participants	trusted;	
firstly,	they	wanted	clinicians	to	provide	accurate	information	and	treatment.	Some	participants	
posed	questions	during	the	interview	relating	to	adjunctive	treatment	such	as	magnetic	socks	or	
herbal	remedies,	they	had	seen	advertised.	Secondly,	they	prioritised	information	that	came	from	
significant	others,	this	was	both	from	important	people	in	their	lives	such	as	partners	and	close	
friends,	and	from	other	people	who	experienced	PDN	first-hand.	The	role	of	others	and	the	
support	they	gave	has	been	included	in	the	superordinate	theme:	Perspectives	on	talking	therapy.	
4.6.2	Theme:	Pragmatic	approach	to	management		
This	theme	contained	four	subthemes:	Keeping	strong	(4.6.2.1)	described	how	the	
participants	mustered	internal	strength	to	‘keep	themselves	going’	with	PDN.	Managing	the	
experience	of	PDN	(4.6.2.2)	collected	all	strategies	participants	explored	to	reduce	the	experience	
and	mental	burden	of	PDN.	The	subtheme	Getting	some	rest	(4.6.2.3)	collected	all	strategies	
employed	to	minimise	fatigue	and	maximise	sleep	quality.	Finally,	I’ll	try	anything	(4.6.2.4)	
captured	all	other	strategies	employed.	
Chapter	4	–	Results	from	the	patient	interview	study	
Page	-	105	
	
4.6.2.1	Subtheme:	Keeping	strong		
A	common	account	from	participants	was	that	it	was	difficult	to	cope	with	PDN.	The	
impacts	on	many	aspects	of	life	were	pervasive	and	draining.		
“I	don’t	know	how	I	cope	really,	I	just,	you	just	have	to	get	on	with	it.”	Kate,	F58.	
There	were	a	number	of	ways	by	which	participants	resisted	the	imposition	of	PDN.	Mark	
described	building	a	wall	around	his	pain,	trying	to	blot	it	from	his	perception.		
“I	try	sort	of,	say,	‘no,	I’m	not	suffering	pain’,	blot	it	out,	build	a	wall	around	it,	block	
it	away.”	Mark,	M62.	
Participants	used	strategies	to	remain	in	control;	these	strategies	could	be	passive:	
“I	hate	going	out,	and	it’s	all	to	do	with	building	up	a	castle	around	you	where	
you’ve	got	some	measure	of	control	is	the	word.”	Bob,	M63.	
The	strategies	could	be	more	active,	maintaining	a	sense	of	self	by	putting	on	make-up	and	
looking	your	best,	despite	PDN.	
“I	just	felt	that	was	a	part	of	me	I	could	control	I	could	get	up,	will	brush	my	[hair]…	
you	know	I	will	dress	nicely	when	you	don’t	feel	like	doing	it	but	that	was	me	
something	I	could	do.”	Mary,	F44.	
Maintaining	this	strength	did	not	come	easily.	Participants	described	ways	of	seeking	
motivation	to	continue	with	the	effort.	
“I	try	and	motivate	myself.	I’m	always	continually	looking	at	power	of	motivation.	I	
continually	look	up	motivational	quotes	wherever	I	can	find	them,	use	them	
examples.”	Daniel,	M67.	
Participants	described	reappraising	and	revising	their	expectations	of	themselves	and	their	
capacity	for	work,	to	maintain	a	positive	outlook	and	avoid	a	sense	of	failure.	There	was	language	
of	accepting	they	had	this	problem,	and	achievements	of	any	size	should	be	looked	at	positively	
for	the	accomplishment,	rather	than	compared	to	how	they	might	have	been	without	PDN.		
“You	know	the	things	and	the	places	will	always	be	there,	they	will	be	there	the	next	
day	so	if	you	don’t	achieve	something	today	there	is	always	tomorrow.”	Joan,	F57.	
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4.6.2.2	Subtheme:	Managing	the	experience	of	PDN	
All	participants	had	experience	of	drug	treatment	aimed	at	reducing	the	experience	of	PDN.	
This	approach	had	been	beneficial	for	some	(Section	4.4.3).	Participants	had	explored	a	variety	of	
alternative	ways	to	reduce	the	pain	they	experienced.	Because	PDN	was	often	described	as	a	
‘burning’	sensation,	the	use	of	cold	was	a	common	approach.	Participants	had	used	topical	
menthol	gels	that	gave	a	cold	sensation,	cold	water	baths	to	soak	their	feet,	and	a	draft	to	blow	
across	their	feet.		One	participant,	when	living	in	Canada,	walked	out	into	the	snow	at	night	to	try	
and	get	some	relief	from	the	pain.		
“I	had	to	have	the	fan	on	all	night	on	the	feet	just	blowing	cold,	cool	air	on	my	feet	
and	sometimes	getting	a	frozen	pack	of	peas	or	something	like	that”	Aaron,	M75.	
“And	it’s	cold	water	straight	out	the	tap,	and	I	stick	my	feet	in	it	until	the	water	goes	
warm.”	Heather,	F57.	
“In	Canada,	I	was	out	in	the	middle	of	winter	in,	in	just	my	slippers	and	pyjamas,	
trying	to	focus,	so	that	I	could	get	to	sleep”.	Mark,	M62.	
Most	participants	found	the	beneficial	effects	were	short	lived,	only	while	the	cold	
sensation	lasted.	Participants	had	also	tried	warmth,	using	warm	water	baths	or	hot	water	
bottles.	Again,	they	found	the	benefits	were	temporary.	
“Well	I	have	done	that,	but	you	can’t	put	your	feet	in	warm	water	for	eight	hours	a	
day.	I’ve	done	it	when	it’s	that	severe,	I’ve	tried	it.”	Philip,	M57.	
Although	participants	had	described	the	painful	sensitivity	to	light	touch	they	experienced,	
some	found	massage	to	their	feet,	either	by	themselves	or	their	partner,	could	be	beneficial.	
“It’s	probably	going	to	sound	really	stupid	but	I	do	find	that	rocking	or	brushing	my	
feet	on	the	bed	linen,	I	find	that	comforting.	I	don’t	know	if	it	stops	the	pain	but	I	
think	it’s	comforting”	Sarah,	F24.	
“Basically	um,	massage	the	area	with	really	firm,	not	just	stroking	the	foot,	but	
really,	almost	with	my	fist.”	Dawn,	F68.	
“My	wife	massages	with	some	oil	and	my	feet	feel	a	lot	better	and	I	can	walk	a	bit	
better.”	Clive,	M86.	
As	well	as	physical	techniques	to	their	feet,	some	participants	had	made	adaptations	to	
their	home	environment	to	aid	with	day-to-day	tasks.	Acquisition	of	equipment	allowed	
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maintaining	a	level	of	function	and	independence.	Maintaining	a	level	of	function	in	the	home	
was	integral	to	another	common	strategy	-	keeping	physically	occupied	with	day-to-day	tasks	and	
so	distracted	from	the	pain	they	experienced.		
	“I	find	if	I	sit	down	or	a	lie	down	to	ease	the	pain	with,	that	I	can	do	with	the	chronic	
pain,	that	doesn’t	work	with	the	diabetic	neuropathy.	And	I’ve	found	that	the	best	
form	of,	of	controlling	it	is,	is	keep	myself	busy.”	Mark,	M62.	
“I	feel	that	in	the	day	my	brains	got	plenty	to	think	about	and	do	and	I’m	looking	at	
things	and	doing	things	and	um	involved	in	things	of	all	sorts	of	different,	different	
things	in	life	and	it’s	fine.”	Lisa,	F69.	
Similarly,	participants	found	mental	distraction	techniques	useful	in	focussing	their	
attention	away	from	the	experience	of	symptoms.	
“I	use	a	distraction	technique	of	various	methods.	One,	one	I	use	often,	is	I	imagine	I	
am	winning	sums	of	like	one	hundred	and	eight	million	pounds	on	a	lottery	and	how	
can	I	make	peoples’	lives	better	out	of	that	money?	And	then	another	day	I	might	
think	I’d	just	won	twenty	thousand,	other	days	it	might	be	sixty	thousand	and	that	
will	actually	take	me	about	an	hour	after	my	walking.”	Daniel,	M67.	
	“Then	I’m	thinking,	remember	the	ocean	and	blue	sky	and	how	it	really,	really	
rained.	Immediately	when	this	[pain]	is	going	‘bang,	bang,	bang’	like	this,	I’m	over	
here	thinking	the	very	first	time	I	took	the	children	to	Stonehenge	when	they	were	
small,	the	very	first	time	I	drove	to	Cornwall	on	my	own	with	them	in	the	car.	I	think	
of	all	the	little	things	that	are	trapped	somewhere	in	my	memory	and	they	bring	
them	out.”	Anne,	F52.	
4.6.2.3	Subtheme:	Getting	some	rest	
Fatigue	and	sleep	disturbance	did	not	affect	all	participants;	there	were	some	whose	sleep	
was	unaffected	(Section	4.5.4.3).	However,	when	present,	the	impact	on	sleep	and	rest	and	the	
consequent	difficulty	with	tiredness	and	concentration	were	significant,	but	participants	had	
received	no	advice	for	sleep	or	rest	strategies.		
There	were	various	strategies	explored	by	participants	to	manage	their	downtime	and	sleep	
quality.	They	used	rest	from	physical	activity	to	manage	the	pain	that	the	physical	activity	may	
have	aggravated.		
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“I	sometimes	can	go	and	make	a	cup	of	tea	and	sit	down	for	ten	minutes,	because	
you	know,	you’ve	got	to	take,	just,	just	rest	yourself.”	Mike,	M65.	
“I	have	to	sit	down	and	rest	because	they	[feet]	really,	really	hurt	[…]	he’s	always	
there	to	sort	of	hold	me	up	and	say,	‘oh,	we’ll	sit	down	for	a	little	while	and	that.’”	
Kate,	F58.	
There	were	specific	references	that	going	back	to	bed	or	staying	in	bed	was	the	least-worst	
option,	but	these	approaches	did	not	remove	the	neuropathy	pain	completely.		
“Ian	will	tell	you	when	I	say	to	him	‘I’m	at	collapsing	point’,	I	just	have	to	collapse	on	
the	bed	and	I	have	to	let	the	tiredness	take	over.”	Anne,	F52.	
“I	think,	oh,	well	I’ll	go	to	bed,	you	know	just	lay	in	bed,	read	a	book	or	listen	to	
some	music,	but	you	see	you’re	not	free	from	the	neuropathy.”	Philip,	M57.	
Participants	described	experimenting	with	a	range	of	relaxation	strategies	to	manage	pain,	
and	then	continuing	with	these	regularly	because	they	were	useful.	These	strategies	included	
listening	to	music,	visualization	techniques	and	body	scan	techniques.		
“I’ll	put	the	music	on	and	the	headphones	on.	Then,	before	I	get	to	that	stage,	I’ll	
put	the	music	on	and	I	will	really	try	to	calm	down,	it	doesn’t	always	work.”	Anne,	
F52.	
“It’s	almost	like	I’m	visualising	a	big	block	of,	like	a	block	of	ice	or	a	block	of	stone,	
which	is	the	pain	and	visualising	that	and	just	chipping	away	at	it	and	it	does	start	
to	you	know,	if	I’ve	got	myself	in	a	kind	of	nice	state	of	thought	and	concentration	it	
sometimes	works	so	I	would	say	that	is	definitely	a	method	that	I	use	well.”	Sam,	
M53.	
Participants	described	using	breathing	exercises	as	an	active	relaxation	strategy	to	help	
them	manage	the	pain	they	experienced.	All	these	participants	had	experienced	contact	with	
psychological	services,	either	specifically	for	the	PDN	they	experienced,	or	as	part	of	a	PMP	for	
persistent	LBP.		
“I	get	the	shakes	when	I	can’t	…	it	gets	like	this	and	my	body	will	tense	and	I	have	to	
do	my	breathing	exercises	[…]	I	would	relax	back	on	the	pillows,	I	would	take	a	deep	
breath	in,	I	would	slowly	let	it	out	and	then	I	would	breathe	just	like	that.	I	would	try	
and	let	the	neck	go	and	shoulders	go	and	take	it	right	down	the	arms	till,	um,	I	start	
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feeling	like	okay,	I’m	feeling	a	bit	more	gelled	[chilled]	now,	I’m	not	feeling	so	
tense.”	Anne,	F52.	
“You	concentrate	on	your	breathing	for	a	little	while	very	deeply,	err	and	it	takes	
your	mind	off	other	things	that	are	happening	in	your	body.”	Barbara,	F80.	
Other	participants	were	aware	of	relaxation	but	had	never	applied	it	consistently	with	the	
aim	of	managing	their	pain.	Others	had	difficulty	implementing	the	advice	they	had	received,	
usually	due	to	family	or	work	pressures	precluding	protected	time	to	experiment.		
“Um,	the	ones	where	you,	you	know,	you	need	at	least	ten	minutes,	and	to	be	in	a	
quiet	place,	and	to	be	very	focused.	She	provided	me	with	the	tapes,	different	sorts	
of,	um	...	You	know,	somebody	talking	about,	you	know,	visualise	a	red	spot,	kind	of	
thing	[...]	No,	not	really.	I	mean,	I	will	occasionally	do	it,	and	sometimes,	at	night,	I	
do	force	myself	to	[relax].”	Sally,	F48.	
There	were	frequent	references	to	sleep	strategies.	Some	participants	had	been	prescribed	
specific	sleeping	tablets,	but	often	did	not	tolerate	the	side	effects	the	next	morning.	Participants	
described	a	routine	for	bedtime	that	included	avoiding	caffeine,	some	form	of	relaxation	and	time	
to	wind	down	from	the	day.	
“I’ll	just	try	and	unwind	and	I	might	read	for	like	five	ten	minutes	because	usually	
find	I	can	relax	quite	a	bit	if	I	read	so	most	nights	I	do	tend	to	read	once	I’m	in	bed.”	
Mary,	F44.	
“I	always	try	and	work	the	same	routine.	I’ve	usually	sat	down	for	an	hour	or	so,	
maybe	a	bit	longer	of	an	evening,	watching	television.	I	always	have	a	milky	drink	
last	thing	at	night.	I	always	take	my	dog	out	for	about	10	minutes	last	thing	at	
night,	then	she	gets	put	to	bed	with	a	biscuit	and	I	take	myself	upstairs.	I	do	the	
same	thing	every	night.”	Barbara,	F80.	
Because	of	the	sensitivity	from	the	sheets,	participants	questioned	why	no	one	had	
designed	some	kind	of	cradle	to	lift	the	sheets	from	their	feet.	Some	participants	had	to	get	up	
and	walk,	they	would	rather	experience	the	pain	from	walking,	but	this	choice	had	clear	impacts	
on	being	able	to	achieve	a	restful	night’s	sleep.	
“…the	only	way	I	can	get	any	relief	is	to	either	stand	up	or	walk	around	and	even	
then	it	doesn’t	relieve	it,	it’s	just	not	the	centre	of	everything	in	your	brain.”	Joan,	
F57.	
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4.6.2.4	Subtheme:	I’ll	try	anything		
This	theme	captured	the	diverse	range	of	techniques	participants	had	experimented	with	to	
manage	their	PDN.	They	had	tried	electro-acupuncture	pens,	chiropractic	treatment	and	
machines	to	stimulate	circulation.	
“What	it	is	actually	is	acu-stimulation	and	it’s	sort	of	electric	pulses	given	to	certain	
parts	of	the	ear.	In	the	same	sort	of	principal	as	acupuncture.”	Sam,	M53.	
“And	we	went	there	and	we	laid	on	this	thing	and	he	pummelled	your	back	and	
whatever	and	they	did	it	say	for	£37.00	at	first	and	then	of	course	it	went	up	to	
about	£300	and	odd	and	I	said	no	I	am	not	paying	£300	and	odd.	[…]	No	I	don’t	
think	it	did	make	a	difference.”	Clive,	M86.	
Bob	was	a	particularly	experimental,	trying	cling	film	wrap,	fish	pedicures	and	walking	on	
stinging	nettles:	
“I	tried	strapping	them	in	cling	film.	[…]	I	tried	the	little	fishes	in	the	water.”	Bob,	
M63.		
“The	most	potent	thing	I’ve	tried	to	work	was	stingy	nettle	funnily	enough.	Yeah,	I’d	
take	my	shoes	and	socks	off	and	I’d	walk	in	stingy	nettles	tended	to	take	away	the	
other	pain	temporarily.	It	didn’t	work	long-term	but	that’s	how	far	I	was	prepared	to	
go	to	try	anything.”	Bob,	M63.	
Participants	described	experimenting	with	legal	drugs	such	as	alcohol.	There	were	some	
benefits,	particularly	as	an	aid	to	sleep,	but	they	were	conscious	of	the	difficulty	in	balancing	the	
benefits	with	potential	negatives	of	over-reliance	and	addiction.		
“It	would	be	so	easy	just	to	get	a	bottle	of	Scotch	and	drink	it.”	Mark,	M62.	
One	participant	had	experimented	with	cannabis	but	found	it	no	use.	
Perhaps	because	people	had	experienced	less	than	optimal	success	with	medication,	and	
there	were	few	other	strategies	being	recommended	by	HCPs,	participants	explained	they	had	no	
option	but	to	experiment	with	anything	that	may	be	of	benefit.	Despite	wide	ranging	attempts,	
the	participants	had	found	little	benefit	from	any	of	these	diverse	approaches.	
“You	get	sometimes	to	the	point	where	you	think,	I’d	try	anything...?”	Ellen,	F63.	
They	generally	took	a	pragmatic	approach	to	these	strategies,	that	was	best	summarized	by	
this	quote	from	the	code	Doing	what	works:	
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“Well,	that’s	it	-	what	works	for	one	doesn’t	always	work	for	somebody	else.”	Ellen,	
F63.	
4.7	Superordinate	theme:	Perspectives	on	physical	activity	
There	is	a	distinction	between	physical	activity	required	for	day-to-day	life,	and	exercise,	
which	is	structured	physical	activity	undertaken	with	the	aim	of	improving	health.	The	interview	
participants	did	not	necessarily	make	this	distinction	and	so	this	theme	considered	their	
perspectives	on	physical	activity	and	exercise	as	synonymous.	
Due	to	pain	and	loss	of	sensory	awareness,	participants	frequently	described	uncertainty	
with	walking	and	fear	of	falling	(Section	4.5.4).	To	mitigate	these	fears	and	maintain	a	tolerance	
for	walking,	participants	had	adopted	walking	aids	for	balance	and	a	sense	of	safety.	
“I	walk	with	walking	sticks	when	I’m	out	because	I’m	always	falling	and	I	suppose	
it’s	because	of	the	pain	and	I	don’t	always	recognise	where	my	foot	is”	Kate,	F58.	
“I	always	take	my	stick	with	me	now,	always	and	I	just	feel	a	lot	safer	with	that	so	if	
I	do	have	that	wobbly	minute,	I’ve	got	my	stick	if	I’m	not	holding	on	to	anything	
else.”	Mary,	F44.	
Some	participants	had	purchased	or	been	provided	with	mobility	scooters	or	wheelchairs.	
There	was	some	reluctance	to	use	these	as	they	were	viewed	as	a	further	sign	of	disability.	
“I	miss	steps	and	things	like	that.	Sometimes	I	have	to	use	a	wheelchair,	but	I	try	not	
to,	but	I	sometimes	have	to	resort	to	that”	Kate,	F58.	
But	there	was	an	understanding	that	these	aids	allowed	potential	walking	distance	to	be	
extended,	facilitating	opportunities	for	time	away	from	the	house.		
“If	it’s	wheelchair,	it’s	wheelchair,	you	know?”	Ellen,	F63.	
“I’m	using	a	wheelchair	now	to	get	from	A	to	B,	to	go	that	distance.”	Mary,	F44.	
Some	participants	described	specific	exercises	done	to	maintain	their	physical	health.	The	
aims	of	the	exercise	were	variably	to	maintain	strength,	fitness,	standing	balance	or	body	
flexibility.		
Some	participants	had	been	advised	to	use	resistance	bands	or	go	to	a	gym	to	maintain	
strength.	
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“I	sometimes	do	a	bit	of	exercising	with	elastic,	you	know	those	long	elastic	straps.	I	
try	to	do	that.	And	again	that’s	done	in	a	routine,	I	do	so	many	above	my	head,	so	
many	across	my	chest	and	then	that’s	packed	up	and	put	away.”	Barbara,	F80.	
“I’m	even	in	discussion	with	the	doctors,	they	have	said	that	you	know	going	to	the	
gym	and	being,	staying	active,	and	doing	what	I	can	when	I’m	there	may	help	with	
obviously	kind	of,	well	not	muscle	wastage	but	losing	the	strength.”	Sarah,	F24.	
Sarah	was	the	youngest	participant	and	at	the	time	of	interview	was	off	work	due	to	her	
PDN	symptoms.	She	described	her	reluctance	to	go	to	a	gym	and	potentially	be	seen	out	in	public	
whilst	deemed	not	fit	for	work.	
“I’m	starting	to	get	a	little	bit	better	about	going	out	during	the	day	when	I	would	
normally	be	at	work”	Sarah,	F24.	
One	participant	had	taken	up	cycling	because	this	allowed	her	to	maintain	cardiovascular	
fitness	in	a	manner	that	did	not	aggravate	the	pain	as	much	as	walking	and	it	provided	some	
focussed	distraction.		
“Cycling	up	hills,	or	dealing	with	traffic	is	a	distraction	from	maybe	thinking	about	
my	feet,	whereas	walking	around	...	I	used	to	do	a	lot	of	walking	–	less	so	since	I’ve	
moved	to	[city]	–	but,	when	I	was	younger,	I	did	loads	of	fell	walking.”	Sally,	F48.	
Primary	care	exercise-on-referral	schemes	were	not	felt	to	be	targeted	towards,	or	
inclusive	for	PDN.	
“You	get	GP	referral	[exercise	schemes]	but	obviously	that’s	when	you’ve	had	
broken	limbs	or,	or	strokes	or	things	like	that,	they	all	do	that,	but	nothing	else.	I	
would	be	the	first	on	the	queue	if	there	was	some	sort	of	programme	like	that.”	Lisa,	
F69.	
Mary	had	been	advised	some	exercises	using	a	physioball	to	maintain	balance.	
“Sitting	on	the	ball	was	from	sort	of	the	physio	that	I	had	quite	a	few	years	ago	to	
try	and	help	my	balance.”	Mary,	F44.	
The	most	usual	exercises	described	were	ankle	rolls,	to	maintain	some	flexibility	and	
movement	in	the	lower	legs.	Participants	had	not	been	advised	to	do	these	movements	by	
clinicians,	but	had	initiated	them	independently	feeling	they	were	potentially	helpful	and	unlikely	
to	cause	damage.		
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“I	do	sit	and	do	some	exercising	of	my	feet	when	I’m	sitting	down	at	times	[…]	Yes,	
and	try	to	keep	the	muscles	going	there,	but	I’m	sure	that	I’m	not	doing	all	I	should	
do	or	couldn’t	do,	but	I	don’t	know	what	else	to	do?”	Lisa,	F69.	
“I	am	just	moving	my	legs	now,	you	can’t	see	them,	but	I	am	moving	them	just	to	
get	them	going,	but	the	pain	is	there.”	Clive,	M86.	
Participants	described	feeling	better	for	having	completed	some	exercise	and	achieved	
positive	health	benefits.		
	“Actually	you	get	this	sense	of	achievement	don’t	you,	you	know,	if	you’ve	done	
sort	of	three	quarters	of	an	hour,	um	physical	exercise,	where	you’d	be	just	sat	at	
home	maybe	doing	nothing.	[…]	It’s	as	if	exercise	actually	overrides	everything	that	
you	feel,	I’m	conscious	of	this	pain	nearly	all	the	time,	but	I’m	distracted,	if	I’m	doing	
something.”	Jane,	F68.	
Participants	expressed	concern	about	losing	their	physical	fitness	and	function	over	the	
years	and	some	did	engage	in	general	exercises,	within	the	limits	of	their	pain,	to	maintain	their	
health	as	best	as	possible.	However,	no	participant	had	been	given	specific	advice	for	exercise	
that	may	have	beneficial	effects	for	their	PDN,	nor	had	they	been	advised	of	exercises	that	were	
to	be	avoided.	This	led	to	uncertainty	about	how	best	to	approach	exercise,	with	PDN.	
“Um	nobody’s	ever	said	yes,	you	know,	you	could	do	things	like	exercises	that	would	
help	or	anything	like	that,	so	I,	I’ve	never,	never	really	um	looked	at	it”.	Lisa,	F69.	
“It	[exercise]	is	a	big	thing	and	I	think	a	lot	of	people	most	probably	would	want	to	
do	it	in	an	almost	in	a	controlled	[manner],	so	there	would	be	no	way	I	would	next	
week	go	off	to	my	local	gym	and	start	[exercising].”	Mary,	F44.	
From	this	uncertainty,	the	participants	who	did	want	to	be	more	active	wanted	specific	
guidance	from	HCPs	about	appropriate	and	safe	exercises	for	PDN.		
“Then	if	that’s	a	sort	of	an	achievable	thing	to	do,	then	okay	you	start	off	with	just	
one	minute,	but	you	can	work	up	to	five	minutes,	but	you	know	you’re	doing	the	
right	thing,	I	think	guidance	like	that	would	be	useful.”	Lisa,	F69.	
“I’d	say	it’s	sort	of	up	there	as	being	very	important	I’d	be	more	than	happy	if	
somebody	came	along	and	said	‘Right,	we’re	doing	this.’”	Mary,	F44.	
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One	participant	had	specifically	researched	the	role	of	exercise	for	the	PDN,	and	was	
pessimistic	about	the	likely	benefit.	
“Well,	I’ve	read	up	on	this	thing	quite	wildly,	I’ve	read	up	on	the	type	of	exercises	
you	can	do,	some	of	the	foot	exercises	you	can	do,	some	of	the	strategies	you	can	
use	and	I’ve	tried	many	of	them,	I	need	to	you	know,	the	way	I	look	at	it,	this	pain	
originates	from	the	damaged	nerve	and	there	is	nothing	you	can	do	about	nerve	
pain”.	Aaron,	M75.	
In	summary,	some	participants	were	frustrated	they	were	unable	to	be	more	physically	
active.	Pain	was	the	common	limiting	factor.	Although	some	participants	had	made	adaptations	to	
their	expectations	of	exercise	type	and	intensity,	they	were	able	to	achieve	or	manage	less	
activity	than	they	wanted.		
There	was	uncertainty	about	how	best	to	approach	exercise,	particularly	anything	that	
maybe	specifically	aimed	at	reducing	or	managing	PDN.	Participants	had	not	received	clear	
guidance,	other	than	standard	foot	protection	advice	given	to	all	people	with	diabetes.	The	desire	
to	be	more	active	was	not	universal	amongst	participants	but	those	who	did	want	to	be	more	
active	wanted	clear	advice	from	clinicians.	A	competing	view	existed	that	pain	was	due	to	nerve	
damage,	and	there	was	no	mechanism	by	which	exercise	could	improve	this	situation.	
4.8	Superordinate	theme:	Perspectives	on	talking	therapy	
Of	the	twenty-three	participants,	two	had	received	psychological	therapy	input	specifically	
for	PDN	and	one	had	attended	two	PMPs	(UK	and	Canada)	for	persistent	LBP.	The	majority	of	
participants	had	not	discussed	psychological	support	with	their	HCPs.		
This	superordinate	theme	contained	two	themes:	Open	to	talking	therapy	options	and	How	
can	talking	help?	
4.8.1	Theme:	Open	to	talking	therapy	options		
There	were	a	number	of	key	areas	participants	discussed	positively	in	relation	to	talking	
therapy.	For	some	participants,	there	was	openness	to	the	idea	that	psychology	and	mood	state	
were	directly	relevant	to	the	issues	of	PDN.	Participants	described	help	to	manage	mood	and	help	
to	manage	stress	as	the	areas	where	talking	therapy	maybe	most	useful.	They	described	partners	
and	other	people	who	experienced	PDN	as	most	valued	for	discussing	and	sharing	these	issues.	
Lastly,	professional	psychological	help	had	been	found	useful	but	the	difficulty	in	accessing	
psychological	services	through	the	NHS	was	raised.		
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Some	participants	came	to	a	realisation	that	the	problems	they	experienced	due	to	PDN,	
were	more	than	pain	and	physical	impediment.	Their	experience	of	particularly	unhelpful	moods	
and	their	reactions	to	stressful	events,	made	them	approach	medical	services	to	access	
psychological	therapy.	
“I	would	say	that	I	probably	took	the	first	step	into	asking	for	some	help	and	
guidance,	it	wasn’t	offered	to	me,	and	then	it	was	‘oh	yeah,	actually	I	think	I	might	
need	to	speak	to	someone	because	I’m	feeling	a	bit	low	about	how	I	was	feeling’”.	
Sarah,	F24.	
“Um,	I	think,	I	think	the	psychological	impact	is	probably	the	next	thing,	really.”	
Sally,	F48.	
There	was	awareness	that	moods	were	difficult	to	manage	and	had	a	negative	effect	on	
overall	quality	of	life.	
“I	think	the	management	of	mood	would	be	quite	useful	and	how	to	cope	with	that	
because	um,	it’s	just	incredibly	wearing	at	times.”	Dawn,	F68.	
Similar	to	other	persistent	pain	conditions,	some	participants	had	identified	life	stress	as	an	
aggravating	factor:	stress	from	living	with	PDN,	from	relationships	and	work	were	identified	as	
issues.		
“I	think	if	you	can	understand	what	the	stress	is	about	or	what	has	caused	that	
stress	in	the	first	place,	you	can	manage	it	better;	therefore,	you	can	understand	it	
better.”	Anne,	F52.	
“And	plus	the	fact,	I	find	stress	aggravates	it	[PDN].”	Heather,	F57.	
“I	also	enrolled	myself	on	a	six-week	group	course	that	was	about	stress	and	mood	
management,	which	has	been	quite	helpful.”	Sarah,	F24	
Participants	viewed	being	able	to	talk	about	the	issues	experienced	or	the	causes	of	stress	
positively.	Some	found	close	family	members,	especially	partners,	to	be	best	at	listening	and	
understanding.	Other	participants	did	not	want	to	burden	their	partner	further	and	preferred	
being	able	to	talk	to	a	friend	who	might	be	more	objective.		
	“…	he	has	seen	it	since	it	started	[PDN]	and	he	is	my	husband,	he	is	my	best	friend,	
so	him	being	there	reassures	me,	there	is	nothing	that	I	could	tell	him	that	he	
wouldn’t	judge	me	for.”	Joan,	F57.	
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Some	participants	had	accessed	psychological	support	specifically	for	PDN.	They	viewed	
this	opportunity	positively	for	the	affordance	it	provided	to	discuss	the	impact	of	PDN	with	a	
neutral	professional;	they	felt	professional	detachment	was	beneficial	and	more	appropriate	than	
discussing	the	issues	with	either	family	or	friends.		
	“That	feels	quite	good,	being	able	to	just	be	somewhere	else,	talking	to	somebody	
else.	I	think	that’s	quite	good	for	some	of	my	stress,	but	it	doesn’t	help	with	the	pain	
of	course,	but	just	being	able	to	talk	to	somebody	different	because	I’ve	no	idea	of	
anybody	who	lives	in	this	area,	I’ve	got	no	relatives	or	friends	here”.	Kate,	F58.	
“I	could	really	have	done	with	talking	to	somebody	[psychology]	who	is	totally	
distant,	they’re	not	family	members,	they’re	not	my	GP	who	hasn’t	got	the	time	for	
you	to	sit	there	and	like	off	load	to	him	so	it	is	quite	nice	sometimes.”	Mary,	F44.	
The	professional	perspective	of	a	psychologist	had	helped	Sally	to	reappraise	the	
implications	(amputation)	she	feared	about	the	symptoms	she	experienced	(pain).		
“I	think	the	single	most	useful	thing	that	she	pointed	out	to	me	was	that	for	me,	the	
problem	was	not	the	pain,	it	was	what	it	symbolized	[potential	future	amputation].”	
Sally,	F48.	
Psychologists	often	use	CBT	models	for	their	consultations	with	patients	and	this	holistic	
approach	had	been	useful	to	make	links	between	the	psychological	and	the	physical	process:	
“we	did	a	little	bit	about	[CBT]	and	we	spoke	about	behaviour	patterns	and	the	
unhelpful	thinking	that	people	have	in	general	and	obviously	how	I	can	change	the	
way	that	I	think.	I	mean	it	has	been	really	helpful	to	hear	from	someone	else’s	
perspective.”	Sarah,	F24.	
As	well	as	family	and	friends,	participants	described	there	were,	or	could	be,	particular	
benefits	in	talking	with	others	who	experienced	and	so	understood	the	impact	of	PDN.	
“Yeah,	knowing	what	other	people	are	going	through	the	same	thing.”	Bob,	M63.	
“…maybe	through	talking	to	other	people	who	do	experience	it,	[is]	something	I	
could	benefit	from.”	Sally,	F48.	
	“…nobody	understands	what	I’m	going	through	unless	it’s	another	diabetic	or	it’s	
somebody	else	suffering	neuropathy	because	they’re	going	through	the	same	
thing.”	Philip,	M57.	
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One	participant	had	attended	PMPs	both	in	Canada	and	the	UK	for	management	of	
persistent	LBP.	Although	not	specific	to	neuropathic	pain,	he	had	applied	the	strategies	from	
these	PMPs	to	the	impacts	of	PDN	he	experienced.		
“I	would	advise	if	anybody	that	suffers	with	this	diabetic	neuropathy,	if	they	can	get	
down	to	a	pain	management	course,	take	it.	[…]	Okay,	relaxation,	exercise,	all	the	
things	that	I	do	with	the	chronic	pain,	applies	to	the	neuropathy.”	Mark,	M62.	
There	were	issues	with	accessing	talking	therapy,	whether	family	or	peer	support.	Dawn	
lived	alone	in	a	small	isolated	village	and	noted	the	absence	of	someone	to	talk	things	through	
with.	The	demand	for	psychology	services	within	NHS	Trusts	meant	there	were	waiting	lists	so	
access	was	not	as	timely	as	might	be	hoped	for.	
“I	have	to	say	I	live	alone	so	you	know,	talking	it	through	with	anyone,	well	I	
suppose	that	might	help	actually,	but	I	live	right	out	in	the	sticks	so	there’s	not	
actually	anyone	here.”	Dawn,	F68.	
	“Bearing	in	mind	even	though	we	have	two	[psychologists]	that	we	use	for	the	
diabetes	clinics,	they	are	also	used	for	the	whole	of	the	hospital	so	there’s	quite	a	
long	[wait	list].”	Mary,	F44.	
4.8.2	Theme:	How	can	talking	help?		
In	a	counter	view	to	the	previous	theme,	not	all	participants	were	open	to	the	idea	of	
psychology.	They	were	very	clear	that	PDN	was	due	to	nerve	damage	and	not	effected	by	mood	
state.	They	did	not	want	advice	from	other	people,	particularly	those	who	did	not	have	PDN	and	
were	not	keen	on	any	form	of	talking	therapy.	
There	was	a	strong	view	from	some	that	talking	about	PDN	and	its	impacts	were	not	
appropriate	-	how	could	mood	state	affect	the	pain	experienced	from	nerve	damage	in	the	feet?		
“But	I	don’t	know,	my	pain	is	my	pain,	I	don’t	see	how	anyone	else	can	help	with	it,	
I’ve	had	it	now	for	four	or	five	years	and	I’m	coping	with	it	the	way	I	can”.	Aaron,	
M75.	
“I’ve	been	offered	them	[counselling]	by	the	doctor,	you	know,	if	you	want	to	see	
someone,	you	can	talk	it	through,	or	what-have-you.	I	don’t	know	if	I	believe	in	that	
sort	of	stuff.	[…]	I	can	imagine	me	hearing	something	that	sounds	absolutely	crazy	
to	me,	and,	you	know,	I	would,	I’d	be	the	sort	of	bloke	that	would	say,	‘oh,	pull	the	
other	one’.”	Neil,	M66.	
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Neil	went	on	to	say	his	perspective	of	talking	therapy	was	changing.	He	was	now	severely	
disabled	by	the	pain	he	experienced	and	that	he	may	be	willing	to	try	different	approaches.	
“When	you	get	more	desperate	(laughs),	you	begin	to	think,	well,	it	wouldn’t	hurt,	
but	would	it	help?”	Neil,	M66.	
Participants	wondered	how	counsellors	or	psychologists	without	PDN	could	understand	the	
health	problems	that	they	had	to	cope	with.	
“Just	because	she	has	been	through	university	and	think	that	she	knows	everything,	
I	just	said	you	know,	she	won’t	know	how	to	cope	with	my	problem.	You	see	these	
young	people	around,	social	workers	and	so	on,	they	have	no	practical	experience.”	
Aaron,	M75.	
The	contribution	of	peer-support	groups	had	both	positive	(in	the	previous	theme)	and	
negative	opinions.	Lisa	felt	that	peer-support	groups	would	not	provide	the	support	she	was	
interested	in	and,	if	she	were	to	talk	to	someone	they	needed	to	be	a	medical	psychiatrist,	
otherwise	it	would	not	be	‘proper’.		
“I	don’t	want	to	go	to,	self-help	groups	I	think	[they]	are	a	load	of	old	biddies	sitting	
round	going	‘oh	well,	I	take	these	tablets,	well	I	take	those,	oh	these	are	better’	and	
I	think	‘no,	not	interested’.	But	if	it	was	something	that	was,	professionally	led,	
that’s	a	whole	different	ball	game	and	I	can,	I	can	accept	that.”	Lisa,	F69.	
	“I’m	afraid	I’m	traditional	medicine,	I’m	afraid,	I	don’t,	um,	you	know	to	me	it,	
[sigh]	I	don’t	like	the	thought	of	any	sort	of	quackery	medicine	coming	in	if	you	[…]	if	
I	spoke	to	a	psychiatrist	I’d	want	to	know	he	was	a	properly	qualified,	not	one	of	
these	pseudo-psychiatrist	[laughing].”	Lisa,	F69.	
One	participant	simply	found	talking	to	people	who	were	not	her	immediate	family	difficult,	
and	could	not	conceive	of	attending	any	kind	of	group	programme.	
4.9	Results	summary	
This	study	used	qualitative	interview	methods	to	investigate	the	impacts	people	experience	
due	to	PDN.	It	found	substantial	impact	on	many	aspects	of	day-to-day	function	and	quality	of	
life.	The	strategies	people	used	to	cope	with	PDN	were	also	explored.	Participants	reported	
variable	benefit	from	medication	which	led	them	to	explore	a	wide	range	of	strategies	aiming	to	
minimise	the	experience	and	impact	of	PDN.	The	degree	of	success	of	these	strategies	was	
individual.	Lastly,	this	study	explored	whether	people	with	PDN	felt	PMP	strategies	might	be	
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appropriate	to	help	them	cope	with	their	experience.	There	was	uncertainty	about	physical	
activity	parameters,	and	some	people	wanted	specific	guidance	of	what	exercise	to	do	and	what	
to	avoid.	There	was	ambivalence	toward	psychological	therapy	with	some	positive	perspectives	
based	on	previous	experiences	but	also	strong	views	that	PDN	had	nothing	to	do	with	mood	state,	
and	hence	targeted	psychological	approaches	were	inappropriate.	
4.9	Discussion	
4.9.1	The	issue	of	PDN	impact	
What	was	previously	known	about	the	impact	of	PDN	has	been	outlined	in	Chapter	1.	This	
introduction	highlighted	that	PDN	is	painful,	makes	walking,	standing	and	general	activity	more	
difficult.	Sleep	quality	and	mood	states	are	generally	worse	in	people	with	PDN	compared	to	
people	with	diabetes	alone	(Collins,	Corcoran	and	Perry,	2009;	Reddy	et	al.,	2010).	These	previous	
studies	used	questionnaires	to	gather	data,	most	commonly	the	BPI,	NeuroQOL,	MOS,	HADS,	SF36	
and	EQ5D	(Alleman	et	al.,	2015).	The	construction	these	questionnaires	have	a	restricted	range	of	
questions	and	responses.		
This	interview	study	has	demonstrated	that	PDN	has	a	more	wide-ranging	impact	on	many	
aspects	of	physical,	cognitive	and	social	function	than	previous	literature	suggests.	
To	look	at	one	outcome	measure	in	greater	detail,	the	BPI	asks	respondents	to	consider	
seven	domains:	general	activity,	walking	ability,	sleep,	life	enjoyment,	mood,	normal	work	and	
relationships	with	other	people.	The	diverse	range	of	impacts	found	in	the	current	study	makes	
simple	categorisation	into	one	of	the	above	difficult.	The	theme	A	range	of	negative	emotions	
included	participants’	accounts	related	to	the	experiences	of	worry,	frustration,	anger,	
depression,	embarrassment	and	thoughts	towards	suicide.	The	BPI	requires	the	respondent,	who	
may	well	have	a	range	of	these	emotions	outlined	above,	to	condense	this	emotional	range	to	be	
reflected	in	a	single	answer.		
The	BPI	contains	one	scale	for	Interference	of	pain.	The	subtheme	A	shrinking	world	
contained	codes	including	losing	mobility,	stepping	back	from	physical	activity,	losing	
independence	and	had	to	stop	driving.	It	was	appropriate	to	bring	these	descriptions	together	in	
the	study	analysis	and	to	reflect	them	as	a	higher-level	theme,	but	again,	it	would	seem	
challenging	to	capture	these	diverse	impacts	accurately	on	one	BPI	interference	scale.		
This	is	not	to	suggest	that	existing	quantitative	research	studies	are	of	no	benefit,	rather	
this	study	adds	the	personal	insight	to	the	experience	of	living	with	PDN.	Questionnaire	outcome	
measures	delineate	the	questions	asked	and	the	potential	responses.	This	allows	analysis	at	the	
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population	level,	but	maybe	less	than	ideal	at	the	individual	level	(Kerry	et	al.,	2013;	Anjum,	Kerry	
and	Mumford,	2015).		
Participants	described	impacts	that	are	not	captured	by	existing	questionnaires	including	a	
sense	of	isolation	from	their	close	family	and	local	community.	This	impact	is	present	within	the	
theme	Affects	those	around	me,	where	participants	described	withdrawing	from	their	family	
when	pain	flared	up.	Also	subthemes:	A	shrinking	world	where	people	had	less	independence	and	
self-determination	than	they	wished,	and	Increasingly	on	my	own	where	people	described	
struggling	to	maintain	a	social	life	and	being	socially	isolated.		
It	has	been	suggested	that	the	unpredictable	pattern	of	neuropathic	pain	can	be	a	factor	
leading	to	social	isolation	(Closs	et	al.,	2009).	This	pattern	is	in	contrast	to	other	pain	mechanisms,	
for	instance	osteoarthritis	inflammatory	pain	often	has	a	diurnal	pattern	which	allows	people	to	
schedule	social	and	physical	activity	(Smart	et	al.,	2012a).	This	predictability	can	allow	some	
control	over	the	impact	of	pain.	In	contrast,	the	lack	of	predictability	that	characterizes	
neuropathic	pain	does	not	allow	control	by	activity	scheduling	(Daniel	et	al.,	2007).			
In	a	study	with	older	adults	with	neuropathic	pain	(60yrs+),	the	main	causes	for	social	
isolation	were	perception	of	physical	limitations	and	uncertainty	about	how	pain	symptoms	
would	react	(Sofaer-Bennett	et	al.,	2007).	The	limitations	included	being	unable	to	participate	in	
physical	activity	such	as	days	out	and	feelings	of	reduced	self-esteem.	Uncertainty	included	the	
potential	to	have	disturbed	sleep	the	night	before,	and	to	be	feeling	more	anxious	and	less	
confident.	Although	this	sample	(n=16)	had	diagnoses	of	neuropathic	spinal	pain	and	PHN,	there	
were	clear	similarities	with	the	current	study	population.		
Participants	in	the	current	study	were	very	clear	about	the	hidden	nature	of	PDN	(themes:	
A	very	personal	problem	and	An	internal	perception)	and	this	added	to	their	sense	of	isolation.	
The	participants	often	did	not	know	anyone	else	with	PDN.	While	they	may	be	aware	of	friends	
and	family	who	were	diabetic,	they	did	not	have	peer-validation	for	their	experiences	of	PDN.	This	
hidden	nature,	where	they	had	significant	levels	of	pain	but	their	feet	looked	normal,	was	a	
conundrum	or	paradox	to	them.	The	apparent	inconsistency	between	subjective	experience	and	
objective	‘reality’	led	some	people	to	keep	the	problem	to	themselves.	They	expressed	concern	
about	what	wider	society	thought	of	them.	If	they	were	unable	to	explain	to	themselves	how	their	
feet	looked	normal	but	hurt,	how	could	they	explain	this	to	others?		
These	themes	of	isolation	and	concern	with	societal	opinions	have	been	mirrored	in	other	
qualitative	studies	with	people	who	experience	persistent	pain.	Closs	et	al.	(2009)	found	many	
relationships	had	been	negatively	affected	by	lack	of	understanding	from	others,	particularly	
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around	pain	severity	and	associated	disability.	Non-specific	LBP	is	often	associated	with	a	lack	of	
clear	causative	structural	factors	and	this	diagnostic	ambiguity	has	led	people	to	feel	stigmatized	
by	others	(Smith	and	Osborn,	2007;	Slade,	Molloy	and	Keating,	2009).	People	with	LBP	perceived	
others	in	their	work	and	personal	lives	to	imply	they	maybe	malingering	and	seeking	financial	gain	
from	their	pain.	In	order	to	avoid	these	situations	the	person	would	stay	home	and	reduce	their	
engagement	with	society.	It	should	be	noted	here	that	no	participants	in	the	current	study	
described	any	advice	or	management	strategies	to	help	reduce	this	sense	of	isolation.		
Clinicians	should	be	aware	they	too	are	potential	causes	for	exacerbating	the	sense	of	
isolation.	A	number	of	interview	participants	described	clinical	appointments	when	they	raised	
the	issue	of	PDN	and	the	distress	it	was	causing,	to	no	avail	(codes	HCP	don’t	ask	and	Nobody	is	
listening).	Participants	described	Conveyor	belt	clinics	where	there	was	no	time	or	opportunity	to	
raise	issues	that	were	pertinent	to	them.	Clinicians	need	to	be	mindful	of	the	opportunity	they	
have	to	increase	iatrogenic	disability	through	the	manner	and	conduct	of	their	clinical	
appointments	(Traeger	et	al.,	2015).		
Research	in	communication	around	LBP	has	demonstrated	the	discrepancy	between	what	
clinicians	say	and	what	patients	hear.	Clinicians	believe	they	provide	clear	information	about	a	
pathology	or	treatment,	but	the	message	heard	by	patients	is	understood	to	be	much	more	
concerning	or	worrying	(Darlow	et	al.,	2012;	Darlow	and	Dowell,	2013).	Participants	in	the	current	
study	used	phrases	such	as	“…nerve	damage…”	when	describing	the	causes	of	their	PDN	
experience.	These	phrases	are	likely	to	derive	from	clinical	appointments	and	suggest	clear	lines	
of	causation	from	their	diabetes,	to	the	pain	and	disability	they	experience.		
The	impact	PDN	has	on	sleep	quality	is	well	documented	(Zelman,	Brandenburg	and	Gore,	
2006;	Alleman	et	al.,	2015),	but	the	outcome	measures	routinely	used	in	quantitative	research	
(for	example,	MOS)	may	not	be	sufficiently	sensitive	to	capture	the	fatigue	impact	of	PDN.	The	
participants	in	the	current	study	identified	the	sense	of	fatigue	they	experienced	through	the	day,	
as	a	separate	issue	to	disturbed	sleep.	This	fatigue	had	consequences	for	day-to-day	life	(Fatigue	
with	PDN)	and	for	people	in	their	work	role	(Struggle	to	get	up	for	work).	The	identification	of	
fatigue	as	an	issue	in	its	own	right	has	only	been	relatively	recent.	Research	in	rheumatoid	
arthritis	found	that	people	would	rate	fatigue	as	a	significant	functional	impact	on	a	daily	basis,	
despite	the	objective	markers	of	disease	activity	being	stable	and	within	appropriate	limits	
(Hewlett	et	al.,	2005).	Advice	for	fatigue	and	sleep	management	is	now	considered	a	core	aspect	
of	management	for	rheumatoid	arthritis	(Cramp	et	al.,	2013).	No	participant	in	this	study	had	
received	any	specific	advice	or	management	strategies	that	focussed	on	sleep	quality	or	fatigue	
management.		
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The	current	study	found	a	breadth	of	impact	which	is	in-line	with	recently	published	results	
from	another	qualitative	study	that	used	mixed	focus	group	and	interview	methods	(Brod	et	al.	
2015a).	The	study	by	Brod	et	al.	(2015a)	was	conducted	in	the	US	with	a	more	ethnically	diverse	
sample	(mainly	Caucasian	and	Black	American	participants	(86%)).	Other	sample	variables	are	
broadly	similar	to	the	current	study.	Brod	et	al.	(2015a)	identified	four	domains	by	which	PDN	
impacted	on	the	lives	of	their	participants:	physical	function,	daily	life,	social/psychological	and	
sleep.	Physical	function	included	issues	such	as	reduced	exercise	capacity,	difficulty	walking	and	
fatigue.	Daily	life	was	affected	at	home	by	reduced	enjoyment,	and	at	work	with	reduced	
productivity.	Participants	described	significant	anxiety	and	limits	to	their	social	life.	The	majority	
had	difficulty	initiating	or	maintaining	sleep.	It	is	encouraging	that	the	range	of	impacts	presented	
by	Brod	et	al.	(2015a)	and	the	current	study,	remain	similar	irrespective	of	the	difference	in	ethnic	
sample	diversity	and	health	care	systems	experienced	by	USA	and	UK	participants.	This	suggests	
some	universality	of	the	experience	of	PDN.		
Brod	et	al.	are	working	to	develop	an	outcome	measure	that	is	based	on	the	patient	
description	of	the	impact	of	PDN	(Brod	et	al.,	2015a).	They	feel	this	is	important	to	allow	
healthcare	interventions	to	be	measured	in	a	form	based	on	the	patient	needs.	The	range	of	
impacts	experienced	was	not	captured	with	sufficient	accuracy	by	current	outcome	measures.	
Whilst	development	of	an	outcome	measure	is	important,	the	current	study	has	moved	in	a	
different	direction,	exploring	participants’	self-management	strategies	and	their	perspectives	on	
pain	management	strategies	as	an	intervention	for	PDN	and	associated	impacts.		
4.9.2	The	issues	related	to	patient	self-management	of	PDN	
Medication	management	is	the	mainstay	of	national	and	international	guidelines	for	PDN	
(Bril	et	al.,	2011;	NHS	BNSSG,	2012;	NICE,	2013a).	There	was	a	range	of	responses	and	approaches	
to	medication.	Some	participants	took	no	medication	for	PDN	because	the	interference	PDN	
caused	did	not	warrant	daily	medication.	Other	participants	had	found	a	medication	strategy	that	
was	effective	and	allowed	them	to	maintain	life	activities	with	minimal	interruption	from	PDN.	
Some	participants	gained	benefit	from	medication,	despite	not	taking	the	drug	as	it	was	
prescribed.	Others	had	not	found	medication	effective;	this	was	due	either	to	minimal	reduction	
in	symptoms,	or	intolerable	side	effects.	Although	taking	detailed	drug	history	was	not	part	of	the	
interview	schedule,	this	range	of	responses	is	broadly	in	line	with	the	suggestion	from	Moore,	
Derry	and	Eccleston	(2013)	noted	earlier,	that	there	were	subgroups	of	‘responders’	and	‘non-
responders’	to	analgesic	medication.		
Participants	began	to	feel	abandoned	once	the	medical	teams	ran	out	of	medication	
options.	From	these	interviews,	participants	felt	abandoned	for	two	reasons,	firstly	because	
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clinicians	may	not	have	allowed	them	an	opportunity	to	describe	the	impacts	of	greatest	
importance.	The	structure	or	conduct	of	individuals’	clinical	appointments	did	not	allow	
discussion	of	issues	such	as	social	isolation	or	sex	life.	A	study	into	the	experiences	of	women	with	
long-term	health	conditions	(18	of	25	with	diabetes)	explored	the	nature	of	the	relationship	
patients	had	with	clinicians	(Fox	and	Chesla,	2008).	Relationships	were	placed	on	a	continuum	
from	‘connected’	to	‘disconnected’.	The	connected	relationships	were	characterized	by	respect	
and	authentic	empathy,	whereas	the	disconnected	relationships	were	characterized	by	the	
patient	feeling	treated	as	a	diagnostic	label,	rather	than	a	person.	This	treatment-as-diagnosis	led	
to	a	sense	of	abandonment,	which	has	been	similarly	identified	in	other	chronic	health	conditions,	
including	rheumatic	diseases	(Haugli,	Strand	and	Finset,	2004),	FMS	(Åsbring	and	Närvänen,	
2002),	irritable	bowel	syndrome	(Håkanson,	Sahlberg-Blom	and	Ternestedt,	2010)	and	persistent	
LBP	(Bunzli	et	al.,	2013;	Snelgrove	and	Liossi,	2009).	
Secondly,	participants	felt	abandonment	because	there	was	no	clear	route	forward	for	help	
to	reduce	or	manage	the	impacts	they	experienced.	Clinicians	were	seen	as	the	source	of	advice	
and	treatment	for	managing	PDN	and	its	impacts.	The	participants	in	the	current	study	found	
there	was	little	or	no	help	forthcoming	from	clinicians	once	medication	options	were	exhausted.		
It	is	clear	PDN	is	a	multi-faceted	condition	requiring	a	multi-faceted	approach	to	
management,	yet	the	majority	of	participants	in	this	study	received	little	or	no	guidance	beyond	
medication.	Only	the	participant	who	had	attended	PMPs	for	other	pain	conditions	had	received	
advice	on	sleep	and	psychological	coping	strategies.		
Participants	sought	information	to	help	them	manage	and	cope	with	PDN	from	many	
sources	including	the	Internet,	newspaper	advertisements	and	social	media	sites.	Participants	had	
experimented	with	a	wide	range	of	approaches	to	help	themselves	–	usually	with	limited	success.	
The	experimentation	with	extreme	techniques	such	as	walking	on	stinging	nettles,	suggest	being	
at	the	end	of	one’s	tether.	Generally,	participants	had	not	been	advised	of	other	evidence-based	
strategies,	that	may	have	positive	benefit.	
4.9.3	The	issues	related	to	physical	activity	
As	noted	in	the	results,	participants	discussed	physical	activity	and	exercise	synonymously.	
No	participant	in	this	study	had	been	advised	about	specific	exercise	or	activity	to	help	with	PDN.	
Their	perspective	on	the	role	of	physical	activity	in	the	management	of	PDN	was	only	speculative.	
While	a	range	of	activity	levels	and	attitudes	to	activity	and	exercise	were	present,	it	was	clear	
participants	would	be	very	cautious	with	starting	any	form	of	physical	activity	that	could	
potentially	increase	their	pain.	The	competing	perspectives	articulated	were	that	activity	hurt	too	
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much	to	be	possible	and,	because	PDN	was	due	to	nerve	damage	in	the	feet,	there	was	no	
mechanism	for	exercise	to	alleviate	the	pain.	
Participants	who	were	more	positive	towards	physical	activity	wanted	advice	from	HCPs,	
rather	than	exercise	professionals	such	as	gym	or	exercise	class	instructors.	They	wanted	the	
advice	to	come	from	someone	who	understood	the	pathologies	of	PDN	and	diabetes.		
Physical	activity	is	a	key	principle	of	diabetes	management	(Nagi	and	Gallen,	2010).	NICE	
guidance	NG28	for	management	of	diabetes	(NICE,	2015b)	refers	readers	to	their	guidance	on	
physical	activity	for	adults	(PH44)	(NICE,	2013b).	General	benefits	of	physical	activity	include	
reduced	development	of	T2DM,	cardiovascular	disease	and	many	musculoskeletal	problems,	also	
an	improvement	in	mood,	stress	management	and	overall	measures	of	wellbeing.		
Despite	public	health	promotion	campaigns,	society	as	a	whole	has	become	less	physically	
active	(Townsend	et	al.,	2015).	The	reasons	for	reducing	activity	levels,	and	the	current	obesity	
rates	are	complex	and	this	discussion	does	not	deal	with	them	in	full.	It	will	focus	on	one	issue	
that	is	of	relevance	to	PDN.	The	reasons	for	maintaining	fitness	through	exercise	and	physical	
activity	are	often	framed	in	terms	of	minimising	the	risk	of	chronic	disease.	By	maintaining	an	
optimum	body	mass	and	fitness	levels	an	individual	is	less	likely	to	develop	T2DM,	cardiovascular	
disease	and	some	cancers.	A	systematic	review	of	the	effect	exercise	had	on	glycaemic	control	
and	body	mass	in	people	with	diabetes	found	that	while	HbA1c	levels	were	improved	(7.65%	
exercise	vs.	8.81%	control,	p<0.001),	there	was	no	change	in	body	mass	(83.02kg	vs	82.48kg,	
p=0.76)	(Boulé	et	al.,	2001).	The	study	authors	concluded	that	the	improvement	in	HbA1c	was	
likely	to	reduce	the	risk	of	diabetes	complications.	In	clinical	practice	this	research	suggests	
people	need	to	invest	time	and	resources	into	exercise,	with	the	expectation	of	not	developing	
complications	and	seeing	no	or	little	change	in	body	mass.	
Chapter	2	presented	the	studies	which	were	retrieved	as	part	of	a	systematic	review,	they	
found	that	regular	engagement	in	aerobic	exercise	did	not	improve	pain	related	to	PDN	(Dixit,	
Maiya	and	Shastry,	2014),	the	statistical	difference	in	outcome	was	due	to	the	control	arm	
worsening	in	pain	scores.	The	practice	of	regular	Tai	Chi	had	positive	effects	on	a	quality	of	life	
measure	(SF36)	that	included	bodily	pain	scale,	but	the	results	from	the	Neuropathy	Total	
Symptoms	score	were	more	cautious	(Ahn	and	Song,	2012).	What	was	consistent	in	these	studies	
were	that	significant	results	arose	because	the	control	arms	worsened	across	the	data	points,	
rather	than	the	intervention	arms	improving.	This	was	whether	the	outcome	measure	was	SF36,	
Michigan	Diabetic	Neuropathy	score,	or	the	NeuroQOL	instrument.		
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The	research	evidence	does	not	currently	indicate	the	effect	that	physical	activity	would	
have	on	pain	in	people	with	PDN.	At	best,	physical	activity	might	reduce	the	possible	worsening	of	
pain.	Lack	of	improvement	in	pain	may	lead	to	the	view	that	physical	activity	is	a	pointless	pursuit	
and	use	of	resources.	It	is	possible	the	participants’	perspectives	that	exercise	would	not	be	an	
effective	approach	may	be	true.	Engagement	in	activity	may	offset	worsening	in	other	aspects	of	
life	quality	but	these	data	come	from	a	few	studies	with	methodological	flaws	and	requires	
verification.	At	present,	there	is	a	lack	of	robust	literature	investigating	different	types	and	
dosages	of	exercise	that	would	allow	clinicians	to	provide	clear	guidance	to	people	with	PDN.		
4.9.4	The	issues	related	to	psychological	coping		
Some	participants	had	exposure	to	psychological	coping	strategies	and	found	these	to	be	of	
benefit,	but	other	participants	were	not	willing	to	consider	mood	and	psychological	variables	as	
relevant	to	their	experience	of	PDN.	When	participants	spoke	about	the	causes	of	PDN	there	were	
strong	Cartesian	descriptions	used,	a	clear	separation	between	mind,	as	a	location	for	mood	and	
emotions,	and	body	as	a	generative	location	for	pain	experience.	Yet	we	know	from	a	wealth	of	
research	that	there	are	bidirectional	interactions	between	mind	and	body	(BPS,	2010;	Kirkengen	
et	al.,	2015).	If	mood	states	are	an	issue	to	the	person	with	PDN,	it	maybe	helpful	for	these	to	be	
acknowledged	by	the	person	and	by	any	clinician	they	are	in	contact	with.	Acknowledgement	of	
patient	distress	has	been	highlighted	as	good	practice	in	the	fields	of	oncology	(Fallowfield	et	al.,	
2001),	palliative	care	(Lamont	and	Christakis,	2001)	and	primary	care	(Pincus	et	al.,	2013;	
Hasenbring	and	Pincus,	2014)	as	examples.		
Having	a	long-term	condition	such	as	DM	is	associated	with	higher	prevalence	rates	of	
depression	than	in	populations	who	do	not	have	these	conditions	(Baumeister,	Hutter	and	Bengel,	
2012).	A	cohort	study	of	people	with	Type	1	and	T2DM	(n=1456)	found	32%	(CI	29.5-34.6%)	
experienced	mild	to	severe	anxiety,	and	22.4%	mild	to	severe	depression	(CI	20.2-24.7%).	These	
results	are	higher	compared	to	those	reported	in	a	recent	study	defining	normative	HADS	data	in	
UK	adults	(n=6280)	in	which	moderate-to-severe	anxiety	was	present	in	12.5%	of	males	and	19%	
of	females,	and	moderate-to-severe	depression	in	6.9%	of	adults	(equal	in	male	and	female	
respondents)	(Breeman	et	al.,	2015).		
It	cannot	be	said	that	diabetes	causes	depression;	there	are	risks	of	increased	depression	
associated	with	lifestyle	factors	such	as	alcohol	and	tobacco	consumption	and	the	risk	is	reduced	
with	higher	socio-economic	status	and	older	age	(Collins,	Corcoran	and	Perry,	2009).	Similarly,	
having	persistent	pain	is	also	associated	with	an	increased	prevalence	of	depression	(Campbell,	
Clauw	and	Keefe,	2003)	and	anxiety	(de	Vlieger,	Crombez	and	Eccleston,	2006).	It	maybe	
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appropriate	to	consider	that	people	with	PDN	have	(at	least)	two	health-related	contributory	
reasons	to	experience	depression.		
The	approach	of	a	clinician	can	determine	if	patients	are	offered	help	to	manage	adverse	
mood	states.	An	interview	study	with	physiotherapists	found	some	clinicians	acknowledged	
patient’s	depression	and	anxiety,	but	did	not	recognise	them	as	contributory	to	the	presentation	
of	LBP,	or	as	variables	modifiable	through	physiotherapy	intervention	(Synnott	et	al.,	2015).	If	
clinicians	do	not	recognise	these	mood	states	in	patients,	or	place	value	on	them	for	clinical	
intervention,	then	it	is	highly	unlikely	that	any	meaningful	treatment	plans	will	be	instigated.		
The	management	of	mood	states	can	involve	passive	and	active	approaches.	Passive	
approaches	include	appropriate	use	of	anti-depressant	and/or	anti-anxiolytic	medication	as	
identified	by	the	patient	and	prescribing	clinician.	A	recent	Cochrane	review	of	treatments	for	
depression	co-occurring	with	diabetes,	found	both	psychological	and	pharmacological	treatments	
were	of	benefit	in	the	short	to	medium	term.	Only	the	prescription	of	anti-depressants	was	
associated	with	a	clinically	meaningful	reduction	in	HbA1c	(Baumeister,	Hutter	and	Bengel,	2012).	
The	active	treatment	approaches	for	depression	include	moderate	exercise,	goal	setting	and	
increasing	social	contact.	For	anxiety	a	graded	exposure	approach	to	worrying	situations	can	be	
appropriate.	These	same	approaches	are	used	for	the	multi-dimensional	management	of	
persistent	pain	(Leeuw	et	al.,	2008;	Bair	et	al.,	2009).		
The	few	participants	who	had	attended	multidisciplinary	PMPs	for	other	reasons,	felt	the	
strategies	taught	on	those	programmes,	particularly	relaxation	techniques,	were	applicable	to	
their	experiences	of	PDN.	The	guidance	provided	by	the	British	Pain	Society	on	running	PMPs	
highlight	that	potential	participants	cannot	be	coerced	to	attend	a	programme	(BPS,	2013).	The	
active	engagement	by	the	participant	in	the	programme	is	vital	as	the	strategies	are	active	rather	
than	passive.	The	rejection	by	a	significant	proportion	of	the	interview	participants	suggests	that,	
at	present,	psychological	approaches	would	not	be	deemed	appropriate	by	many	people	with	
PDN.	
4.10	Limitations	specific	to	the	patient	study	
4.10.1	Interviews	
The	primary	limitation	of	this	study	was	the	lack	of	sociodemographic	diversity	in	the	
sample	population.	All	except	one	participant	identified	as	White	British.	Different	genetic	profiles	
and	ethnic	backgrounds	have	differing	prevalence	rates	for	diabetes	(Gujral	et	al.,	2013).	These	
differences	may	affect	the	tendencies	towards	the	underlying	pathophysiology	of	PDN.	Different	
social	groups	also	have	tendencies	toward	different	pain	coping	strategies,	for	example	African	
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American	patients	report	using	distraction	and	praying/hoping	strategies	for	coping	with	pain,	
whereas	Caucasians	report	greater	use	of	ignoring	and	coping	strategies	(Edwards,	Fillingim	and	
Keefe,	2001;	Hastie,	Riley	and	Fillingim,	2004).	The	participants	in	Brod	et	al.	(2015a),	a	qualitative	
study,	had	a	greater	variety	of	ethnic	backgrounds,	and	the	results	of	that	study	were	in	broad	
agreement	with	those	presented	here.	
Interview	participants	were	not	asked	about	any	religious	beliefs	or	affiliations.	The	
relationship	between	belief	and	pain	coping	appears	complex.	It	appears	some	aspects	of	religion	
can	be	adaptive	to	supporting	living	with	persistent	pain,	and	other	aspects	may	be	maladaptive	
and	be	more	associated	with	passive	behaviours	(Wachholtz,	Pearce	and	Koenig,	2007).	
As	identified	in	Chapter	3,	the	philosophical	position	of	qualitative	research	is	that	results	
do	not	aim	to	be	generalizable	beyond	the	context	in	which	the	original	data	were	gathered.	The	
results	and	conclusions	of	this	study	should	be	considered	with	the	known	lack	of	ethnic	diversity,	
the	unknown	religious	beliefs	that	existed	in	the	population	of	participants,	and	the	social	context	
of	the	NHS	system	in	the	UK.	
Lastly,	the	perspectives	on	physical	activity	and	psychological	coping	reported	by	
participants	were	essentially	speculative.	Although	the	PMP	outline	was	used	as	a	prompt	for	
discussion	few	participants	had	actual	experience	of	attending	a	multi-disciplinary	pain	
programme.		
4.10.2	Questionnaire	
The	aim	of	the	complication	questionnaire	was	to	obtain	a	sense	of	how	participants	would	
prioritise	the	management	of	the	diabetes	related	complications	that	they	experienced.	The	
imposition	of	a	rating	scale	of	1=most	interfering	problem,	2=next	most	interfering	etc.	suggested	
that	it	was	possible	to	clearly	rank	these	problems	and	their	management.	In	reality,	participants	
were	often	unable	to	rank	their	problems	in	a	clear	sequential	manner	and	this	was	not	due	to	
any	fault	on	their	part,	but	due	to	the	inflexible	nature	of	the	rating	scale.			
The	design	of	the	questionnaire	did	not	take	into	account	the	different	considerations	
between	complications	that	are	on-going,	such	as	the	management	of	blood	sugar	levels,	and	the	
management	of	occasional	complications,	such	as	minor	foot	ulceration.	Were	this	aspect	of	the	
study	to	be	repeated,	the	questionnaire	should	be	designed	to	take	these	different	considerations	
into	account.	
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4.11	Conclusions	
The	study	has	shown	PDN	has	wide-ranging	impacts	on	quality	of	life,	beyond	those	found	
using	quantitative	questionnaire-based	research	designs.	These	impacts	can	be	reduced	when	
medication	is	successful,	but	there	are	people	for	whom	medication	options	appear	not	to	be	
successful.	Participants	had	not	been	advised	of	other	management	strategies	by	clinicians.	This	
left	them	with	a	sense	of	abandonment	and	resulted	in	them	experimenting	with	uncommon	
management	strategies.	Some	participants	would	be	open	to	physical	activity,	but	others	saw	no	
role	for	activity	in	improving	their	symptoms.	Participants	who	had	psychological	coping	advice	
for	other	persistent	pain	conditions	felt	these	strategies	were	useful	for	PDN,	but	there	was	
ambivalence	from	other	participants,	to	these	strategies.	
Were	a	PDN-specific	pain	management	programme	to	be	available,	it	is	unclear	1)	given	
their	perspectives	on	physical	activity	and	psychological	coping,	whether	patients	would	engage	
and,	2)	whether	clinicians	who	manage	DM	and	PDN	would	feel	such	a	programme	was	
appropriate	for	their	patients.	The	next	chapter	will	present	the	perspectives	from	a	range	of	
clinical	specialists	on	the	appropriateness	of	these	strategies	for	PDN.		
The	uncertainty	from	patient	participants	suggests	more	needs	to	be	understood	about	
their	priorities	for	managing	symptoms	and	impacts	of	PDN	they	experience.	It	maybe	their	main	
priorities	could	be	matched	to	existing	evidence	based	management	strategies.	Equally	it	maybe	
that	patients’	priorities	cannot	be	matched	to	existing	strategies	and	novel,	innovative	
approaches	are	required.	This	question	is	the	focus	of	Chapter	6.	
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Chapter	5	–	Results	from	the	clinician	interview	study.	
Having	described	the	perspective	of	people	with	PDN	in	the	preceding	chapter,	Chapter	5	
details	results	from	the	interview	study	with	clinicians.	Please	refer	back	to	Chapter	3	–	
Methodology	and	methods,	for	the	details	of	the	study	conduct.		
5.1	Clinician	results	
Eighteen	HCPs	were	interviewed	representing	various	disciplines	(see	Table	11).	Sixteen	of	
the	clinicians	were	from	secondary	care	organisations	and	two	from	primary	care.	Ten	clinicians	
were	considered	specialists	in	diabetes	management,	six	as	specialists	in	pain	management	and	
the	two	clinicians	from	primary	care	as	generalist	clinicians.	Interviews	lasted	30-60	minutes.	
Table	11	-	Clinician	professional	role	
Profession	 N=	 Diabetes	 Pain	 General	
Consultant	diabetologist	 4	 4	 	 	
Consultant	anaesthetist	 3	 	 3	 	
Secondary	care	podiatrist	 2	 2	 	 	
Research	nurse	 2	 2	 	 	
Secondary	care	physiotherapist	 2	 	 2	 	
Clinical	psychologist	 1	 	 1	 	
Research	dietician	 1	 1	 	 	
Secondary	care	diabetes	specialist	nurse	 1	 1	 	 	
General	practitioner	 1	 	 	 1	
Primary	care	practice	nurse	 1	 	 	 1	
Total	 18	 10	 6	 2	
	
Results	have	been	presented	within	superordinate	themes	created	from	the	analysis	
(Figure	14).	These	superordinate	themes	have	been	laid	out	as	a	patient	may	journey	through	
health	services	for	help	with	PDN.	Exemplar	quotes	have	been	used,	identified	by	the	clinician’s	
profession.	New	codes	were	created	up	to	the	final	interview,	which	suggested	that	a	point	of	
saturation,	where	all	perspectives	had	been	explored	(Guest,	2006;	Morse,	1995),	was	not	
reached	in	this	study.	It	proved	difficult	to	recruit	clinicians	from	primary	care;	notably,	the	study	
did	not	interview	podiatrists	from	primary	care	who	may	have	different	perspectives	than	their	
colleagues	in	secondary	care.		
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Figure	14	-	Overview	of	clinician	themes	
	
5.2	Superordinate	theme:	Conducting	the	assessment	
Clinicians	spoke	about	two	aspects	of	communication	through	the	assessment,	one	theme	
of	communication	issues	on	the	part	of	the	patient,	and	a	second	theme	of	communication	issues	
they	identified	in	their	own	practice.		
5.2.1	Theme:	Patient	communication	issues	
Clinicians	identified	that	patients	may	not	raise	symptoms	of	neuropathic	pain	during	the	
consultation,	even	if	they	were	experiencing	them.		
	“I	might	see	people	a	few	times	and	then	it	comes	up,	that	they’ve	got	painful	feet	
or	numb	feet	[…]	they	haven’t	thought	that	it’s	something	to	bring	[to	the	
consultation].”	Diabetes	specialist	nurse.	
“…other	times	you	do	have	to	ask	because	they	don't	think	it’s	relevant	for	whatever	
reason	even	though	its	pain	in	their	feet	they	say	‘oh	yeah	well	it	keeps	me	up	at	
night’.”	Podiatrist	2.	
Clinicians	suggested	patients	were	aware	diabetes	could	cause	sensory	loss	and	numbness,	
but	were	less	aware	that	pain	could	also	be	part	of	the	presentation.			
“…‘Do	you	have	painful	neuropathy?’	and	the	patient	has	gone	‘no’,	do	they	
understand	what	that	sentence	actually	means,	I	strongly	suspect	not	and	that	
probably	needs	to	be	worded	in	a	different	way.”	Research	Nurse	1.	
“The	pain,	I	don’t	think	particularly	they	do,	numbness	and	gangrene,	[…]	they’re	
worried	they’re	going	to	get	gangrenous	feet	but	I,	perhaps	they	don’t	link	it	[pain]	
particularly.”	Practice	Nurse.	
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“I	don't	think	people	mention	to	them	the	possibility	of	getting	pain	as	a	result	of	
their	neuropathy.”	Diabetes	Consultant	4.	
Clinicians	suggested	it	took	time	to	build	a	therapeutic	relationship.	Some	symptoms,	such	
as	erectile	dysfunction,	would	not	be	raised	at	first	consultation	but	at	subsequent	meetings	once	
trust	was	established.	
“I	think	very	often	it	is	only	once	they	feel	comfortable	with	you,	and	they’ve	built	up	
that	relationship,	and	they	have	had	a	little	bit	of	education	during	the	
consultation.”	Research	Nurse	1.	
5.2.2	Theme:	Clinician	communication	issues	
Clinicians	identified	that	patients	were	not	solely	responsible	for	raising	pain	as	an	issue;	
and	noted	issues	within	their	own	clinical	practice	and	communication	skills.	Some	clinicians	
indicated	that	they	were	not	routinely	asking	about	pain	symptoms.	
“Often	these	people	will	come	in	and	unfortunately	no	one	before	will	have	asked	
them	about	any	symptoms	that	they	have	around	pain.”	Diabetes	Consultant	2.	
“We	are	trying	to	change,	actually	starting	to	ask	people	‘Are	you	in	pain,	do	you	
have	trouble	sleeping,	what	is	it	one	foot,	both	feet,	how’s	it	going?’	and	you	start	
to	drill	down	what	actually	is	the	problem.”	Podiatrist	1.	
	“I	don’t	do	often	enough	is	to	say,	you	know	‘Are	you	getting	any	trouble	with	your	
feet?’”	Diabetes	Specialist	Nurse.	
Clinicians	noted	they	each	had	special	interests;	only	when	pain	and	associated	pain	
management	strategies	were	part	of	the	individual	clinicians’	interests,	were	they	likely	to	
develop	specific	communication	skills	in	these	areas.	
“I	think	with	all	of	these	things,	it	is	someone	putting	their	head	above	the	parapet	
and	being	really	interested	in	it.	[PDN]	is	their	particular	interest	and	develop	the	
skills	and	expertise	of	managing	those	patients.”	Diabetes	Consultant	3.	
“I	think	that	having	a	specialist	service	to	go	to	is	extremely	important	and	part	of	
that	is	the	expertise	and	the	knowing	what	other	services	are	around	and	part	of	it	
is	actually	the	fact	that	they	really	get	listened	to	and	the	benefit	of	going	where	a	
specialist	is	really	interested	in	all	the	details	of	this	intractable	problem.”	Diabetes	
Consultant	4.	
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Organisational	contexts	were	identified	which	could	further	reduce	the	likelihood	of	
enquiring	about	pain.	Within	the	diabetes	multidisciplinary	team	individual	clinicians	described	
focussing	on	a	specific	aspect	of	patient	management.	
“Um,	but	generally,	my	role	is	about	managing	glucose	levels.”	Diabetes	Specialist	
Nurse.	
“We	are	very	good	at	things	like	eye	screening	and	any	of	the	other	microvascular	
complications,	you	know	checking	their	kidneys,	checking	their	eyes,	however	
neuropathy	maybe	‘I’ve	got	some	pains	in	my	feet’	sometimes	that's	overlooked.”	
Research	Dietician.	
In	primary	care	the	computer	system	consultation	proforma	did	not	include	an	opportunity	
to	add	pain	symptoms.	
“we	talk	about	the	pulses;	do	we	talk	about	pain?	No,	we	don’t	actually,	there’s	
nowhere	to	record	it	[on	the	proforma].	[…]	It’s	probably	lost	data	actually.”	Practice	
Nurse.	
Other	clinicians	routinely	considered	pain	in	their	consultation,	or	stated	it	was	the	
patient’s	agenda,	which	was	at	the	centre	of	the	consultation.	
“It	depends	on	how	you	organise	your	clinical	consultation,	mine’s	usually	‘Nice	to	
see	you,	why	are	you	here?	What’s	on	your	agenda	today?’”	Diabetes	Consultant	3.	
	“As	long	as	someone	has	a	pain	condition,	it’s	always	based	on	that	individual	
assessment.	[…]	because	everyone	is	so	different	anyway,	everyone	has	got	different	
lives,	different	responsibilities,	they’ve	got	different	fears,	views,	different	ways	of	
coping,	and	again	it’s	[assessment]	really	highlighting	the	main	issues	for	that	
person.”	Physiotherapist	1.	
In	summary,	participants	identified	issues	from	both	sides	of	the	clinical	encounter	which	
contributed	to	PDN	and	its	impacts	not	being	raised.	If	PDN	or	its	impacts	were	not	raised	they	
could	not	be	dealt	with	or	management	strategies	discussed.		
5.3	Superordinate	theme:	The	patient	presentation	
This	superordinate	theme	contained	three	themes:	Diagnosing	PDN	described	how	
clinicians	arrived	at	a	certain	diagnosis	for	the	patient’s	problem;	Impact	-	Psychological,	and	
Impact	-	Physical,	described	what	clinicians	noted	in	patients	with	PDN	(Figure	15).	
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Figure	15	-	Patient	presentation	
	
	
	
	
	
	
5.3.1	Theme:	Diagnosing	PDN	
Clinicians	from	primary	and	secondary	care,	whether	considered	specialists	or	generalists,	
highlighted	the	difficulty	of	being	certain	in	the	diagnosis	of	PDN,	rather	than	a	differential	
diagnosis.	Possible	differential	diagnoses	included	vascular	pain,	neuropathic	pain	from	lumbar	
spine	nerve	root	compression	or	spinal	stenosis,	and	neuropathic	pain	from	excessive	alcohol,	
vitamin	deficiency	or	other	causes.	They	described	using	objective	clinical	assessment	procedures	
(sensitivity	assessment	with	monofilaments)	or	referral	for	tests	by	other	departments	(nerve	
conduction	studies).	All	the	clinicians	stressed	the	most	important	aspect	of	their	assessment	was	
listening	to	the	patient’s	subjective	history.	They	were	interested	in	the	distribution	of	the	
symptoms,	the	words	used	to	describe	the	symptoms,	and	the	pattern	across	a	day.	The	
subjective	narrative	informed	their	objective	assessment	that	confirmed	or	refuted	a	hypothesis	
of	PDN.		
“Right,	so	take	a	full	history,	and	the	first	question	I	immediately	ask	myself	‘Is	this	
painful	diabetic	neuropathy,	or	have	they	got	other	causes	for	the	pain?’	The	vast	
majority	do	indeed	have	it,	very	occasionally	I	see	people	where	it	is	not	clear	or	
where	they	have	a	second	cause	for	pain	as	well.”	Diabetes	Consultant	1.	
“I	want	to	exclude	that	there	is	something	else	going	on,	that	it	is	not	an	ischaemic	
pain	rather	not	a	neuropathy,	that	it’s	neuropathic	pain	rather	than	an	ischaemic	
pain.”	Diabetes	Consultant	2.	
	“or	other	kinds	of	things	that	can	sometimes	mimic	it.	Once	I’m	pretty	clear	with	
the	diagnosis	then	we’d	start	trying	treatments	and	follow	the	various	protocols	
that	are	available	for	managing	it,	so	starting	off	with	something	like	amitriptyline.”	
GP.	
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When	convinced	that	PDN	was	the	patient’s	most	appropriate	diagnosis,	clinicians	
identified	a	wide	variety	of	impacts	PDN	had	on	the	individual,	both	psychological	and	physical.	
5.3.2	Theme:	Impact	-	Psychological	
This	theme	contained	clinicians’	reflections	on	how	PDN	affected	patients’	moods	or	
cognitions.	Most	frequently,	clinicians	identified	the	patients	as	having	some	level	of	depression.	
Clinicians	rarely	used	validated	measures	to	screen	for	depression,	but	inferred	the	affected	
mood	from	the	patient’s	language	and	behaviours	and	their	own	knowledge	of	chronic	health	
conditions.		
“a	lot	of	them	[patients]	are	of	low	mood,	some	can	be	irritable	with	family	
members,	[…]	not	that	I’m	a	doctor	or	anything	but	they	seem	depressed	to	me.”	
Podiatrist	2.	
“They've	lost	their	jobs,	their	families	are,	you	know,	their	relationships	are	in	
trouble,	as	I'm	sure	you're	aware	there	is	a	huge	incidence	of	anxiety	and	depression	
in	pain	patients.”	Pain	Consultant	1.	
The	specialist	diabetes	clinicians	were	interested	in	depression	for	the	impact	it	had	on	
management	of	diabetes.	Self-motivation	required	to	continually	manage	blood	sugars	could	be	
negatively	affected	by	depression.	Positive	coping	behaviours	might	not	be	as	frequent	in	the	
presence	of	low	mood.		
“I	think	what	we	try	to	do	is,	we	know	that	people	who	have	psychological	and	
psychiatric	comorbidities	do	not	engage	with	treatments	well	and	do	much	worse,	
we	know	that	it	has	impact	on	their	overall	[blood	glucose]	control	and	compliance	
with	medications	[…]	we	can	treat	them	from	the	psychiatric	and	psychological	
comorbidities	point	of	view	in	order	to	improve	their	micro-	and	macrovascular	
complications	and	hopefully	in	doing	so	have	some	impact	on	their	overall	health.”	
Diabetes	Consultant	2.	
Clinicians	noted	anxiety	in	patients.	They	described	patients	were	worried	about	causes	of	
pain,	whether	something	more	sinister	had	been	missed,	patients	were	often	concerned	about	
the	unpredictable	pattern	of	pain,	and	were	concerned	pain	indicated	possible,	or	further,	
amputation	would	be	needed.		
“They	don't	do	things	because	they	are	worried	it	will	trigger	their	pain.”	Diabetes	
Consultant	1.	
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“…which	makes	the	pain	appear	worse,	which	makes	the	anxiety	worse	and	so	on.	
So	if	you	can	help	reduce	the	anxiety	that	they’re	[in],	it’s	not	necessarily	going	to	
get	any	worse,	it’s	not	going	to	be,	not	necessarily	serious,	It’s	not	a	sign	of	cancer	
or	something	disastrous.”	GP.	
“…you	have	people	saying	‘I	had	my	leg	off	last	year	and	a	few	weeks	ago	I	noticed	
there	was	a	problem	with	my	foot	but	I	didn't	want	to	trouble	you’.”	Podiatrist	1.	
Some	clinicians	described	the	emotional	burden	of	guilt	in	some	patients.	They	considered	
guilt	arose	because	patients	had	been	given	advice	and	management	strategies	over	the	years	
that,	for	one	reason	or	another,	they	had	been	unable	to	follow	optimally	and	had	therefore	
developed	complications.	These	complications	could	include	macrovascular	and	microvascular	
complications	such	as	PDN.		
“I	struggle	a	bit	with	this	idea	of	fault	and	blame,	and	how	with	the	one	of	the	
psychological	themes	with	diabetic	patients	particularly	those	with	complications	
are	‘I’m	getting	my	comeuppance,	I	should	have	as	a	child…	if	only	as	a	teenager	I	
hadn’t…’	all	of	that	‘well	I	deserve	it	don't	I	because	I’ve	not	controlled	my	sugars	
I’ve	not	looked	after	myself	properly’.”	Psychologist.	
“They	reflect	back	on	themselves	and	they	think	‘because	I	now	have	these	problems	
it	must	be	my	fault	I’ve	not	dealt	with	this	very	well,	I	am	to	blame’.	So,	they	very	
much	blame	themselves,	beat	themselves	up	about	it	and	have	awful	feelings	of	
guilt	and	everything,	which	actually	makes	it	incredibly	difficult	for	them	to	look	at	
managing.”	Research	Nurse	1.	
Clinicians	identified	PDN	had	effects	beyond	the	person	who	experienced	it,	to	include	their	
wider	family	and	friends.		
“So	family	issues,	pain	can	stop	you	from	sleeping,	it	can	make	you	grumpy,	it	can	
make	you	sad,	it	can	impact	all	the	interpersonal	relationships	with	members	of	
your	family.	So	then	you	end	up	with	marriage	breakdown	or	not	being	able	to	feel	
that	you’re	giving	your	children	a	good	time,	or	your	grandchildren.	So	yeah,	it’s	
much	broader	consequences	than	just	the	impact	on	yourself.”	Pain	Consultant	2.	
5.3.3	Theme:	Impact	-	Physical	
Clinicians	identified	PDN	had	impacts	on	a	wide	range	of	day-to-day	physical	and	functional	
capacities.	The	majority	of	clinicians	commented	on	the	impact	PDN,	and	pain	generally,	had	on	
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sleep	quality.	They	noted	the	increased	difficulty	people	had	in	coping	with	pain	and	life,	if	they	
have	not	slept	well.		
“I	think	it	affects	people	a	lot,	um	because	of	the	pain,	because	of	the	sleep	
disturbance,	so	I	think	it	is	a	miserable	complication	and	of	course	diabetic	
complications	cluster	together.	[…]	because	you’re	not	sleeping	and	you	can’t	get	
away	from	it	and	you	can’t	get	it	properly	controlled.”	Diabetes	Consultant	4.	
“I	commonly	hear	people	with	painful	neuropathy	that	sleeping	sometimes	is	
difficult	because	of	the	pain	they	are	experiencing.”	Research	Dietician.	
Clinicians	described	how	patients	were	restricted	in	walking,	both	by	PDN	and	also	by	
diabetes	and	other	related	complications.	
“Many	of	the	patients	I	see	are	immobile	because	of	their	pain	but	also	because	of	
their	other	multiple	co-morbidities	with	diabetes.”	Diabetes	Consultant	1.	
“Well,	from	the	diabetes	perspective	she	was	ah,	a	large	lady	and	because	of	her	
neuropathy	she	wasn't	very	mobile.”	Pain	Consultant	3.	
Clinicians	were	mindful	of	the	way	impacts	connected	with	one	another,	for	example	being	
unable	to	work	due	to	PDN	could	lead	to	reduced	social	life	and	sense	of	self-worth.	
“Yeah,	so	if	they	can’t	work	because	of	their	diabetic	pain,	and	then	that	means	that	
they	feel	either	they’re	isolated	at	home	with	their	pain,	because	their	work	gave	
them	a	social	side	of	things,	or	they	feel	worthless	because	they’re	not	contributing	
to	the	family,	or	the	family	are	in	financial	difficulty	because	they	were	the	main	
breadwinner.”	Pain	Consultant	2.	
The	challenge	of	managing	the	unpredictable	pattern	of	PDN	was	highlighted.	The	
observation	that	PDN	did	not	worsen	in	line	with	physical	activity,	but	could	have	a	‘mind	of	its	
own’,	meant	it	was	difficult	to	gain	control	over	the	experience.		
“Talking	about	base	line	setting,	he	[person	with	PDN	in	a	PMP]	was	saying	‘Actually	
this	just	isn’t	relevant	for	me,	I’ve	done	all	that’,	he	was	saying	‘I’ve	paced	myself,	it	
makes	no	difference,	I	can	have	a	good	day,	I	can	have	a	bad	day,	it	doesn’t	seem	to	
relate	to	my	activity	very	much’.”	Physiotherapist	2.	
“And	my	perception	of	diabetic	pain	is	that	it’s	not	that	their	limbs	don’t,	activity	
doesn’t	necessarily	flare	their	pain	up.”	Pain	Consultant	2.	
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Although	clinicians	were	cognizant	of	the	broad	impacts	PDN	had	both	physically	and	
psychologically,	they	stressed	these	impacts	could	not	be	disentangled	from	the	psychological,	
physical	and	functional	consequences	of	other	diabetic	complications.	This	made	considering	
management	strategies	more	challenging.	Specialist	diabetes	clinicians	including	medical	
consultants,	podiatrists	and	nurses,	from	both	secondary	and	primary	care	were	consistent	in	this	
view.	
“I	think	so,	the	difficulty	is	sending	some	of	these	people	to	another	appointment,	
which	is	a	difficulty,	when	they	are	coming	up	here	once	or	twice	a	week,	they	are	
seeing	their	GP,	they	are	seeing	their	diabetes	specialist	nurse,	they	might	be	seeing	
their	consultant,	let	alone	having	X-rays,	their	retinal	screening,	the	numerous	other	
appointments	they	have	to	attend	anyway,	they’re	not	well	people,	trying	to	fit	in	
something	else	a	lot	of	them	have	kidney	problems	as	well	so	are	under	the	kidney	
specialist	and	seeing	them	regularly.	It	mounts	up	to	an	awful	lot	of	appointments.”	
Podiatrist	1.	
“I’m	not	the	most	unlucky	person	in	the	world	to	have	eight	different	chronic	
diseases,	actually	this	all	stems	from	my	diabetes.”	Research	Nurse	1.	
To	summarise	section	5.3,	all	clinicians	from	primary	and	secondary	care,	whether	
generalists,	diabetes	or	pain	specialists,	were	familiar	with	the	presentation	of	PDN.	They	were	
clear	that	people	experienced	significant	amounts	of	pain	with	associated	distress	and	functional	
impediment.	The	diabetes	specialists	recognised	that	PDN	added	further	difficulties	to	the	
experience	of	living	with,	and	managing	diabetes	as	a	long-term	condition.	They	stressed	that	
people	with	PDN	were	nearly	always	encumbered	with	other	comorbidities	due	to	their	diabetes.	
5.4	Superordinate	theme:	Current	management	of	PDN	
This	superordinate	theme	contained	two	themes:	Drugs	are	what	you	do,	and	Management	
in	pain	clinic.	This	last	theme	contained	a	subtheme	describing	the	clinicians’	views	of	PDN	in	their	
PMPs,	as	they	currently	existed	–	PDN	in	PMPs	(Figure	16).	
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Figure	16	-	Current	management	of	PDN	
	
5.4.1	Theme:	Drugs	are	what	you	do	
In	line	with	the	evidence	base,	a	strong	theme	from	the	clinicians	was	-	Drugs	are	what	you	
do.	The	clinicians	most	likely	to	be	actively	involved	in	managing	people	with	PDN	(GP,	Practice	
nurse,	DSN	and	Consultants)	all	described	pharmacology	as	their	initial	strategy	with	the	aim	of	
reducing	pain	and	subsequent	impact.		
“I	will	say	you	need	to	see	your	GP,	talk	about	duloxetine	as	being	the	
recommended	first	approach	and	write	to	the	GP	to	say.”	Diabetic	Specialist	Nurse.	
	“It	would	be	a	question	of	whether	we	initiate	treatment	for	it	and	just	see	whether	
having	Duloxetine	or	Amitriptyline	or	whether	that	actually	makes,	makes	a	
difference	to	that	pain.”	Practice	Nurse.	
When	clinicians	consider	medication,	they	were	well	aware	of	the	evidence	base	and	
appropriate	guidance	documents.	
“So,	at	the	moment	the	NICE	guidelines	and	The	British	Pain	Society	all	really	say	the	
same	thing,	there	are	only	three	drugs	worth	using	Duloxetine,	Pregabalin	and	
Amitriptyline	and	the	real	question	is	in	what	order	and	in	what	combination?”	
Diabetes	Consultant	1.	
“I	think	we	all	play	around	with	these	various	medications	because	they’re	useful	
but	none	is	the	panacea	for	painful	peripheral	neuropathy.”	Diabetes	Consultant	3.	
Clinicians	were	clear	their	primary	aim	was	to	reduce	the	pain	experienced	and	hence	the	
related	impact	of	PDN.	
“I	mean	that's	our	first	responsibility	as	pain	doctors	is	to	try	and	reduce	the	
intensity	of	the	pain	itself,	because	sometimes	that's	possible,	sometimes	it's	not	
but,	if	it	hadn’t	been	tried	then	it	needs	to	be	tried.”	Pain	Consultant	1.	
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“I	also	see	my	role	as	making	sure	that	they	have	explored	medicines	as	much	as	
they	want	to	explore	them,	accepting	that	most	drugs	we	use	for	chronic	pain	are	
only	about	30%	effective.”	Pain	Consultant	2.	
However,	they	were	also	aware	side	effects	were	a	common	issue	and	could	limit	
successful	analgesic	management.		
“And	so	you’ll	get	some	patients,	most	patients	have	tried	something,	but	a	lot	of	
patients	have	been	bunged	onto	quite	a	high	dose	of	an	anti-neuropathic	agent,	
which	they’ve	not	got	on	with	and	they’ve	failed	with.”	Pain	Consultant	2.	
“if	the	patient	doesn't	take	the	amitriptyline	because	it	sends	them	to	sleep.”	
Diabetes	Consultant	4.	
Clinicians	were	cognizant	that	many	medications	prescribed	for	patients	with	PDN	lacked	
efficacy.	Consultants	described	the	common	scenario	of	patients	who	had	been	through	multiple	
medications	with	no	benefit.	
“We	see	that	they	have	been	through	amitriptyline,	duloxetine,	Pregabalin,	
morphine,	codeine	and	you	name	it.	I	often	say	to	them	that	it	looks	like	you’ve	been	
through	a	lot	of	medications	that	may	or	may	not	have	helped,	and	the	patients	
often	say	‘Nothing	helps’.”	Diabetes	Consultant	2.	
“Whereas	there's	others,	and	it's	probably	more	common	where	whatever	you	do	
makes	no	difference	whatsoever	from	an	actual	pain	intensity	point	of	view.”	Pain	
Consultant	1.	
This	led	to	a	situation	and	feeling	of	Clinical	Impotence.	
“Um	it’s,	well	you	know,	‘you	just	have	to	put	up	with	it’,	is	the	message	and	I	give	
that	message	sometimes,	[…]	I	don’t	know	what	else	to	suggest.”	Diabetic	Specialist	
Nurse.	
“That's	probably	why	we	don't	get	more	referrals	with	people	with	PDN	because	I	
imagine	what	happens	is	a	lot	of	GPs	and	even	diabetologists	think	that	they've	
followed	the	guidelines.	They've	given	the	Gabapentin	and	whatever	else	there	is	
and	that	hasn’t	worked	so	there's	nothing	that	can	be	of	any	benefit	for	these	
people.”	Pain	Consultant	1.	
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5.4.2	Theme:	Management	in	pain	clinic	
The	second	theme	was	Management	in	Pain	clinic.	There	were	perceived	discrepancies	
between	published	prevalence	rates	of	PDN	in	the	wider	community,	and	the	relatively	low	
frequency	by	which	people	with	PDN	were	seen	in	pain	clinic.	Specialist	clinicians	in	pain	clinics	
and	PMPs	(Psychologist,	Pain	consultants	and	Physiotherapists),	described	seeing	few,	if	any,	
patients	with	a	primary	diagnosis	of	PDN.		
“Yeah	we	do	but	surprisingly	few	given	that	it's	so	prevalent.”	Pain	Consultant	1.	
“We	don’t	see	a	lot	of	people	here	with	primary	neuropathic	pain,	why	might	that	
be,	particularly	diabetic	neuropathy,	because	it’s	common?	If	it’s	so	common,	why	
don’t	we	see	it	in	the	pain	clinic	and	why	don’t	we	see	people	further	down	the	line	
in	the	pain	management	programme?”	Physiotherapist	2.	
“I	don't	suppose	I’ve	had	anyone	with	type	2	with	neuropathic	pain.”	Psychologist.	
Referral	routes	to	pain	clinic	were	via	the	patient’s	GP,	their	secondary	care	diabetes	
clinicians	and	occasionally	from	a	tertiary	care	PDN	specialist	clinic.	Clinicians	described	the	lack	of	
structured	approach	to	accessing	specialist	management;	it	was	only	assertive	patients	who	got	
referred.		
“…only	those	people	that	shout	the	loudest,	there’s	no	overall	global	holistic	view	
for	this”	Diabetes	consultant	1.	
The	pain	consultants	described	their	clinical	consultation	with	people	who	have	PDN	as	no	
different	to	those	with	any	other	person	in	pain.	Their	main	aim	was	to	listen	to	the	patients’	
problems,	to	understand	their	clinical	history	and	what	interventions	had	been	tried.	They	wanted	
to	ensure	that	all	possible	conditions	had	been	considered,	so	they	could	treat	persistent	pain	
appropriately,	and	not	miss	another	condition	that	could	be	managed.		
“I	don’t	think	my	approach	to	a	diabetic	patient	would	be	any	different	to	my	
approach	to	anybody	that	walks	in.	So	I	tend	to	do	a	consultation,	it’s	a	45	minute	
consultation	and	I	tend	to	get	to	an	endpoint	of	offering	them	various	different	pain	
clinic	options	by	a	route	of	a	conversation.”	Pain	Consultant	2	
They	felt	their	role	was	to	rationalise	the	medication	and	to	decrease	the	analgesia	where	
there	was	little	benefit	to	pain,	or	excessive	side	effects.		
“And	then	there’s	the	group	who	are	on	quite	a	big	cocktail	[of	drugs],	who	are	not	
sure	what	they’re	on,	and	I	might	say	‘Actually	shall	we	just	try	taking	one	off,	one	
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at	a	time	and	just	see	what	happens?’.	[…]	I	guess	to	get	rid	of	side	effects	they	
might	be	experiencing.”	Pain	Consultant	2.	
Pain	Consultants	use	injection	therapy	interventions	for	some	pain	conditions,	but	
discounted	these	as	inappropriate	for	PDN.	
“Yeah	I	mean	nerve	root	block	would	be	completely	useless	for	diabetic	peripheral	
neuropathy,	I	mean	I	guess	you	could	conceive	that	an	epidural	might	possibly	be	of	
some	benefit,	but	as	far	as	I'm	aware	there's	absolutely	no	evidence	for	it.”	Pain	
Consultant	1.	
5.4.2.1	Subtheme:	PDN	in	PMPs	
This	subtheme	contained	clinicians’	views	on	whether	PMPs	as	currently	formulated	were	
appropriate	for	PDN.	Clinicians	who	delivered	PMPs	had	two	perspectives:	1)	there	were	
differences	in	PDN	that	needed	considering	and	2)	the	need	for	pain	management	should	be	
based	on	the	person	not	the	pathology.	These	were	speculative	because,	as	mentioned,	clinicians	
in	PMPs	had	seen	very	few	people	with	primary	PDN	referred	to	their	services,	and	diabetes	
clinicians	had	little,	if	any,	direct	experience	of	the	kinds	of	physical	and	psychological	strategies	
deployed	in	PMPs.		
“I	know	very	few	people	that	have	gone	through	[PMPs]	with	primary	neuropathic	
pain	and	that’s	very	interesting	and	I	don’t	know	why	that	is,	but	we	don’t	seem	to	
see	them	very	much.”	Physiotherapist	2.	
Clinicians	were	aware	neuropathic	conditions	were	often	spontaneous	in	pattern,	rather	
than	related	to	activity.	They	therefore	questioned	how	relevant	some	strategies	of	PMPs	were	
that	focussed	on	activity	patterns.	
“There	is	also	a	sense	in	which	‘how	can	our	exercise	programme	impact	on	that	
[PDN],	when	this	pain	is	not	particularly	activity-induced?’	So	there	is	that	other	
challenge	now,	from	my	perspective	I	understand	that	these	nervy	kind	of	
unpleasant	sort	of	neuropathic	neuropathies	can	be	impacted	by	stress	levels,	
autonomic	arousals,	all	those	things.”	Psychologist.	
Similarly,	one	diabetes	consultant	felt	most	of	the	PMP	strategies	presented	could	be	
useful,	but	questioned	how	Patterns	of	activity	(Appendix	6),	could	make	much	difference	to	a	
person’s	experience	of	PDN.	
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“They’re	all	[strategies]	really	relevant	I	would	have	thought	-	‘patterns	of	activity’	I	
don't	know	how	much	difference	that	actually	makes”	Diabetes	Consultant	4.	
In	a	counter	viewpoint,	clinicians	considered	the	mechanism	for	someone’s	pain	was	
immaterial,	if	they	had	persistent	pain	then	many	of	the	management	strategies	could	be	
appropriate.	
“And	I	don't	think	there	will	be	any	difference	between	what	kind	of	pain	
management	programme	would	be	useful	for	somebody	with	diabetic	peripheral	
neuropathy,	or	any	other	type	of	neuropathic	pain,	I	don't	see	their	needs	are	any	
different	from	other	patients	who	are	in	the	pain	management	programme.”	Pain	
Consultant	1.	
“But	I	also	think	that	the	impact	on	their	lives	is	just	as	significant	as	somebody	
who’s	had	a	big	accident,	or	they	may,	the	reason	they	may	see	me	is	because	they	
have	diabetes	but	they	also	happen	to	have	had	something	else	stressful	that’s	
happened	to	them.	So	all	those	things	that	happen	to	a	musculoskeletal	patient	
could	happen	to	a	diabetic	patient,	like	loss	of	earnings.”	Pain	Consultant	2.	
Pain	clinicians	did	not	feel	it	appropriate	to	base	treatment	on	a	person’s	assumed	pain	
physiology,	as	even	pain	that	appeared	related	to	tissue	damage	(nociceptive	mechanism)	would	
have	increasing	contributions	from	neuropathic	and	central	pain	mechanisms.	
“Whatever	the	original	cause	of	that	pain,	whether	it	was	purely	a	nociceptive	cause	
like	a	back	problem,	they'd	have	had	it	for	so	long	that	it	would	have	become	
neuropathic	in	nature	because,	you	know,	the	pain	will	have	become	centralised	
which	is	by	definition,	I	think	anyway,	neuropathic.	So	I	don't	think	there's,	erm,	a	
great	deal	of	difference.”	Pain	Consultant	2.	
Overall,	there	were	two	perspectives	from	clinicians,	1)	that	people	with	PDN	have	some	
differences	in	presentation	and	hence	need	different	consideration	of	management	strategies,	
versus	2)	pain	and	the	impacts	it	has	should	be	assessed	individually	and	not	dictated	by	
diagnostic	label.	As	this	final	quote	from	the	Psychologist	interviewed	suggests,	it	was	important	
to	remember	the	person	at	the	centre	of	the	impacts,	rather	than	the	disease	process:	
“I	think	the	reason	we	don't	get	many	for	pain	management	with	diabetic	
neuropathy	[pause]	is	a	fatalistic	sense	with	the	diabetologists	that	it’s	all	part	of	
your	diabetes.”	Psychologist.	
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5.5	Superordinate	theme:	Potential	for	improved	management	of	PDN?	
This	superordinate	theme	(Figure	17)	contained	three	themes:	Navigation	to	PMP	
described	how	patients	might	find	their	way	through	the	health	service	to	PMPs;	Learning	to	
Manage	described	clinicians’	perspectives	on	strategies	they	felt	useful	for	managing	and	living	
with	PDN.	Lastly,	clinicians’	considerations	for	developing	specific	PMPs	for	PDN	-	Potential	for	
PDN	PMP.	Theme	Learning	to	manage	contained	five	subthemes:	Getting	some	rest	and	
relaxation;	Patient	coping	skills;	Managing	spontaneous	pain;	Management	through	physical	
activity	and	Management	of	mood.		
Figure	17	-	Potential	for	improved	management	of	PDN?	
	
5.5.1	Theme:	Navigation	to	PMP	
In	order	to	access	a	PMP	clinicians	need	to	first	consider	this	approach	as	a	clinical	option.	
Diabetes	clinicians	were	not	necessarily	familiar	with	pain	management	approaches,	or	of	the	
existence	or	relevance	of	their	local	PMPs.		
‘Yeah,	and	after	that	[medication	management]	I	don’t	know	where	to	go.”	Diabetic	
Specialist	Nurse	1.	
Others	were	aware	of	PMPs	but	had	to	refer	the	patient	back	to	primary	care	and	leave	the	
decision	on	further	management	to	the	discretion	of	the	GP.	Local	care	pathways	did	not	specify	a	
point	at	which	patients	might	be	referred	to	a	PMP.		
“I	suppose	it’s	not	clear,	I	don't	think,	easily	how	we	might	access	them	[PMPs]	
referral	pathways	of	ease	to	them	it	would	be	something	to	put	on	this	integrated	
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care	pathway	[BNSSG	DM	management	document]	if	there	was	a	clear	mandate	to	
say	‘yes,	we’ll	take	these	patients’.”	Diabetes	Consultant	3.	
Secondary	care	pain	specialists	highlighted	navigation	was	not	straightforward	for	patients	
or	other	clinicians	in	secondary	care.	They	had	rarely	received	referrals	direct	from	diabetes	
clinics	and	acknowledged	patients	often	had	to	be	referred	by	primary	care.		
“…a	diabetic	specialist	wouldn't	have	direct	access	to	our	pain	management	
programme,	so	they	would	have	to	go	probably	back	to	the	GP	and	back	in.”	
Psychologist.	
“I	don't	think	I've	ever	had	one	from	a	diabetic	clinic,	I've	only	ever	had	them	from	
GPs.”	Pain	Consultant	4.	
Some	pain	clinicians	highlighted	exclusion	criteria	for	PMPs	often	include	progressive	
diseases.	Clinicians	raised	the	issue	because	PDN	would	fit	this	exclusion	criterion	if	it	were	strictly	
applied.		
“One	of	these	absolute	criteria,	the	patient	does	not	have	malignant	disease	or	
progressive	degenerative	diseases	such	as	ankylosing	spondylitis	or	rheumatoid	
arthritis.	And	quite	a	lot	of	us,	including	me,	have	a	slight,	I	slightly	disagree	with	
that,	because	you	could	put	diabetics	into	that	group	as	well,	because	it’s	a	
progressive	disease.”	Pain	Consultant	2.	
5.5.2	Theme:	Leaning	to	manage	
This	theme	contained	five	subthemes.	Each	of	these	subthemes	captured	the	clinicians’	
perspectives	on	wider	strategies	for	managing	PDN.	Clinicians	felt	patients	needed	help	to	
manage	sleep	and	stress	(Getting	some	rest	and	relaxation)	and	spontaneous	symptoms	
(Managing	spontaneous	pain).	They	also	felt	that	patients	needed	help	to	develop	coping	skills	
(Patient	coping	skills).	Lastly,	clinicians’	perspectives	of	physical	activity	and	psychological	coping	
as	strategies	have	been	brought	together	in	two	subthemes	-	Management	through	physical	
activity	and	Management	of	mood.	
5.5.2.1	Subtheme:	Getting	some	rest	and	relaxation	
When	considering	potential	non-pharmacological	management	strategies,	the	inclusion	of	
strategies	to	improve	sleep	and	manage	fatigue	was	felt	vital.		
“You	know	strategies	for	sleep	I	probably	would	put	that	1	or	number	2,	it	is	the	
thing	that	most	of	my	patients	complain	about.	[…]	a	question	I	often	ask	patients	is	
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‘If	I	could	wave	a	magic	wand	and	get	rid	of	one	of	your	pains	at	any	one	time	what	
would	it	be?’	and	they	almost	all	universally	say	‘I’d	like	a	better	night’s	sleep’.	So	
sleep	is	a	big	deal”	Diabetes	Consultant	1.	
“…strategies	for	sleep	would	certainly	be	helpful	because	very	often	that	is	what	
keeps	them	awake	at	night	[…]	you	cannot	manage	when	you’re	sleep	deprived.”	
Research	Nurse	1.	
Clinicians	were	aware	sleep	and	fatigue	were	not	synonymous.	They	were	aware	fatigue	
could	be	an	initial	presenting	symptom	of	diabetes,	and	fatigue	was	a	potential	warning	sign	of	
both	hypo-	and	hyperglycaemic	states.	
“Sometimes	presenting	with	fatigue	is	one	of	the	first	things	is	the	way	people	get	
diagnosed	in	the	first	place,	so	I	think	I	would	stuff	something	in	there	about	fatigue	
management.”	Psychologist.	
They	were	aware	of	research	and	clinical	approaches	from	other	medical	areas	indicating	
fatigue	management	could	be	useful	for	their	patients.	
“I	think	there’s	a	lot	of	stuff	that	I've	heard	coming	out	of	rheumatology	is	that	the	
rheumatologists	are,	have	been	asking	about	symptom	sets	of	people	with	
rheumatoid	pain.	And	actually,	the	thing	that	is	the	top	of	the	list	is	not	pain,	it’s	
fatigue.”	Pain	Consultant	2.	
Clinicians	were	aware	that	stress	further	aggravated	the	impact	of	PDN	on	patients,	stress	
could	exacerbate	the	pain	and	pain	itself	was	stressful.	Responses	to	stress	often	incorporated	
choices	of	food,	which	may	not	be	beneficial	to	overall	diabetes	management.	
“There	is	that	other	challenge	now,	from	my	perspective	I	understand	that	these	
nervy	kinds	of	unpleasant	sort	of	neuropathic	neuropathies	can	be	impacted	by	
stress	levels,	autonomic	arousals,	all	those	things.”	Psychologist.	
“I	will	certainly	discuss	with	patients	about	stress	management,	in	particular	with	
type	2s’	in	relationship	to	food,	I	do	a	little	bit	of	that	work	with	them	because	very	
often	people	choose	food	to	manage	their	stress.”	Research	nurse	1.	
In	order	to	manage	stress,	clinicians	felt	relaxation	strategies	such	as	breathing	practice	or	
mindfulness	could	be	appropriate.	
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“You	know,	if	focusing	on	breathing	can	help,	then	in	the	middle	of	the	night	that	
might	be	a	useful	thing	to	do.”	Diabetic	Specialist	Nurse.	
“I	think	for	pain	management,	if	you’ve	got	bandaged	feet	but	you	can	still	go	onto	
a	mat	and	do	relaxation	exercises.”	Pain	Consultant	2.	
“We	do	relaxation,	we	don't	do	a	mindfulness-based	programme,	but	we	do	use	
mindfulness	based	language	sometimes,	[…]	if	that	was	on	someone’s	flare-up	plan	
as	part	of	a	way	of	managing	a	flare-up,	that	would	be	useful.”	Physiotherapist	1.	
Clinicians	were	aware	of	the	complex	interplay	between	pain	symptoms,	stress,	lack	of	
sleep,	feeling	fatigued,	sensations	of	blood	glucose	level	and	management	of	diabetes	generally.	
They	were	clear	these	interactions	were	not	linear	and	that	if	one	strategy	did	not	succeed	in	
helping	the	patient	to	cope,	then	other	strategies	needed	to	be	explored.	
5.5.2.2	Subtheme:	Managing	spontaneous	pain	
A	hallmark	of	predominantly	neuropathic	pain	from	the	literature	and	from	the	patient	
interviews	was	the	unpredictable	pattern	of	symptoms.	Clinicians	recognised	this	pattern	could	
lead	patients	to	avoid	potentially	aggravating	pain	but	this	had	consequences	for	reducing	activity	
and	function.	
“I	don’t	know	how	widespread,	fear	avoidance,	fear	of	damage	is	for	people	with	
diabetic	neuropathy,	because	I	don’t	work	with	them	I	don’t	know	how	common	it	
is,	I	wonder	if	that	might	be	a	difference.	[…]	Yes.	That	there	may	almost	be	a	value	
of	saying	well	let’s	do	non-weight	bearing	or	reduced	weight	bearing	exercise.”	
Physiotherapist	2.	
Clinicians	were	aware	PMPs	tended	to	advocate	pacing	as	a	strategy	to	minimise	
aggravation	of	pain	by	activity,	with	the	aim	of	giving	control	back	to	the	person	experiencing	the	
pain.	They	suggested	these	strategies	were	less	likely	to	be	successful	with	spontaneous	or	
paroxysmal	pain.	
“But	one	of	the	things	that	pain	management	is	sort	of	predicated	on	is	that	if	you,	
stay	within	your	limits	and	gradually	work	towards	goals	that	things	will	improve	
and	actually	with	that	sort	of	...	paroxysmal	pain	then	actually	that	sort	of	
incremental	benefit	doesn’t	really	accrue.”	Pain	Consultant	3.	
Indeed,	some	clinicians	who	had	experience	of	people	with	neuropathic	pain	on	their	PMPs	
reported	that	patients	had	told	them	pacing	did	not	work.	
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“he	was	saying	“you	know	I’ve	paced	myself,	it	makes	no	difference,	I	can	have	a	
good	day	I	can	have	a	bad	day	it	doesn’t	seem	to	relate	to	my	activity	very	much.”	
Physiotherapist	2.	
5.5.2.3	Subtheme:	Patient	coping	skills	
Clinicians	felt	potential	clinical	services	needed	to	emphasize	patient	responsibility	in	
managing	their	experience	of	PDN.	They	were	aware	that	peoples’	approaches	to	health	
responsibility	varied.	
“…acknowledging	and	taking	responsibility	for	their	own	health	and	choices,	trouble	
is	I	see	a	lot	of	passengers”	[here	the	clinician	is	referring	to	a	patient	who	takes	a	
passive	approach	to	self-management,	as	opposed	to	active	(a	“driver”)].	Diabetes	
Consultant	3.	
In	addition	to	varying	levels	of	responsibility,	patient’s	ability	to	then	self-manage	health	
conditions	could	vary,	dependent	on	intrinsic	and	extrinsic	factors.	
“A	lot	of	what	we	do	is	try	to	help	people	manage	their	condition	and	manage	their	
lives	more	broadly,	you	know	their	condition	is	part	of	their	life	and	their	life	impacts	
upon	their	condition,	so	quite	often	in	general	practice	we	accompany	people	
through	their	journey.”	GP.	
	‘Acceptance’	was	often	used;	patients	had	to	accept	they	had	diabetes,	they	had	to	accept	
the	need	to	make	diet	and	lifestyle	changes	and	accept	the	need	to	manage	their	PDN.	Specialist	
pain	clinicians	raised	acceptance	as	an	on-going	process,	not	a	destination.	
“You	do	a	lot	of	acceptance	work	with	people	with	pain,	they	have	to	accept	that	
they	have	a	pain	condition	in	order	to	build	in	strategies	and	it’s	very	similar	around	
diabetes.	So,	from	that	point	of	view	it	could	be	helpful,	it	could	allow	people	to	
explore	those	difficulties.”	Physiotherapist	1.	
Some	pain	clinicians	did	identify	possible	differences	between	accepting	diabetes,	a	clearly	
defined	disease	process,	and	accepting	persistent	pain,	which	is	often	considered	a	symptom	of	a	
pathology	not	yet	diagnosed.	
“I	suspect	a	lot	of	diabetic	people,	even	if	they	haven’t	managed	it	very	well,	have	
had	to	accept	they’ve	got	to	live	with	it	[DM]	because	it’s	not	going	to	go	away.	
Whereas	a	lot	of	pain	patients	are	still	looking	for	an	answer.	[…]	The	problem,	and	I	
wonder	if	the	diabetic	people	are	probably	better	at	acceptance	because	they	know	
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what	they’ve	got	[DM],	whereas	a	chronic	widespread	pain	condition	is	quite	hard	
to	get	people	to	accept.”	Pain	Consultant	2.	
Support	from	other	people	was	considered	vital	for	effective	self-management.	Clinicians	
suggested	that	people	with	PDN	often	felt	isolated,	both	physically	due	to	mobility	restrictions	
and	emotionally	knowing	no	one	else	with	similar	problems.		
“I	am	sure	it	would	be	beneficial,	it	[PDN]	can	be	incredibly	isolating	and	the	kind	of	
people	who	get	it	tend	to	feel	they	are	very	isolated	anyway,	they	are	often	the	
older	people.”	Diabetes	Consultant	4.	
The	clinicians’	awareness	of	patient’s	isolation	and	possible	lack	of	support	reflect	similar	
themes	identified	in	the	patient	interviews.	Support	to	mitigate	isolation	could	come	from	family	
and	friends.	
“I	mean	if	you	were	managing	all	of	this	without	any	support	at	home	then	that’s	
hard	too	isn’t	it	[…]	it’s	actually	thinking	well	friendship	supports	or	family	supports	
maybe	that’s	important.”	Practice	nurse.	
“the	ones	[patients]	who	do	better	are	the	ones	who	have	family	and	support,	the	
ones	who	don't	do	very	well	are	the	ones	who	don't	want	to	engage	at	all,	so	they	
don't	have	any	family	or	support.”	Podiatrist	1.	
Clinicians	shared	the	view	of	participants	in	the	patient	interviews,	that	peer-support	from	
other	people	with	PDN	was	possibly	viewed	as	more	trustworthy	than	advice	from	professionals	
with	no	personal	experience.	
“Which	may	actually	work	better	is	somebody	with	diabetes	who’s	had	experience	
of	the	whole	of	the	condition	and	all	that	that	entails,	managing	their	diet,	
managing	injections	for	example,	dealing	with	those	tussles	between	do	I	eat	a	bit	
more,	what’s	the	impact	of	that	and	all	of	that	psychological	challenge.	Am	I	good,	
am	I	bad,	who	is	in	charge	is	it	the	diabetes,	or	is	it	me?”	Physiotherapist	2.		
“It’s	better	that	they	hear	from	other	patients	rather	than	professionals	[laughs]”	
Research	nurse	1.	
5.5.2.4	Subtheme:	Management	through	physical	activity	
All	clinicians	interviewed	considered	increasing	physical	activity	levels	would	be	useful	for	a	
multitude	of	reasons.	They	identified	that	patients	often	left	the	house	less	frequently	than	
before	PDN,	had	reduced	specific	physical	activity	and	had	fewer	social	engagements	that	
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included	physical	activity.	They	had	often	become	less	physically	fit.	These	changes	to	activity	
level	made	overall	diabetes	management	more	complicated.	The	loss	of	fitness	could	further	
impact	on	other	complications	and	co-morbidities	the	patient	experienced.	
“But	that	said	I	certainly	think	that	some	form	of	physical	rehabilitation	is	
important,	a	lot	of	the	patients	I	see	tend	to	become	more	and	more	constricted	and	
more	and	more	house	bound	because	they	don't	do	things	because	they	are	worried	
it	will	trigger	their	pain.”	Diabetes	Consultant	1.	
	“Somebody’s	got	cardiovascular	problems	because	of	their	diabetes,	like	angina,	
and	they	can’t	exercise,	and	actually	part	of	their,	part	of	pain	management	is	
trying	to	get	some	sort	of	physical	activity,	that	would	be	a	barrier,	but	that	would	
be	the	same	for	a	lot	of	our	patients.”	Pain	Consultant	2.	
Clinicians	recognised	being	more	physically	active	and	increasing	the	variety	of	day-to-day	
activities	patients	could	then	engage	in,	would	likely	benefit	the	person’s	mood	state.	This	would	
have	the	additional	benefit	of	reducing	the	focus	on	pain,	by	introducing	distraction	through	
engagement	and	occupation.		
“That	by	exercising	alright	won’t	do	them	any	harm,	in	fact	it	may	well	do	them	
good	both	physically	and	psychologically,	so	empowering	people	to	live	normal	
lives.”	GP.	
“Just	doing	something	can	actually	improve	your	mood	and	make	you	feel	as	though	
you've	achieved	doing	something	because	these	patients	very	often	feel	‘I	definitely	
cannot	do	it’,	‘I	cannot	do	it	because	of	the	pain’,	and	whereas	if	you	say	have	you	
tried	this	and	they	can	actually	do	something	it	might	make	them	feel	like	of	‘oh,	
that's	really	good	actually’”.	Research	Nurse	1.	
Some	clinicians	specifically	felt	exercise	would	increase	blood	supply	to	areas	of	the	body	
where	it	was	compromised	due	to	cardiovascular	disease.	They	also	identified	the	release	of	
endogenous	opioids	caused	by	moderate	exercise	could	improve	overall	sense	of	wellbeing.		
“It’s	very	difficult	to	get	them	out	[being	more	active]	which	would	be	helpful	
because	it	would	help	their	circulation,	their	whole	being.”	Podiatrist	1.	
“Exactly,	endorphins	after	exercise	and	feeling	better	about	themselves.”	Research	
Nurse	2.	
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Although	clinicians	identified	potential	benefits	of	increasing	physical	activity,	diabetes	
clinicians	expressed	specific	cautions.	The	medical	consultants	stressed	diabetes	affected	many	
physiological	systems,	which	led	to	more	complex	medical	presentations	than	maybe	usual	in	
PMPs.		
“I	think	physical	activity	has	to	be	very	carefully	thought	out,	it	would	be	unwise	to	
say	to	them	‘get	out	on	a	bike’,	might	be	alternative	ways	like	swimming”.	Diabetes	
Consultant	2.	
“So	I	think	it’s	about	context	and	saying	‘What	do	we	genuinely	think	we	can	get	the	
patient	back	to?’	in	other	words,	‘What	degree	of	their	immobility	or	lack	of	physical	
activity	is	directly	due	to	the	pain	as	compared	to	their	other	co-morbidities?’”	
Diabetes	Consultant	1.	
Diabetes	clinicians	were	specifically	concerned	about	the	risks	increasing	physical	activity	
could	pose	to	someone	with	insensate	feet.	They	worried	patients	might	be	encouraged	to	
increase	activity	levels	without	being	reminded	of	the	need	for	due	care	of	their	feet	and	checking	
footwear	was	appropriate	to	avoid	ulceration.	It	should	be	noted	that	none	of	the	diabetes	
clinicians	had	any	direct	experience	of	observing	PMPs	being	delivered.	
“I	think	one	just	has	to	be	a	bit	circumspect	in	pushing	activity,	because	I’ve	seen	in	
other	areas	of	diabetic	neuropathy	people	inadvertently	say	‘well,	you	need	to	do	
more’	and	then	the	patients	come	with	foot	damage	because	of	following	
recommendations	and	doing	more	but	damaging	their	skin	and	then	ending	up	with	
problems.”	Diabetes	Consultant	3.	
“I	think	that's	a	great	idea,	my	only	concern	with	our	patients	is	that	most	of	them	
don't	have	any	protective	sensation,	so	they	are	at	massive	risk	of	ulceration.”	
Podiatrist	2.	
Diabetes	clinicians	questioned	the	difficulties	present	for	patients	to	engage	with	the	
increasing	their	physical	activity.	These	difficulties	included	the	interactions	present	between	
activity	levels,	mood	state,	obesity	and	others	in	society.	
“Sometimes	their	willingness	to	accept	it	because	when	people	are	very	depressed	
all	they	want	to	do	is	cocoon	themselves	somewhere	rather	than	necessarily	go	to	
the	gym	with	their	BMI	of	50	and	expose	themselves	to	strangers,	so	is	lots	of	other	
issues	around	why	people	do	not	want	to	be	active”.	Diabetes	Consultant	2.	
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They	felt	it	also	depended	on	whether	patients	were	adept	at	self-managing	their	condition	
and	the	complications	that	may	come	with	it.	
“…not	easily,	not	easily,	I	think	sometimes	it	depends	whether	they	are	a	passenger	
or	a	driver.”	Diabetes	Consultant	3.	
	In	contrast,	the	clinicians	who	were	actively	involved	in	PMPs	(physiotherapists	and	
psychologist)	or	referred	to	such	programmes	(pain	consultants)	did	not	share	the	concerns	about	
the	risks	of	increasing	a	person’s	activity	level.	Physiotherapists	described	how	physical	activity	
was	introduced	and	used	in	PMPs.	They	described	how	each	person	was	individually	assessed	to	
find	a	baseline	for	each	of	the	exercises.	These	exercises	were	functional;	they	aimed	to	replicate	
some	part	of	daily	movement.	The	overall	aim	was	to	gradually	increase	physical	capacity.	
“Absolutely	completely	and	utterly	that's	the	basis	of	it,	it’s	not	random	shoulder	
exercises	and	they’re	not	aimed	at	curing	anything,	they’re	aimed	at	improving	
overall	activation,	reversing	deconditioning	that	has	happened.”	Psychologist.	
“…they	can	be	modified	as	well,	so	I	suppose	the	bottom	line	is,	you	know,	even	if	
it’s	difficult	you	can	always	do	a	small	amount	of	one	or	you	can	do	it	in	a	different	
way,	so	there’s	always	a	way	of	developing	that	exercise	programmes.”	
Physiotherapist	1.	
Focussing	on	the	risks	specific	to	insensate	feet,	these	clinicians	felt	they	were	aware	of	the	
dangers	and	the	assessment	required	to	optimise	safety.	They	considered	the	activity	component	
of	PMPs	could	be	adapted	to	the	needs	of	this	population.	
	“In	fact,	the	exercises	are	no	different	than	daily	functional	tasks,	[…]	it’s	all	part	of	
our	normal	movement,	so	in	terms	of	the	worry	about	damage,	that	wouldn’t	be	a	
worry	that	I’d	necessarily	have.	Obviously,	if	people	had	open	ulcers	…”	
Physiotherapist	1.	
“Is	one	form	of	exercise	more	useful	than	another,	but	if	they’re	saying	I	have	
problems	weight	bearing	is	it	actually	helpful	to	see	that	at	face	value	and	say	‘okay	
let’s	do	some	non-weight	bearing	exercise’	in	a	way	that	we	just	wouldn’t	do	in	a	
pain	management	programme.”	Physiotherapist	2.	
Clinicians	were	also	cognizant	of	the	need	to	check	footwear	was	appropriate	and	check	
feet	before	and	after	any	form	of	exercise.	They	were	aware	patients	were	taught	and	reminded	
of	these	checks	frequently	by	diabetic	specialist	clinicians	and	felt	strongly	these	checks	were	
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integral	to	the	patients’	responsibilities	for	managing	their	diabetes.	These	checks	were	
considered	part	of	the	patient’s	self-management.	
“…they’ve	been	told	all	the	time	that	they’ve	got	to	look	after	their	feet	because	
they	might	be	numb	and	that	they’ve	got	to	prevent	themselves	getting	foot	
ulceration	and	things”	Diabetes	Consultant	4.	
“It	would	be	perfectly	reasonable	to	encourage,	as	part	of	self-care	that	people	
should	[check	their	feet],	but	whether	it’s	before	they	do	specific	exercise	or	whether	
it	is	part	of	what	they	do	every	morning,	I	would	have	thought	it	is	part	of	what	you	
should	be	doing	every	morning?”	Psychologist.	
5.5.2.5	Subtheme:	Management	of	mood	
As	highlighted	in	Section	5.3,	clinicians	were	aware	PDN	was	associated	with	worsening	
depression	and	anxiety	states.	Clinicians	from	both	diabetes	and	pain	specialities,	and	from	
primary	care	considered	psychological	support	would	have	a	beneficial	role	with	people	who	have	
PDN.	
“But	psychologically	there’s	definitely	a	need	for	them,	just	as	there	is	for	any	
patient	who’s	struggling	to	cope	with	their	pain.”	Pain	Consultant	2.	
“Of	course	it’s	really	important	to	look	at	the	psychological	aspects	because	two	
people	can	have	apparently	the	same	pathological	or	an	anatomical	problem.”	GP.	
One	consultant	compared	the	difference	between	staffing	in	adult	and	paediatric	diabetes	
clinics.	The	inclusion	of	clinical	psychologist	support	was	common,	if	not	universal,	in	paediatric	
and	adolescent	clinics.	Other	than	the	stress	of	managing	a	long-term	health	condition	at	a	young	
age,	this	was	a	time	when	young	people	with	diabetes	were	least	likely	to	have	additional	
complications	to	deal	with.	Once	in	adult	clinics	the	access	to	psychological	support	becomes	
much	more	restricted	and	difficult	to	access.		
“I	think	what	we	are	lacking	for	not	just	here	but	nationally	is	a	good	and	robust	
service	that	will	offer	psychological	help	to	people	in	chronic	disease	in	general	and	
diabetes	in	particular.	It’s	funny	though	you	would	not	find	a	paediatric	hospital	
where	there	isn’t	a	clinical	psychologist	on	the	team	for	patients	with	diabetes.”	
Diabetes	Consultant	2.	
Clinicians	described	improvement	in	depression	could	lead	to	subsequent	improvement	in	
function,	quality	of	life	and	overall	diabetes	management.	
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“It	gives	me	a	better	understanding	if	I	know	something	about	their	depression,	how	
they’re	going	to	be	able	to	self-manage	and	make	any	changes.	It’s	no	point	to	ask	a	
patient	to	make	any	changes	if	they’re	not	in	the	right	place	and	not	able	to	do	so.”	
Research	nurse	1.	
“and	a	lot	of	people	suffer	with	depression	with	their	diabetes	as	well	I’d	say	the	
majority	of	patients	they	come	to	us	and	they	are	depressed	and	comfort	eat,	adds	
onto	weight.”	Research	nurse	2.	
Goal	setting	was	highlighted	as	important	by	physiotherapists.	Physiotherapists	would	
often	use	individualised	goal	setting	with	patients	to	help	them	achieve	something	and	so	manage	
depression.	
“So	moving	into	a	cognitive	behaviour	approach	was	more	rehabilitation	based	was	
more	goal	focussed	which	isn’t	directly	about	the	experience	it’s	about	moving	
forwards	with	life.”	Physiotherapist	2.		
5.5.3	Theme:	Potential	for	PDN	Pain	management	programmes	
Clinicians	provided	some	considerations	for	how	PDN-specific	PMPs	might	be	used	or	fit	
into	the	existing	clinical	pathways.	It	should	be	highlighted	these	were	suppositions,	as	they	had	
no	experience	of	such	a	programme	specifically	for	people	with	PDN.	
Overall,	there	were	positive	opinions	that	PMPs	could	be	useful	in	helping	people	to	cope	
better	with	the	impacts	of	PDN.		
“I	think	everything	[strategies]	on	there	would	actually	be	really	useful.”	Research	
nurse	1.	
“All	of	them	[strategies]	are	relevant	every	single	one	of	them”	Podiatrist	1.	
Clinicians	did	not	feel	a	programme	could	replace	drug	therapy,	but	it	could	be	used	
alongside	medication.	
“I	think	probably	I	mean	you	wouldn't	want	it	after,	because	it	will	help	you	cope	
with	what	the	drugs	can	achieve,	and	I	don't	think	it	would	probably	be	a	substitute	
for	the	drugs…”	Diabetes	Consultant	4.	
They	did	feel	a	programme	more	likely	to	be	effective	if	delivered	earlier,	rather	than	later,	
in	the	development	of	PDN.	
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“I	sometimes	think	that	the	people	we	get	here	it’s	almost	too	late	for	some	of	these	
things,	they	are	kind	of	too	far	gone	to	have	effective	interaction	with,	in	terms	of	
psychology.’	Podiatrist	2.	
They	considered	a	potential	programme	would	not	be	necessary	for	everyone,	but	targeted	
to	those	people	who	were	struggling	to	cope	with	their	pain,	its	impacts	and	other	events	that	
were	on-going	in	their	life.	
“I	would	say	probably	glove	and	stocking	distribution	pain,	neuropathic	pain,	but	
with	quite	a	lot	of	lacking,	so	they’re	lacking	in	coping	mechanism.	So,	they’ll	have	
other	baggage	around	that,	it’ll	either	be,	you	know,	it’s	usually	a	combination	of	
factors,	it’s	either	financial	difficulties	and	family	difficulties,	or	anger	management	
difficulties	or	things	which	are	allowing	them	to	now,	which	are	not	enabling	them	
to	cope	with	their	pain.	So,	levels	of	distress	that	are	high,	not,	so	it’s	not	likely	to	
just	be	diabetes	and	pain,	there’s	likely	to	be	other	things	going	on.”	Pain	
Consultant	2.	
It	should	also	be	considered	whether	the	person	was	at	a	point	where	they	were	ready	to	
make	behavioural	changes	for	PDN	management.	These	patient	perspectives	can	change,	and	on-
going	reassessment	maybe	required.	
“Some	patients	if	you	just	suggest	to	them	that	what	they	would	benefit	from	is	a	
pain	management	programme	when	you	first	meet	them	you	will	just	fail	because	
they	won't	...	they're	not	ready	to	accept	that.”	Pain	Consultant	2.	
“Some	patients	go	‘oh,	I	don't	think	I	like	the	sound	of	that	[PMP],	that's	not	for	me,	
I	want	a	treatment	for	my	pain’,	many	of	them	are	far	more	pragmatic	and	
reasonable,	particularly	once	they	have	seen	me	in	clinic	a	number	of	times	and	they	
know	I’m	at	the	end	of	the	road.”	Diabetes	Consultant	1.	
5.6	Discussion	
A	range	of	secondary	care	clinicians	who	were	specialists	in	diabetes	and	pain	
management,	and	clinicians	from	primary	care	were	interviewed	for	this	study.	All	clinicians	were	
aware	of	the	variety	of	impacts	living	with	PDN	can	have	on	peoples’	lives.	The	primary	strategy	
identified	was	prescription	of	analgesic	medications,	or	referral	to	a	clinician	who	could	prescribe.	
When	these	medications	failed,	there	was	uncertainty	around	alternative	management	strategies.	
Pain	specialist	clinicians	felt	that	PMPs	could	be	adapted	to	the	specific	needs	of	people	with	PDN.	
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When	considering	the	applicability	of	PMP	strategies	to	PDN,	there	were	differing	perspectives	
between	groups	of	specialist	clinicians,	which	will	be	explored	in	this	discussion.	
5.6.1	Clinical	impotence	
Some	clinicians	identified	they	did	not	ask	sufficiently	probing	questions	around	PDN	
symptoms.	This	was	usually	either	because	the	clinical	focus	of	their	consultations	was	another	
facet	of	diabetes	management,	or	they	knew	the	patient	had	PDN,	but	had	exhausted	all	
medication	options	and	so	did	not	ask	because	they	had	no	alternative	management	strategies.	
This	issue	may	not	be	specific	to	PDN	as	there	have	been	calls	in	medicine	for	improved	
consistency	and	depth	of	pain	assessments	(Ballantyne	and	Sullivan,	2015).	As	persistent	pain	of	
many	causes	has	become	more	prevalent	and	increasingly	costly	to	the	person,	health	care	
systems	and	society,	clinicians	have	been	advised	to	consider	pain	as	the	fifth	vital	sign,	along	
with	blood	pressure,	temperature,	heart	and	breathing	rate	(Gatchel	et	al.,	2007;	Ballantyne	and	
Sullivan,	2015).	Guidance	suggested	better	measurement	would	lead	to	better	management,	and	
self-report	scales	(NRS	or	VAS)	were	the	most	appropriate	assessment	tools	(Schiavenato	and	
Craig,	2010).	A	reduction	of	self-reported	pain	severity	then	becomes	the	aim	of	treatment.	
Researchers	now	suggest	however	that	reliance	on	self-report	scales	is	not	appropriate	as	they	
not	sufficiently	nuanced	to	allow	the	patient	to	communicate	their	experience	(Schiavenato	and	
Craig,	2010).	Ballantyne	and	Sullivan	(2015),	in	their	recent	editorial,	highlight	the	meaning	
patients	attribute	to	pain,	including	the	sense	of	helplessness	and	hopelessness	can	have	large	
impacts	on	peoples’	lives.	These	features	of	peoples’	experience	of	living	with	pain	related	to	
PDN,	and	the	issue	with	questionnaire-based	research,	have	been	explored	in	Chapter	4.		
Pain	assessments	are	complex	interactions;	researchers	have	advanced	a	model	of	the	
clinical	encounter	that	allows	considering	the	ways	through	which	thorough	assessment	of	PDN	
could	succeed	or	fail	(Schiavenato	and	Craig,	2010).	The	model	(Figure	18)	highlighted	that	
patients	must	attribute	meaning	to	their	experience,	and	this	meaning	differs	with	social	and	
cultural	context;	this	has	clear	concordance	with	the	MOM	and	Neuromatrix	models	outlined	in	
Chapter	1	(Gifford,	1998b;	Melzack,	2001).	Patients	have	to	express	their	experience	by	means	of	
verbal,	facial	and	non-verbal	communication	cues.	The	clinician	needs	to	assess	and	interpret	
these	cues	prior	to	making	clinical	judgements.		
To	this	point,	Schiavenato	and	Craig	(2010)	describe	the	process	as	‘communication-as-
interaction’,	two	participants	in	a	clinical	relationship	gaining	an	understanding	of	the	problem.	
They	term	the	next	step	where	an	intervention	or	treatment	occurs	as	‘communication-as-
transaction’.		
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Figure	18	-	Pain	assessment	as	a	transaction,	from	Schiavenato	and	Craig	(2010),	(reproduced	with	
permission)	
	
The	model	shown	above	contains	a	number	of	features	relevant	to	the	current	clinician	
interview	study.	The	vertical	line	Trust-Security	highlights	the	balance	between	patient’s	
expression	of	pain	by	non-verbal	and	verbal	means	and	the	clinician’s	assessment.	Individual	
clinicians	are	on	a	spectrum	between	an	empathic	and	sceptical	stance;	if	a	patient	believes	a	
clinician	to	be	sceptical	of	their	experience,	they	may	increase	their	pain	expression	in	order	to	
emphasise	their	need	for	treatment.	If	a	patient	is	stoical	to	their	pain	experience,	the	clinician	
may	conclude	treatment	of	pain	is	not	indicated.	The	decision	by	the	clinician	to	treat	or	not	to	
treat	pain,	and	how	concordant	that	decision	is	with	the	patient’s	expectations,	is	the	transaction	
in	question.	This	description	of	clinical	relationships	has	resonance	to	the	spectrum	between	
‘connected’	and	‘disconnected’	(Fox	and	Chesla,	2008),	that	were	described	in	Chapter	4,	section	
4.9.2.		
’Assumption	of	mutuality’	describes	the	assumption	that	patients	seek	healthcare	to	reduce	
pain,	and	clinicians	feel	moral	and	ethical	imperatives	to	reduce	pain.	If	the	clinical	pain	
assessment	is	biased	toward	only	using	pain	self-report	measures	because	expectation	of	pain	
reduction	is	assumed	and	so	must	be	measured,	the	patient	may	not	be	allowed	the	opportunity	
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to	disclose	the	impacts	they	truly	would	want	help	to	reduce.	If	clinicians	assume	patients	are	
seeking	pain	reduction,	yet	feel	they	have	no	viable	treatment	options,	the	dissonance	between	
their	moral/ethical	drive	and	their	clinical	treatment	options	may	cause	them	to	divert	away	from	
opening	discussions	around	the	patient’s	PDN	(Schiavenato	and	Craig,	2010).	
Within	their	paper	Schiavenato	and	Craig	(2010)	suggest	one	reason	why	clinicians	do	not	
hear	the	patient	narrative	to	be:	incompetence	or	poor	clinical	knowledge/skills	(Table	1,	pg670).	
The	diabetes	specialist	clinicians	interviewed	in	this	study	did	not	appear	incompetent,	but	some	
felt	clinically	impotent	because,	beyond	medication,	they	had	no	management	strategies	to	offer	
patients	with	PDN.	The	clinicians	in	this	study	were	experienced	in	their	respective	professions.	
Having	reached	a	level	of	expertise,	the	organisational	culture	clinicians	worked	in	may	not	have	
permitted	them	to	admit	there	were	deficits	in	their	knowledge,	or	it	maybe	they	were	not	aware	
of	what	they	did	not	know.		
5.6.2	Differing	concern	about	physical	activity	
The	diabetes	clinicians	interviewed	had	specific	concerns	about	increasing	the	level	of	
physical	activity	in	people	who	had	insensate	feet.	They	were	concerned	that	without	appropriate	
foot	checks	for	patients	and	training	for	clinicians,	tissue	breakdown	may	occur,	leading	to	
ulceration	and	potential	amputation.	The	pain	clinicians	were	aware	of	the	risk	to	insensate	feet	
and	the	need	to	check	feet	regularly;	they	felt	exercise	could	be	individualised	appropriately	to	
patients	with	PDN.	
The	perspectives	of	clinicians	likely	reflect	their	clinical	experience.	Podiatrists	in	secondary	
care	were	managing	people	who	had	critical	tissue	damage	potentially	requiring	amputation.	This	
interview	study	did	not	succeed	in	recruiting	podiatrists	from	primary	care	who	have	a	greater	
role	in	monitoring	people	in	their	caseload,	rather	than	actively	treating	ulceration.	Pain	clinicians	
are	not	exposed	to	people	with	ulceration	in	the	same	way	as	podiatrists.		
Given	the	known	risk,	it	is	surprising	not	all	studies	investigating	physical	activity	in	the	
diabetic	population	routinely	record	or	report	adverse	events	related	to	ulceration	or	skin	lesions.	
For	example	Dixit,	Maiya	and	Shastry	(2014)	investigating	aerobic	exercise	highlight	
considerations	were	made	to	foot	care	and	hypoglycaemia	during	and	after	exercise,	but	made	no	
comment	on	whether	the	participants	experienced	any	foot	injuries	due	to	the	exercise(Dixit,	
Maiya	and	Shastry,	2014).	Toth	et	al.	(2012)	and	Kluding	et	al.	(2012)	reported	adverse	events	
related	to	hypoglycaemia	and	pain	but	none	related	to	foot	damage;	Yoo	et	al.	(2015)	did	not	
report	on	adverse	events.	
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A	recent	non-systematic	review	highlighted	specific	considerations	for	prescription	of	
exercise	in	patients	with	neuropathy	(Colberg	and	Vinik,	2014).	Advice	included:	regular	foot	
checks	and	appropriate	footwear,	‘mild	to	moderate’	intensity	weight	bearing	exercise	(both	
aerobic	and	resistance	based),	low	impact	exercise	(water	walking,	hydrotherapy,	chair	based	
exercise),	non-weight	bearing	exercise	if	current	foot	ulceration	were	present	and	inclusion	of	
balance	challenge	exercise	to	mitigate	the	risk	of	falling.	Colberg	and	Vinik	(2014)	do	not	define	
what	they	mean	by	‘mild	to	moderate’	intensity	activity.	Moderate	activity	has	been	defined	as	an	
intensity	when	talking	in	sentences	becomes	difficult,	and	is	recommended	as	the	required	
intensity	of	activity	to	reduce	the	risk	of	many	chronic	health	conditions	(NICE,	2013b;	Townsend	
et	al.,	2015;	WHO,	2017;	Sparling	et	al.,	2015).	This	guidance	for	activity	is	generic	and	does	not	
take	into	account	other	risk	factors	such	as	potential	to	ulcerate.	
There	appears	a	need	for	better	consistency	in	reporting	adverse	events	related	to	foot	
tissue	damage	in	studies	of	physical	activity	in	the	diabetic	neuropathy	population.	Currently	
clinicians	are	caught	between	appropriate	caution	to	avoid	injury	and	amputation	and	wanting	to	
encourage	people	to	increase	physical	activity	for	the	associated	physical	and	mental	health	
benefits.		
5.6.3	Treating	the	condition	or	treating	the	person?	
The	diabetes	specialist	clinicians	were	well	aware	that	people	with	PDN	had	coexistent	
psychological	and	social	issues.	There	was	lack	of	concordance	between	the	widespread	impacts	
identified,	and	the	single	modality	management	strategy,	medication,	which	tended	to	be	
employed.	These	clinicians	were	well	aware	of	the	guidance	for	PDN	and	neuropathic	pain	
management,	from	local,	national	and	international	sources.	Reflecting	on	the	language	used,	it	
could	be	suggested	that	they	considered	treating	the	condition	of	PDN.		
National	and	international	guidelines	for	pharmacology	are	similar	but	not	completely	
concordant	recommendations	(Bril	et	al.,	2011;	Spallone,	2012;	NICE,	2013a).	The	details	of	these	
pharmacological	recommendations	can	be	found	in	Chapter	1,	section	1.3.	These	guidance	
documents	are	focussed	on	treating	the	condition	of	PDN,	rather	than	the	person	with	the	
condition.		
The	language	used	by	pain	specialists	that	were	interviewed	focussed	on	the	individual	
needs	of	the	person	who	they	assessed	in	clinic.	They	felt	the	person’s	diagnostic	label	to	be	less	
important	than	what	impacts,	due	to	pain,	that	person	was	experiencing.	They	then	considered,	
in	conjunction	with	the	person,	whether	these	impacts	could	be	mitigated	by	strategies	taught	in	
PMPs,	and	whether	the	person	was	engaged	with	the	ethos	and	aims	of	the	programme.		
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This	difference	in	treatment	approach	between	diabetes	and	pain	clinicians	reflects	a	wider	
debate	about	pain.	Diabetes	is	considered	a	disease	in	its	own	right.	Whether	T1	or	T2,	patients	
understand	diabetes	to	be	a	diagnosis	based	on	their	presenting	symptoms.	Persistent	pain	in	
comparison	has,	for	millennia,	been	considered	a	symptom	of	some	underlying	pathology	that	has	
yet	to	be	diagnosed.	Only	in	the	more	recent	age	of	neuroimaging	has	pain	been	reconsidered	as	
having	the	hallmarks	of	a	disease	process	(Tracey	and	Bushnell,	2009).	In	the	absence	of	other	
explanatory	causes,	persistent	pain	is	now	considered	a	diagnosis.	If	pain	is	considered	a	long-
term	disease	with	no	curative	treatment	options	available,	then	management	of	pain	becomes	
philosophically	more	in-line	with	management	of	other	long-term	diseases,	such	as	diabetes.		
There	have	been	similar	developments	in	the	approach	to	management	of	LBP.	Guidance	
has	developed	from	focussing	on	LBP	as	pathology,	to	using	stratification	tools	that	aim	to	
individualise	management	packages.	The	STarTBack	questionnaire	is	based	on	variables	that	are	
both	known	to	affect	the	prognosis	for	acute	LBP	developing	into	a	persistent	pain	problem,	and	
are	modifiable	by	treatment	(Hay	et	al.,	2008;	Main	et	al.,	2012).	Rather	than	treating	all	people	
with	LBP	as	a	homogenous	group,	these	questions	allow	a	person’s	specific	attitudes	and	fears	to	
be	assessed	and	then	addressed,	if	required.			
Helping	diabetes	specialist	clinicians	to	consider	the	person	with	PDN	individually,	rather	
than	as	a	diagnostic	label,	would	facilitate	the	consideration	of	management	strategies	other	than	
medication	and	reduce	the	feeling	of	clinical	impotence.	There	are	however	two	considerations;	
firstly,	the	literature	reviewed	in	Chapter	2	demonstrated	a	paucity	of	research	exploring	the	
utility	of	pain	management	strategies	in	PDN.	There	is	a	need	for	further	research	investigating	
how	these	strategies	may	need	to	be	adapted	to	be	appropriate	and	acceptable	to	people	with	
PDN.	Secondly,	diabetes	clinicians	identified	people	with	diabetes	as	medically	complex	with	
multiple	issues	that	may	affect	their	ability	to	engage	with	physical	rehabilitation	and	other	pain	
management	strategies.		
5.7	Limitations	specific	to	the	clinician	study	
Gaining	access	to	interview	clinicians	proved	difficult.	All	clinicians	had	very	busy	diaries	
and	a	number	of	potential	interview	participants	declined	the	invitation	to	participate	due	to	time	
pressures.	There	were	participants	from	secondary	care	clinics	representing	two	NHS	trusts,	but	
some	were	from	the	same	team.	This	may	have	led	to	underlying	team	philosophies	being	
represented	in	the	interviews.	For	example,	had	podiatrists	been	recruited	from	different	
organisations,	there	may	have	been	more	variety	in	the	perspectives	of	that	profession.		
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Professions	such	as	podiatrists	and	physiotherapists	work	in	both	primary	and	secondary	
care	roles.	This	study	only	recruited	representatives	of	these	professions	from	secondary	care.	It	
is	possible	the	perspectives	of	podiatrists	in	secondary	care	diabetes	foot	clinics,	where	the	focus	
is	on	healing	ulcerated	areas	of	the	foot	to	avoid	amputation,	may	differ	to	their	colleagues	who	
work	in	primary	care.	The	focus	in	primary	care	would	be	on	regular	monitoring	rather	than	
dealing	with	clinical	crises.		
Clinicians	from	primary	care	were	recruited	through	advert	in	the	Primary	Care	Research	
Network	bulletin.	This	may	have	led	to	only	research	active	or	interested	clinicians	being	aware	of	
the	study.	This	process	also	meant	primary	care	clinicians	were	recruited	and	interviewed	last.		
The	interviews	with	secondary	care	clinicians	were	chronologically	earlier	in	the	study,	allowing	
questions	raised	by	one	interview	to	be	checked	in	subsequent	interviews,	this	was	not	possible	
with	primary	care	clinicians.		
5.8	Conclusions	
Diabetes	specialist	and	primary	care	clinicians	were	aware	of	the	multi-faceted	impacts	
PDN	had	on	peoples’	lives.	Their	primary	management	option	was	evidence-based	medication	
strategies,	which	were	not	always	successful.	Once	these	were	exhausted	they	had	few	
alternative	management	strategies	to	offer	and	could	feel	clinically	impotent.		
Pain	specialist	clinicians	felt	strategies	they	currently	employed	for	persistent	pain	of	other	
causes	could	be	beneficial	but	may	need	adaptation	(approaches	to	physical	exercise)	or	selection	
(acceptance	rather	than	pacing).	Their	focus	was	on	the	person	with	pain	rather	than	the	
diagnostic	label.		
The	risk	diabetes	clinicians,	particularly	podiatrists	voiced,	regarding	damage	from	
increasing	exercise	load	on	insensate	feet	is	important	to	recognise.	Pain	specialists	were	aware	
of	the	need	for	regular	foot	checks,	a	conservative	approach	to	exercise	load	and	alternative	
types	of	exercise.	Further	research	is	required	to	develop	the	evidence	base	for	activity	
prescription	with	best	ratio	of	risk	to	benefit.	
People	with	PDN	may	be	more	medically	complex	than	the	majority	of	patients	that	are	
referred	to	PMPs,	due	to	multiple	diabetes-related	comorbidities.	These	comorbidities	are	
interconnected	and	need	considering	were	a	PDN	specific	PMP	to	be	designed.	Other	than	this	
consideration,	there	were	no	a	priori	reasons	given	by	clinicians	in	this	study	for	not	further	
investigating	the	appropriateness	of	pain	management	strategies	for	people	with	PDN.		
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The	previous	two	chapters	have	outlined	the	findings	of	two	interview	studies.	Some	
patients	interviewed	were	sceptical	that	PMP	strategies	were	applicable	to	the	impacts	of	PDN	
they	experienced.	Clinicians	felt	that	many	of	the	strategies	maybe	helpful	but	highlighted	that	
people	with	PDN	were	more	medically	complex	than	usual	participants	in	PMPs	and	that	care	was	
required	particularly	with	regard	to	physical	activity.		
The	next	chapter	will	describe	the	conduct	of	an	Internet	survey	that	asked	people	with	PDN	
to	highlight	which	impacts	of	PDN	they	most	prioritised	for	better	management.	The	impacts	
presented	in	the	survey	were	based	on	the	findings	from	the	patient	interview	study	(Chapter	4).	
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Chapter	6	–	An	Internet	survey	investigating	the	impact	of	Painful	Diabetic	
Neuropathy	(PDN)	and	patient	treatment	priorities.	
Chapter	4	described	the	results	of	an	interview	study	with	people	who	experience	PDN.	The	
results	highlighted	the	impacts	of	PDN	are	more	than	pain	alone.	Early	chapters	of	this	thesis	have	
outlined	the	existing	evidence	for	PMPs	for	persistent	pain	(Chapter	1),	and	the	current	scarcity	of	
evidence	that	exists	for	using	these	strategies	with	people	who	have	PDN	(Chapter	2).	This	chapter	
will	describe	an	Internet	survey	study	that	asked	people	with	PDN,	of	all	the	impacts	of	PDN	they	
experienced,	what	did	they	most	want	help	to	manage	better?	The	results	will	help	to	explore	
whether	the	priorities	people	report	can	be	matched	to	strategies	from	PMPs.	
6.1	Introduction	
The	qualitative	interview	study	with	patient	participants	presented	in	Chapter	4	
demonstrated	a	range	of	opinions	on	the	acceptability	of	physical	activity	and	psychological	
coping	strategies	for	managing	PDN.	Participants,	who	were	keen	to	be	active,	wanted	
professional	advice	on	activity	to	avoid	flare	of	their	pain.	Other	participants	were	sceptical	that	
physical	activity	could	have	any	beneficial	effect	on	their	pain	experience.	Participants	with	
experience	of	psychological	interventions	felt	these	interventions	were	beneficial.	Other	
participants	were	ambivalent	to	the	role	that	psychological	interventions	could	have	on	their	pain.		
The	study	in	Chapter	4	also	demonstrated	that	PDN	impacted	on	many	areas	of	life,	far	
more	broadly	than	represented	by	the	outcome	measures	often	used	in	quantitative	
epidemiological	PDN	research.	For	instance,	the	interview	participants	described	a	range	of	
emotions	including	embarrassment	and	anger.	They	described	the	impact	PDN	had	on	their	
appetite	and	the	subsequent	effect	this	had	on	their	diabetes	management.	They	described	
significant	social	isolation,	loss	of	independence	and	a	reduction	in	their	confidence	to	engage	
with	society	and	the	world	around	them.	Impacts	of	this	type	are	not	frequently	captured	by	
existing	outcome	measures	therefore	incidence	of	the	broad	range	of	PDN	impacts	is	unknown.	
Only	one	study	was	located	which	asked	people	with	PDN	to	identify	their	priorities	for	
treatment	(Schneider	et	al.,	2014).	Increased	activity	levels	(29.3%,	CI	27.5	to	31%)	and	walking	
ability	(24.4%,	CI	22.8	to	26.1%)	were	identified	by	the	participants	as	the	most	important	
outcomes	(Schneider	et	al.,	2014).	Whilst	these	results	come	from	a	large	sample	population	
(n=2245)	participants	were	asked	for	their	opinions	on	a	restricted	range	of	possible	treatment	
priorities	derived	from	the	BPI	(general	activity,	mood,	walking,	work,	personal	relations,	sleep	
and	life	enjoyment).	This	restricted	range	may	not	have	included	the	priorities	that	were	most	
important	to	participants.	
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Analgesic	treatment	aimed	at	pain	reduction	can	be	considered	successful	from	the	
population	average	change	(Raskin	et	al.,	2014;	Happich	et	al.,	2014;	Hoffman	et	al.,	2010),	but	
there	are	subgroups	who	appear	to	be	‘non-responders’	to	medication	(Moore,	Derry	and	
Eccleston,	2013).	A	large-scale	meta-analysis	of	randomised	controlled	trials	for	neuropathic	pain	
medication	found	NNTs	of:	6.4	Duloxetine,	7.7	Pregabalin	and	7.2	Gabapentin.	The	NNT	statistic	
indicates	how	many	patients	need	to	be	given	the	drug	for	one	to	get	30-50%	pain	reduction	
(Finnerup	et	al.,	2015).	The	NNTs	suggest	that	significant	proportions	of	people	prescribed	these	
medications	experience	little	benefit	in	terms	of	pain	reduction.	These	quantitative	results	were	
reflected	by	the	participants’	experiences	of	medication	management	outlined	in	Chapter	4;	
medication	use	was	a	balance	between	positive	and	negative	affects	but	was	rarely	perfect	in	pain	
reduction	and	sometimes	failed	(Moore	et	al.	2013).	
For	other	persistent	pain	conditions	clinicians	have	developed	multi-modal	interventions	
using	physical	activity	and	psychological	interventions	to	help	people	improve	their	overall	quality	
of	life	with	pain.	
The	recent	Cochrane	meta-review	found	that	in	many	pathologies	associated	with	
persistent	pain,	physical	activity	had	inconsistent	effects	on	pain	severity	(Geneen	et	al.,	2017).	
Chapter	2	found	few	studies	specifically	investigating	physical	activity	in	PDN,	and	concluded	that	
there	was	inconclusive	evidence	activity	reduced	pain.	Both	Geneen	et	al.	(2017)	and	Chapter	2	
suggested	physical	activity	improves	physical	function,	mental	health	and	overall	health-related	
quality	of	life.	There	was	however	notable	scepticism	amongst	interview	participants	that	physical	
activity	was	an	appropriate	form	of	treatment	for	PDN	(Chapter	4).	
Considering	moods	and	thoughts,	PDN	has	a	close	association	with	depression	and	anxiety.	
A	longitudinal	study	of	people	with	PDN	found	HADS	scores	worsened	across	an	18-month	follow-
up	period	(Vileikyte	et	al.,	2009).	Multiple	regression	models	demonstrated	that	baseline	
disability	and	unsteadiness	on	feet,	but	not	pain	intensity,	were	predictive	of	changes	in	
depression	at	18	months.		
Research	highlighted	the	relationship	between	depression	and	pain	is	bi-directional,	with	
one	worsening	the	other.	Depression	also	has	associations	with	altered	behavioural	responses,	
such	as	dietary	choice	and	reduced	activity	engagement,	these	behavioural	reactions	to	
depression	have		subsequent	impact	on	overall	diabetes	management	(Jain	et	al.,	2011;	Kiecolt-
Glaser,	2010).		
Two	recent	cross-sectional	studies	have	examined	the	relationships	between	pain,	
cognitions,	social	state	and	function	in	people	with	PDN	(Selvarajah	et	al.,	2014;	Geelen	et	al.,	
2016).	Selvarajah	et	al.	(2014)	examined	the	contribution	made	to	emotional	distress	by	clinical,	
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social	and	cognitive	factors.	They	found	pain	intensity	contributed	weakly	to	regression	models	
for	depression	and	did	not	contribute	to	models	for	anxiety.	Social	factors	such	as	marital	status	
were	found	to	contribute	to	anxiety;	and	thoughts	of	helplessness	(Pain	Catastrophizing	Scale	
sub-scale)	contributed	to	both	anxiety	and	depression	to	a	greater	extent	than	pain	intensity.	
Geelen	et	al.	(2016)	conducted	a	study	which	examined	the	relationships	between	catastrophizing	
thoughts	and	pain-related	disability	(Geelen	et	al.,	2016).	Multiple	linear	regressions	identified	
significant	association	between	pain	catastrophizing	and	patient	self-rating	of	reduced	activity	
due	to	pain	(Physical	Activity	Decline	measure).	Of	importance,	they	found	pain	intensity	did	not	
significantly	contribute	to	this	association.	The	authors	concluded	that	addressing	patients’	beliefs	
regarding	pain	and	activity	may	have	clinical	utility.	These	studies	demonstrate	that	associations	
exist	between	emotions,	cognitions	and	function,	in	the	population	with	PDN,	as	commonly	found	
in	other	populations	with	persistent	pain.	These	studies	highlight	that	pain	intensity	has	a	small	or	
non-existent	role	in	mediating	or	predicting	depression	and	anxiety.	Recognition	that	thoughts,	
moods	and	function	are	interconnected,	and	subsequent	challenge	to	these	variables	may	help	
people	with	PDN	to	maintain	function	and	quality	of	life.	
There	is	a	rationale	for	considering	non-pharmacological	management	strategies	in	
managing	the	impacts	of	PDN.	However,	there	are	two	issues	that	must	be	considered,	firstly	the	
systematic	review	conducted	as	part	of	this	thesis	found	a	paucity	of	robust	evidence	to	support	
strategies	from	PMPs	being	used	with	people	who	have	PDN	(Chapter	2).	Secondly,	and	perhaps	
more	importantly,	the	patient	interview	study	highlighted	that	participants	had	mixed	views	on	
the	appropriateness	of	such	strategies,	particularly	the	potential	role	of	psychological	help	
(Chapter	4).	The	majority	of	interview	study	participants	had	not	experienced	either	psychological	
support	or	multi-disciplinary	pain	programmes,	so	their	perspectives	on	these	programmes	were	
speculative.	Those	participants	who	had	direct	experience	of	PMPs	felt	there	to	be	benefit	to	the	
strategies	(see	Chapter	4,	section	4.10).	
To	move	beyond	pharmacological	therapies	and	explore	adjunctive	management	
interventions	that	maybe	applicable	to	the	range	of	impacts	experienced	by	people	with	PDN,	the	
focus	must	be	on	patient	experience	and	their	priorities.	This	focus	would	ensure	any	
interventions	appear	plausible	and	relevant	to	their	issues,	and	hopefully	increase	engagement	
with	these	strategies.	The	interview	study	presented	in	Chapter	4	resulted	in	68	individual	codes	
that	related	to	impacts	of	PDN.	Due	to	the	qualitative	nature	of	the	study	and	predominantly	
White	British	sample	it	cannot	be	assumed	that	the	findings	relate	to	the	wider	population	with	
PDN.		
The	one	previous	study	exploring	patient	treatment	priorities	(Schneider	et	al.	2014)	had	a	
large	sample	group,	but	was	methodologically	limited	due	to	the	narrow	range	of	choices	
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presented	to	participants.	The	current	study	aimed	to	build	on	the	range	of	impacts	identified	
through	patient	interviews	(Chapter	4)	and	use	these	to	explore	patient	management	priorities.	
The	results	will	allow	an	exploration	of	whether	patients’	priorities	can	be	mapped	to	existing	
management	interventions.			
6.2	Study	aims	
This	study	aimed	to	further	understanding	of	the	way	PDN	impacts	on	peoples’	lives.	It	also	
aimed	to	develop	understanding	of	the	healthcare	priorities	patients	have	in	helping	them	to	
manage	these	impacts.			
The	research	objectives	were:	
1. To	conduct	an	Internet	survey	exploring	how	people	with	PDN	experience	a	range	of	PDN	
impacts,	and	the	resulting	effect	on	quality	of	life.	
2. If	sample	size	was	sufficient,	to	explore	whether	respondents	experience	different	
impacts	of	PDN,	dependent	on	a	range	of	socio-demographic	and	clinical	variables	
(measures	of	diabetes	control	and	pain	ratings).		
3. To	analyse	whether	there	are	associations	with	respondent	pain	coping	strategies.	
4. To	list	the	top	priority	impacts	of	PDN	which	respondents	most	frequently	want	help	to	
manage	more	effectively.	
5. To	analyse	whether	these	priorities	differ	between	sub-groups	of	respondents:	by	sex,	
type	of	diabetes,	pain	category	and	whether	they	have	sought	clinical	help	for	their	PDN	
or	not.	
The	primary	research	questions	were:	
1. What	were	the	impacts	of	PDN	on	quality	of	life	as	selected	from	an	impact	list	informed	
by	patient	interviews?	
2. What	were	the	top	priorities	respondents	have	for	support	from	healthcare	services?	
The	secondary	research	questions	were:	
1. What	were	the	frequencies	respondents	experience	each	of	58	statements	on	the	impact	
of	PDN?	
2. For	each	statement	endorsed,	how	did	respondents	rate	the	severity	of	impact	on	quality	
of	life?	
3. Were	there	associations	between	the	impacts	experienced	and	active/passive	pain	coping	
strategies?	
4. Did	the	treatment	priorities	differ	between	subgroups	of	respondents?	
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6.3	Methodology	
Surveys	can	be	undertaken	in	a	range	of	different	ways	including	face-to-face,	postal	and	
via	the	Internet.	For	this	study,	the	Internet	was	the	preferred	medium	as	it	allowed	wide	ranging	
and	quick	marketing	to	potential	respondents,	responses	can	be	anonymised	easily	and	it	is	
usually	low	cost.		
A	review	of	epidemiological	studies	showed	only	2%	of	2094	epidemiological	articles	
published	in	high	impact	factor	journals	(2008-9)	used	Internet	survey	methods	(Van	Gelder,	
Bretveld	and	Roeleveld,	2010).	Van	Gelder	et	al.	(2010)	highlighted	some	challenges	with	
electronic	surveys:	1)	Internet	access	is	not	universal,	so	this	leads	to	an	element	of	demographic	
selection	bias	and,	2)	the	data	acquired	from	Internet	surveys	differed	in	reliability	and	validity	to	
that	acquired	from	face-to-face	surveys.	Other	authors	contend	that	these	concerns	have	not	
been	shown	to	effect	the	response	rate	or	quality	of	data	acquired	through	Internet	surveys	
(Nicolaas	et	al.,	2014).	
6.4	Method	
UWE	has	a	license	with	Qualtrics,	an	Internet	survey	service	provider.	Qualtrics	provide	an	
on-line	service	that	aids	with	survey	design,	distribution	and	collection	of	results	data.		
6.5	Ethical	approval	
The	UWE	Health	and	Applied	Sciences	Faculty	research	ethics	committee	granted	
permission	for	this	survey	(HAS/15/11/038).	As	part	of	the	survey	design	process	an	amendment	
was	applied	for	due	to	changes	in	wording	and	structure	of	the	survey.	The	amendment	was	
granted	approval	(12/1/16,	Appendix	20).	
6.6	Diagnostic	screening	questions	
This	survey	required	the	development	of	a	short	series	of	screening	questions	to	allow	
identification	of	people	with	PDN	by	self-report.	PDN	has	some	variation	in	presentation	and	
possible	delay	in	diagnosis	(Daousi	et	al.,	2004;	Sadosky,	Hopper	and	Parsons,	2014);	thus,	if	
Diagnosis	of	PDN	by	a	medical	professional	had	been	set	as	a	strict	inclusion	criterion,	many	
people	who	have	the	condition	might	have	been	excluded.	A	set	of	screening	questions	were	
developed	in	conjunction	with	Professor	David	Wynick	(Consultant	Endocrinologist,	and	national	
PDN	specialist,	University	Hospitals	Bristol	NHS	Foundation	Trust)	that	were	intended	to	
rigorously	screen	for	the	clinical	features	of	PDN.		
1. Do	you	often	have	pain	or	odd	sensations	in	your	feet?	Y/N		
a. If	Y	-	one	or	both?	
2. Do	you	often	have	pain	or	odd	sensations	in	your	hands?	Y/N	
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a. If	Y	-	one	or	both?	
3. At	what	time	of	day	is	the	pain	in	your	feet	(and	hands)	worse?	Night,	day,	no	pattern.		
4. Have	you	had	a	diagnosis	from	a	health	care	professional	that	the	pain	in	your	feet	(and	
hands)	is	related	to,	or	a	complication	of,	your	diabetes?	Y/N	
The	majority	of	people	with	PDN	would	be	expected	to	report	pain,	in	both	feet	(hand	
symptoms	tend	to	develop	over	time),	which	is	worse	at	night	(Tesfaye	et	al.,	2010).		
6.6.1	Inclusion	criteria	
• Self-reported	diagnosis	of	type	1	or	type	2	diabetes.	
• Self-reported	clinical	diagnosis	of	PDN,	or:	
• Self-reported	symptoms	indicative	of	a	diagnosis	of	PDN	(bilateral	foot	pain,	possible	
additional	bilateral	hand	pain,	worse	at	night),	even	without	a	clinical	diagnosis.	
6.6.2	Exclusion	criteria	
• Self-reported	symptoms,	which	were	inconsistent	with	a	likely	diagnosis	of	PDN	
(unilateral	foot	pain,	hand	pain	without	foot	pain).	
• No	Internet	access.	
Internet	surveys	cannot	provide	certainty	that	the	inclusion	criteria	are	met	because	they	
rely	on	self-report	rather	than	objective	clinical	criteria,	however	this	screening	process	was	felt	
likely	to	rule	out	respondents	who	did	not	have	PDN.	
6.7	Survey	design	process	
The	research	student	initially	created	the	survey	online,	using	Qualtrics.	Substantial	
sections	of	the	survey	asked	patients	to	reflect	on	the	influence	PDN	had	on	their	quality	of	life.	
Whilst	the	definition	of	“quality	of	life”	is	varied	and	contested	(Barcaccia	et	al.,	2013),	this	study	
used	an	amended	WHO	definition.	The	WHO	consider	quality	of	life	to	be	wholly	subjective	and	
comprising	of	both	positive	and	negative	aspects	of	a	person’s	“physical	health,	psychological	
state,	level	of	independence,	social	relationships	and	their	relationship	to	salient	features	of	their	
environment”	(WHO,	1995).	The	final	part	of	the	definition	was	felt	to	lack	clarity	for	the	average	
reader	which	may	have	resulted	in	a	high	drop-out	rate.	The	wording	of	the	survey	questions	
asked	respondents	to	consider	whether	each	impact	had	any	effect	on	“their	physical	health,	
psychological	state,	level	of	independence,	social	relationships	and	their	freedom	to	move	around	
their	environment	as	you	would	expect”.	
Respondents	were	asked	to	consider	each	impact	statement	and	score	its	influence	on	their	
quality	of	life,	using	a	5-point	Likert	scale.	The	scale	was	described	as:	0=do	not	experience	this	
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impact,	1=experienced	but	no	impact	on	QoL,	2=experienced	and	minimal	impact	on	QoL,	
3=experienced	and	moderate	impact	on	QoL	and	4=experienced	and	large	impact	on	QoL.	
The	impact	statements	were	developed	directly	from	the	interview	study	with	patients	
(Chapter	4,	section	4.5).	Each	NVivo	code	identifying	an	impact	of	PDN	(n=68)	was	considered	for	
inclusion.	A	statement	was	written	reflecting	the	nature	of	the	impact	on	the	person	with	PDN.	
Eleven	codes	were	excluded	because	they	were	either	near	duplicates,	the	code	reflected	a	
positive	counterpoint	to	the	usual	difficulties	of	PDN,	the	participants	were	transitory,	or	they	
were	statements	of	impact	made	by	a	partner	(please	see	Table	12).	
Table	12	-	Impact	codes	excluded	from	survey	
Impact	code	excluded	 Reason	for	exclusion	
Sleep	not	disturbed	 Positive	counter	point	
Able	to	work	 Positive	counter	point	
Carry	on	with	social	life	 Positive	counter	point	
Changing	jobs	 Transitory	impact	
Returning	to	work	 Transitory	impact	
Advice	for	foot	care	 Not	a	direct	impact	of	PDN	
Foot	position	 Pain	management	strategies	could	not	alter	
this	
Always	been	independent	 Combined	with	Loss	of	independence	
Chronic	pain	 Related	to	chronic	pain	other	than	PDN	
Knowing	I	can’t	help	 Impact	on	partner	of	interviewee	
Templar	torture	 Combined	with	other	impacts	related	to	
subjective	pain	experience	
	
Prior	to	undertaking	a	pilot	phase	the	survey	was	trialled	with	two	EPRPs.	The	role	of	EPRPs	
has	been	discussed	previously	(see	Chapter	3,	section	3.12).	Both	EPRPs	had	been	participants	in	
the	patient	interview	study	and	had	contributed	directly	to	the	development	of	the	survey	impact	
statements.	They	had	given	consent	to	be	contacted	about	future	studies.	The	EPRPs	met	
individually	with	the	research	student	and	Professor	Fiona	Cramp,	who	took	written	notes.	No	
audio	or	video	recordings	of	these	meetings	were	made,	and	any	data	obtained	by	completing	the	
survey	were	deleted.		
The	aims	of	the	meetings	were	to	ensure	the	structure	of	the	survey	appeared	logical,	that	
the	language	used	in	the	questions	was	clear	and	not	ambiguous	(face	validity),	and	finally	that	
EPRPs	read	and	understood	the	impact	statements	with	the	same	intention	as	the	research	
student	(content	validity).	As	the	EPRPs	read	through	the	PIS	and	completed	the	survey	online,	
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they	were	asked	to	verbalise	their	thoughts,	to	explain	what	they	thought	the	questions	were	
asking	and	what	they	thought	the	impact	statements	referred	to.	The	resulting	discussion	was	
then	used	to	refine	the	survey,	prior	to	a	pilot	phase.		
The	changes	to	wording	of	the	impact	statements	following	the	meetings	with	the	EPRPs	
have	been	summarized	in	Table	13.	
Table	13	-	Development	of	survey	wording	
Issues	raised	by	EPRP	 Original	phrase/question	 Revised	phrase/questions	
Symptoms	experienced	are	
not	always	best	described	as	
pain	
Do	you	often	have	pain	in	
your	feet/hands?	
Do	you	often	have	pain	or	
odd	sensations	in	your	
feet/hands?	
People	have	routine	
medication	and	pain	flare-up	
medication		
Please	select	medications	
used	for	PDN	
1	-	Please	select	medications	
used	routinely	for	PDN	
2	-	Please	select	medications	
used	for	pain	flare-ups	of	PDN	
Term	‘mean’	was	felt	too	
harsh	
When	PDN	flares	up	I	can	be	
mean	to	those	around	me	
When	PDN	flares	I	can	be	less	
tolerant	to	those	around	me	
Keeping	PDN	to	one’s	self	
depended	on	social	context	
I	keep	my	problems	with	PDN	
to	myself	
1	–	I	keep	my	problems	with	
PDN	from	those	around	me	
2	–	I	keep	my	problems	with	
PDN	from	my	wider	social	
network	
Wanted	to	clarify	a	choice	
was	made	to	restrict	or	stop	
driving	
PDN	affects	my	ability	to	drive	 PDN	makes	me	think	about	
driving	carefully	
EPRP	had	an	emotional	
response	to	the	breadth	of	
impacts	portrayed	
	 Added	further	signposting	to	
support	for	PDN	at	the	end	of	
the	survey	
	
EPRPs	considered	that	presenting	58	statements,	from	which	to	choose	three,	was	
impractical.	A	tension	existed	between	either,	presenting	all	58	statements	and	leaving	
respondents	free	to	choose	their	top	priorities,	or	grouping	the	statements	and	therefore	making	
the	prioritisation	process	more	manageable.	One	grouping	option	was	to	ask	respondents	to	
choose	priorities	from	the	statements	they	rated	most	impactful	on	their	quality	of	life,	for	
instance	≥3/4	on	the	Likert	scale.	This	was	discounted	because	it	would	stop	respondents	from	
prioritising	impacts	that	were	less	severe,	but	experienced	more	frequently,	than	the	more	severe	
but	less	frequently	experienced	impacts.		
Another	option	was	to	group	the	impacts	by	the	type	of	impact,	(see	column	in	Appendix	
19).	The	researcher	had	externally	imposed	these	categories	(mood,	function,	social,	sensory,	rest	
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etc.)	onto	the	coded	interview	data	and	they	had	not	been	endorsed	by	people	with	PDN.		
Respondents	needed	freedom	to	choose	those	statements	that	were	most	important	to	them.	
Being	forced	to	choose,	for	instance,	one	impact	statement	from	each	category	would	1)	impose	
the	structure	that	all	categories	were	equally	relevant	and	2)	impose	categorisation	from	the	
perspective	of	the	researcher,	a	clear	source	of	researcher	bias.		
It	was	clear	from	the	meeting	with	EPRPs	that	asking	participants	to	prioritise	three	items	
out	of	58	could	result	in	a	large	number	either	not	completing	the	process,	or	not	giving	a	fully	
considered	response.	A	two-stage	process	was	subsequently	designed	to	break	down	the	task.	
Firstly,	the	respondents	would	select	a	short-list	of	up	to	ten	impacts	that	were	most	important	to	
them.	They	would	subsequently	rank	these	choices	with	1=top	priority	for	management,	through	
to	10=tenth	priority	for	management.	This	process	allowed	respondents	to	self-limit	the	number	
of	impacts	that	were	most	important	to	them.		
6.7.1	Survey	pilot	phase		
A	pilot	phase	was	undertaken	to	test	the	process	of	the	online	survey.	An	information	pack	
was	created	which	contained	a	covering	letter,	PIS	for	the	pilot	survey	and	a	further	sealed	
envelope	that	contained	the	PIS	for	the	full	survey.	The	pilot	PIS	letter	asked	people	to	open	the	
full	survey	envelope	if	they	were	willing	to	take	part.	The	process	was	initially	tested	on	two	
research	colleagues	who	were	naïve	to	the	research	study.	They	were	specifically	asked	to	
highlight	any	unclear	text	or	instructions.	Some	language	was	amended	as	a	result	of	their	
feedback.	Participants	from	the	interview	study	who	had	given	permission	to	be	contacted	about	
future	research	were	subsequently	sent	the	pilot	information	pack,	see	Appendix	19.		
The	pilot	survey	included	two	extra	questions.	Firstly,	responders	were	asked	to	input	their	
study	number,	which	was	contained	in	the	pilot	information.	This	number	allowed	the	researcher	
to	identify	who	had	completed	the	pilot	survey,	and	only	send	reminder	letters	to	non-
responders.	A	reminder	was	sent	two	weeks	after	the	initial	request,	after	which	there	was	no	
further	attempt	to	recruit	to	the	pilot.	A	final	free	text	question	provided	the	respondents	with	an	
opportunity	to	make	comments	about	the	survey.	These	could	be	technical	issues	they	
experienced,	language	or	wording	issues	or	any	other	comments	that	they	believed	to	be	
relevant.		
6.7.2	Results	of	the	pilot	survey	phase	
There	were	eight	responses	to	the	pilot	survey,	a	34%	opt-in	rate,	with	all	respondents	
completing	the	survey	in	total	(0%	drop	out	rate).	The	duration	of	time	to	compete	the	survey	
ranged	from	22	to	43	minutes	(mean	32	minutes).	Based	on	these	responses,	the	PIS	was	updated	
to	reflect	the	likely	time	required	to	complete	the	survey.		
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In	the	free	text	responses,	there	were	two	themes:	firstly,	related	to	the	choice	of	impacts	
to	prioritise.	One	respondent	had	difficulty	dragging	the	choices	to	the	short	list	box,	another	
commented	on	the	range	of	options	(58	statements).	The	second	theme	contained	comments	
that	respondents	wanted	more	information	on	PDN,	particularly	the	causes.	Signposts	to	sources	
of	further	information	on	PDN	were	added	at	the	end	of	the	survey.	
Three	respondents	contacted	the	research	student	by	email	or	phone	because	they	were	
unable	to	access	the	survey	on-line.	The	pilot	PIS	contained	a	website	address	URL	that	the	
respondents	were	required	to	put	into	their	Internet	browser	manually	
(https://tinyurl.com/npv9kz7).	There	were	some	difficulties	with	this	process.	The	final	survey	
was	delivered	by	email	and	on	websites,	so	the	web	address	for	the	survey	was	an	automated	
hyperlink.	This	was	felt	to	overcome	the	problems	the	pilot	respondents	had	faced.		
The	comments	from	the	pilot	respondents	can	be	found	in	Appendix	21.	The	final	survey	
structure	is	outlined	in	the	following	section.	
6.8	Final	survey	content	
6.8.1	Screening	questions	[4	questions]	
The	four	diagnostic	screening	questions	described	in	section	6.6.		
6.8.2	Demographic	Information	[10	questions]	
This	included:	sex,	age,	ethnicity,	type	of	diabetes,	duration	of	diabetes	and	PDN	
symptoms,	current	analgesia	for	PDN	(routine	and	during	a	flare-up),	home	status	(living	alone,	
with	partner,	with	family	or	other)	and	work	status	(working,	retired,	unemployed	or	other).	
Respondents	were	asked	to	rate	their	average	pain	for	the	past	week	(0-10	NRS).		
6.8.3	Self-rating	of	diabetes	control	[1	question]	
This	question	was	important	because	sub-optimal	glycaemic	control	tends	to	be	associated	
with	development	and	severity	of	PDN.	The	wording	of	the	question	was	developed	with	
Professor	Wynick.	
“From	my	own	blood	monitoring	and	discussions	with	health	professionals	I	consider	the	
management	of	my	blood	sugars	as:	very	good,	good,	moderate,	poor	or	very	poor.”	
6.8.4	Coping	Strategies	Questionnaire	(CSQ)	[14	questions]	
This	investigated	the	use	of	different	coping	styles	for	chronic	pain	and	has	been	validated	
for	neuropathic	pain	(post	herpetic	neuralgia	(Haythornthwaite	et	al.,	2003)).	The	CSQ	
characterises	respondents	as	using	either	active	or	passive	coping	strategies.	Active	coping	styles	
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are	associated	with	improved	functioning	and	adjustment	with	living	with	persistent	pain	
compared	with	passive	styles	(Jensen	et	al.,	2003;	Snow-Turek,	Norris	and	Tan,	1996).	It	is	
important	to	characterise	respondents	in	this	way	because	recent	studies	have	shown	
catastrophizing	thoughts	(passive	coping)	contributed	to	both	anxiety	and	depression	(Selvarajah	
et	al.,	2014)	and	reduced	physical	activity	(Geelen	et	al.,	2016).	
6.8.5	Impact	of	PDN	[58	statements]	
Part	1	–	frequency	and	severity	of	impact	on	quality	of	life.	
Respondents	were	asked	to	read	a	list	of	58	impact	statements.	The	development	of	these	
statements	has	been	described	in	section	6.7,	the	full	list	can	be	found	in	Appendix	18.	They	were	
invited	to	rate	on	a	5-point	uni-polar	Likert	scale,	whether	they	experienced	each	impact	and	if	so	
how	their	experience	of	this	impact	affected	their	quality	of	life.	These	impacts	were	randomised	
in	the	order	they	were	presented	to	each	respondent.	
There	was	a	free	text	section	for	respondents	to	add	other	impacts	they	did	not	feel	were	
represented	in	the	presented	list.	This	free	text	response	allowed	for	the	possibility	that	the	
interview	study	(see	Chapter	4)	did	not	gather	data	fully	representative	of	the	UK	PDN	population.	
Part	2	–	priorities	for	help	with	management	
Respondents	were	asked	to	consider	the	58	impact	statements,	then	short	list	up	to	10	of	
the	impacts,	and	place	in	order	of	priority	for	which	they	wanted	better	management.			
Finally,	two	questions	asked	if	they	had	sought	clinical	help	for	their	experience	of	PDN	
(y=help-seeking	population,	n=not	help-seeking	population)	and	if	so,	from	whom	(diabetes	
consultant,	pain	consultant,	practice	nurse,	diabetes	specialist	nurse,	GP,	podiatrist,	
physiotherapist,	psychologist,	other	(free	text)	–	multiple	selection	possible).		
6.9	Sampling	and	recruitment	strategy	
In	order	to	obtain	results	with	the	greatest	possible	validity	and	relevance	to	the	broader	
PDN	population,	this	study	sought	responses	from	a	wide	range	of	people	with	PDN.	PDN	
becomes	more	common	as	people	age	(Shakher	and	Stevens,	2011),	so	sampling	hoped	to	include	
older	adults	(60yrs+).	PDN	affects	people	with	T1	and	T2DM	and	both	sexes.	Diabetes	has	higher	
prevalence	rates	in	South	Asian	and	other	minority	ethnic	groups	(Gujral	et	al.,	2013).	The	
interview	study	from	which	the	impact	statements	were	derived	was	not	ethnically	diverse,	so	it	
was	important	to	access	people	from	different	ethnic	backgrounds.		
DUK	support	was	secured	to	market	this	research	study.	Diabetes	peer-support	group	
networks	run	nationwide	and	are	organised	by	local	people.	Peer-support	group	meetings	are	
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held	in	venues	and	locations	that	are	accessible	to	the	local	population	with	diabetes.	DUK	
actively	work	to	encourage	engagement	in	self-managing	diabetes	in	areas	of	social	deprivation	
and	from	ethnic	minorities	(DUK,	2015),	as	these	populations	are	more	at	risk	of	diabetes	and	the	
associated	complications	(Claydon,	Campbell-Richards	and	Hill,	2013).	This	study	used	the	
communication	processes	that	exist	between	DUK,	the	peer	support	group	organisers	and	their	
members	to	market	this	survey.	The	membership	profile	of	DUK	was	outlined	in	section	3.5.2.3.		
The	study	was	also	posted	on	Internet	discussion	forums	that	focussed	on	PDN.	Patient	
forums	hosted	by	DUK	(diabetes.org.uk),	Diabetes	Forum	(diabetes.co.uk)	and	Diabetes-support	
(diabetes-support.co.uk)	were	used.	New	threads	were	started	to	maintain	the	study	information	
near	the	top	of	forum	listings	and	the	wording	of	the	headline	was	altered	to	encourage	
participation.	These	processes	for	recruitment	were	active	between	February	and	April	2016		
Each	of	these	strategies	for	recruitment	included	a	webpage	address	to	access	the	survey.	
Office	for	National	Statistics	data	suggested	that	76%	(CI	74-78%)	of	UK	adults	access	the	Internet	
on	a	daily	basis.	On	average	people	aged	over	65	years	access	the	Internet	at	least	daily	(42%)	or	
weekly	(13%);	they	use	a	significant	amount	of	this	access	for	researching	goods	and	services	
(44%)	(ONS,	2014).	These	data	suggested	the	survey	recruitment	strategies	had	a	good	chance	of	
reaching	the	desired	populations.		
6.10	Data	analysis	
The	sample	sociodemographic	and	clinical	data	were	analysed	with	descriptive	statistics.	
Descriptive	and	frequency	data	analysis	were	conducted	to	describe	the	number	and	percentage	
of	respondents	who	did	not	experience	(0	on	the	Likert	scale),	or	did	experience	(1-4	on	the	Likert	
scale)	each	impact	statement.	
The	free	text	responses	identifying	additional	participant	impacts	not	included	within	the	
list	of	statements,	were	collated.	The	researcher	compared	these	free	text	comments	against	the	
existing	code	structure	developed	in	the	patient	interviews,	to	identify	whether	there	were	new	
impacts	the	interviews	had	not	described	(Braun	and	Clarke,	2006).	A	second	independent	
research	supervisor	verified	this	process	and	the	findings	were	discussed	with	the	supervisory	
team.			
Principal	Component	Analysis	(PCA)	was	used	to	reduce	the	58	impact	statements	to	a	
smaller	number	of	summary	indices.	These	summary	indices	were	explored	for	any	correlations	
with	sociodemographic	(home	status,	work	status,	age	and	sex)	and	clinical	subgroups	(diabetes	
well/not	well	controlled,	and	pain	ratings).	
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The	CSQ	data	were	compared	against	data	from	the	same	measure	used	with	other	
neuropathic	pain	conditions.	Cohen’s	d	(Cohen,	1988)	was	used	to	investigate	any	statistical	
difference	in	coping	strategies	between	these	two	data	samples.	Correlation	analyses	were	
performed	between	the	pain	CSQ	and	the	impacts	identified	by	respondents.	In	the	event	of	
missing	data,	if	respondents	had	rated	more	than	51	questions	(85%)	from	the	survey	section,	the	
mean	impact	rating	was	used	for	imputation	for	the	missing	data	point(s).	If	respondents	rated	
fewer	than	85%	of	the	impacts,	then	their	case	was	excluded	from	the	analysis.	Histograms	were	
used	to	check	for	normal	distribution	and	Pearson’s	correlation	statistic	used	to	examine	
correlations	between	impact	and	coping	style.	
The	analysis	of	respondent	priorities	was	based	on	similar	research	investigating	the	
priorities	patients	had	for	pharmacological	management	of	rheumatoid	arthritis	(Sanderson	et	al.,	
2010).	The	priorities	assigned	to	impacts	by	respondents	were	transformed	using	an	inverse	scale	
(1st	priority=10,	2nd	priority=9	…	10th	priority=1,	not	selected=0).	For	each	impact	these	scores	
were	summed.	This	sum	was	presented	as	a	percentage	of	the	possible	maximum	priority.		
For	example	–	if	10	respondents	had	endorsed	an	impact	as	one	of	their	priorities,	and	all	
respondents	were	to	rate	it	their	highest	priority	(reverse	score	10),	the	maximum	sum	would	be	
100/100	or	100%.	If	their	reversed	scores	actually	sum	40,	this	impact	would	be	calculated	at	
40/100	or	40%.	Presenting	the	data	in	this	way,	rather	than	a	simple	sum	of	priorities	has	two	
benefits	for	the	analysis.	Firstly,	it	helped	to	address	the	balance	between	many	respondents	
rating	an	impact	as	a	low	priority	choice,	and	few	respondents	rating	an	impact	as	a	high	priority.	
Were	scores	to	have	been	summed,	an	impact	rated	first	priority	by	two	respondents	(2x10=20)	
would	have	the	same	weighting	applied	as	an	impact	rated	fifth	priority	by	four	respondents	
(4x5=20).	This	approach	used	the	ratio	percentage	to	account	for	the	number	of	respondents	who	
endorse	an	impact	as	a	priority.	Using	the	examples	above,	two	respondents	rating	an	impact	first	
priority	20/20	or	100%,	or	four	respondents	rating	an	impact	fifth	priority	20/40	or	50%.	
Secondly,	this	approach	ensured	the	calculation	of	impact	priority	was	done	for	each	
impact,	not	each	respondent.	Respondents	who	selected	more	priority	impacts	would	not	have	
undue	influence	on	the	data,	compared	to	respondents	who	may	have	selected	fewer	than	10	
impacts	as	priorities.	
Descriptive	analysis	explored	whether	different	priorities	existed	by	respondent’s	sex,	type	
of	diabetes,	pain	levels	and	whether	they	had	sought	help	for	the	impacts	of	PDN	they	
experienced.	
All	analyses	were	performed	using	either	Microsoft	Excel	2011	for	Mac	(Microsoft	
Corporation,	California	2010)	or	IBM	SPSS	v22	(IBM	Corporation,	2015)	as	appropriate.	
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6.11	Results	
There	were	107	individual	responses	to	the	survey	with	78	eligible	data	sets	once	the	case	
definition	was	applied.	Overall	there	was	a	dropout	rate	of	40%;	this	occurred	either	early	in	the	
survey	at	the	demographic	and	clinical	sections	or,	for	those	who	described	meeting	the	eligibility	
criteria,	later	in	the	survey	when	asked	to	rate	the	58	impact	statements.	A	sample	of	62	
completed	the	survey	in	full.		
6.11.1	Sample	demographics	
The	sample	(n=78,	see	Table	14	below)	of	eligible	respondents	included	43	women	(55%)	
female,	and	had	a	mean	age	of	57	(SD13)	years.	Forty-nine	respondents	(63%)	had	T2DM	and	26	
(33%)	had	T1DM.	Sixty-eight	respondents	(87%)	self-rated	their	glycaemic	control	as	very	good,	
good	or	moderate,	with	nine	(13%)	rating	their	control	as	poor	or	very	poor	and	one	missing	data	
item.	Respondents	had	been	diagnosed	with	diabetes	for	a	mean	17.8	(SD13.7)	years	and	had	
symptoms	of	PDN	for	a	mean	7.3	(SD6.3)	years.	Respondents	were	retired	(n=36,	46%),	employed	
(n=26,	33%)	or	unemployed	(n=11,	14%).	Seventy	respondents	(90%)	of	the	sample	identified	as	
White	British.		
Table	14	-	Internet	survey	respondent	characteristics	
Characteristic	 N=78	 %	or	Mean	±	SD	(range)	
Sex	
Male	
Female	
	
35	
43	
	
45%	
55%	
Ethnicity	
White	British	
Asian/Asian	British	
Mixed	ethnic	groups	
Other	(White	non-British,	White	Irish,	
Hispanic	and	European)	
	
70	
3	
1	
4	
	
90%	
4%	
1%	
5%	
Work	status	
Employed	
Unemployed	
Retired	
Other	
Missing	
	
26	
11	
36	
4	
1	
	
33%	
14%	
46%	
5%	
1%	
Home	status	
Living	alone	
Living	with	partner	
Living	with	family	members	
Other	
	
22	
34	
21	
1	
	
28%	
43%	
27%	
1%	
Type	of	diabetes	
Type	1	
Type	2	
Missing	
	
26	
49	
3	
	
33%	
63%	
4%	
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Characteristic	 N=78	 %	or	Mean	±	SD	(range)	
Self-rating	of	diabetes	management	
Very	good	
Good	
Moderate	
Poor	
Very	poor	
Missing	
	
18	
22	
28	
4	
5	
1	
	
23%	
28%	
36%	
5%	
6%	
1%	
Age	 	 57	±	13	(26-84	years)	
Diabetes	duration	 	 17.8	±	13.7	(1-57	years)	
PDN	duration	 	 7.3	±	6.3	(1-33	years)	
Average	pain	score	past	week	(0-10)	 	 6	±	2.4	
	
Table	15	outlines	the	analgesic	medication	used	by	the	respondents	(n=78).	Twenty	(26%)	
did	not	use	any	regular	medication	for	managing	PDN,	41	(53%)	were	using	medications	as	
recommended	by	NICE	for	the	management	of	PDN	(NICE,	2013a).	Individuals	were	most	
commonly	using	one	class	of	medication	(mode=1)	but	the	range	extended	from	nil	to	five	classes	
of	medication.	Respondents	were	using	multiple	medications	so	responses	total	more	than	100%.	
When	PDN	flared,	the	sample	respondents	increased	the	use	of	weak	opioids	such	as	
Tramadol	and	Co-codamol.	
Table	15	-	Internet	sample	medication	use	
Medication	class	 Regular	use	n=,	(%)	 Flare	up	use	n=,	(%)	
Anti-epileptics	(Pregabalin	or	Gabapentin)	 23	(29%)	 15	(19%)	
Amitriptyline	 10	(12%)	 7	(9%)	
Duloxetine	 8	(10%)	 3	(4%)	
Sum	total	of	NICE	recommendation	
medication	
41	(53%)	 25	(32%)	
Over	the	counter	analgesia	(Paracetamol	or	
ibuprofen)	
23	(29%)	 23	(29%)	
Weak	opiates	(Co-codamol	or	Tramadol)	 11	(14%)	 28	(35%)	
Strong	opiates	(Morphine)	 9	(11%)	 8	(10%)	
Pain	patch	 4	(5%)	 1	(1%)	
Capsaicin	cream	 3	(4%)	 2	(2%)	
Other	medications	 13	(16%)	 13	(16%)	
Nil	medication	 20	(26%)	 15	(19%)	
	
6.11.2	Impact	based	on	frequency	
Table	16	shows	the	ten	most	frequently	experienced	impacts.		
Table	16	-	Ten	most	experienced	impacts	of	PDN	
Impact	statement	 %	Experienced	(1-4	
Likert),	n=62	
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I	have	to	check	my	feet	regularly	for	possible	injury	 94.8	
I	am	worried	that	my	PDN	will	get	worse	in	the	future	 93.4	
My	sleep	is	disturbed	due	to	PDN	 91.8	
PDN	causes	me	to	have	numb	feet	 91.7	
PDN	leads	me	to	get	frustrated	 89.7	
My	feet	look	normal	but	I	have	this	severe	pain	 88.7	
PDN	affects	my	ability	to	concentrate	 86.7	
PDN	gives	me	a	sense	of	restless	legs	 85.0	
When	PDN	flares	up	I	can	be	less	tolerant	to	those	around	me	 84.5	
PDN	makes	walking	difficult	 83.6	
	
Table	17	shows	the	ten	least	frequently	experienced	impacts.	Only	the	last	four	impacts	–	
frequent	cramps,	headaches,	memory	difficulty	and	suicidal	ideation	were	endorsed	as	
experienced	by	less	than	half	the	respondent	sample.	The	complete	list	of	all	impact	statements	
can	be	found	in	Appendix	22.		
Table	17	-	Ten	least	experienced	impacts	of	PDN	
Impact	statement	 %	Not	experienced	
(0	Likert),	n=62	
PDN	makes	me	worried	about	going	out	of	the	house	 44.1	
PDN	makes	me	feel	embarrassed	 44.6	
My	PDN	affects	my	close	family	 44.8	
It	bothers	me	what	other	people	think	of	me	due	to	the	problems	I	have	
with	PDN	
45.0	
I	worry	how	our	money	will	be	affected	because	of	PDN	 45.8	
I	get	more	breathless	than	before	I	had	PDN	 48.2	
I	get	cramp	more	frequently	than	before	I	has	PDN	 50.0	
PDN	affects	my	memory	 50.8	
PDN	can	lead	me	to	have	headaches	 53.4	
I	have	contemplated	suicide	due	to	my	PDN	 70.7	
	
6.11.3	Impact	based	on	severity	
Table	17	and	18	show	the	impacts	as	rated	by	severity	of	impact	on	quality	of	life.	Table	18	
shows	the	ten	most	severe	impacts;	these	were	the	summed	responses	3	and	4	on	the	Likert	scale	
(‘moderate’	and	‘large’	impact).	These	most	severe	impacts	included:	worry	for	the	future	(84%),	
perceptions	of	others	(76%),	cramp	(76%),	sleep	disturbance	(75%)	and	frustration	(75%).		
Table	18	-	Ten	most	severe	impacts	of	PDN	
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Impact	statement	 %	3/4	or	4/4,	n=62	
I	am	worried	that	my	PDN	will	get	worse	in	the	future	 84.2	
It	bothers	me	that	other	people	can't	see	I	have	this	problem	 76.3	
I	get	cramp	more	frequently	than	before	I	has	PDN	 75.9	
My	sleep	is	disturbed	due	to	PDN	 75.0	
PDN	leads	me	to	get	frustrated	 75.0	
PDN	affects	a	wide	range	of	activities	that	I	want	to	do	 75.0	
PDN	causes	me	to	have	numb	feet	 74.5	
PDN	can	lead	me	to	have	headaches	 74.5	
I	have	reduced	my	physical	activity	due	to	PDN	 74.5	
PDN	affects	my	social	life	 74.2	
	
Table	19	shows	the	ten	least	severe	impacts;	these	were	the	summed	responses	1	and	2	on	
the	Likert	scale	(‘no’	and	‘small’	impact).		
Table	19	-	Ten	least	severe	impacts	of	PDN	
Impact	statement	 %	1/4	or	2/4,	n=62	
PDN	hurts	so	much	it	brings	tears	to	my	eyes	 41.7	
My	skin	is	sensitive	to	the	lightest	touch	 43.1	
PDN	makes	me	feel	embarrassed	 44.4	
PDN	affects	my	appetite	for	food	 44.8	
I	get	more	breathless	than	before	I	had	PDN	 44.8	
I	worry	how	our	money	will	be	affected	because	of	PDN	 45.5	
I	don’t	understand	why	I	have	PDN	 47.1	
My	overall	quality	of	life	is	really	affected	by	PDN	 51.4	
PDN	affects	our	family	holidays	 51.9	
PDN	and	balance	problems	lead	me	to	fall	over	 52.9	
	
The	decrease	in	impact	severity	from	top	rated	(84.2%)	to	bottom	rated	(52.9%)	across	58	
impact	statements	has	been	plotted	as	a	graph	(Figure	19).	The	full	list	of	impacts	based	on	
severity	of	effect	on	quality	of	life	can	be	found	in	Appendix	23.		
6.11.4	Analysis	of	free	text	additions	
Fifteen	respondents	added	free	text.	The	full	transcripts	of	this	text	can	be	found	in	
Appendix	24.	This	text	was	assessed	against	the	code	structure	from	the	patient	interviews	and	30	
codes	were	identified.	Twenty-seven	codes	were	already	in	existence	but	three	new	codes	were	
required	to	accommodate	issues	that	had	not	been	raised	previously:	autonomic	neuropathy;	
self-harming	behaviour	and	hand	numbness.		
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6.11.5	Principal	Component	Analysis	
The	study	protocol	included	PCA	to	reduce	the	58	impact	statements	to	a	smaller	number	
of	summary	indices	(Floyd	and	Widaman,	1995).	Calculations	of	precise	sample	sizes	required	for	
PCA	are	contentious.	A	precedent	in	literature	suggests	5-10	participants	per	variable	with	a	
minimal	sample	size	of	at	least	100-200	participants.	A	counter	argument	examines	the	factor	
loading	size	within	a	calculated	solution,	as	a	measure	of	stability	of	that	solution	(Floyd	and	
Widaman,	1995).	A	sample	size	of	500	was	set	as	sufficient,	with	at	least	20	responses	per	
variable	to	be	analysed.	This	sample	was	not	achieved	meaning	that	PCA	could	not	be	supported.	
6.11.6	Correlation	between	impacts	of	PDN	and	the	Coping	Strategies	Questionnaire	(CSQ)	
Visual	inspection	of	the	data	set	showed	some	missing	data.	After	discussion	with	the	
supervisory	team,	the	following	strategy	was	adopted	in	order	to	maximise	the	dataset.	If	
respondents	had	completed	more	than	51	questions	(85%)	of	this	section,	the	mean	impact	score	
for	that	case	was	calculated	and	this	value	used	to	replace	missing	data	points.	This	approach	
aimed	to	maximise	the	useable	dataset,	by	retaining	cases	that	would	otherwise	be	discarded	due	
to	a	few	missing	items	in	the	survey.	The	approach	of	overall	mean	imputation	(using	the	whole	
sample	mean	to	replace	a	missing	data	point)	has	precedent	in	literature	(Donders	et	al.,	2006)	
but	is	known	to	reduce	the	extent	of	sample	deviation.	Replacement	with	individual	case	mean	
imputation	was	felt	appropriate	to	minimise	the	statistical	shift	that	was	inevitable.	This	process	
was	applied	to	five	cases	that	had	omitted	fewer	than	7	(15%)	of	the	questions,	providing	a	
sample	of	n=48	for	analysis.		
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Figure	19	-	Impacts	with	most	effect	on	quality	of	life	
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The	CSQ	was	scored	for	each	subscale	in	line	with	Jensen	et	al.	(2003).	The	overall	score	for	
Active	coping	was	the	sum	of	Diverting	attention,	Reinterpreting	pain	sensations,	Coping	with	
pain	and	Activity.	The	Passive	coping	score	was	the	sum	of	Catastrophizing	and	Praying/Hoping;	
these	are	in	line	with	literature	recommendations	(Snow-Turek	et	al.	1996).		
The	descriptive	results	for	the	CSQ	can	be	seen	in	Table	20,	higher	scores	represent	greater	
use	of	that	coping	strategy.	Table	20	presents	comparison	data	from	a	survey	of	68	people	with	
PHN,	a	neuropathic	pain	condition	subsequent	to	Herpes	Zosta	virus	(Haythornthwaite	et	al.,	
2003).	The	mean	and	standard	deviation	data	from	these	studies	have	been	used	to	calculate	the	
effect	size	between	these	sample	populations	(Cohen,	1988).	
Table	20	-	Pain	Coping	Strategies	Questionnaire	(CSQ)	descriptive	results	
	Coping	domains	 Mean	(SD),	
n=48	
Comparison	data,	
mean	(SD)	a,	n=68	
Cohen’s	effect	
size	(d)	
Diverting	attention	(DA)	 3.98	(3.40)	 2.27	(1.5)	 0.65	
Reinterpret	sensations	(R)	 3.76	(2.89)	 0.86	(1.2)	 1.31	
Coping	(Co)	 5.69	(3.46)	 3.34	(1.5)	 0.88	
Activity	(Act)	 5.94	(3.04)	 2.80	(1.2)	 1.35	
Ignore	sensations	(Ig)	 4.89	(3.60)	 2.19	(1.2)	 1.00	
Active	coping	(DA,	R,	Ig,	Co	and	Act)	 24.03	(11.71)	 -	 -	
Catastrophizing	(Cat)	 5.67	(3.86)	 1.72	(1.3)	 1.37	
Praying/Hoping	(Pr)	 4.76	(3.44)	 3.44	(1.7)	 0.48	
	Passive	coping	(Cat	and	Pr)	 10.36	(6.42)	 -	 -	
a	Haythornthwaite	et	al.	2003	
	
6.11.6.1	Correlation	of	CSQ	with	total	number	of	impacts	experienced	
The	total	number	of	impacts	experienced	was	any	impact	statement	scored	1-4	on	the	
survey.	Missing	data	were	not	imputed	for	these	variables.	It	was	not	appropriate	to	assume	that	
a	respondent	had	missed	a	specific	question	by	oversight,	rather	than	omitted	it	for	other	
reasons.		
A	correlation	was	then	calculated	between	the	total	number	of	impacts	experienced	and	
Active	and	Passive	CSQ	scales.	For	all	the	analyses,	histograms	were	plotted	and	data	were	
checked	for	normal	distribution.	A	normal	distribution	was	approximated	for	all	supporting	the	
calculation	of	Pearson’s	correlation	statistic.	
Table	21	outlines	the	correlation	results.	There	was	significant	correlation	between	the	
number	of	impacts	experienced	and	CSQ	Passive	coping	scale	(r=0.537,	p<0.001).	As	the	degree	of	
passive	coping	increases,	so	do	the	number	of	experienced	impacts.	There	was	no	significant	
correlation	between	CSQ	Active	coping	and	experienced	impacts	(r=0.235,	p=0.156).		
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6.11.6.2	Correlation	of	CSQ	with	the	mean	severity	of	impacts	experienced	
Any	missing	impact	severity	data	were	replaced	with	the	individual	case	mean	as	previously	
described	(Section	6.10).	This	process	ensured	cases	were	complete	for	inclusion	in	the	
calculation,	rather	than	adding	any	impact	to	the	case	profile.	
	There	was	significant	correlation	between	the	mean	severity	of	impacts	experienced	and	
CSQ	Passive	coping	scale	(r=0.587,	p<0.001).	As	passive	coping	strategies	increased,	so	did	the	
mean	severity	of	impact	on	quality	of	life,	for	the	impacts	experienced.	There	was	no	correlation	
between	CSQ	Active	coping	and	mean	severity	of	impacts	experienced	(r=0.019,	p=0.905),	see	
Table	21.	
6.11.6.3	Correlation	of	CSQ	with	the	total	severity	of	impacts	experienced	
The	total	severity	score	was	calculated	by	calculating	the	sum	of	the	impact	ratings	(Likert	
1-4)	for	each	impact	endorsed	by	the	respondents.	This	provided	a	metric	that	reflected	both	the	
count	and	severity	of	the	impacts	experienced.		
There	was	significant	correlation	between	the	sum	for	total	impacts	experienced	and	CSQ	
Passive	coping	scale	(r=0.619,	p<0.001).	As	passive	coping	strategies	increased,	so	did	the	total	
score	of	impacts	experienced.	There	was	no	significant	correlation	between	CSQ	Active	coping	
and	total	severity	of	impacts	experienced	(r=0.155,	p=0.32),	see	Table	21.	
Table	21	-	Correlation	results	for	CSQ	and	impacts	of	PDN		
	 CSQ	Active	coping	 CSQ	Passive	coping	
Impact	count	(n=43)	 r=0.235,	p=0.156	 r=0.537**,	p<0.001	
Mean	impact	severity	(n=48)	 r=0.019,	p=0.905	 r=0.587**,	p<0.001	
Total	impact	severity	(n=48)	 r=0.155,	p=0.32		 r=0.619**,	p<0.001		
**.	Correlation	is	significant	at	the	0.01	level	(2-tailed).	
	
6.11.7	Seeking	help	for	PDN	
Thirty-seven	respondents	(60.7%)	had	sought	help	from	clinicians,	see	Table	22	below.	
Three	professional	groups	were	mainly	represented	–	GPs	(31.8%),	podiatrists	(20.6%),	and	
Diabetes	consultants	(16.8%).	These	professions	total	69.2%	of	the	clinicians	consulted.	DSNs	
accounted	for	3%	of	the	clinicians	consulted	for	help	managing	PDN.	
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Table	22	-	Have	you	sought	help	for	your	PDN?	
Have	you	sought	help	from	any	health	professional	to	help	
you	to	cope	with	PDN?	
n	(%)	
Yes	 37	(60.7)	
No	 24	(39.3)	
If	yes,	who	from…	 	
GP	 34	(31.8)	
Podiatrist	 22	(20.6)	
Diabetes	consultant	 18	(16.8)	
Physiotherapist	 9	(8.4)	
Pain	consultant	 8	(7.5)	
Diabetes	specialist	nurse	 3	(2.8)	
Psychologist	 3	(2.8)	
Other	-	Cardiovascular	consultant	 1	(1.9)	
Other	-	Neurologist	 1	(1.9)	
	
6.11.8	Patient	priorities	for	help	in	managing	PDN	
Overall,	56	of	58	impacts	were	rated	as	a	priority	by	at	least	one	respondent.	Tables	21-26	
contain	a	percentage	column	that	displays	the	sum	of	priority	ranking,	as	a	percentage	of	the	
potential	maximum	for	the	respondents	in	that	sub-group	(for	example,	if	n=78,	(x/780)*100,	
where	x=the	sum	of	priority	score).	The	approach	to	analysis	for	this	stage	of	the	study	can	be	
found	in	Section	6.10	Data	analysis.		
From	the	sample	as	a	whole	(Table	23)	the	most	reported	top	priorities	were:	sleep	
disturbance	(21.9%	of	maximum	possible	priority);	followed	by	worry	about	physical	fitness	
(14.1%),	numb	feet	(13.5%),	difficulty	walking	(12.1%),	worry	that	PDN	will	worsen	in	the	future	
(11.5%)	and	depression	associated	with	PDN	(11%).	
Table	23	-	Top	10	priorities	for	management	of	PDN	impact	
Impact	statement	 Overall	%,	n=78	
My	sleep	is	disturbed	due	to	PDN	 21.9	
I	worry	about	keeping	my	physical	fitness	due	to	PDN	 14.1	
PDN	causes	me	to	have	numb	feet	 13.5	
PDN	makes	walking	difficult	 12.1	
I	am	worried	that	my	PDN	will	get	worse	in	the	future	 11.5	
PDN	leads	me	to	feel	depressed	 11.0	
PDN	gives	me	a	sense	of	restless	legs	 10.0	
PDN	makes	it	difficult	to	buy	shoes	that	are	comfortable	 10.0	
I	have	to	be	careful	walking	due	to	my	balance	 10.0	
PDN	leads	me	to	get	frustrated	 8.8	
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The	least	reported	priorities	were:	affected	appetite,	changes	to	self-image,	not	coping	with	
PDN	(all	<1%),	and	lastly,	restricted	dancing	and	thinking	of	others,	both	with	0%	priority	(Table	
24).	
Table	24	-	10	least	priorities	for	management	of	PDN	impact	
Impact	statement	 Overall	%,	n=78	
I	have	difficulty	doing	my	job	due	to	PDN	 1.2	
I	struggle	to	get	up	for	work	due	to	the	PDN	 1.0	
PDN	can	lead	me	to	have	headaches	 1.0	
My	PDN	affects	my	close	family	 1.0	
It	bothers	me	what	other	people	think	of	me	due	to	the	
problems	I	have	with	PDN	
1.0	
PDN	affects	my	appetite	for	food	 0.9	
My	self-image	has	changed	due	to	PDN	 0.8	
I	don't	cope	well	with	PDN	 0.1	
PDN	has	stopped	me	going	dancing	 0.0	
I	always	have	to	think	about	the	needs	of	other	people	 0.0	
	
6.11.8.1	Priority	by	sex	
When	priorities	were	examined	based	on	respondent	sex,	sleep	remained	the	top	priority	
for	men	(25.1%)	and	women	(19.3%)	(Table	25).	Physical	fitness	remained	in	the	top	four	for	both	
sexes	(Male	4th	14%,	Female	2nd	14.2%).	Walking	related	issues	were	a	priority	for	both	sexes	but	
for	different	reasons	with	men	identifying	balance	as	an	issue	(12.9%)	and	women	identify	the	
purchase	of	comfy	shoes	as	difficult	(13.3%).		
Table	25	-	Priorities	by	sex	
Impact	statement	 Male	%,	
n=35	
Female	
%,	n=45	
Impact	statement	
My	sleep	is	disturbed	due	to	PDN	 25.1	 19.3	 My	sleep	is	disturbed	due	to	PDN	
PDN	causes	me	to	have	numb	feet	 17.1	 14.2	 I	worry	about	keeping	my	physical	
fitness	due	to	PDN	
I	have	to	be	careful	walking	due	to	
my	balance	
16.3	 13.3	 PDN	makes	it	difficult	to	buy	
shoes	that	are	comfortable	
I	worry	about	keeping	my	physical	
fitness	due	to	PDN	
14.0	 13.0	 I	am	worried	that	my	PDN	will	get	
worse	in	the	future	
PDN	makes	walking	difficult	 12.9	 11.4	 PDN	makes	walking	difficult	
PDN	affects	my	ability	to	do	every	
day	jobs	
12.3	 11.2	 PDN	gives	me	a	sense	of	restless	
legs	
PDN	leads	me	to	feel	depressed	 11.4	 10.7	 PDN	leads	me	to	feel	depressed	
When	PDN	flares	up	I	can	be	less	
tolerant	to	those	around	me	
10.3	 10.7	 PDN	leads	me	to	get	frustrated	
I	have	lost	confidence	to	be	myself	
due	to	PDN	
10.3	 10.5	 PDN	causes	me	to	have	numb	feet	
I	am	not	the	person	I	was	before	I	
developed	PDN	
10.0	 9.8	 I	have	to	check	my	feet	regularly	
for	possible	injury	
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6.11.8.2	Priority	by	type	of	diabetes	
Sleep	remained	the	top	priority	irrespective	of	the	respondent’s	type	of	diabetes	(Type	1	
27.7%,	Type	2	20.2%)	(Table	26).	The	two	subgroups	similarly	prioritised	issues	affecting	their	
fitness	and	issues	that	maybe	related	to	their	walking	(balance,	cramp	and	numbness).		
Table	26	-	Priorities	by	diabetes	type	
Impact	statement	 Type	1	
%,	n=26	
Type	2	
%,	n=49	
Impact	statement	
My	sleep	is	disturbed	due	to	PDN	 27.7	 20.2	 My	sleep	is	disturbed	due	to	PDN	
I	worry	about	keeping	my	physical	
fitness	due	to	PDN	
20.0	 15.7	 PDN	causes	me	to	have	numb	
feet	
PDN	makes	walking	difficult	 15.0	 13.1	 I	am	worried	that	my	PDN	will	get	
worse	in	the	future	
PDN	and	balance	problems	lead	me	
to	fall	over	
14.2	 12.9	 PDN	leads	me	to	feel	depressed	
I	get	cramp	more	frequently	than	
before	I	has	PDN	
13.8	 12.2	 I	have	to	be	careful	walking	due	
to	my	balance	
PDN	affects	my	ability	to	do	every	
day	jobs	
13.5	 11.8	 I	worry	about	keeping	my	physical	
fitness	due	to	PDN	
I	have	to	check	my	feet	regularly	for	
possible	injury	
12.7	 11.8	 PDN	makes	it	difficult	to	buy	
shoes	that	are	comfortable	
PDN	gives	me	a	sense	of	restless	
legs	
12.3	 11.6	 I	have	lost	confidence	to	be	
myself	due	to	PDN	
PDN	leads	me	to	get	frustrated	 9.6	 9.6	 PDN	makes	walking	difficult	
When	PDN	flares	up	I	just	want	to	
be	on	my	own	
9.6	 9.2	 When	PDN	flares	up	I	can	be	less	
tolerant	to	those	around	me	
	
6.11.8.3	Priority	by	pain	intensity	
Respondents	provided	an	average	pain	score	(NRS)	for	the	preceding	week.	Pain	scores	are	
subjective	and	do	not	offer	a	clear	impartial	way	by	which	to	categorise	participants	(Korff,	Jensen	
and	Karoly,	2000).	The	choice	to	use	NRS	provided	categorical	pain	data	that	could	be	considered	
alongside	the	other	subgroup	categories	explored.	An	initial	process	created	three	categories:	
mild	(NRS	0-3),	moderate	(4-6)	and	severe	pain	(7-10)	and	resulted	in	a	substantially	larger	sub-
group	with	severe	pain	(mild	n=15,	moderate	n=24	and	severe	n=39).	Creating	two	categories	for	
low	pain	(NRS	0-5)	and	high	pain	(6-10)	created	two,	more	balanced	categories	(low	pain	n=30,	
high	pain	n=48).		
Irrespective	of	pain	category,	sleep	remained	the	main	priority	(Table	27).	The	high	pain	
subgroup	reported	greater	emotional	impacts	–	depression	(16%),	worry	about	fitness	(13.5%),	
frustration	(11.3%)	and	loss	of	confidence	(10.8%)	than	the	low	pain	subgroup.	The	high	pain	
subgroup	was	the	only	respondent	subgroup	to	prioritise	an	impact	specifically	relating	to	the	
subjective	pain	experience	-	My	feet	look	normal	but	I	have	this	severe	pain	(10.4%).	The	priorities	
of	the	low	pain	subgroup	included	sensory	symptoms	not	explicitly	painful	-	numb	feet	(16%),	
restless	legs	(15.3%),	and	functional	impediments	-	the	need	to	check	feet	regularly	(11%).	
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Emotional	concerns	regarding	the	prognosis	for	PDN	(15.3%),	and	the	impact	PDN	might	have	on	
financial	security	(15%)	remained	in	the	low	pain	subgroup.	
Table	27	-	Priorities	by	pain	category	
Impact	statement	 High	
pain	%,	
n=48	
Low	pain	
%,	n=30	
Impact	statement	
My	sleep	is	disturbed	due	to	PDN	 19.4	 26.0	 My	sleep	is	disturbed	due	to	PDN	
PDN	makes	walking	difficult	 17.7	 16.0	 PDN	causes	me	to	have	numb	feet	
PDN	leads	me	to	feel	depressed	 16.0	 15.3	 I	am	worried	that	my	PDN	will	get	
worse	in	the	future	
I	worry	about	keeping	my	physical	
fitness	due	to	PDN	
13.5	 15.3	 PDN	gives	me	a	sense	of	restless	
legs	
PDN	causes	me	to	have	numb	feet	 11.9	 15.0	 I	worry	how	our	money	will	be	
affected	because	of	PDN	
PDN	leads	me	to	get	frustrated	 11.3	 14.7	 PDN	makes	it	difficult	to	buy	shoes	
that	are	comfortable	
I	have	to	be	careful	walking	due	to	
my	balance	
10.8	 11.0	 I	have	to	check	my	feet	regularly	for	
possible	injury	
I	have	lost	confidence	to	be	myself	
due	to	PDN	
10.8	 9.0	 PDN	affects	me	as	soon	as	I	put	my	
foot	to	the	ground	in	the	morning	
My	feet	look	normal	but	I	have	this	
severe	pain	
10.4	 8.7	 I	have	to	be	careful	walking	due	to	
my	balance	
PDN	affects	my	ability	to	do	every	
day	jobs	
9.4	 8.3	 I	get	cramp	more	frequently	than	
before	I	has	PDN	
	
6.11.8.4	Priority	by	help	seeking	status	
There	were	noticeable	similarities	between	the	priorities	of	those	who	had	sought	help	for	
PDN	and	those	who	had	not	(Table	28).	Sleep	disturbance	(help	seeking	25.9%,	non-help	seeking	
31.3%)	and	worry	about	physical	fitness	(help	seeking	18.9%,	non-help	seeking	16.7%)	remained	
similar	between	these	two	groups	and	when	compared	to	other	sub-groups	examined.	
There	were	also	differences.	The	respondents	who	sought	help	prioritised	certain	impacts	
to	a	greater	extent	than	the	respondents	who	did	not.	These	impacts	were	walking	(help	seeking	
21%,	non-help	seeking	6%),	depression	(help	seeking	18%,	non-help	seeking	8%)	and	pain	in	the	
morning	(help	seeking	14%,	non-help	seeking	1.3%).	These	three	impacts	were	not	in	the	top	10	
for	respondents	who	had	not	sought	help	so	have	been	added	as	extra	lines	in	Table	28.	
The	impacts	that	occur	in	both	subgroups	have	been	colour	coded	to	aid	comparison	in	
Table	28.		
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Table	28	-	Priorities	by	help	seeking	behaviour	
Impact	statement	 Help	
seeking	
%,	n=37	
Not	help	
seeking	
%,	n=24	
Impact	statement	
My	sleep	is	disturbed	due	to	PDN	 25.9	 31.3	 My	sleep	is	disturbed	due	to	PDN	
PDN	makes	walking	difficult	 21.6	 22.5	 PDN	causes	me	to	have	numb	feet	
I	worry	about	keeping	my	physical	
fitness	due	to	PDN	
18.9	 17.5	 I	am	worried	that	my	PDN	will	get	
worse	in	the	future	
PDN	leads	me	to	feel	depressed	 17.8	 16.7	 I	worry	about	keeping	my	physical	
fitness	due	to	PDN	
PDN	affects	me	as	soon	as	I	put	my	foot	
to	the	ground	in	the	morning	
14.6	 16.3	 I	have	to	check	my	feet	regularly	for	
possible	injury	
PDN	affects	my	ability	to	do	every	day	
jobs	
14.1	 15.8	 I	don’t	understand	why	I	have	PDN	
PDN	causes	me	to	have	numb	feet	 13.8	 15.4	 PDN	gives	me	a	sense	of	restless	legs	
PDN	makes	it	difficult	to	buy	shoes	that	
are	comfortable	
13.5	 14.2	 I	have	lost	confidence	to	be	myself	
due	to	PDN	
When	PDN	flares	up	I	can	be	less	
tolerant	to	those	around	me	
13.5	 12.1	 I	have	to	be	careful	walking	due	to	
my	balance	
My	overall	quality	of	life	is	really	
affected	by	PDN	
13.5	 11.7	 PDN	makes	it	difficult	to	buy	shoes	
that	are	comfortable	
	 	 8.0	 PDN	leads	me	to	feel	depressed	
	 	 6.0	 PDN	makes	walking	difficult	
	 	 1.3	 PDN	affects	me	as	soon	as	I	put	my	
foot	to	the	ground	in	the	morning	
	
6.11.8.5	Combining	the	subgroup	priorities	
To	explore	priorities	according	to	participant	subgroup	a	table	was	created	combining	the	
top	five	priorities	for	each	(Table	28).	Six	impacts	were	included	in	the	top	five	priorities	for	at	
least	three	of	the	seven	subgroups:	sleep	strategies,	physical	fitness,	difficulty	walking,	
experiencing	numb	feet	and	both	depression	and	anxiety,	related	to	PDN.	The	top-5	priorities	
from	the	sub-group	who	have	not	sought	help	for	PDN	are	included	in	Table	29	for	comparison,	
these	are	not	dissimilar	to	the	priorities	of	those	who	have	sought	help.		
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Table	29	-	Top	5	priorities	by	sub-group	
Impact	statement	 Men	
(n=35)	
Women	
(n=45)	
Type	
1	
(n=26)	
Type	
2	
(n=49)	
High	
pain		
NRS	
6-10	
(n=48)	
Low	
pain	
NRS	
0-5	
(n=30)	
Help	
seeking	
(n=37)	
Not	
help	
seeking	
(n=24)	
My	sleep	is	disturbed	due	to	PDN	 1	 1	 1	 1	 1	 1	 1	 1	
I	worry	about	keeping	physical	fitness	
due	to	PDN	 4	 2	 2	 	 4	 	 3	 4	
PDN	makes	walking	difficult	 5	 5	 3	 	 2	 	 2	 	
PDN	causes	me	to	have	numb	feet	 2	 	 	 2	 5	 2	 	 2	
I	am	worried	that	PDN	will	get	worse	
in	the	future	 	 4	 	 3	 	 3	 	 3	
PDN	leads	me	to	feel	depressed	 	 	 	 4	 3	 	 4	 	
I	have	to	be	careful	walking	due	to	
my	balance	 3	 	 	 5	 	 	 	 	
PDN	makes	it	difficult	to	buy	shoes	
that	are	comfortable	 	 3	 	 	 	 	 	 	
PDN	and	balance	problems	lead	me	
to	fall	over	 	 	 4	 	 	 	 	 	
I	get	cramp	more	frequently	than	
before	I	has	PDN	 	 	 5	 	 	 	 	 	
PDN	gives	me	a	sense	of	restless	legs	 	 	 	 	 	 4	 	 	
I	worry	how	money	will	be	affected	
because	of	PDN	 	 	 	 	 	 5	 	 	
PDN	affects	me	as	soon	as	I	put	my	
foot	to	the	ground	in	the	morning	 	 	 	 	 	 	 5	 	
I	have	to	check	my	feet	regularly	for	
possible	injury	 	 	 	 	 	 	 	 5	
NRS	–	Numerical	rating	scale;	Green	box	–	impacts	prioritised;	Numerals	indicate	order	of	top-5	priorities.		
	
6.12	Discussion	
In	this	Internet	survey	a	wide	range	of	impacts,	drawn	from	interviews	with	people	with	
PDN,	were	presented	to	participants.	The	majority	of	impacts	were	identified	by	the	survey	
respondents	as	present	in	their	lives	and	affect	these	impacts	had	on	quality	of	life	ranged	from	
small	to	large.	People	who	used	passive	coping	strategies	experienced	a	greater	negative	impact	
on	their	quality	of	life,	but	active	coping	was	not	shown	to	be	adaptive	or	to	attenuate	these	
impacts.	Respondents	were	free	to	choose	the	impacts	they	would	prioritise	to	manage	better,	
and	there	were	some	consistent	themes	through	the	selection	of	priorities,	irrespective	of	
respondent	subgrouping.					
6.12.1	Frequency	of	impacts	
Fifty-four	of	the	fifty-eight	impact	statements	were	individually	recognised	as	being	
experienced	by	at	least	half	the	sample.	These	findings	highlight	the	impacts	of	PDN	on	the	
individual	as	multi-faceted,	wide-ranging	and	pervasive.	Within	the	top-10	experienced	impacts,	
were	statements	that	described	the	subjective	sensations	of	PDN	(My	feet	look	normal	but	I	have	
this	severe	pain,	PDN	causes	me	to	have	numb	feet,	PDN	gives	me	a	sense	of	restless	legs),	but	the	
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top-10	also	included	psychological	impacts	(Worry	that	PDN	will	get	worse	in	the	future,	PDN	
leads	me	to	be	frustrated);	social	impacts	(PDN	makes	me	less	tolerant	to	those	around	me);	and	
functional	impacts	(I	have	to	check	my	feet	regularly	for	possible	injury,	My	sleep	is	disturbed,	PDN	
makes	walking	more	difficult).	The	impact	PDN	affects	my	ability	to	concentrate	could	be	
considered	social	and/or	functional.	
6.12.1.1	Impacts	associated	with	neuropathy	
Four	of	these	impacts	–	numb	feet,	restless	legs,	needing	to	check	feet	for	damage	and	
difficulty	walking	–	were	indicative	of	diabetic	neuropathy,	the	prerequisite	for	developing	PDN.	It	
was	not	surprising	that	the	majority	of	respondents	had	experience	of	these	impacts,	as	some	
degree	of	impairment	due	to	neuropathy	would	be	expected,	even	without	the	experience	of	
pain.		
The	most	frequent	impacts	experienced	highlight	the	disconnect	between	insensate	
neuropathy	and	neuropathic	pain.	Respondent’s	most	frequent	impact	(94.8%)	reflected	the	need	
to	check	their	feet	for	injury	because	neuropathy	had	reduced	the	normal	protective	reactions	to	
tissue	damage.	Engaging	in	regular	injury	surveillance,	and	finding	no	damage	to	account	for	the	
pain,	was	an	impact	experienced	by	88.7%	of	respondents.	This	disconnect	was	a	strong	theme	in	
the	patient	interview	study	(see	Chapter	4	section	4.7)	where	participants	increasingly	kept	their	
pain	to	themselves,	and	did	not	raise	it	with	family	and	friends,	because	they	could	not	explain	
the	experience.	
“You	know	what	I	mean,	they’re	not	gnarled	and	knotty,	they	look	quite	ordinary	
feet	and	yet	they’ve	got	this	most	incredible	pains.”	Lisa,	F69.	
Pathologies	often	associated	with	persistent	pain	have	a	range	of	visibility	to	the	observer.	
People	with	rheumatoid	arthritis	affecting	their	hands	tend	to	have	more	obvious	joint	redness	
and	deformity	than	those	who	do	not	have	RA	(Stone,	2009).	People	with	Complex	Regional	Pain	
Syndrome	often	have	a	limb	that	is	oedematous	and	red	(McCabe	and	Blake,	2008).		In	contrast,	
other	pathologies	causing	pain	have	minimal	visibility	to	indicate	their	presence.	For	example,	it	is	
not	possible	to	see	lumbar	or	cervical	disc	pathologies	without	MRI	scans	(Suri	et	al.,	2014).	Nerve	
conduction	studies,	a	common	objective	measure	of	nerve	function,	can	be	within	normal	range	
in	people	with	diabetic	neuropathy	(Horowitz,	2006).	For	all	these	clinical	examples,	there	
remains	no	clear	relationship	between	objective	signs	and	personal	pain	experience.	Due	to	these	
inconsistencies,	people	with	persistent	pain	problems	have	felt	scepticism	from	others	toward	
their	experience	(Smith	and	Osborn,	2007),	even	stigmatized	as	malingers	(Slade,	Molloy	and	
Keating,	2009;	Cohen	et	al.,	2011).		
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Concern	about	the	opinion	and	reactions	of	others	is	a	common	experience	when	living	
with	a	persistent	and	private	pain	experience	(Bunzli	et	al.,	2013;	Cohen	et	al.,	2011;	Smith	and	
Osborn,	2007).	A	focus	group	study		explored	peoples’	expectations	of	a	pain	clinic	whilst	they	
were	waiting	for	a	first	assessment	(Allcock,	Elkan	and	Williams,	2007).	The	sample	(n=18	in	three	
focus	groups)	mainly	experienced	persistent	spinal	pain,	with	only	one	person	with	facial	
neuropathic	pain.		A	strong	theme	of	expectation	for	a	diagnosis	was	found,	as	this	would	provide	
validation	to	society	for	the	pain	the	person	experienced.	Diabetes	is	not	uncommon	and	there	is	
awareness	amongst	the	general	public	that	DM	can	cause	numb	feet,	but	the	symptom	of	pain	is	
under-recognised	by	the	public	and	HCPs	(Taylor-Stokes	et	al.,	2011).		
Providing	diagnostic	labels	has	not	been	shown	to	have	significant	effects	on	health	
outcomes	in	FMS.	FMS	presents	with	a	range	of	physical,	mood	and	social	impacts	and	patient	
response	to	the	diagnosis	can	be	variable,	some	finding	it	useful	to	validate	their	experience,	
others	finding	the	label	had	negative	connotations	(Karjalainen	et	al.,	2009).	A	prospective	study	
with	100	people,	n=28	with	an	existing	diagnosis	of	FMS	and	n=72	newly	diagnosed	with	FMS	
were	followed	for	3	years	(White	et	al.,	2002).	Between	group	analysis	found	no	meaningful	
differences	in	measures	of	symptom	severity,	FMS	impact	or	health	service	usage	between	the	
groups	from	attribution	of	the	FMS	label.	The	study	did	not	include	any	qualitative	enquiry	to	
establish	whether	the	FMS	label	had	altered	the	participants’	quality	of	relationships	and	
interactions	with	others	in	their	social	networks.		
6.12.1.2	Impacts	associated	with	cognitions	
Psychologically,	respondents	were	worried	for	their	future	with	PDN,	and	frustrated	by	
PDN.	There	have	been	few	large-scale	long-term	epidemiological	studies	in	PDN,	to	elucidate	the	
natural	history	of	the	condition.	Up-to-date	reviews	often	cite	the	same	few	studies.	Boulton	et	
al.	(1983)	followed	39	patients	with	PDN	over	four	years	and	found	no	change	in	pain	ratings	
across	that	time	(mean	5.3(SD2.0)	to	5.6(SD2.5),	non-significant);	Benbow	et	al.	(1994)	followed	
33	patients	with	follow	up	at	mean	3.6	years,	and	found	88%	improved	in	pain	rating	and	only	
12%	worsened.	In	contrast	Galer	et	al.	(2000)	in	a	retrospective	survey	(n=105)	found	71%	of	
respondents	estimated	their	PDN	had	worsened	since	first	onset,	15%	rated	it	unchanged	and	
12%	rated	it	as	improved.	The	discrepancy	of	these	conflicting	data	continues	in	current	reviews	
(Coppini,	2016)	and	this	leaves	clinicians	and	patients	uncertain	for	future	changes	in	pain.	
The	impact	phrase	used	in	this	survey	–	PDN	leads	me	to	get	frustrated	–	was	developed	
from	the	descriptions	interview	participants	gave	of	limitations	in	day-to-day	activity	(Chapter	4	
section	4.5.3).	The	survey	development	process	asked	EPRPs	to	sense	check	the	statements	but	
survey	respondents	may	have	had	different	interpretations,	so	caution	is	suggested.	With	this	
caveat,	if	we	take	frustration	to	relate	to	restrictions	in	the	present,	rather	than	due	to	past	life	
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experiences	or	potential	futures,	there	are	links	to	other	frequently	experienced	impacts.	For	
example,	there	are	clear	links	between	frustration	(impact	experienced	89.7%),	ability	to	
concentrate	(86%),	reduced	tolerance	to	those	around	me	(84.5%),	and	difficulty	walking	(83.6%).	
Walking	between	tasks,	even	within	the	home	is	usually	necessary	to	some	degree.	Pain	has	been	
described	as	an	interfering	perception,	one	that	demands	attention	and	so	diverts	attention	away	
from	competing	tasks	(Morley	and	Williams,	2015).	Frustration	can	be	thought	of	as	opposition	in	
the	pursuit	of	an	outcome;	there	is	a	sense	of	conflict	in	the	language	used.	Some	interview	
participants	described	less	confrontational,	more	adaptive	strategies	to	achieve	what	they	
planned	day-to-day.	These	strategies	included	waiting	for	a	day	when	pain	was	less	severe	to	
address	the	task,	using	walking	aids	to	reduce	worry	of	falling	or	hiring	a	wheelchair	to	extend	the	
distance	they	could	go	from	the	car.		
“You	know	the	things	and	the	places	will	always	be	there,	they	will	be	there	the	next	
day	so	if	you	don’t	achieve	something	today	there	is	always	tomorrow.”	Joan,	F57.	
The	self-perception	of	problem	solving	ability	and	the	impact	of	worrying	about	pain	has	
been	explored	with	people	with	chronic	pain	(de	Vlieger,	Crombez	and	Eccleston,	2006).	Using	the	
Problem-Solving	Inventory,	a	measure	of	participant’s	perception	of	their	own	behaviours	related	
to	problem-solving,	pain	clinic	patients	(n=185,	54%	LBP)	had	a	mean	score	of	91.86	(SD25.43),	
which	was	not	significantly	different	when	compared	to	a	community	cohort	(mean	90.46	
(SD24.36).	Problem	solving	behaviours	did	not	contribute	to	regression	models	for	pain	or	pain-
related	disability.	Reduced	confidence	in	problem	solving	did	have	a	positive	correlation	with	
depression	(r=0.24,	p<0.01)	and	pain-related	disability	(r=0.16,	p<0.01).	Study	participants	also	
completed	the	Worrying	Domains	Questionnaire.	Previous	research	had	used	cluster	analysis	to	
define	five	domains	of	worry:	1)	relationships,	2)	lack	of	confidence,	3)	aimless	future,	4)	work	
incompetence	and	5)	finances.	The	total	Worrying	Domains	Questionnaire	score	was	not	
significantly	different	between	the	two	groups	(pain	clinic	mean	25.75	(SD19.78);	community	
cohort	24.85	(SD18.61)).	Worrying	and	catastrophizing	about	pain	did	contribute	toward	models	
for	depression	(β=0.35,	p<0.005	and	β=0.29,	p<0.005,	respectively).		
Neither	the	interview	study	(Chapter	4)	nor	this	survey	study	were	designed	to	explore	
whether	adaptive	problem	solving,	or	less	confrontational	approaches	to	day-to-day	frustrations	
had	any	bearing	on	quality	of	life.	Reflecting	on	the	patient	interviews	suggests	that	those	who	
described	active	problem	solving	and	adaptations	in	the	presence	of	PDN,	were	more	optimistic	
describing	less	impact	on	their	quality	of	life.	It	would	be	interesting	to	quantify	how	people	with	
PDN	consider	their	own	problem	solving	abilities	using	specific	outcome	measures	and	an	
appropriately	powered	sample	size.		
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The	issue	of	worrying	and	catastrophizing	about	pain	returns	to	the	first	impact	discussed	in	
this	section,	that	respondents	were	frequently	concerned	about	their	future	prognosis	with	PDN.	
The	issue	of	frustration,	with	the	connotation	of	day-to-day	restrictions	of	agency	also	returns	to	
the	philosophical	underpinnings	of	common	psychological	interventions	for	pain	–	ACT	and	CBT	
(see	Chapter	1	section	1.5.2).	ACT	particularly	focuses	on	reducing	the	use	of	behaviours	and	
thinking	styles	that	involve	resistance,	rather,	emphasising	behavioural	and	psychological	
flexibility	(McCracken	and	Vowles,	2014).			
6.12.1.3	Impacts	associated	with	function	
Sleep	was	identified	as	the	third	most	frequent	impact	(91.8%).	This	is	reflective	of	the	
known	affect	PDN	has	on	sleep	from	quantitative	research	(Zelman,	Brandenburg	and	Gore,	
2006),	as	well	as	other	neuropathic	pain	conditions	such	as	MS	(Braley,	2015),	and	non-specific	
wide	spread	pain	conditions	(McBeth	et	al.,	2015).	Reduced	sleep	quality	impairs	the	person’s	
resilience	to	cope	with	living	with	persistent	health	problems	(Sivertsen	et	al.,	2015).		
When	effective,	analgesic	medication	for	pain	can	reduce	the	impacts	of	a	pain	condition.	
For	example,	Hoffman	et	al.	(2010)	in	a	study	with	n=401	people	with	PDN,	found	a	30-39%	
reduction	in	pain	was	associated	with	a	mean	reduction	of	-2	points	(on	a	0-10	scale)	interference	
in	sleep	quality.	Using	a	different	metric	for	pain	reduction	they	found	if	the	pain	reduced	from	
‘severe’	to	‘moderate’	intensity,	sleep	interference	reduced	by	a	mean	-5	points	(BPI).	Whether	
such	changes	are	meaningful	to	the	person	are	unknown,	studies	to	define	the	minimum	clinically	
important	difference	have	tended	to	focus	on	pain	reduction,	rather	than	pain	interference	
reduction.		
Nonetheless,	the	relationships	between	sleep,	pain	and	cognitive	variables	are	complex.	
Sleep	disturbance	and	pain	are	suggested	to	have	bidirectional	associations	whereby	one	
symptom	negatively	affects	the	other	(Sivertsen	et	al.,	2015;	Finan,	Goodin	and	Smith,	2013).	
Although	inter-related,	the	evidence	suggests	the	relationship	is	weighted	toward	sleep-related	
cognitions	having	a	larger	impact	on	sleep,	than	pain	severity	(McBeth	et	al.,	2015).	For	PDN	an	
association	has	been	found	between	worsening	sleep	quality	and	both	increased	pain	(r=0.40	
p<0.001)	and	increased	symptoms	of	depression	(r=0.30,	p<0.001).	Sleep	disturbance	was	shown	
to	mediate	the	effect	of	pain	on	depression	scores	from	r=0.34	to	r=0.29	(both	p<0.001)	(Hughes	
et	al.,	2016).		
The	rationale	for	the	use	of	Amitriptyline	for	persistent	pain	can	be	based	on	sedative	side	
effects.	Patients	do	not	report	less	pain,	but	that	they	can	cope	better,	having	slept	better.	This	
finding	was	present	in	both	patient	and	clinician	interview	results.	
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“…if	the	pain	is	worst	at	night	that	would	push	me	more	towards	Amitriptyline,	
because	Amitriptyline	tends	to	cause	a	bit	of	sedation	and	therefore	actually	helps	
people	with	sleep.”	Diabetes	Consultant	1.	
Walking	was	another	day-to-day	functional	act	impeded	by	PDN.	Eighty-three	per	cent	of	
respondents	experienced	walking	issues	because	of	PDN.	This	finding	was	consistent	with	other	
quantitative	research	that	found	walking	and	sleep	to	be	most	interfered	with	by	PDN	(BPI	
subscale	4.6-5.6/10	(Tölle,	Xu	and	Sadosky,	2006;	Galer,	Gianas	and	Jensen,	2000;	Hoffman	et	al.,	
2010)).	Seventeen	per	cent	of	survey	respondents	did	not	experience	issues	from	PDN	when	
walking.	A	number	of	interview	participants	described	being	‘aware’	of	their	feet,	but	not	‘in	pain’	
when	walking	(Chapter	4	section	4.5.4).	Subjective	appraisal	of	meaning	and	context	can	have	the	
effect	of	changing	the	unpleasantness	of	an	experience	(Bartolo	et	al.,	2013;	Moseley	and	Arntz,	
2007).		
6.12.1.4	Impacts	least	frequently	experienced	
The	least	experienced	impact	of	PDN	was	contemplation	of	suicide	(not	experienced	by	
70.7%).	This	result	was	a	relative	outlier,	as	the	second	least	experienced	impact	-	PDN	leads	me	
to	have	headaches	–	was	not	experienced	by	53.4%	of	respondents.	This	result	does	however	
imply	that	30%	of	people	with	PDN	had	suicidal	thoughts	at	some	time.	This	would	be	a	significant	
number	of	people	if	representative	of	the	UK	population	with	PDN.	A	review	of	suicide	in	a	range	
of	chronic	pain	conditions	found	people	with	persistent	pain	were	more	than	twice	as	likely	to	
commit	suicide	than	those	without	pain,	with	lifetime	prevalence	found	to	be	5-14%	(Tang	and	
Crane,	2006).	Tang	and	Crane	(2006)	identified	eight	risk	factors	for	suicide,	these	included	pain-
related	sleep-onset	insomnia,	pain	catastrophizing,	helplessness	in	the	face	of	pain	and	reduced	
problem-solving	ability.	These	issues	were	all	been	identified	by	the	survey	respondents,	and	in	
the	wider	population	with	PDN	(Zelman,	Brandenburg	and	Gore,	2006;	Geelen	et	al.,	2016;	
Sullivan,	Lynch	and	Clark,	2005).		
Other	less	frequently	experienced	impacts	have	associations	with	central	sensitisation	as	a	
predominant	pain	mechanism.	Headaches	are	not	part	of	the	diagnostic	criteria	for	PDN	(Peltier,	
Goutman	and	Callaghan,	2014),	yet	47%	of	respondents	associated	them	with	PDN.	Headaches,	
particularly	involving	light	sensitivity,	have	been	suggested	part	of	the	symptom	profile	for	pain	
with	predominantly	central	mechanism	(Nijs	et	al.	2010).	Similarly,	PDN	affecting	memory	was	
identified	by	50%	of	respondents.	Cognitive	decline	(Biessels,	Deary	and	Ryan,	2008)	and	
prolonged	stress	over	the	life	span	(Chrousos,	2009)	have	been	associated	with	diabetes	and	can	
manifest	as	problems	with	reduced	short-term	memory.	
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Some	impacts,	which	appear	similar,	were	present	in	both	high	frequency	and	low	
frequency	analysis.	Worry	about	PDN	into	the	future	(93.4%),	presented	as	a	general	concern	for	
future	prognosis,	and	within	the	least	frequent	impacts	–	Worry	about	going	out	of	the	house	
(44%)	and	Worry	about	how	money	will	be	affected	(45%).	Similarly,	When	PDN	flares	I	can	be	less	
tolerant	to	those	around	me	(84.5%)	is	comparable	to	My	PDN	affects	my	close	family	(44.8%).		
The	occurrence	of	similar	impacts	in	both	high	and	low	frequency	analysis	could	be	
explained	by	a	number	of	factors:	1)	respondents	selected	the	rating	for	each	impact	considering	
their	own	situation	-	if	retired	and	not	dependent	upon	work	for	income,	then	selecting	an	impact	
related	to	future	earnings	would	be	less	likely;	2)	all	impact	statements	were	derived	from	
interviews	where	the	participants	used	their	own	words	to	describe	the	impacts	of	PDN.	The	
phrasing	of	impact	statements	was	kept	faithful	to	the	language	used	in	these	interviews.	Had	the	
response	rate	been	sufficient,	PCA	would	have	collapsed	the	58	individual	impacts	to	a	reduced	
number	of	indices	for	discussion.	
6.12.2	Severity	of	impacts	
It	was	interesting	to	note	the	top-10	most	severe	impacts	of	PDN	(Table	18)	did	not	include	
any	that	described	the	subjective	pain	experienced	with	PDN.	Rather,	the	impacts	in	Table	18	may	
be	classed	as	psychological	(worry,	frustration),	social	(other	peoples’	opinions,	social	life)	and	
functional	(sleep,	general	activities,	physical	activity).	The	sensory	impacts	of	cramp	and	
numbness,	reported	in	this	study,	are	common	with	non-painful	diabetic	neuropathy	(Peltier,	
Goutman	and	Callaghan,	2014).	Headaches	had	not	previously	been	linked	with	PDN	but	have	
with	central	pain	states	(Nijs,	Van	Houdenhove	and	Oostendorp,	2010),	yet	headaches	related	to	
PDN	were	experienced	by	47%	of	the	respondents	and	rated	as	having	a	severe	impact	on	quality	
of	life	when	present	(74.5%).	
These	results	were	plotted	in	graphical	form	in	Figure	19.	The	least	rated	impact	for	
severity	(PDN	and	balance	problems	lead	me	to	fall	over)	was	rated	1	or	2/4	(no	or	minimal)	for	
impact	on	quality	of	life	by	52.9%	of	respondents,	therefore	rated	as	3	or	4/4	(moderate	or	large)	
by	47%	of	respondents.	Although	this	discussion	dichotomizes	the	results	to	the	great	and	least	
impact	on	respondent	quality	of	life,	the	reality	is	not	black	and	white.	
6.12.2.1	Impacts	affecting	quality	of	life	the	most	
The	impact	on	quality	of	life	rated	as	most	severe	by	participants	was	worry	about	PDN	
worsening	in	the	future.	The	natural	history	of	PDN	is	uncertain	from	the	few	longer-term	studies	
available	(see	section	6.12.1.2	for	details)	meaning	that	it	is	not	possible	to	allay	patient’s	worry	
about	future	prognosis	and	impact.	
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The	impact	rated	second	for	severity,	related	to	the	perception	of	others.	The	discussion	in	
section	6.12.1.1	remains	relevant	when	considering	impact	severity	as	well	as	frequency.	
Reductions	in	sleep	quality	are	known	to	have	negative	associations	with	quality	of	life	
(McBeth	et	al.,	2015;	Finan,	Goodin	and	Smith,	2013)	and	to	increase	the	risk	of	depression	
(Hughes	et	al.,	2016)	and	suicide	(Tang	and	Crane,	2006),	the	discussion	in	section	6.12.1.3	
remains	relevant	when	considering	impact	severity	as	well	as	frequency.		
Three	impacts	(PDN	affects	a	wide	range	of	activity,	I	have	reduced	my	physical	activity	due	
to	PDN,	and	PDN	affects	my	social	life)	may	all	be	considered	measures	of	engagement	with	the	
society	that	surrounds	the	person.	A	reduction	in	life	engagement	is	common	in	other	persistent	
pain	conditions	but	is	not	linear	to	the	intensity	of	pain	experienced;	rather,	engagement	can	be	
mediated	by	cognitive	factors	such	as	fear-avoidance	and	catastrophizing	(Vlaeyen	and	Linton,	
2000;	Wideman	et	al.,	2013).	Models	of	fear/avoidance	(Vlaeyen	&	Linton	2000)	highlight	that	
withdrawal	from	life	engagement	will	likely	lead	to	loss	of	fitness	and	increased	depression,	which	
in	turn	increase	the	pain	experience.	This	vicious	circle	can	be	very	difficult	to	break,	but	has	clear	
links	to	the	impact	respondents	rated	most	severe	–	the	prognosis	of	PDN.		
Restrictions	to	daily	activity,	physical	activity	and	social	life	are	possible	sub-issues	that	
contribute	to	the	impact	of	PDN	leads	me	to	get	frustrated	(75%).	This	survey	study	has	shown	
frustration	to	be	frequent	as	well	as	severe	in	the	effect	it	has	on	quality	of	life.	Please	refer	back	
to	section	6.12.1.2	for	more	discussion	on	the	role	of	frustration	in	PDN.		
6.12.2.2	Impacts	affecting	quality	of	life	least		
It	was	surprising	PDN	hurts	so	much	it	brings	tears	to	my	eyes	was	rated	as	having	no,	or	
minimal	impact	on	their	quality	of	life	by	41.7%	of	the	sample.	The	wording	of	the	impact	
statement	came	from	an	interview	quote	and	it	is	possible	that	different	wording	would	have	led	
to	different	results.	The	absence	of	pain	from	the	most	severe	impacts	and	its	presence	in	the	
least	severe	impacts,	highlights	focus	on	pain	reduction	per	se,	may	not	be	the	patient’s	priority	
for	PDN	management.	
Similarly,	My	skin	is	sensitive	to	the	lightest	touch,	as	a	description	of	allodynia,	one	of	the	
clinical	hallmarks	of	neuropathic	pain	and	central	sensitisation	(Smith	et	al.,	2012),	was	rated	as	
having	little	impact	on	life	quality	by	43.1%	of	respondents.	Interview	participants	(Chapter	4)	
often	described	the	sensory	irritation	from	the	bed	sheets	contributing	to	their	disturbed	sleep.	
Although	this	impact	was	within	the	10	least	severe	impacts	the	respondents	were	nearly	equally	
divided	regarding	the	severity	of	the	impact.	
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Three	impacts	may	be	considered	together	-	PDN	makes	me	feel	embarrassed	(44.4%),	I	
don’t	understand	why	I	have	PDN	(47.1%),	and	PDN	and	balance	problems	lead	me	to	fall	over	
(52.9%).	The	issue	of	understanding	the	causes	for	PDN	would	seem	to	have	links	to	the	difficulty	
interview	participants	and	survey	respondents	had	for	explaining	their	pain	experience	with	little	
sign	of	damage.	The	risk	of	falls	increases	with	neuropathy	and	falling	could	be	embarrassing.	
Interview	participants	described	other	people	assuming	they	were	drunk	if	they	fell	in	the	street.		
Without	the	benefit	of	statistical	models	the	planned	PCA	would	have	provided,	it	appears	
that	impacts	rated	most	severe	on	quality	of	life	may	be	considered	higher-level	descriptions	of	
problems,	and	those	rated	less	severe	are	more	specific	examples	of	the	higher-level	problems.	If	
an	impact	statement	had	direct	resonance	to	the	respondent’s	experience,	they	would	select	the	
specific	example,	if	not,	the	respondent	may	choose	an	impact	statement	more	global	in	
implication.	For	example:	It	bothers	me	that	other	people	can’t	see	I	have	this	problem	is	a	high-
level	impact	statement,	that	could	contain	a	number	of	sub-impacts	–	PDN	and	balance	problems	
lead	me	to	fall	over,	I	don’t	understand	why	I	have	PDN,	which	may	or	may	not	be	of	direct	
relevance	to	a	survey	respondent.	
6.12.3	Impacts	are	associated	with	other	diabetes	complications	and	sociodemographic	
variables	
The	introduction	presented	sociodemographic	risk	factors	associated	with	the	development	
of	DM	(Chapter	1,	section	1.1.5).	Chapter	1	also	described	the	co-morbidities	associated	with	
diabetes,	and	how	these	co-morbidities	may	be	considered	complications	in	their	own	right.	This	
survey	did	not	ask	details	of	social	variables,	such	as	postcode,	or	presence	of	common	co-
morbidities,	such	as	cardiovascular	disease	or	nephropathy.	Nevertheless,	all	respondents	will	
have	a	unique	profile	of	these	social	and	clinical	variables,	and	these	variables	necessarily	affect	
one	another	in	a	complex	manner.	
An	example	of	such	complexity	can	be	seen	in	the	Norwegian	HUNT3	study	(Tomasdottir	et	
al.,	2013,	2015).	In	HUNT3	health	data	were	collected	from	an	ethnically	homogenous	and	socially	
equitable	region.	The	researchers	gathered	self-report	data	on	a	range	of	health	and	
sociodemographic	variables.	They	recorded	the	prevalence	of	twenty-one	chronic	health	
conditions,	including	DM,	and	twelve	factors	associated	with	stress	responses	(for	example,	blood	
pressure,	heart	rate,	C-reactive	protein	and	cholesterol	levels).	Tomasdottir	et	al.	(2013)	
examined	the	clustering	of	diseases	across	the	sample	population.	They	found	that	if	DM	were	
considered	the	index	disease,	9%	(55/607)	of	people	would	have	no	other	comorbidities	and	51%	
(313/607)	would	have	three	or	more	comorbidities.	In	comparison,	for	people	with	persistent	LBP	
as	the	index	condition,	23%	(1825/7927)	had	no	other	comorbidity	and	27%	(2145/7927)	had	
three	or	more	comorbidities.		
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Respondents	in	HUNT3	were	also	asked	one	question	on	the	quality	of	their	childhood	(5	
points,	very	good	to	very	difficult).	A	general	trend	toward	increasing	prevalence	of	chronic	health	
conditions	was	found	as	the	self-rating	of	childhood	experience	worsened.	For	those	with	a	‘very	
good’	childhood,	27%	had	no	health	conditions,	and	22%	had	three	or	more	chronic	health	
conditions.	For	those	with	a	‘very	difficult’	childhood,	less	than	5%	had	no	health	conditions	and	
57%	had	more	than	three	health	conditions	(OR	1.90	(CI	1.79	to	2.02)).	Diabetes	prevalence	
increased	from	4%	(very	good	childhood)	to	7%	(very	difficult	childhood)	(Tomasdottir	et	al.,	
2013).	
Tomasdottir	et	al.	(2015)	put	forward	the	hypothesis	that	difficult	family	upbringing	as	well	
as	other	sociodemographic	variables	and	life	experiences,	can	contribute	to	allostatic	overload.	
Allostasis	is	where	multiple	systems	compete	to	find	homeostatic	balance,	but	these	systems	are	
not	in	isolation	and	so	affect	one	another	(Chrousos,	2009;	Tsigos	and	Chrousos,	2002).	With	
sustained	stress	from	life	and	social	factors	the	resilience	of	bodily	systems	maybe	so	challenged	
that	chronic	physical	and	mental	health	problems	develop.	
Measures	of	social	deprivation	have	been	found	as	risk	factors	for	developing	PDN	in	
people	with	T1DM	(Anderson	et	al.,	2014).	Anderson	et	al.	(2014)	surveyed	1621	medical	records	
for	patients	with	T1DM	who	were	receiving	treatment	for	neuropathic	pain	(n=280).	Records	
included	Townsend	Deprivation	Index	(TDI)	data,	a	measure	that	counts	unemployment,	non-car	
ownership,	non-house	ownership	and	household	overcrowding	as	variables	for	social	deprivation.	
The	TDI	ranges	from	-5	to	+7,	with	higher	score	indicating	more	social	deprivation.	There	were	
significant	differences	in	TDI	between	those	with	neuropathic	pain	to	those	without.	Patients	
were	more	likely	to	score	TDI	≥	1	(34.3%	vs.	27.1%,	p<0.001).	Multi-variant	analysis	showed	each	
unit	increase	of	TDI	was	associated	with	11%	increase	in	the	odds	ratio	to	require	pharmacological	
management	of	neuropathic	pain	(OR	1.11	(CI	1.05	to	1.17),	p<0.001).	This	was	independent	of	
age,	sex,	HbA1c,	BMI	and	blood	pressure.		
The	diabetes	clinicians	interviewed	were	keen	to	stress	that	patients	who	had	developed	
microvascular	complications,	would	inevitably	also	present	with	macrovascular	complications	
(peripheral	and	cardiac	vascular	disease,	nephropathy,	other	mobility	restrictions	from	
neuropathy).	They	highlighted	that	any	potential	interventions	for	PDN	would	need	to	consider	
these	other	issues	in	its	design.	The	complications	and	co-morbidities	are	particularly	relevant	to	
exercise	prescription	and	the	risk	to	insensate	feet.	They	are	also	relevant	because	many	of	these	
non-PDN	issues	are	associated	with	psychological	impacts,	therefore	any	psychological	
intervention	needs	to	be	specific	to	the	impact	of	PDN	and	possibly	applicable	to	other	causes	of	
distress.		
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For	PDN,	which	has	impacts	both	wide-ranging	and	interconnected,	it	is	not	surprising	a	
mono-modal	approach	to	management	thorough	analgesic	medication	has	been	less	than	
successful.	As	outlined	earlier,	the	response	statistics	(NNTs)	for	the	recommended	medications	
are	low,	and	this	survey	now	demonstrates	that	people	with	PDN	do	not	necessarily	prioritise	
pain	reduction.	With	common	impact	co-occurrence,	it	may	be	appropriate	to	consider	more	
multi-modal	approaches	for	overall	management	of	PDN,	within	the	context	of	common	diabetic	
co-morbidities.	
6.12.4	Coping	with	PDN	
In	comparison	to	the	population	with	PHN	(Haythornthwaite	et	al.,	2003),	the	survey	
respondents	reported	engaging	in	higher	levels	of	active	coping	strategies.	Reinterpretation	of	
symptoms,	Activity	engagement	and	Ignoring	symptoms,	all	had	large	effect	sizes	of	1.0-1.35	
(Cohen’s	d).	Survey	respondents	also	reported	using	passive	coping	strategies	to	a	greater	extent	
than	the	PHN	cohort.	Catastrophizing	was	highest	in	the	survey	sample,	with	the	largest	effect	
size	(d=1.37),	similarly	Praying	was	higher	in	the	survey	cohort	than	the	PHN	cohort	with	a	
medium	effect	size	(d=0.48).	
Examining	the	correlation	between	coping	strategies	and	impacts	of	PDN	there	were	strong	
associations	between	passive	coping	strategies	and	the	impact	of	PDN.	This	association	was	
present	whether	the	number	of	impacts	(r=0.537),	the	severity	of	impacts	(r=0.587),	or	the	total	
score	of	impacts	(r=0.619,	all	p<0.001)	was	considered.	If	respondents	employed	passive	coping	
strategies,	they	reported	a	greater	impact	of	PDN	on	their	lives.		
However,	engagement	in	active	coping	strategies	did	not	have	an	association	with	the	
impact	of	PDN,	whether	number	of	impacts	(r=0.235),	severity	of	impacts	(r=0.019)	or	total	score	
(r=0.155,	all	non-significant)	were	considered.	It	would	seem	employing	active	strategies	such	as	
activity,	diverting	attention	and	ignoring	sensations,	do	not	necessarily	mitigate	the	experienced	
impact	of	PDN.		
6.12.4.1	Current	models	for	coping	with	persistent	pain	
Coping	with	pain	is	a	broad	subject	area	and	there	are	multiple	theoretical	models	currently	
used	for	conceptualising	the	cognitive	and	behavioural	processes	involved.	Consequently,	there	
are	many	outcome	measures	for	aspects	of	these	theoretical	models.	This	study	used	the	CSQ	as	
an	outcome	measure	that	quantified	behaviours	on	the	continuum	between	active	and	passive	
coping.	For	there	to	be	such	an	asymmetric	relationship	between	patients’	coping	styles	and	PDN	
impacts	suggests,	either	active	strategies	really	do	have	no	benefit	to	PDN	or,	the	constructs	of	
active	coping	captured	by	the	PCS	questionnaire	were	not	appropriate	for	this	population.	
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There	may	be	more	nuanced	approaches	to	coping	that	should	be	considered.	A	recent	
study	examined	pain-related	coping	using	the	Brief	Pain	Coping	Inventory-2	(BPCI-2),	an	outcome	
measure	containing	two	domains:	traditional	pain	management	(pacing,	exercise,	positive	self-
statements,	distraction)	and	psychological	flexibility	(acceptance	of	pain/distress,	present	
moment	focus	and	engagement	in	valued	activity)	(Vowles	et	al.,	2014).	This	cross-sectional	study	
(n=324,	community	pain	service,	50%	LBP)	found	no	association	between	use	of	traditional	pain	
management	approaches,	and	measures	of	patient	function	(-0.09	to	0.08,	non-significant).	There	
was	greater	correlation	between	subscales	measuring	psychological	flexibility	and	patient	
function	(-0.3	to	-0.45,	all	p<0.005).	The	strategies	Vowels	et	al.	(2014)	defined	as	Traditional	pain	
management	strategies	were	consistent	with	those	defined	as	Active	Coping	by	the	CSQ.	
The	study	by	Vowles	et	al.	(2014)	supported	previous	work	trying	to	disentangle	coping	
with	pain,	from	acceptance	of	pain	(McCracken	and	Eccleston,	2003;	Turner,	Jensen	and	Romano,	
2000).	McCracken	&	Eccleston	(2003)	found	measures	of	coping	were	weakly	associated	with	
patient	function,	whereas	acceptance	was	more	strongly	associated	with	greater	activity,	better	
work	status	and	less	depression,	anxiety	and	disability.	Turner	et	al.	(2000)	found	patient	coping	
was	associated	with	physical	function	but	not	depressed	mood;	catastrophizing	was	associated	
with	depression	but	not	physical	function,	and	measures	of	patient	belief	were	associated	with	
both	physical	function	and	depression.	Creating	an	encompassing	model	of	these	wide-ranging	
constructs	is	beyond	the	scope	and	aim	of	this	thesis,	but	there	are	aspects	from	these	cited	
studies,	and	other	literature	that	are	relevant.	
Chapter	1	outlined	the	neurobiology	of	PDN.	A	common	feature	of	neuropathic	pain	is	
spontaneous	exacerbations.	Previous	research	found	people	with	neuropathic	pain	did	not	find	
strategies	taught	by	musculoskeletal	PMPs,	such	as	pacing,	to	be	useful	in	managing	spontaneous	
pain	exacerbations	(Daniel	et	al.,	2007,	2015).	The	results	of	the	current	survey	suggested	using	
active	coping	strategies,	those	frequently	advised	by	PMPs,	do	not	mitigate	the	impact	of	PDN.		
There	is	little	current	evidence	exploring	psychological	approaches	to	managing	PDN	
(Chapter	2),	but	it	maybe	promotion	of	acceptance	and	psychological	flexibility	could	be	beneficial	
for	this	population.	In	their	review	of	notions	related	to	quality	of	life,	Barcaccia	et	al.	(2013)	note	
other	authors	have	considered	QOL	as	“the	gap	between	what	a	person	is	capable	of	doing	and	
being,	and	what	they	would	like	to	do	and	be;	in	essence	it	is	the	gap	between	capability	reality	
and	expectations”.		If	people	were	able	to	engage	in	valued	activities	despite	pain,	this	may	help	
to	reduce	the	severity	of	impacts	identified	in	this	study	(Table	18).	If	people	could	engage	in	the	
functions	and	social	activities	identified,	they	may	rate	their	quality	of	life	as	improved,	whilst	also	
providing	physical	loading	and	stress	to	their	tissues	that	may	offset	ulceration	(Chapter	5,	section	
5.6.2).	
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6.12.5	Priorities	for	management	
During	the	survey	design	process	literature	searches	were	completed	to	find	precedents	for	
scoring	and	analysing	patient	priorities	in	managing	disease	impacts.	Studies	were	located	that	
investigated	priorities	of	people	with	RA	to	find	the	impacts	most	important	for	improving	with	
medication	strategies	(Sanderson	et	al.,	2010).	Rheumatology	patients	present	with	a	range	of	
issues	that	the	spectrum	of	anti-inflammatory	medication	options	does	not	adequately	address.	
Inflammatory	pain,	such	as	that	experienced	in	RA,	has	specific	mechanisms	that	are	distinct	from	
neuropathic	mechanisms	in	PDN,	so	research	findings	may	be	informative	but	cannot	be	assumed	
to	transpose	to	PDN.	The	analytic	approach	to	calculate	patient	priority	scores	used	in	the	current	
study	was	based	on	the	method	used	by	Sanderson	et	al.	(2010a).		
Despite	examining	a	variety	of	subgroups	within	the	survey	sample,	certain	impacts	were	
consistently	prioritised	by	respondents.	The	top	six	impacts	that	respondent	subgroups	
consistently	wanted	help	to	manage	were:	sleep	disturbance,	worry	about	physical	fitness,	
difficulty	walking,	numb	feet,	anxiety	for	the	future	and	depression.	The	functional	nature	of	
these	priorities	has	similarities	and	differences	to	the	findings	of	Schneider	et	al.	(2014).	
Schneider	at	al.	(2014)	had	asked	patients	with	PDN	to	select	which	areas	of	interference	due	to	
PDN	they	wanted	pain	treatment	to	improve.	The	areas	of	interference	were	the	subscales	from	
the	BPI.	They	found	increased	activity	levels	(29.3%,	CI	27.5	to	31%)	and	walking	ability	(24.4%,	CI	
22.8	to	26.1%)	were	the	highest	priorities,	with	sleep	rated	third	(14.7%,	CI	not	specified).	In	
contrast	this	survey	found	sleep	problems	were	consistently	the	top	priority	(21.9%),	irrespective	
of	patient	subgroup.	Worry	about	physical	fitness	(14.1%)	and	difficulty	walking	(12.1%)	could	be	
considered	analogous	to	the	BPI	interference	scales	of	increasing	activity	and	walking.		
It	is	notable	that	respondents	did	not	highly	prioritise	the	pain	of	painful	neuropathy.	
Respondents	in	the	high	pain	category	subgroup	rated	My	feet	look	normal	but	I	have	this	severe	
pain	as	their	9th	treatment	priority	(10.4%).	PDN	affects	me	as	soon	as	I	put	my	foot	to	the	ground	
in	the	morning	was	within	the	top-10	priorities	for	respondents	with	low	pain	(9%)	and	those	who	
had	sought	help	(14%).	It	was	surprising	to	find	subjective	pain	experiences	were	relatively	low	in	
priority	compared	to	functional	and	cognitive	impacts	of	PDN,	since	pain	severity	is	the	focus	of	
the	treatment	guidelines	and	the	majority	of	current	research	on	PDN	management.		
Pharmacology	research	has	investigated	sleep	disturbance	and	fatigue	in	PDN	specifically,	
using	the	SF36	vitality	sub-score	as	a	measure	of	fatigue	(Fishbain	et	al.,	2009).	Baseline	vitality	
scores	were	found	to	be	lower	for	the	cohort	with	DM/PDN	(mean	47.7(SD18.8)),	than	the	
population	with	DM	alone	(55.7(SD21.6))	or	the	healthy	population	(59.9(SD22.1)).	Treatment	
with	Duloxetine	compared	to	placebo	reduced	pain	severity	(mean	-2.7(SD2.3)),	night	pain	(-
2.9(SD2.5)),	and	sleep	interference	(-3.1(SD3.0)),	and	increased	vitality	(8.7(SD18.6),	all	p≤0.001).	
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A	path	analysis	was	conducted	and	it	was	concluded	that	improvements	in	vitality	were	primarily	
due	to	reduced	pain.	The	study	does	not	highlight	that	Duloxetine,	a	selective	serotonin-
norepinephrine	reuptake	inhibitor,	is	a	centrally	acting	anti-depressant.	No	data	were	provided	on	
depression	at	baseline	or	follow	up	points,	and	depression	did	not	appear	to	be	considered	within	
the	pathway	analysis.	The	issue	of	Duloxetine	as	an	analgesic	and	antidepressant	has	been	
addressed	in	a	post-hoc	analysis	of	study	data,	where	patients	with	PDN	and	notable	depression	
were	found	to	respond	preferentially	to	Duloxetine	compared	to	Pregabalin	(anti-epileptic	
medication)	(Ziegler	et	al.,	2014).		
The	diabetes	clinicians	were	clear	they	understood	PDN	had	a	range	of	impacts	on	the	
person,	in	terms	of	mood,	sleep	and	social	function,	yet	beyond	medication	they	had	few	
management	options.	Once	medication	strategies	were	exhausted	they	had	little	to	offer	the	
person.	The	pain	clinicians	interviewed	during	the	study	presented	in	Chapter	5	were	clear	they	
felt	an	ethical	obligation	to	ensure	all	potential	analgesic	treatments	had	been	explored	(see	
chapter	5,	section	5.4.1),	and	there	were	possible	strategies	to	manage	impacts	of	pain	depending	
on	the	patients’	presentation,	beyond	medication.	
This	study	highlighted	that	people	have	a	range	of	priorities	beyond	just	pain	relief	and,	
when	considered	with	the	results	of	the	patient	interview	study,	have	a	range	of	perspectives	on	
non-pharmacological	strategies.	It	would	seem	appropriate	that	clinical	consultations	are	
sufficiently	open	to	allow	these	priorities	and	perspectives	to	be	articulated	between	clinician	and	
patient,	and	appropriate	treatment	decisions	made.	The	treatment	decisions	formulated	in	
collaboration	between	clinician	and	patient	may	still	focus	on	pain	reduction,	but	where	pain	was	
not	the	patient	priority,	or	medication	options	exhausted,	other	treatment	options	which	do	
match	their	expectations	and	priorities	need	considering.		
6.13	Limitations	
6.13.1	Sample	bias	
Sample	bias	is	the	error	between	sample	population	and	whole	population	data,	which	can	
occur	when	the	sample	does	not	adequately	represent	the	population.	This	survey	required	
sampling	a	population	who	were	homogenous,	in	that	they	all	experienced	symptoms	consistent	
with	PDN	but	were	heterogeneous	for	other	sociodemographic	and	clinical	variables.		
The	characteristics	of	the	survey	population	had	similarities	to	the	interview	study	
presented	in	Chapter	4.	The	survey	sample	had	a	similar	percentage	of	sex	split	(male	45%,	
compared	to	47%)	and	types	of	diabetes	(T2DM	63%,	compared	to	56%).	The	respondents	were	
slightly	younger	(survey	population	mean	age	57	years,	compared	to	interview	study	mean	62.5	
years,	p=0.109),	and	the	age	range	in	both	studies	extended	from	24	to	86	years.	The	survey	
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respondents	were	less	likely	to	be	retired	(46%	compared	to	86%)	and	had	been	diagnosed	with	
diabetes	and	PDN	for	less	time	than	the	interview	sample	(diabetes	-	mean	17.8(SD13.7)	years,	
compared	to	mean	23.5(SD17.8)	years,	p=0.04;	PDN	-	mean	7.3(SD6.3)	years,	compared	to	
10.3(SD7.3)	years,	p=0.02).	In	terms	of	age	and	duration	with	diabetes	and	PDN,	the	samples	are	
representative	of	the	wider	UK	population.	To	minimise	non-completion	of	the	study,	information	
about	comorbidities	and	DM	complications	were	not	requested	so	the	full	clinical	profile	of	survey	
respondents	is	not	known.	
The	statements	of	impact	used	in	this	survey	were	derived	from	an	ethnically	homogenous	
population	that	could	lead	to	bias	in	results	and	conclusions	if	translated	to	the	entire	diabetes	
population.	In	an	attempt	to	mitigate	this	bias,	this	survey	allowed	respondents	to	add	their	own	
experience	of	the	impact	of	PDN	as	free	text	response,	if	the	statements	presented	did	not	
encompass	their	experience.	
The	free	text	comments	added	by	respondents	required	creation	of	three	new	codes	to	
encompass	the	impacts	they	described	(see	section	6.11.4).	These	codes	were	subsumed	within	
the	theme	structure	developed	in	Chapter	4	and	did	not	lead	to	any	significant	alterations	the	
theme	structure.	However,	the	survey	sample	was	again	predominantly	White	British	(90%)	and	
caution	should	be	exercised	when	extrapolating	the	results	of	this	survey	to	populations	with	
different	sociocultural	make	up.		
6.13.2	Sample	size	
A	sample	size	was	specified	to	meet	requirements	for	conducting	a	PCA,	but	this	sample	
size	was	not	met.	The	results	and	discussion	for	impact	frequency	and	severity	are	based	on	data	
for	all	58	impacts,	and	not	a	reduced	number	of	indices	PCA	may	have	provided.	The	subgroup	
analysis	of	respondent	priorities	further	reduced	the	sample	size	present	within	each	sub-group.	
These	results	should	be	considered	preliminary	and	require	further	research	using	different	
survey	distribution	options	to	increase	the	response	and	consequent	sample	size	and	
sociodemographic	variety.		
6.13.3	Priorities	chosen	without	contingencies	
In	asking	respondents	to	prioritise	the	impacts	they	wanted	help	with,	each	impact	was	
considered	a	separate	entity	or	issue.	This	survey	did	not	allow	respondents	the	option	to	suggest	
certain	priorities	maybe	dependent	or	contingent	on	other	variables.	For	instance,	loss	of	physical	
fitness	and	walking	ability	were	rated	as	priorities	by	five	of	the	seven	subgroups	examined.	
Improving	these	aspects	of	physical	function	maybe	contingent	on	more	manageable	pain	levels.	
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6.14	Conclusions	
This	study	has	taken	impacts	drawn	from	qualitative	research	and	presented	them	within	
an	Internet	survey.	This	has	allowed	the	impacts	of	PDN	described	by	interview	participants	to	be	
validated	and	endorsed	(or	not)	by	a	larger	population.	The	individual	impacts	presented	were	
experienced	by	at	least	half	of	the	respondent	sample	and	were	often	rated	as	having	a	moderate	
to	large	impact	on	quality	of	life.	The	impact	statements	that	referred	to	the	subjective	
experience	of	PDN	were	not	as	highly	rated	as	might	be	expected,	whereas	functional,	mood	and	
social	impacts	were	rated	as	having	the	most	impact	on	quality	of	life.		Similarly,	when	asked	to	
select	which	impacts	were	most	important	to	manage	better,	respondents	selected	sleep,	daily	
function,	worry	and	depression	related	to	PDN	over	the	subjective	experience	of	pain.		
Passive	coping	strategies	had	strong	association	with	more	frequent	and	more	severe	
impact	ratings,	but	active	coping	strategies	were	not	associated	with	reduction	of	impact.	The	
strategies	required	to	meet	patient	priorities	will	be	the	focus	of	the	next	chapter.	It	will	explore	
whether	or	not	the	priorities	identified	in	this	study	can	be	mapped	to	existing	strategies	to	aid	in	
their	management.	
	
This	chapter	has	described	an	Internet	survey	to	explore	the	priorities	people	with	PDN	had	
for	improved	management.	The	options	presented	were	based	on	the	interview	study	in	Chapter	4.	
The	following	chapter	will	consider	the	top	six	priorities	in	detail,	examining	the	clinical	implication	
of	each	and	directions	for	further	research.	
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The	previous	chapter	detailed	the	results	of	an	Internet	survey	that	asked	respondents	
which	impacts	of	PDN	they	would	prioritise	for	better	management	strategies.	When	the	top	5	
priorities	for	the	seven	subgroups	were	examined,	there	were	six	specific	impacts	consistently	
prioritised.	This	chapter	will	present	a	discussion	of	the	management	strategies	currently	in	
existence	for	these	six	impacts	that	may	be	of	benefit	to	people	with	PDN.	It	will	consider	how	
these	potential	interventions	could	be	delivered	to	help	people	cope	with	these	priority	impacts	
and	make	suggestions	for	further	research	within	each	section.		
This	thesis	aimed	to	examine	whether	physical	and	psychological	strategies	from	PMPs	
would	be	considered	relevant	and	acceptable	to	people	with	PDN	and,	if	so,	how	they	may	need	
to	be	refined	for	this	specific	population.	Figure	20	-	Evidence	synthesis,	represents	the	current	
situation:	DM	and	associated	complications	are	increasing	in	prevalence,	current	PDN	
management	focusses	primarily	on	medication	with	minimal	use	of	specialist	pain	management	
strategies.	The	new	knowledge	developed	from	the	studies	within	this	thesis	can	now	be	
considered	alongside	research	from	existing	pain	management	and	other	chronic	disease	
management	approaches.	This	combined	knowledge	will	inform	the	potential	viability	of	
adjunctive	management	strategies	for	PDN.	This	process	will	also	highlight	where	further	research	
is	required.	
The	survey	presented	in	Chapter	6	found	six	priorities	were	commonly	rated	as	important	
by	respondents.	There	was	some	consistency	in	these	even	when	subgroups	of	respondents	were	
examined.	Each	of	these	priorities	will	be	considered	in	the	following	sections	detailing	the	
evidence	for	management	and	suggestions	for	further	research	as	required.		
Although	the	impacts	identified	in	Chapter	6	had	commonalities	between	subgroups	they	
were	not	uniform.	The	diabetic	specialist	and	primary	care	clinicians	interviewed	(see	Chapter	5)	
were	clear	that	individual	patients	presented	with	differing	profiles	of	clinical	issues.	The	
interviews	with	both	clinicians	and	patients	suggest	the	impacts	associated	with	PDN	do	not	sit	
with	any	one	member	of	the	diabetes	multi-disciplinary	team	(MDT),	or	exclusively	in	either	
primary	or	secondary	care.	Rather,	it	is	the	responsibility	of	the	clinician	to	ensure	their	
consultations	allow	the	person	to	raise	issues	which	are	of	most	importance	to	them.	It	is	then	
the	responsibility	of	the	clinician	to	either	suggest	strategies	to	manage	that	impact,	or	to	know	
how	to	refer	to	the	appropriate	clinician	or	service.	The	suggestions	in	the	following	sections	
could	be	used	by	individual	clinicians,	as	well	as	forming	components	of	a	MDT	PDN	intervention.	
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Figure	20	-	Evidence	synthesis	
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The	following	sections	will	now	describe	each	impact	prioritised	by	respondents	in	the	
Internet	survey	and	consider	the	clinical	and	research	implications	of	each.	
7.1	My	sleep	is	disturbed	due	to	PDN	
Nearly	all	patient	interview	participants	described	diminished	sleep	quality,	or	consequent	
day-to-day	difficulties	resulting	from	lack	of	sleep.	Clinicians	would	often	consider	using	
Amitriptyline	due	to	its	sedative	side	effects,	but	excessive	drowsiness	the	following	day	was	a	
common	complaint	from	patients.	No	interviewees	reported	receiving	any	advice	about	sleep	
strategies.	
Sleep	disturbance	due	to	PDN	was	the	top	management	priority	for	all	sub-groups	
examined.	Pain	and	sleep	disturbance	have	a	close	relationship.	Recent	literature	reviews	suggest	
that	while	pain	can	affect	measures	of	sleep	adequacy	and	quality,	the	stronger	relationship	is	for	
disturbed	sleep	to	worsen	the	pain	experience	(Sivertsen	et	al.,	2015;	Tang,	2009).	While	pain	and	
insomnia	maybe	precipitated	at	the	same	time,	the	impact	pain	has	on	sleep	quality	reduces	over	
time,	but	the	effect	cognitive	and	behavioural	factors	have	on	pain	appear	more	enduring	(Tang,	
2009).		
Existing	CBT	PMPs	often	include	sleep	hygiene	strategies	education,	but	there	is	clearly	less	
content	specific	to	sleep	than	CBT	for	Insomnia	(CBT-I)	programmes.	CBT-I	has	greater	content	on	
specific	sleep	strategies	(sleep	restriction),	stimulus	control	approaches	(sleep	when	sleepy	not	
tired,	regular	get	up	time,	increase	the	association	between	bed	and	sleep)	and	paradoxical	
intention	(reduce	the	effort	to	sleep	and	so	reduce	performance	anxiety)	(Edinger	and	Means,	
2005;	Trauer	et	al.,	2015).	PMPs,	where	the	focus	is	on	managing	pain,	use	single-item	self-report	
measures	or	do	not	routinely	report	sleep	outcomes,	therefore	data	are	limited	on	the	effect	
standard	PMPs	have	on	sleep.	A	systematic	review	by	Tang	(2009),	including	studies	specifically	
investigating	CBT	for	insomnia	with	people	in	pain	(n=3	studies),	found	some	positive	benefits,	
with	improved	sleep	efficiency	(Cohen’s	d	effect	sizes	1.0-2.0)	and	reduced	sleep	onset	latency	
(effect	size	0.9-2.1).	All	three	studies	included	found	no	benefit	for	participants’	pain	ratings.		
In	comparison,	CBT-I	programmes	have	a	greater	evidence	base	for	improving	measures	of	
insomnia	in	people	with	a	primary	sleep	disorder.	A	systematic	review	of	CBT	for	primary	
insomnia	(n=19	studies)	concluded	that	measures	of	sleep	quality	increased	by	clinically	and	
statistically	significant	levels	post-treatment,	when	compared	against	no	active	treatment	(sleep	
onset	reduced	by	19	minutes	(CI	-23.9	to	-14.1),	and	sleep	efficiency	(time	asleep/time	in	bed	
as	%)	increased	by	9.9%	(CI	8.1	to	11.7)	(Trauer	et	al.,	2015).	The	authors	note	their	eligibility	
criteria	excluded	studies	that	included	common	medical	comorbidities	of	insomnia,	so	their	
results	may	only	be	applicable	to	primary	insomnia.	
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Programmes	based	on	ACT	have	also	addressed	insomnia.	ACT	has	a	different	focus	than	
CBT,	promoting	strategies	to	address	metacognitive	processes	(thinking	about	thinking)	rather	
than	challenging	the	cognitions	themselves.	A	model	of	ACT	for	insomnia	makes	a	distinction	
between	primary	arousal	–	expectations	about	sleep,	worry	about	the	daytime	consequences	of	
reduced	sleep,	and	secondary	arousal	–	the	cognitive	bias	toward	certain	thoughts,	rigidity	in	
thinking	and	attachment	to	these	thoughts	(Ong,	Ulmer	and	Manber,	2012).	Ong,	Ulmer	and	
Manber	(2012)	suggest	four	stances	that	can	be	more	adaptive:	balance	(allowing	sleepiness	to	
guide	bed	time),	flexibility	(sleep	intentions	change	with	context),	equanimity	(patience	and	not	
striving	for	sleep)	and	commitment	to	values	(focus	on	important	aspects	of	life	despite	a	range	of	
thoughts	and	emotions).	A	recent	case	series,	non-randomised	trial	examined	ACT	for	insomnia	in	
people	who	had	not	responded	to	CBT-I	interventions	(Hertenstein	et	al.,	2014).	The	researchers	
found	insomnia-related	quality	of	life	improved	significantly	(p=0.017)	and	was	sustained	at	three-
month	follow	up.	This	preliminary	study	was	small	scale	(n=11)	and	did	not	have	an	active	control	
group,	so	results	cannot	be	assigned	to	the	intervention	with	certainty.	
7.1.1	Clinical	implications	
Sleep	was	the	top	priority	for	survey	respondents	suggesting	that	management	of	sleep	
issues	associated	with	PDN	requires	clinical	strategies.	Clinicians	who	are	involved	in	the	
management	of	PDN	need	to	have	skills	to	advise	patients	on	sleep	strategies.	It	may	be	
appropriate	to	base	this	advice	on	CBT-I	principles,	but	further	research	specifically	using	CBT-I	in	
neuropathic	pain	conditions	is	required.	With	the	aim	for	the	patient	requiring	as	few	
appointments	as	possible,	there	is	no	reason	why	members	of	the	current	diabetes	MDT	could	
not	be	trained	to	provide	appropriate	sleep	advice.	It	may	also	be	appropriate	to	bring	other	
clinicians	into	the	MDT	team,	specifically	Occupational	Therapists	who	may	have	more	specific	
experiences	discussing	and	advising	sleep	strategies.		
The	issue	of	MDT	skill	mix,	or,	ensuring	the	patient	sees	the	right	clinician	for	help	with	the	
impacts	of	PDN	they	prioritise	as	soon	as	possible,	will	be	discussed	in	detail	in	section	7.7.		
7.1.2	Research	implications	
Robust	measures	of	sleep	should	be	used	in	any	future	research,	preferably	that	have	been	
validated	for	use	with	neuropathic	pain,	for	example	the	MOS	scale	(Dworkin	et	al.,	2005).	It	is	
difficult	to	use	self-report	measures	for	sleep,	as	these	must	be	completed	retrospectively	and	
inherent	error	exists	trying	to	quantify	an	experience	during	which	respondents	were	
unconscious.	The	alternative	option,	using	sleep	laboratories,	would	be	costlier	but	provide	
empirical	measures	of	sleep	duration	and	sleep	architecture	(Nicholson	and	Verma,	2004).	
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The	PROSPERO	database	maintains	a	register	of	completed	and	on-going	systematic	
reviews.	There	were	studies	identified	as	underway	on	CBT	for	primary	insomnia	and	in	FMS.	
There	were	no	systematic	reviews	investigating	ACT	for	insomnia	currently	registered	(searched	
December	2016).	The	UK	Clinical	Trials	Gateway	had	no	studies	of	psychological	interventions	for	
insomnia	currently	registered	(searched	Feb	2017).	
7.2	I	worry	about	keeping	my	physical	fitness	due	to	PDN	
In	the	patient	interviews,	there	was	a	range	of	patient	discourse	about	exercise	for	health.	
Some	participants	were	acutely	aware	of	altered	capacity	for	exercise	and	the	implications	for	
health,	while	others	did	not	raise	this	topic.	Although	there	are	technical	differences	in	the	
definition	of	physical	activity	(day-to-day	functional	activity)	and	physical	exercise	(specific	activity	
for	health	benefits)	(Caspersen,	Powell	and	Christenson,	1985),	interview	participants	did	not	
explicitly	make	this	distinction.	The	following	sections	will	make	a	distinction	where	possible,	but	
the	researcher	is	mindful	there	are	significant	practical	overlaps	between	these	categories.		
Physical	activity	is	an	important	aspect	of	pain	and	symptom	management	for	a	range	of	
clinical	presentations	including	LBP	(NICE,	2009,	2016),	FMS	(Karjalainen	et	al.,	2009;	Busch	et	al.,	
2013),	osteoarthritis	(NICE,	2015a)	and	fatigue	(Cramp	and	Byron-Daniel,	2012).	Promoting	
physical	activity	and	exercise	is	central	to	all	musculoskeletal	PMPs	(BPS,	2013).	A	recent	
Cochrane	overview	(Geneen	et	al.,	2017)	included	21	systematic	reviews	investigating	exercise	
interventions	for	persistent	pain	problems;	measures	of	physical	function	were	extracted	from	
these	as	secondary	outcomes.	Fourteen	reviews	(n=129	studies,	>9559	participants)	
demonstrated	statistical	improvements	in	physical	function,	for	at	least	one	follow-up	time	point.	
Highlighting	the	results	of	Busch	et	al.	(2007)	who	reviewed	exercise	for	FMS,	as	a	condition	most	
comparable	to	PDN,	they	found	aerobic	exercise	(four	studies,	253	participants)	significantly	
improved	physical	function	with	a	moderate	effect	size,	SMD	0.66	(CI	0.41	to	0.92,	p<0.0001).	
The	effect	PMPs	have	on	physical	disability	has	been	systematically	reviewed.	Kamper	et	al.	
(2015)	found	measures	of	disability	were	reduced	by	SMD	0.23	(CI	0.06	to	0.40)	when	compared	
to	treatment	as	usual	(six	trials,	n=722	participants)	and	by	SMD	0.68	(CI	0.16	to	1.19)	when	
compared	to	physical	treatment	modalities	(10	trials,	n=1169	participants).	The	review	authors	
note	that	the	included	studies	were	of	low	to	moderate	quality	and	had	significant	statistical	
heterogeneity	(I2	>90%),	so	results	should	be	viewed	with	some	caution.		
Exercise	prescription	in	PMPs	is	predicated	on	helping	participants	find	their	baseline	of	
exercise,	which	does	not	flare	pain,	and	gradually	increase	that	level.	A	message	that	pain	does	
not	equal	injury	is	often	used	(BPS,	2013).	The	clinical	fact	that	patients	with	neuropathy	can	have	
injury	to	their	feet	without	the	protective	experience	of	pain	is	a	key	difference	and	
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consideration.	Having	insensate	feet	is	not	a	contraindication	to	weight	bearing	activity	(Colberg	
and	Vinik,	2014;	Sacco	and	Sartor,	2016),	but	engaging	in	physical	activity	requires	checking	feet	
as	part	of	regular	self-management	behaviour,	and	all	clinicians	involved	with	diabetes	should	
ensure	people	are	performing	these	checks	regularly	(NICE,	2004,	2015b).	
Chapter	2	found	engaging	in	regular	physical	activity	may	not	alter	subjective	pain	
experience	in	PDN	but	may	retard	pain	worsening.	Improvement	in	secondary	outcome	measures	
suggest	possible	benefits	to	other	aspects	of	life	such	as	increased	social	engagement	(Ahn	and	
Song,	2012)	and	reduced	emotional	distress	(Dixit,	Maiya	and	Shastry,	2014),	these	outcomes	
maybe	important	to	people	who	valued	physical	fitness	and	health.	Diabetes	clinicians	expressed	
concern	that	people	with	PDN	may	damage	their	feet	if	encouraged	to	exercise	without	
appropriate	protection	behaviours,	however	pain	clinicians	were	cognizant	of	the	risk	and	felt	
there	were	alternative	exercise	options	available	(Chapter	5,	section	5.6.2).	
7.2.1	Considerations	required	when	prescribing	activity	
The	term	prescribing	is	used	deliberately	to	reflect	that	patients	with	PDN	are	uncertain	
what	to	do	physically,	and	so	seek	advice	from	medical	clinicians.	The	clinicians	who	give	advice	
on	physical	activity	need	to	include	what	to	do,	when	to	do	the	activity	and	how	long	for	-	this	is	
analogous	to	advice	giving	for	regimes	of	prescription	medication.	Clinicians	who	prescribe	
medication	should	also	work	with	patients	to	ensure	the	medication	benefits	outweigh	the	side	
effects	and	the	patient	is	empowered	to	understand	the	medication	to	optimally	self-manage.	For	
activity	prescription,	clinicians	need	to	work	with	patients	to	ensure	their	advice	is	acceptable	and	
can	fit	with	the	patient’s	life,	and	that	side	effects	(tissue	break	down	specifically)	are	minimised	
or	monitored.	The	patient	will	then	be	in	a	position	to	self-manage	their	activity	level.		
There	are	many	reasons	why	a	person	with	diabetic	neuropathy	might	develop	foot	
ulceration.	These	include	foreign	objects	in	their	footwear,	ill-fitting	footwear	and	tissue	loading	
in	excess	of	that	which	can	be	tolerated.	A	recent	study	investigating	peak	plantar	pressures	(PPP)	
in	the	foot,	compared	weight	bearing	and	non-weight	bearing	exercises	to	walking	on	a	level	
surface	(Shah	and	Mueller,	2012).	Weight	bearing	heel	raise	exercise	was	found	to	increase	
forefoot	PPP	by	27%	compared	to	level	walking,	but	there	was	no	difference	in	PPP	for	all	other	
weight	bearing	exercises	(climbing	stairs,	sit	to	stand,	toe	raises	and	single	leg	stand).	The	
researchers	also	demonstrated	that	non-weight	bearing	exercises	(stationary	bike,	balance	ball	
exercise	and	active	plantar/dorsiflexion)	were	associated	with	lower	PPP	(58-83%)	compared	to	
both	weight	bearing	exercise	and	flat	walking.	This	suggests	that	different	forms	of	physical	
activity	are	likely	associated	with	different	levels	of	risk	to	insensate	feet.		
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Researchers	investigating	exercise	for	peripheral	neuropathy	have	recorded	and	published	
rates	of	adverse	events.	Shah	and	Mueller	(2012)	reported	no	adverse	events	related	to	the	
exercises	in	their	study.	Otterman	et	al.	(2011)	conducted	a	pre-post	study	of	cardiovascular	and	
strength	exercise	with	twenty-two	people	who	had	diabetic	peripheral	neuropathy	(Otterman	et	
al.,	2011).	Participants	and	exercise	instructors	were	advised	to	conduct	appropriate	foot	checks	
throughout	the	study	period.	Of	the	participants	who	completed	the	exercise	programme	
(n=20/22),	50%	had	a	history	of	foot	ulceration.	The	researchers	reported	58	adverse	events	of	
which	five	were	foot	related.	The	authors	gave	no	further	details	about	these	events.		
A	further	study	randomised	participants	with	peripheral	neuropathy	between	non-weight	
bearing	and	weight	bearing	exercise	for	a	twelve	week	protocol	(Mueller	et	al.,	2013).	Participants	
and	exercise	instructors	were	advised	to	conduct	appropriate	foot	checks	throughout	the	study	
period.	Within	the	study	period	13	superficial	foot	lesions	(seven	in	weight	bearing,	six	in	non-
weight	bearing	arms)	and	four	ulcers	(one	in	weight	bearing,	three	in	non-weight	bearing	arms)	
were	recorded.	The	study	authors	highlight	these	were	descriptive	results,	as	the	study	was	not	
powered	for	adverse	events	to	be	considered	an	outcome	measure.		
A	major	risk	factor	for	foot	ulceration	is	previous	history	of	ulceration.	The	predicted	annual	
incidence	rises	from	4.5%	in	the	diabetic	population	with	no	history	of	ulceration,	to	31.7%	in	the	
population	with	ulceration	history	(LeMaster	et	al.,	2008).	LeMaster	et	al.	(2008)	randomised	79	
participants	with	diabetic	neuropathy	to	receive	balance	and	strength	exercise	in	the	intervention	
arm,	or	foot	care	advice	in	the	control	arm.	The	participants	were	followed	for	up	to	one	year.	
The	authors	considered	the	history	of	ulceration	in	the	participants	(42%)	and	calculated	the	
predicted	likely	incidence	of	ulceration	within	one	year	to	be	15.9%.	At	study	conclusion,	the	
actual	ulcer	prevalence	of	17%	was	considered	clinically	similar	between	study	arms,	and	to	the	
existing	epidemiological	data.	Balance	and	strength	exercise	did	not	appear	to	increase	rates	of	
ulceration.		
History	of	ulceration	is	also	associated	with	physical	activity	levels.	A	prospective	study	of	
100	participants	with	diabetes,	measured	daily	steps	(Armstrong	et	al.,	2004).	Participants	were	
followed	for	a	minimum	of	25	weeks	(mean	37.1	weeks	(SD12.3))	or	until	they	developed	a	foot	
ulcer.	This	occurred	in	eight	participants	who	were	significantly	less	active	than	the	remaining	
population	(809	steps	(SD612)	vs.	1394	steps	(SD868),	p=0.03)	and	had	greater	variation	in	activity	
level	in	the	two	weeks	prior	to	ulceration	than	the	participants	who	did	not	ulcerate.	The	Physical	
Stress	Theory	(Mueller	and	Maluf,	2002)	suggests	tissues	adapt	depending	on	the	physical	load	
placed	on	them.	Reduced	load	leads	to	tissue	atrophy	and	hence	reduced	capacity	to	absorb	
physical	load.	Excess	load	may	lead	to	tissue	damage	and	even	death.	If	load	can	be	applied	at	an	
optimum	magnitude	and	rate,	tissue	hypertrophy	occurs	and	tissue	resilience	is	increased.	Recent	
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studies	have	used	this	model	to	suggest	patients	could	be	at	risk	of	ulceration	with	too	little	
activity,	as	well	as	too	much	(LeMaster	et	al.,	2008;	Mueller	et	al.,	2013;	Shah	and	Mueller,	2012).	
They	suggest	avoidance	of	weight	bearing	activity	can	lead	to	tissue	atrophy	and	hence	an	
increased	risk	of	ulceration.	
Physical	activity	has	been	shown	to	have	a	generally	positive	effect	on	measures	of	quality	
of	life	for	people	with	persistent	pain	(Geneen	et	al.,	2017),	and	it	may	be	that	physical	activity	
would	have	a	similar	effect	within	PDN.	Research	using	case	series	design,	and	only	reporting	on	
quality	of	life	outcomes	were	excluded	from	the	review	presented	in	Chapter	2,	but	the	studies	
cited	above	do	suggest	some	benefit	to	activity.	For	example,	Otterman	et	al.	(2011)	found	
participant	perceived	limitation	of	function	reduced	after	the	activity	intervention	(mean	-1.4	on	a	
0-10	scale,	CI	-0.5	to	-2.2,	p=0.003)	and	Yoo	et	al.	(2015)	found	improvements	in	the	BPI-PDN	
walking,	work,	relationships	and	sleep	interference	subscales	following	the	intervention	(all	
p<0.02).	These	studies	were	of	small	sample	size	and	were	not	randomised,	so	caution	needs	to	
be	exercised	when	considering	whether	the	results	are	clinically	relevant.	
The	studies	included	in	Chapter	2	and	presented	above,	demonstrate	inconsistent	reporting	
of	adverse	events	related	to	physical	activity	and	so	uncertainty	remains	about	the	parameters	
(dosage)	of	activity	(%	of	full	weight	bearing,	intensity	of	effort,	duration	of	activity,	frequency	of	
activity	per	day/week/month)	that	represent	the	optimum	ratio	between	least	risk	of	foot	
damage	and	greatest	benefit	for	physical	health,	mental	health	and	quality	of	life	measures.	The	
clinicians	interviewed	(Chapter	5),	specifically	the	secondary	care	podiatrists,	were	highly	
concerned	that	physical	activity	could	lead	to	foot	damage.	The	inconsistency	of	reporting	foot-
related	adverse	events	means	the	actual	risk	of	various	forms	of	physical	activity	cannot	be	stated	
with	any	certainty.	
7.2.2	Clinical	implications	
Prescription	of	exercise	is	sometimes	considered	a	simple	task;	it	is	unlikely	to	be	so	in	PDN.	
Clinicians	interviewed	were	keen	to	stress	that	people	with	PDN	would	have	a	range	of	other	
diabetes-related	complications	and	other	comorbidities	that	would	need	consideration	(Chapter	
5).	However,	even	within	‘simple’	musculoskeletal	clinical	settings	motivational	techniques	and	
other	psychological	approaches	can	be	necessary	to	engage	people	in	physical	exercise.	Diabetes	
clinicians	may	need	to	consider	using	principles	of	Motivational	Interviewing	(Rollnick	et	al.,	2005;	
McGrane	et	al.,	2015)	to	help	patients	initiate	and	then	maintain	some	form	of	physical	exercise.	
Studies	have	used	cardiovascular	exercise,	with	intensity	based	on	the	person’s	heart	rate	reserve	
(see	Chapter	5,	section	5.6.2),	but	there	are	many	exercise	options	for	people	with	insensate	feet	
including	controlled	full	weight	bearing	exercise	–	Tai	Chi,	pilates,	yoga	or	walking;	partial	weight	
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bearing	exercise	–	walking	in	water	or	recumbent	exercise	bikes,	or	non-weight	bearing	exercise	–	
hydrotherapy	or	chair	based	exercise	classes.		
Clinicians	should	be	cautious	promoting	significant	pain	reduction	as	the	expected	
outcome.	The	clinical	discussion	may	need	to	be	biased	toward	improving	other	aspects	of	quality	
of	life	(Davies	et	al.,	2015).	Consideration	needs	to	be	taken	of	the	patient	resources	(time,	
money,	access),	their	interests	and	intrinsic	motivation	to	experiment.	Initiating	an	increase	in	
exercise	levels	must	be	gradual	and	accompanied	by	regular	foot	checks	(Colberg	and	Vinik,	
2014).	As	was	discussed	earlier,	a	constant	challenge	in	sustaining	exercise	for	health	reasons	is	
that	the	benefits	of	exercise	may	not	be	immediately	obvious	(Chapter	4	section	4.9.3).		
7.2.3	Research	implications	–	exercise	for	fitness	
Chapter	5	section	5.6.2	highlighted	there	were	differing	professional	views	on	the	most	
appropriate	form	of	activity	for	people	with	PDN.	Studies	investigating	physical	exercise	have	
specified	the	nature	and	intensity	of	the	exercise	and	this	is	to	be	encouraged.	However	not	all	
studies	record	rates	of	adverse	events	related	to	foot	damage,	so	the	exact	parameters	of	
exercise	to	achieve	optimum	risk/benefit	ratio	remain	unclear.	These	are	critical	data	to	capture	
because	it	would	inform	both	patients	and	clinicians	about	the	risks	involved	with	increasing	
exercise	levels.		
From	the	patient	perspective,	every	person	has	differing	interests	and	motivation	for	
physical	exercise.	Outside	of	elite	sports,	the	effectiveness	for	any	specific	exercise	being	better	
than	another	for	fitness,	is	dependent	more	on	the	person	consistently	participating	in	the	form	
of	exercise,	be	that	Tai	Chi,	swimming	or	cardiovascular	exercise,	rather	than	the	form	itself.	
Physical	exercise	research	to	date	has	focussed	primarily	on	the	form	of	exercise,	to	elucidate	the	
effect	on	the	participant’s	pain	or	quality	of	life;	another	approach	would	be	to	take	the	lead	from	
the	participant’s	interest	in	any	form	of	physical	activity	and	develop	that	activity	as	a	way	toward	
increased	fitness.	
7.2.4	Research	implications	–	activity	as	exercise	
If	a	person	does	not	have	motivation	to	engage	in	exercise,	they	may	have	more	motivation	
to	engage	in	some	physical	activity	which	has	different	connotations	(to	them)	than	exercise.	It	
would	be	beneficial	to	understand	more	about	the	links	between	activity	and	quality	of	life	in	
PDN,	and	what	factors	are	relevant	for	altering	activity	levels.	
	PDN	has	similarities	to	other	neuropathic	pain	conditions	such	as	MS	and	research	into	
physical	activity	and	function	from	other	pathologies	maybe	useful	to	consider.	In	MS,	pain	is	
caused	by	autoimmune	breakdown	of	the	myelin	sheath	surrounding	spinal	cord	neurons.	Pain	
related	to	MS	has	impacts	similar	to	PDN	with	decreased	physical	function,	disturbed	sleep	
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(Braley,	2015),	associations	with	depression	and	anxiety	and	is	difficult	to	manage	with	analgesia	
alone	(Harrison	et	al.,	2015a,	2015b).		
Qualitative	research	with	people	with	MS	(Harrison	et	al.,	2015a)	described	two	themes	
relating	to	how	people	manage	and	cope	with	their	pain	experience.	One	theme	was	a	‘Pain	
reduction’	agenda;	here	patients	described	‘fighting’	the	pain	they	experienced,	and	being	in	a	
‘Catch-22’	position	of	pain	leading	to	deconditioning,	and	vice	versa.	The	second	theme	was	a	
‘Managing	and	accepting	pain’	agenda,	this	was	typified	by	being	in	touch	with	their	body,	
knowing	their	limitations	and	working	with	pain,	in	order	to	manage	it.		
The	same	research	team	conducted	a	systematic	review	of	empirical	studies	to	understand	
the	psychosocial	variables	experienced	by	people	with	MS	that	might	be	modifiable	(Harrison	et	
al.,	2015b).	They	found	similar	associations	between	psychological	constructs	and	MS-related	
function	that	are	present	in	non-specific	persistent	pain.	Pain	catastrophizing	was	associated	with	
greater	pain	interference	and	pain	acceptance	was	associated	with	less	pain	interference.		
Pain	catastrophizing	has	been	shown	specifically	in	PDN	to	be	associated	with	both	
increased	perceived	disability	(β=0.311,	p<0.001)	and	reduced	quality	of	life	(β=0.373,	p<0.001)	
(Geelen	et	al.,	2016).	Pain-related	catastrophizing	appears	to	consistently	have	a	mediating	role	in	
engagement	in	function	and	daily	activity,	in	chronic	pain	generally	(de	Boer,	Struys	and	
Versteegen,	2012)	and	neuropathic	pain	specifically	(Harrison	et	al.,	2015b;	Geelen	et	al.,	2016).	It	
is	unknown	how	similar	the	profile	of	pain	acceptance	is	for	people	with	PDN,	to	people	with	MS.	
It	is	currently	unknown	whether	there	are	associations	between	acceptance	of	PDN	and	
either	patient	day-to-day	activity	or	ratings	of	quality	of	life.	Using	quantitative	measures	of	pain	
acceptance,	such	as	the	BPCI-2	(described	in	section	6.12.4),	in	addition	to	the	existing	functional	
measures,	would	contribute	to	understanding	whether	promoting	pain	acceptance	had	a	positive	
association	with	function	and	quality	of	life.	In	conjunction	with	on-going	research	in	other	
neuropathic	pain	conditions,	this	may	indicate	which	cognitive	factors	are	important	in	relation	to	
patient	function	and	quality	of	life	and,	depending	on	the	findings,	whether	these	are	best	
targeted	with	CBT	or	ACT	based	approaches.	For	example,	there	is	existing	evidence	from	other	
conditions,	that	facilitating	acceptance	using	ACT	can	mediate	quality	of	life	(Nicholas	and	
Asghari,	2006),	whereas	challenging	catastrophic	thinking	can	be	approached	using	ACT	(Hughes	
et	al.,	2017)	or	CBT	(Pincus	and	McCracken,	2013)	approaches.		
7.3	PDN	makes	walking	difficult	
Walking	is	a	human	function	that	spans	the	dichotomy	between	activity	and	exercise	
(Caspersen,	Powell	and	Christenson,	1985).	Walking	has	a	critical	function,	both	in	its	own	right	
for	activity	and	pleasure,	and	as	a	method	of	moving	around	the	environment	to	achieve	daily	
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tasks.	Interview	participants	described	the	difficulty	of	walking,	even	short	distances,	with	PDN.	
Further	to	this,	people	with	PDN	have	a	higher	risk	of	amputation	than	those	without	(odds	ratio	
1.52	(CI1.15	to	1.99)	(Ritzwoller	et	al.,	2009)).	The	interview	sample	(n=23)	included	one	person	
with	unilateral	amputation	and	one	person	with	bilateral	below	knee	amputations.	People	with	
amputations	due	to	neuropathy	would	experience	additional	impediment	to	walking.	
For	PDN	it	would	not	be	clinically	appropriate	to	suggest	a	person	avoid	walking	completely	
due	to	the	potential	consequences	for	general	health	and	DM	management,	or,	that	they	walk	
with	no	regard	for	the	amount	of	pain	they	experience.	Rather,	a	graded,	moderate	approach	to	
walking	would	be	appropriate,	and	in-line	with	advice	for	other	long	term	conditions	such	as	FMS	
(Busch	et	al.,	2013;	Karjalainen	et	al.,	2009),	chronic	obstructive	pulmonary	disease	(Güell	et	al.,	
2000)	and	chronic	non-specific	pain	(Geneen	et	al.,	2017).	
Guidance	for	healthy	levels	of	physical	activity	have	been	translated	as	equivalent	to	10,000	
steps	daily.	This	guidance	has	been	studied	with	participants	who	were	obese	(n=35)	(Castres	et	
al.,	2016).	Using	pedometers	to	count	daily	steps	over	a	six-month	period,	participants	were	
encouraged	to	increase	their	daily	step	count	by	1000	per	week,	until	at	10,000	steps	daily.	At	
post-intervention,	there	were	changes	in	body	mass	(mean	-3.8kg,	p<0.01),	hip	circumference	
(mean	-4.6cm,	p<0.05)	and	anxiety	(HADS	questionnaire)	(mean	-1.2,	p<0.05).	However,	the	
validity	of	10,000	steps	daily	is	not	a	complete	surrogate	marker	for	achieving	the	advised	time	
intensity	levels	(150	minutes/week	in	10-minute	intervals)	of	physical	activity	(White	et	al.,	2013).	
White	et	al.	(2013)	provided	participants	with	both	pedometers	and	activity	monitors.	Activity	
monitors	record	time	as	well	as	steps,	so	can	establish	the	consistency	and	continuity	of	activity	
(time	intensity)	rather	than	just	a	sum	total	of	steps	for	the	day.	The	study	found	only	moderate	
positive	predictive	value,	that	participants	with	a	step	count	≥10,000	steps/day	were	meeting	the	
time	intensity	guidelines	(Men:	sensitivity	46.5,	specificity	85.2,	positive	predictive	value	16.7;	
women:	67.9,	90.3,	26.7	respectively)	(White	et	al.,	2013).	For	health	benefits	to	accrue	walking	
must	be	at	an	appropriate	intensity	and	volume	and	strategies	to	both	motivate	and	facilitate	
people	to	achieve	these	variables	are	critical.	
7.3.1	Clinical	implications	
As	stated	above,	walking	is	critical	for	daily	function	and	restrictions	have	potential	further	
impacts	on	physical	and	mental	health.	There	appear	to	be	a	number	of	causes	for	reduced	
walking.	These	include	the	severity	of	pain	experienced	(Hoffman	et	al.,	2010),	but	also	the	
degree	of	worry	and	fear	related	to	physical	function	(Geelen	et	al.,	2016;	Selvarajah	et	al.,	2014).		
Techniques	to	facilitate	walking	may	include	provision	of	walking	aids	such	as	elbow	
crutches.	Crutches	have	been	shown	to	reduce	the	foot	PPP	in	people	with	diabetic	neuropathy	
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and	to	increase	the	sense	of	balance	and	security	(Kwon	and	Mueller,	2001).	This	potential	
benefit	needs	to	be	considered	against	the	obvious	impediment	to	upper	limb	use.	Since	PDN	is	
not	causally	related	to	weight-bearing	it	is	not	clear	whether	use	of	crutches	would	necessarily	
reduce	the	impact	of	PDN	on	walking.		
The	use	of	activity	monitors	and	setting	specific	goals	may	help	to	motivate	people	to	
gradually	increase	their	walking	capacity.	Overlap	exists	here	with	the	previous	section	since	
appropriate	foot	checks	are	required	as	part	of	self-management.	It	is	appropriate	to	suggest	that	
clinicians	involved	with	PDN	need	to	have	practical	skills	to	help	people	engage	in	some	physical	
activity	with	due	regard	for	foot	protection	and	existing	comorbidities.	These	practical	skills	
include	effective	communication	to	facilitate	exploration	of	the	thoughts	and	beliefs	the	person	
has	about	physical	activity.		
In	addition	to	practical	physical	approaches,	clinicians	need	to	help	patients	consider	their	
own	cognitions	regarding	walking.	People	who	have	struggled	with	walking	for	years	may	well	
develop	a	range	of	discouraging	or	hopeless	thoughts	and	beliefs.	The	process	of	slowing	down	
the	cognitive	process	to	understand	thoughts	better	is	a	fundamental	approach	of	CBT	(Vlaeyen	
and	Morley,	2015).	CBT	aims	to	help	patients	consider	the	validity	of	their	cognitions	and	when	
necessary	whether	they	can	be	reappraised	to	be	less	negative.	In	contrast,	rather	than	
reappraising	thoughts,	ACT	aims	to	help	people	disengage	from	negative	thoughts,	or	to	reduce	
their	reactions	to	these	thoughts	(McCracken	and	Vowles,	2014).	Currently	there	are	PMPs	based	
on	CBT	and	ACT	approaches.	Helping	patients	to	deal	with	negative	cognitions	are	central	to	these	
programmes,	whatever	the	philosophical	underpinnings.	Not	enough	is	currently	known	about	
the	cognitions	that	are	prevalent	for	people	with	PDN,	to	suggest	whether	CBT	or	ACT	represents	
the	most	appropriate	clinical	approach.		
Walking	was	a	specific	function	that	emerged	as	a	code	from	the	patient	interviews	and	
consequently	was	presented	in	the	Internet	survey.	The	twin	approaches	of	1)	a	paced	graded	
physical	approach	to	the	activity	combined	with	2)	considering	what	cognitions	are	associated	
with	an	activity,	and	then	challenging	or	managing	these	where	necessary,	could	be	applied	to	
any	functional	activities	of	importance	to	the	person.	
7.3.2	Research	implications	
It	is	important	that	robust	measures	of	walking	function	are	used	in	future	research.	There	
are	numerous	measures	of	physical	function;	the	Walk-12	test	was	originally	developed	to	
measure	walking	function	in	MS	but	has	been	validated	for	peripheral	neuropathy	generally	
(Graham	and	Hughes,	2006).	In	much	the	same	way	that	Section	7.2	focussed	on	loss	of	physical	
fitness	and	how	clinicians	may	encourage	patients	to	engage	in	a	variety	of	physical	activities	in	a	
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manner	that	would	not	increase	their	risk	of	foot	damage	or	potential	amputation,	research	into	
walking	requires	individualised	protocols	to	establish	the	person’s	baseline	walking	and	measure	
their	daily	step	count	(Castres	et	al.,	2016).	This	graded	approach	will	help	to	elucidate	the	
appropriate	dosage	of	walking.	This	may	be	achieved	and	facilitated	using	a	pedometer	or	smart	
phone	activity	monitor	(Smith	et	al.,	2004).	Future	research	on	walking	needs	to	evaluate	the	
changes	to	measures	of	walking	using	measures	such	as	the	Walk-12,	but	also	explore	the	
associations	with	patient’s	quality	of	life,	rather	than	pain	severity	alone.	
7.4	PDN	causes	me	to	have	numb	feet	
Diabetic	sensory	neuropathy,	without	pain,	is	the	most	common	form	of	peripheral	
neuropathy	(Waldman,	2000).	Loss	of	afferent	cutaneous	sensation	reduces	the	normal	response	
to	tissue	damage,	which	then	predisposes	to	tissue	ulceration.	Sensory	loss	affects	afferent	
proprioceptive	information	relating	to	joint	position	sense;	this	information	is	critical	for	balance	
and	locomotor	control	(Peltier,	Goutman	and	Callaghan,	2014).		
There	is	evidence	from	basic	science	that	physical	movement	can	affect	the	nerve	
physiology	that	underpins	sensory	neuropathy.	Axoplasmic	fluid	acts	as	the	transportation	
medium	in	neurones,	carrying	ion	channels	from	the	cell	body	to	their	destination	in	the	cell	
membrane,	and	intracellular	signalling	molecules	back	to	the	cell	body.	This	fluid	becomes	more	
viscous	when	neurones	are	held	static,	and	less	viscous	when	moved,	a	thixotropic	property	
(Bove,	2008;	Dilley	and	Bove,	2008).	This	physiological	property	underpins	neurodynamics,	an	
aspect	of	manual	therapy	and	active	exercise	common	in	physiotherapy	(Nee	and	Butler,	2006).		
Research	has	found	positive	correlations	between	neurodynamic	test	responses	and	
responses	to	manual	palpation	of	nerve	tracts,	although	the	participant	groups	experienced	
musculoskeletal	neuropathic	pain,	rather	than	related	to	diabetes	(Walsh	and	Hall,	2009;	Schmid	
et	al.,	2009).	Kumar	et	al.	(2011)	assessed	patient	responses	to	straight	leg	raise	and	manual	
palpation	of	neural	tracts	in	the	lower	leg	in	healthy	participants,	and	people	with	diabetes,	
sensory	neuropathy	and	PDN.	The	group	with	PDN	had	straight	leg	raise	range	of	mean	41.2˚	
(SD15.8)	and	were	sensitive	to	palpation	of	their	peroneal	and	tibial	nerve	tracts.	The	non-
diabetic	control	group	had	straight	leg	raise	range	of	81.8(SD4.8)˚	and	experienced	no	symptom	
provocation	on	palpation	(Kumar	et	al.,	2011).	These	results	suggest	these	clinical	assessment	
techniques	have	validity	for	diagnosing	the	presence	of	neuropathy	symptoms	and	so	
consequently	may	have	use	in	treatment.	
There	have	been	attempts	to	explore	neurodynamic	treatment	for	PDN.	Neurodynamic	
treatment	involves	specific	sequences	of	body	movements	to	increase	the	mechanical	load	in	a	
nerve	tract	at	one	end,	whilst	simultaneously	off-loading	the	tract	at	the	other	end.	The	
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participant’s	tibial	nerve	may	be	caused	to	‘slide’	longitudinally	by	combining	hip	flexion	with	
ankle	plantar	flexion,	then	moving	to	a	position	of	hip	neutral	with	ankle	dorsiflexion.	There	is	
strong	evidence	such	combinations	of	movements	differentially	move	neural	tissue	compared	to	
surrounding	structures	(Coppieters	and	Butler,	2008;	Coppieters	et	al.,	2006;	Coppieters,	Hough	
and	Dilley,	2009;	Alshami,	Souvlis	and	Coppieters,	2008).	Differential	sliding	of	neural	tissue	is	
thought	to	be	beneficial	to	axoplasmic	viscosity	and	intra-neural	metabolic	processes	thus	may	
have	a	direct	effect	on	the	pathophysiology	leading	to	sensory	neuropathy.	
A	treatment	intervention	for	PDN,	of	physical	movements	to	‘slide’	the	sciatic,	peroneal	and	
tibial	nerve	tracts	was	compared	to	passive	movements	of	the	contralateral	ankle	and	foot	joint	
structures	for	the	same	treatment	duration	(Kumar	et	al.,	2010).	Eligible	participants	(n=44)	were	
randomised	to	receive	the	neurodynamic	intervention	to	either	their	left	or	right	leg	first,	
followed	by	the	sham	intervention	to	the	opposite	leg.	The	study	recorded	vibration,	and	hot	and	
cold	perception	thresholds.	On	the	side	treated	using	neurodynamic	exercise,	there	were	
improvements	in	all	the	outcomes	measured.	The	changes	suggested	improvements	in	sensory	
physiology	of	the	nerve	tracts.	However,	the	post-treatment	follow	up	was	limited	to	15	minutes,	
so	whether	changes	were	sustained	or	clinically	meaningful	is	unknown.		
The	same	research	group	conducted	a	small-scale	randomised	study	(n=32)	using	
neurodynamic	exercise	for	the	common	peroneal	nerve,	in	addition	to	a	standard	package	of	care	
(walking	prescription,	diet	and	lifestyle	changes)	(Kumar,	Adhikari	and	Jeganathan,	2012).	This	
study	had	a	five-week	follow-up	period.	The	addition	of	peroneal	nerve	exercises	improved	
vibration	perception	and	thermal	perception	thresholds,	as	well	as	measures	of	pain	and	quality	
of	life.	The	study	has	only	been	reported	as	an	abstract	which	did	not	present	participant	co-
morbidities	or	other	data	needed	for	full	appraisal.		
The	study	by	Kluding	et	al.	(2012)	has	been	described	earlier	in	section	7.2.	In	addition	to	
the	outcome	measures	described,	skin	biopsy	was	used	to	visualise	intra-epidermal	nerve	density	
and	axonal	branching.	A	reduction	in	nerve	fibre	branching	is	a	hallmark	of	small-fibre	
neuropathies	such	as	PDN.	There	was	an	increased	density	of	branch	nodes	per	nerve	fibre	after	
exercise	intervention,	from	mean	0.16(SD0.15)	to	0.27(SD0.19)	(p=0.008)	at	the	proximal	biopsy	
site	(20cm	from	iliac	spine,	lateral	thigh)	but	not	in	the	distal	biopsy	site	(10cm	above	lateral	
malleolus).	There	were	no	changes	in	nerve	conduction	or	quantitative	sensory	testing.	The	
authors	highlight	the	changes	in	density	seen	at	the	proximal	site,	but	not	the	distal	site,	may	
reflect	the	greater	severity	of	distal	pathophysiological	changes	(Kluding	et	al.,	2012).		
Numb	feet	are	often	associated	with	increased	risk	of	falling	(van	Schie,	2008).	A	systematic	
review	found	six	eligible	studies	examining	interventions	to	improve	balance	in	peripheral	
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neuropathy	(Ites	et	al.,	2011).	Only	one	study	investigating	lower	limb	strengthening	exercises	
(wall	slides,	single	leg	stands,	open	and	closed	chain	ankle	strengthening)	was	found	to	improve	
measures	of	balance	(Richardson,	Sandman	and	Vela,	2001).	This	single-blind	controlled	study	
was	small	scale	(20	participants	randomised	to	each	arm)	but	all	participants	had	diabetes-related	
peripheral	neuropathy.	Measures	of	balance	(tandem	stance,	functional	reach	and	uni-pedal	
stance)	all	improved	in	the	intervention	arm	compared	to	the	control	arm	(p<0.004	at	post-
intervention	time	point).		
7.4.1	Clinical	implications	
There	have	been	small	scale	studies	exploring	the	role	exercise	may	play	in	improving	nerve	
function,	but	the	evidence	is	currently	limited.	Strength	and	balance	exercises	may	help	to	
maintain	proprioceptive	responses	and	so	reduce	the	risk	of	falls	(Richardson,	Sandman	and	Vela,	
2001).	Movement	of	any	kind	–	neurodynamics	(Kumar,	Adhikari	and	Prabhu,	2011),	Tai	Chi	(Hung	
et	al.,	2009)	and	cardiovascular	exercise	(Kluding	et	al.,	2012)	–	may	alter	the	pathophysiological	
changes	that	occur	in	neural	tissue	and	lead	to	sensory	neuropathy,	but	further	research	is	
needed.		
The	key	clinical	management	for	numbness	is	prevention	through	glycaemic	control	
(Peltier,	Goutman	and	Callaghan,	2014;	Smith	et	al.,	2006).	There	are	no	current	pharmacological	
options	for	treating	the	sensory	loss	(Prof	Wynick,	personal	communication),	this	maybe	because	
numbness	is	inherently	less	distressing	than	the	painful	aspect	of	PDN	and	so	does	not	merit	
pharmacological	research	focus.		
Patients	may	have	to	accept	that	numb	feet	are	an	aspect	of	PDN	that	cannot	currently	be	
treated.		
7.4.2	Research	implications	
Research	participants	have	often	had	diabetes	and	PDN	symptoms	for	many	years.	
Duration	of	diabetes	and	relatively	poor	control	of	blood	sugars	are	the	key	causes	for	
development	of	sensory	neuropathy	and	PDN	(Peltier,	Goutman	and	Callaghan,	2014).	A	
Cochrane	review	has	highlighted	that	increasing	exercise	and	making	dietary	changes	in	the	pre-
diabetic	stage	can	reduce	the	relative	risk	of	developing	diabetes	by	37%	(Orozco	et	al.,	2008).	
Early	intervention	to	prevent	the	onset	of	diabetes	is	more	successful	than	dealing	with	the	
consequences.	Studies	investigating	exercise,	whether	for	possible	improvements	in	pain,	
numbness	or	balance,	need	to	recruit	people	earlier	in	their	journey	with	PDN.	Since	the	
pathophysiological	changes	of	PDN	appear	irreversible,	it	seems	intuitively	sensible	to	research	
the	potential	for	non-pharmacological	strategies	earlier	in	the	process	of	pathological	
development,	with	the	aim	of	preventing	significant	impacts,	such	as	disability	and	distress.		
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Randomised	controlled	studies	need	to	be	conducted	that	investigate	whether	intervention	
with	specific	exercises	such	as	yoga	(Willis	Boslego	et	al.,	2017),	neurodynamics	(Kumar,	Adhikari	
and	Prabhu,	2011),	Tai	Chi	(Ahn	and	Song,	2012)	and/or	cardiovascular	exercise	(Dixit,	Maiya	and	
Shastry,	2014;	Toth	et	al.,	2014)	can	arrest	the	development	of	sensory	neuropathy	and	
potentially	PDN.	It	would	be	critical	that	these	studies	have	sufficiently	long	follow	up	duration	to	
help	inform	the	question	of	PDN	prognosis,	and	that	they	record	and	report	on	foot-related	
adverse	events	to	help	establish	the	appropriate	dosage	of	exercise.	This	research	
recommendation	is	relevant	to	all	the	impacts	prioritized	by	survey	respondents.		
There	are	however	organisational	difficulties	in	recruiting	people	to	research	earlier	in	their	
journey	with	PDN.	Chapter	1,	section	1.1.4	highlighted	that	pre-screening	to	predict	the	later	
development	of	DM	is	limited	by	moderate	specificity	and	sensitivity	of	HbA1c	(Barry	et	al.,	2017).	
Once	diagnosed	with	DM	a	patient	should	receive	annual	health	checks	including	nerve	function	
assessment	as	recommended	best	practice	by	NICE	and	QOF	guidance	(NHS	Employers,	2016;	
NICE,	2004,	2015b).	However,	the	primary	care	practice	nurse,	a	clinician	who	conducts	annual	
diabetes	checks,	highlighted	the	computer	system	proforma	did	not	have	the	capacity	for	
identifying	pain	complaints	other	than	as	‘free-text’.	Similarly	an	audit	of	pain	clinic	activity	(BPS,	
2012)	found	neuropathic	pain	appeared	under-represented	in	the	clinical	coding	structure	used	
(Read	Codes).	These	information	technology	issues	currently	make	it	more	difficult	for	
researchers	to	find	and	alert	people	with	symptoms	of	PDN	to	active	research	studies.		
7.5	I	am	worried	that	PDN	will	get	worse	in	the	future	
Interview	study	participants	were	concerned	about	their	prognosis	with	PDN;	this	was	not	
helped	by	the	frequent	failure	of	medications	to	adequately	control	their	symptoms,	and	lack	of	
information	regarding	strategies	beyond	medication	management.	The	natural	history	of	PDN	is	
not	however	certain	(Peltier,	Goutman	and	Callaghan,	2014).	Chapter	6,	section	6.12.1.2	detailed	
the	few	studies	which	have	followed	people	with	PDN	over	time.	Clinicians	are	unable	to	
confidently	alleviate	peoples’	fears	that	PDN	will	get	worse	resulting	in	a	degree	of	patient	
uncertainty.	The	survey	questions	(Chapter	6)	were	specific	to	PDN,	but	it	is	possible	the	
respondents’	worries	for	the	future	included	other	facets	of	diabetes	and	other	health	conditions.		
More	broadly,	the	interview	study	theme	“A	range	of	negative	emotions”,	included	codes	
identifying	specific	worries	about	fitness	and	future	financial	security,	and	the	future	in	more	
general	terms.	Worry,	conceptualised	as	negative	fears	for	the	future,	is	the	cognitive	hallmark	of	
catastrophization	and	there	exists	a	large	body	of	research	exploring	such	cognitions	in	people	
with	pain		(Sullivan,	Lynch	and	Clark,	2005;	Vowles,	McCracken	and	Eccleston,	2008;	van	Damme,	
Crombez	and	Eccleston,	2004).	Higher	levels	of	catastrophizing	have	been	associated	with	greater	
pain	severity	(de	Boer,	Struys	and	Versteegen,	2012),	and	lower	physical	activity	levels,	mental	
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health	and	overall	quality	of	life	(Osborne	et	al.,	2007).	For	these	reasons,	aiming	to	reduce	
catastrophic	thinking	is	a	common	psychological	aim	for	PMP	based	within	CBT	(Smeets	et	al.,	
2006)	and	ACT	principals	(McCracken,	Gauntlett-Gilbert	and	Vowles,	2007).	
7.5.1	Clinical	implications	
The	similarity	between	PDN	and	MS-related	pain	has	been	discussed	in	this	chapter	(section	
7.2).	People	with	MS	have	a	similar	uncertainty	of	how	life	with	their	condition	may	progress	over	
time.	Chapter	6	has	previously	discussed	the	difference	between	active	coping	strategies	and	
acceptance	strategies	(Chapter	6,	section	6.12.4).	People	with	PDN	may	find	it	helpful	if	clinicians	
considered	a	range	of	approaches	beyond	medication.	Firstly,	medication	strategies	need	to	be	
optimised,	with	a	clear	message	to	patients	that	they	are	not	curative.	Medication	is	unlikely	to	
completely	eradicate	the	pain	but	can	be	an	aid	to	function.		
Secondly,	clinicians	need	to	self-evaluate	the	style	and	manner	of	their	clinical	
communication	to	ensure	they	give	the	patient	the	full	freedom	to	raise	the	issues	most	
important	to	them.	Clinicians	may	need	to	develop	skills	in	asking	open,	non-judgmental	
questions,	these	questions	give	the	person	the	opportunity	to	raise	issues	which	they	may	not	
associate	as	being	part	of	the	clinician’s	role.	Physiotherapists,	for	example,	have	been	
encouraged	to	develop	skills	to	inquire	about	mood	state	(Main	et	al.,	2012),	an	aspect	of	life	that	
patients	may	not	associate	with	physical	therapy	(Cooper,	Smith	and	Hancock,	2009).		
Thirdly,	in	many	chronic	health	conditions	with	a	range	of	potential	futures,	worry	will	be	
an	additional	burden	on	the	patient,	and	unlikely	to	be	beneficial	or	lead	to	improvement	in	their	
quality	of	life	(Eccleston	and	Crombez,	2007).	Addressing	worry	has	likely	therapeutic	benefits	
irrespective	of	the	cause.	
Lastly,	clinicians	need	to	consider	whether	they	have	the	necessary	range	of	strategies	to	
help	people	address	and	manage	the	most	important	impacts	of	PDN.	If	the	clinician	does	not	
have	the	strategy/ies	required,	they	need	referral	routes	to	clinical	colleagues	who	maybe	better	
equipped	to	help	the	person.		
This	suggested	approach	aims	to	help	the	clinician	understand	the	issues	the	patient	is	
most	worried	about.	Depending	on	the	issues,	there	may	be	appropriate	clinical	strategies	to	
reduce	worry	and	catastrophizing.	Where	such	strategies	are	not	available	the	clinical	focus	
maybe	toward	helping	people	to	accept	their	pain	experience,	develop	resilience	to	pain	and	
despite	its	presence,	engage	with	life.		
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7.5.2	Research	implications	
In	order	to	reduce	the	impact	of	being	worried	that	PDN	will	get	worse	in	the	future,	more	
needs	to	be	understood	about	its	natural	history.	Such	longitudinal	research	would	be	facilitated	
by	a	consistency	of	clinical	coding	used	on	primary	and	secondary	care	IT	systems.	This	would	
allow	data	searches	looking	for	correlation	of	codes	related	to	DM	and	neuropathic	pain,	or	
preferably	a	specific	code	for	PDN,	and	the	initiation	and	cessation	of	the	range	of	medications	
recommended	for	PDN.	Presence	of	conditions	that	might	require	prescriptions	of	the	same	
neuropathic	pain	medication	(nerve	root	pain)	would	need	to	be	retrieved	and	excluded.	The	
current	system	of	Read	codes	is	being	retired	by	April	2018	and	replaced	with	SNOMED	CT	codes.	
Whether	the	new	coding	system	will	allow	specific	codes	for	PDN	is	unknown.	
More	research	is	needed	to	better	understand	coping	strategies	and	quality	of	life	in	people	
with	PDN.	The	survey	in	Chapter	6	used	the	CSQ,	this	assesses	coping	on	two	scales	of	active	and	
passive	coping	strategies.	It	may	have	been	more	relevant	to	use	outcomes	such	as	the	BPCI-2	or	
Chronic	Pain	Acceptance	Questionnaire.	These	questionnaires	could	be	used	in	longitudinal	
cohort	studies	to	investigate	whether	different	approaches	to	coping	and	traditional	active	
strategies	were	associated	with	changes	in	function	and	patient	quality	of	life.		
7.6	PDN	leads	me	to	feel	depressed	
Depression	has	been	defined	as	“a	negative	schemata	about	self,	the	future	and	the	world,	
which	when	activated	by	stressful	life	events	results	in	processing	bias	that	distorts	perception	
and	maintains	the	negative	thought	pattern,	and	with	them	the	mood	itself”	(Pincus	and	Williams,	
1999).	From	the	patient	interview	study,	it	was	clear	there	were	many	sources	of	stress	for	people	
with	PDN	that	may	have	contributed	to	the	experience	of	depression	–	pain,	work,	finances,	daily	
restrictions,	interrupted	sleep	and	altered	relationships.	These	issues	are	not	uncommon	with	
persistent	pain	states	of	any	cause.		
Depression	in	PDN	is	complex,	with	the	experienced	mood	a	potentially	unique	
combination	of	‘depression	associated	with	diabetes’	(Chapter	1,	section	1.1.6),	‘depression	
associated	with	persistent	pain’	(Chapter	1,	section	1.2.4.2)	and	‘reactive	depression	associated	
with	daily	restrictions	to	personal	agency	and	independence’	(Pincus	and	Williams,	1999).	The	
presence	and	contribution	of	each	of	these	factors	will	be	different	for	each	person.	The	presence	
of	depression	(of	any	cause)	has	close	links	with	reduced	self-management	behaviours	and	social	
interaction,	increased	sedentary	behaviours	and	rumination	–	cognitive	and	behavioural	variables	
that	tend	to	worsen	both	pain	experience	(Gatchel	et	al.,	2007,	2014)	and	diabetes	management	
(Petrak	et	al.,	2015).	
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7.6.1	Clinical	implications	
Clinicians	need	to	open	conversations	with	patients	about	their	mood	and	the	impact	that	
has	on	consequent	pain,	behaviours	and	overall	quality	of	life.	Where	necessary,	they	then	need	a	
range	of	clinical	options	to	help	the	patient.	
Of	the	range	of	advised	medications	for	PDN,	Duloxetine	has	a	centrally	acting,	anti-
depressant	effect.	Duloxetine	appeared	to	have	greater	benefit	in	reducing	pain,	pain-related	
interference	and	improving	mood	states,	than	peripherally	acting	anti-epileptic	medications	
(Pregabalin	and	Gabapentin)	(Happich	et	al.,	2014).	These	findings,	however,	were	based	upon	a	
review	of	clinical	practice,	rather	than	a	controlled	randomised	trial.	
Physiotherapists	manage	depression	by	helping	people	to	set	goals	to	achieve	a	measure	of	
success	and	hence	reduce	the	negative	perceptions	held	(Main	et	al.,	2012;	Carnes	et	al.,	2013).	
These	goals	must	be	of	importance	to	the	person	and	specific,	realistic	and	time-limited.	
Achieving	the	goal	is	likely	to	increase	the	person’s	confidence	to	set	and	achieve	further	goals	
with	increasing	independence,	resulting	in	reduced	depression.	This	clinical	approach	is	widely	
used	for	inflammatory	(Dures	et	al.,	2012)	and	non-inflammatory	arthritic	pain	(NICE,	2015a).		
PMPs	for	persistent	pain	have	a	variety	of	psychological	approaches	for	managing	
depression.	CBT-based	programmes	help	participants	to	identify	cognitions	and	then	evaluate	the	
accuracy	and	validity	of	those	cognitions.	Unhelpful	cognitions	may	then	be	challenged	and	
potentially	reappraised	(Morley	and	Williams,	2015;	Vlaeyen	and	Morley,	2015).		A	Cochrane	
review	of	psychological	therapies	for	pain	extracted	mood	data	as	secondary	outcomes.	CBT	
compared	to	treatment	as	usual,	had	a	positive	effect	on	mood	at	the	post-treatment	time	point,	
with	SMD	-0.38	(CI	-0.57	to	-0.18,	12	studies,	n=899	participants).	This	effect	was	reduced	at	
follow-up	to	SMD	-0.26	(CI	-0.51	to	0.00,	7	studies,	637	participants)	(Williams,	Eccleston	and	
Morley,	2012).			
ACT-based	programmes	help	people	to	gain	distance	from	their	cognitions	hence	reducing	
unhelpful	responses	to	those	cognitions	(Morley	and	Williams,	2015;	Vlaeyen	and	Morley,	2015).	
A	systematic	review	of	ACT	for	persistent	pain	extracted	measures	of	depression	as	secondary	
outcome	data	(Hughes	et	al.,	2017).	The	ACT	interventions	resulted	in	significantly	better	levels	of	
depression	immediately	post	treatment	in	comparison	to	control,	with	a	SMD	-0.52	(CI	-0.80	to	-
0.24).	This	effect	was	reduced	at	three-month	follow	up	(SMD	-0.52	(CI	-0.90	to	-0.14))	and	
became	insignificant	at	six-month	follow	up	(SMD	-0.85	(CI	-1.90	to	0.13).	The	analysis	at	3-month	
time	point	had	large	heterogeneity	(I2	80.5%).	Once	an	outlying	study	was	removed	I2	was	
reduced	to	0%	and	the	effect	size	quoted	above	was	calculated.	This	outlying	study	was	however	
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included	in	the	analysis	of	the	six-month	follow-up	data	and	may	explain	the	wide	95%	confidence	
intervals.		
The	review	by	Hughes	at	al.	(2017)	included	one	study	that	compared	ACT	to	CBT	
(Wetherell	et	al.,	2011).	This	study	(n=114	participants,	age	range	18-89	years,	mean	age	54.9	
years,	30%	neuropathic	pain)	assigned	consecutive	patients	to	treatment	groups.	The	groups	
were	then	randomised	to	either	receive	ACT	or	CBT-based	intervention.	There	were	changes	in	
Beck	Depression	Inventory	scores	for	ACT	arms	(n=57)	(mean	change	-2.32(SD5.87),	p=0.004)	and	
CBT	arms	(n=57)	(mean	change	-3.18(SD6.45),	p=0.0005)	at	post-treatment.	At	six-month	follow	
up	changes	in	depression	had	become	non-significant	for	both	arms.	Hughes	et	al.	(2017)	
calculate	the	data	favoured	CBT	over	ACT	with	a	small	effect	size	of	SMD	0.39	(CI	0.02	to	0.76)	at	
the	post-treatment	time	point;	this	became	an	insignificant	effect	at	later	time	points.		
Specific	to	the	impact	of	depression,	there	are	data	to	support	both	CBT	and	ACT	
approaches.	Both	psychological	approaches	have	support	for	the	cognitive	impacts	identified	by	
the	survey,	which	were:	worry	about	fitness,	the	future,	and	depression.	The	lack	of	clarity	
between	psychological	approaches	appears	consistent	with	the	wider	research	into	psychological	
therapy	in	pain,	where	strategies	to	select	the	appropriate	approach	for	the	person,	rather	than	
the	appropriate	approach	for	the	impact,	is	suggested	as	a	future	direction	of	research	(Vlaeyen	
and	Morley,	2015).	If	medical/psychological	interventions	are	to	be	person-centred	then	
understanding	which	approach	is	likely	suited	to	each	patient	is	important.	
7.6.2	Research	implications	
The	correlation	analysis	presented	in	Chapter	6	found	strong	associations	between	passive	
approaches	to	coping	with	PDN	and	the	severity	of	the	impacts.	Trying	to	avoid	the	pain	or	hoping	
it	would	not	flare	did	not	ameliorate	the	experience	of	PDN.	However,	using	active	coping	
approaches,	at	least	as	defined	by	the	CSQ,	were	not	associated	with	any	lessening	of	impact.		
If	unpredictable	pain	flares	are	interfering	with	achievement	of	day-to-day	activity	and	
contributing	to	a	person’s	depression,	novel	strategies	to	manage	unpredictability	need	to	be	
considered.	Strategies	of	activity	scheduling	and	pacing	place	the	management	strategy	before	
the	activity;	it	maybe	the	activity	needs	to	be	foremost,	and	strategies	to	manage	a	pain	flare	
used	when	and	if	that	flare	occurs.	Such	strategies	might	include	focus	on	the	present	moment,	
rather	than	possible	futures,	as	advocated	by	ACT	and	MBSR.		
The	hypothesis	that	acceptance-based	approaches	are	associated	with	reduced	distress	and	
improved	quality	of	life	could	be	studied	using	either	a	controlled	design	or	a	case-series	design.	
Were	a	controlled	design	used,	care	would	be	needed	designing	the	control	intervention.	Moore	
et	al.	(2010)	highlighted	that	control	interventions	must	have	the	same	credibility	as	the	active	
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arms,	so	non-psychologically	directed	treatment-as-usual	would	not	be	an	appropriate	
comparison.	Here	a	case	series	design,	with	a	waiting	list	control	time	period,	maybe	appropriate.	
The	hypothesis	would	be	that	a	positive	relationship	would	be	found	between	changes	in	pain	
related	acceptance	(using	the	BPCI-2)	and	changes	in	measures	of	function	and/or	distress	at	
post-intervention.	
7.7	Is	there	a	need	for	a	multidisciplinary	Impact	Coping	Skills	programme	for	PDN?	
For	some	people	with	PDN,	who	are	distressed	and	disabled,	a	multidisciplinary	approach	
seems	warranted.	For	other	people,	it	seems	appropriate	to	suggest	that	individual	clinicians	in	
primary	and	secondary	care	could	develop	a	range	of	skills	to	help	the	individual	patient	with	the	
specific	issues	they	raise.		
The	dispersal	of	skills,	particularly	in	psychological	management,	from	specialist	teams	to	
individual	clinicians	has	occurred	in	the	management	of	LBP.	Multidisciplinary	PMPs	including	
psychological	management,	were	restricted	for	the	most	distressed	patients	due	to	limited	
capacity	(Phillips	et	al.,	2008).	Developments	in	stratifying	LBP	by	risk	factors	identified	as	
prognostic	for	the	development	of	persistent	pain,	highlight	that	people	may	require	
psychological	support	in	the	early	stages	of	LBP,	not	just	once	pain	has	been	present	for	a	
significant	time	(Foster,	Hill	and	Hay,	2011;	Hill	et	al.,	2011).	These	developments	have	required	
clinicians	other	than	psychologists,	particularly	physiotherapists,	to	develop	skills	in	identifying	
and	managing	psychological	aspects	of	fear,	worry	and	stress	(Main	et	al.,	2012).	
Some	clinicians	interviewed	identified	a	discrepancy	of	skill	mix	between	paediatric	MDT	
teams,	which	would	nearly	always	have	access	to	clinical	psychologists,	and	adult	MDT.	Patients	in	
adult	secondary	care	services	were	more	likely	to	have	developed	complications	but	would	have	
much	less	access	to	psychologists	(Chapter	5,	section	5.5.2.5).	Up-skilling	the	range	of	clinicians	
involved	in	DM	and	PDN,	to	effectively	address	psychological	issues	would	help	to	alleviate	this	
issue.	
The	term	PMP	is	used	within	this	thesis	to	define	a	multidisciplinary	intervention	that	aims	
to	help	participants	live	with	pain.	This	term	is	common	in	research	literature	and	clinical	practice	
and	the	connotation	understood	both	nationally	and	internationally.	The	term	may	imply	to	
patients	however,	that	their	pain	is	the	focus	of	management,	whereas	reduction	of	subjective	
pain	is	rarely	the	stated	aim	of	these	programmes.	Rather,	the	focus	is	on	quality	of	life	with	pain.	
A	more	appropriate	term	than	PMP	maybe	“Impact	Coping	Skills	Programme”,	it	would	be	
important	to	explore	this	and	other	alternative	terms	using	focus	groups	with	both	patients	and	
clinicians	to	establish	the	most	acceptable	descriptive	label.	
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The	components	described	in	sections	7.1	to	7.6,	could	be	delivered	by	individual	clinicians,	
either	in	primary	or	secondary	care,	or	as	part	of	an	MDT	programme	with	a	focus	on	PDN.	This	
makes	future	studies	into	improved	management	for	the	impacts	of	PDN	prioritised	by	
respondents	in	Chapter	6,	challenging.	A	tension	exists	between	creating	management	packages	
individualised	to	a	patient’s	priorities	and	delivering	a	package	of	strategies	in	a	group	format,	
that	aims	to	cater	for	the	most	frequently	identified	priorities	but	is	bespoke	to	no-one.	Chapter	
6,	Table	29	outlines	how	the	top-6	priorities	presented	in	this	chapter,	had	some	consistency	(for	
example	sleep)	but	were	not	universal	to	all	sub-groups.		
If	a	patient-centred	approach	were	taken,	the	study	design	would	need	to	be	a	case	series	
with	patients	acting	as	their	own	control.	Appropriate	outcome	measures	for	the	specific	impact	
of	PDN	would	be	taken	at	baseline	(time0),	pre-intervention	(time1),	post-intervention	(time2)	and	
longer	term	follow	up	(time3).	Although	aligned	with	clinical	practice	this	study	design	lacks	
randomisation,	consistency	of	outcome	measures,	blinding	of	researchers	to	treatment	allocation	
and	suffers	from	an	inconsistency	of	intervention	delivery.		
An	alternative	would	be	to	design	the	curriculum	for	a	PDN	Impact	coping	skills	programme	
and	perform	a	pilot	study.	Patients	could	be	randomised	between	intervention	and	control	arms,	
a	battery	of	outcome	measures	could	be	consistently	recorded,	the	intervention	manualised	for	
consistency	and	delivered	by	clinicians	not	involved	with	the	data	collection.	There	are	three	
options	for	randomisation:	1)	randomise	eligible,	consenting	individuals	from	recruitment	sites	to	
intervention	or	control	arm;	2)	select	recruitment	sites	with	similar	referral	rates,	social	and	
demographic	variables	and	run	the	intervention	in	one	site,	comparing	data	to	the	control	site.	
This	option	cannot	guarantee	that	the	arms	will	be	equitable	at	baseline	and	there	may	be	
unconsidered	factors	present	in	the	sites	that	bias	the	data.	And	3)	to	randomise	the	delivery	of	
an	Impact	Coping	Skills	Programme	between	study	sites,	but	delivered	by	the	same	clinicians	for	
consistency.		
It	is	clear	future	research	designs	should	consider	potential	MDT	Impact	Coping	Skills	
Programme	as	‘complex’	interventions	as	defined	by	the	Medical	Research	Council		(Walach	et	al.,	
2006;	Craig	et	al.,	2008).	Such	an	intervention	fits	the	criteria	for	complex	because	there	are	
multi-directional	interactions	between	the	person’s	physical	state	and	psychological	state	
(depression,	anxiety,	stress	and	motivation	to	name	four).	There	are	further	interactions	with	the	
person’s	social	situation	-	how	much	support	people	have	from	family,	peers,	Internet	social	
media	groups,	primary	and	secondary	care	medical	teams.	Lastly,	the	person	is	likely	to	have	
additional	diabetes-related	complications	(see	Chapter	1	section	1.1.8)	and	potentially	other	
medical	conditions	which	they	have	to	manage.	Recent	studies	have	used	the	Medical	Research	
Chapter	7	–	Patient	priorities:	clinical	and	research	implications	
Page	226	
Council	framework	to	guide	the	development	of	pain	self-management	courses	for	general	
musculoskeletal	pain	(Carnes	et	al.,	2013).	
	
This	chapter	has	described	the	top	six	impacts	that	respondents	with	PDN	identified	as	their	
priorities	to	have	better	strategies	to	manage.	For	some	impacts	–	sleep	disturbance,	physical	
fitness,	functional	walking,	worry	and	depression	–	there	are	existing	strategies	in	PMPs	that	could	
be	applicable	to	the	population	with	PDN.	Clinicians	advising	physical	activity	will	need	to	be	
appropriately	aware	and	cautious	of	the	need	for	foot	protection	and	checks.	They	will	also	need	
to	take	other	potential	co-morbidities	into	consideration.	In	PMPs	the	impacts	on	mood	have	been	
addressed	using	both	CBT	and	ACT	approaches	and	further	research	is	required	to	understand	
whether	one	approach	would	be	more	beneficial	in	PDN	than	the	other.	There	is	much	less	
evidence	regarding	interventions	for	the	impact	of	numb	feet.		
The	management	strategies	outlined	above	could	be	delivered	according	to	individual	
patient	need,	or	brought	together	to	form	a	PDN	Impact	Coping	skills	course.	The	on-going	
physiological	processes	of	DM	suggest	that	moving	interventions	‘up-stream’	would	be	beneficial	
rather	than	waiting	for	the	impacts	to	become	established.		
The	following	chapter	will	summarise	the	thesis	including	strengths	and	limitations	as	well	
as	some	personal	reflections.	
	
Chapter	8	–	Thesis	summary	
Page	227	
Chapter	8	–	Thesis	summary	
The	previous	chapter	examined	the	top	priorities	selected	by	survey	respondents	and	
considered	the	clinical	and	research	implications	of	each.	This	chapter	will	summarize	the	overall	
thesis	findings,	considering	the	strengths	and	limitations	of	each,	and	highlight	the	new	
knowledge	that	this	thesis	contributes	to	the	field.	It	will	also	provide	a	personal	reflection.		
	
8.1	Thesis	summary	
The	aims	of	this	thesis	were	set	out	in	Chapter	1,	section	1.6.2	and	are	considered	in	the	
following	sections.	
Aim	1)	To	conduct	a	systematic	literature	review	of	the	evidence	investigating	physical	
activity	and	psychological	coping	strategies,	in	the	management	of	PDN.		
Chapter	2	detailed	a	systematic	review	of	the	literature	that	retrieved	studies	investigating	
physical	activity	or	psychological	coping	strategies	for	PDN.	Measures	of	pain	severity	were	
specified	as	primary	outcome	data	and	other	measures	of	quality	of	life	were	considered	
secondary	outcomes.	Few	studies	were	found.	Two	studies	investigating	physical	exercise	found	
inconsistent	results.	Aerobic	exercise	did	not	improve	pain	rating,	the	statistically	significant	
results	presented	were	due	to	the	control	arm	worsening	(Dixit,	Maiya	and	Shastry,	2014).	Tai	Chi	
did	improve	pain	severity	but	the	study	was	not	powered	for	pain	as	an	outcome	measure	and	
the	control	arm	worsening	contributed	to	the	statistical	significance		(Ahn	and	Song,	2012).	
The	above	physical	activity	studies	did	show	a	positive	effect	of	physical	activity	on	
measures	of	quality	of	life	for	participants	in	the	intervention	arms.	However,	quality	of	life	was	
not	the	primary	outcome	of	interest	in	this	literature	review,	and	so	all	available	studies	were	not	
systematically	retrieved.	These	findings	for	physical	activity	were	broadly	in-line	with	the	recent	
Cochrane	overview	for	chronic	pain	(Geneen	et	al.	(2017),	where	activity	was	shown	to	have	more	
consistent	positive	effect	on	function	and	quality	of	life,	than	pain	severity.		
Two	studies	investigating	psychological	approaches	were	also	included:	CBT	(Otis	et	al.,	
2013)	and	mindfulness	relaxation	(Teixeira,	2010).	Otis	et	al.	(2013)	was	biased	by	a	small	sample	
size	and	high	attrition	rate,	and	Teixeira	(2010)	did	not	have	adequate	blinding	of	researchers.	
Chapter	2	found	there	was	currently	insufficient	evidence	to	conclude	whether	psychological	
therapy	had	a	role	in	the	management	of	PDN.	
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New	knowledge		
• There	is	limited	evidence	for	pain	management	strategies	in	managing	PDN	
specifically.		
	
Future	research	considerations	
• Future	research	should	consider	strategies	to	manage	quality	of	life	more	broadly,	
than	focus	on	pain	severity	in	isolation.		
• Patient	and	clinician	opinions	of	PMP	strategies	are	unknown	therefore	two	
interview	studies	were	designed	to	explore	these.	
	
Aim	2)	To	explore	peoples’	experiences	of	living	with	and	self-managing	PDN,	and	their	
perspectives	on	physical	activity	and	psychological	coping	strategies	for	PDN	management.	
An	interview	study	was	conducted	with	people	who	experience	PDN.	The	methodology	was	
described	in	Chapter	3	and	the	results	presented	in	Chapter	4.	This	study	found	PDN	had	a	wide	
range	of	impacts	on	peoples’	lives.	These	impacts	were	more	varied	than	had	been	captured	
previously	by	research	using	quantitative	questionnaires	(Alleman	et	al.,	2015).	Participants’	
experiences	of	medical	management	were	usually	based	on	medication,	with	no	adjunctive	
strategies	suggested.	They	had	experimented	with	a	variety	of	management	strategies	
themselves,	usually	to	no	benefit.	There	was	scepticism	about	how	physical	activity	or	
psychological	approaches	could	be	beneficial	for	PDN,	but	those	who	had	attended	PMPs	for	
other	reasons	felt	the	strategies	did	have	applicability	to	PDN.		
A	strength	of	this	study	was	the	consistency	of	research	approach	from	research	questions	
formulation	to	data	collection	and	analysis.	Using	one-to-one	interviews	allowed	participants	to	
freely	discuss	their	experiences	and	management	of	PDN.	Careful	supervision	and	guidance	from	
the	supervisory	team	helped	to	ensure	the	data	and	analysis	were	not	prejudiced	or	biased	by	the	
novice	researcher.	The	repeat	coding	and	analytic	approach	(described	in	Chapter	3,	sections	
3.11.4	and	5)	ensured	the	participants’	views	were	accurately	reflected	in	the	results	and	
conclusions.		
There	were	two	key	limitations.	Firstly,	the	lack	of	ethnic	diversity	(22/23	participants	
identified	as	White	British).	Pain	has	many	cultural	and	social	nuances	(Edwards,	Fillingim	and	
Keefe,	2001)	and	while	qualitative	research	does	not	claim	to	be	generalizable	beyond	the	sample	
population	(Petty,	Thomson	and	Stew,	2012a),	it	was	disappointing	not	to	recruit	a	sample	with	
wider	ethnic	diversity.	Later	studies	(Internet	survey,	Chapter	6)	were	developed	based	on	the	
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codes	identifying	the	impacts	of	PDN	generated	by	this	interview	study.	These	codes	were	
developed	from	an	ethnically	homogenous	sample	and	this	limitation	needs	to	be	recognized	for	
its	influence	on	the	later	study.		
	Secondly,	most	interview	participants	had	not	attended	PMPs	so	their	perspectives	were	
not	based	on	experience.	The	participants	who	had	attended	PMPs	for	other	pain	experiences	felt	
the	strategies	could	be	applied	to	PDN.	
New	knowledge:	
• The	impacts	of	PDN	are	broader	and	more	varied	than	reflected	by	published	
studies	based	on	existing	questionnaires.		
• Physical	activity,	for	some	people	with	PDN,	acts	as	a	distraction,	or	they	alter	their	
expectations	for	a	specific	activity	in	order	to	maintain	general	activity	levels.	
• In	relation	to	psychological	support,	those	who	have	experienced	contact	with	
psychologists,	either	through	PMPs	or	individual	psychology	appointments,	find	this	
beneficial	for	considering	and	challenging	negative	cognitions.	
• Views	on	how	applicable	physical	activity	and	psychological	support	are	individual	
to	the	person	and	cannot	be	generalised	to	the	pathology	of	PDN.	Some	patients	
would	be	more	open	to	a	PMP	approach	than	others.	
	
Future	research	considerations	
• To	explore	the	treatment	priorities	of	patients	further,	an	Internet	survey	was	
designed	using	the	impacts	developed	in	the	patient	interview	study.		
	
Aim	3)	To	explore	specialist	clinicians’	current	strategies	for	management	of	PDN	(as	one	
form	of	diabetic	complication),	and	their	perspectives	on	physical	activity	and	psychological	
coping	strategies	for	PDN	management.	
An	interview	study	was	conducted	with	specialist	diabetes	clinicians,	specialist	pain	
clinicians	and	representatives	from	primary	care	who	had	experience	of	treating	people	with	PDN.	
The	methodology	was	presented	in	Chapter	3	and	the	results	in	Chapter	5.	It	was	clear	from	the	
diabetes	clinicians	they	were	aware	of	the	range	of	impacts	experienced	by	people	with	PDN,	
specifically	highlighting	sleep	disturbance,	depression,	anxiety,	mobility	issues	and	social	isolation.	
Yet	they	described	having	few	strategies	beyond	medication	to	manage	these	impacts.	Diabetes	
clinicians	raised	two	specific	concerns	regarding	strategies	from	PMPs,	1)	that	people	with	PDN	
were	at	risk	of	tissue	damage	if	excessive	physical	activity	was	advised	and	2)	that	people	with	DM	
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and	PDN	would	likely	have	a	range	of	other	complications	and	comorbidities	that	made	them	
medically	more	complex	than	the	‘usual’	participants	in	a	PMP.		
Pain	specialist	clinicians	described	many	PMP	strategies	could	be	applicable	to	people	with	
PDN.	They	were	aware	some	strategies,	particularly	pacing	physical	function,	may	not	be	so	
applicable	and	novel	strategies	maybe	required.	This	finding	was	supported	by	other	research,	for	
instance	Daniel	et	al.	(2015),	who	described	difficulty	accommodating	the	specific	needs	of	people	
with	neuropathic	pain	in	‘standard’	PMPs.	Pain	clinicians	were	cognisant	of	the	risks	physical	
activity	could	pose	to	insensate	feet	but	had	other	non-	or	partial-weight	bearing	exercise	options	
available	to	minimise	that	risk.	
By	using	one	to	one	interview	the	clinicians	interviewed	were	able	to	give	their	opinions	
freely.	Because	interviews	were	conducted	over	a	number	of	months,	issues	raised	in	one	
interview	could	be	explored	further	in	subsequent	interviews	if	necessary.	There	were	limitations	
to	the	sample	population.		Only	secondary	care	podiatrists	were	interviewed,	so	the	perspectives	
of	primary	care	podiatrists,	whose	role	is	ulcer	prevention	rather	than	treatment,	may	differ.	Only	
one	GP	and	one	practice	nurse	were	recruited	and	so	there	may	have	been	other	primary	care	
experiences	of	managing	PDN	that	have	not	been	captured.		
New	knowledge:	
• Diabetes	clinicians	are	aware	of	the	wide-ranging	impact	of	PDN	but	only	routinely	
consider	medication.		
• Diabetes	specialists	and	primary	care	clinicians	considered	all	PMP	strategies	were	
potentially	beneficial	to	people	with	PDN,	but	with	two	caveats:	people	with	DM	
were	likely	to	be	more	medically	complex	than	those	with	MSK	pain	conditions,	and	
there	were	risks	of	foot	damage	associated	with	physical	activity.	
• The	perspectives	of	diabetes	clinicians	were	not	based	on	direct	experience	of	
PMPs.		
• Pain	specialist	clinicians	have	options	to	adapt	physical	activity	to	be	suitable	for	
people	with	PDN.	
	
Future	research	directions	
• The	concerns	of	diabetes	clinicians	will	be	vital	to	consider	and	address	in	future	
research.	
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Aim	4)	To	explore	which	impacts	of	PDN	people	prioritise	for	improved,	or	alternative,	
management	strategies.	
Based	on	the	impacts	described	in	Chapter	4	(Aim	2),	an	Internet	survey	was	created	to	
explore	how	frequent	and	severe	these	impacts	were,	and	to	establish	respondents’	priorities	for	
improved	management	strategies	(Chapter	6).	In	essence	this	study	aimed	to	build	management	
strategies	based	on	the	patients’	experiences	and	priorities,	rather	than	by	clinicians	assuming	
what	strategies	were	required	by	their	patients.	Of	the	58	impact	statements,	only	four	were	
experienced	by	less	than	half	of	the	survey	respondents.	This	highlighted	how	extensive,	and	
varied	between	individuals,	the	impact	of	PDN	can	be	on	peoples’	lives.	This	finding	provided	an	
element	of	triangulation	to	the	impact	results	of	the	interviews	(Mays	and	Pope,	2000;	Doyle,	
Brady	and	Byrne,	2009).	These	impacts	reduced	patients’	quality	of	life,	and	this	was	in-line	with	
existing	research	(for	a	summary	please	see	Alleman	et	al.	(2015)),	but	critically,	these	impacts	
included	issues	not	present	in	the	usual	questionnaires	used	in	PDN	quantitative	research.	The	
body	of	research	using	these	questionnaires	as	outcome	measures,	may	not	be	measuring	
outcomes	of	relevance	to	the	population	with	PDN.		
The	study	explored	associations	between	the	impacts	experienced,	and	active	or	passive	
pain	coping	strategies.	There	was	strong	positive	correlation	between	passive	coping	(as	defined	
by	the	CSQ)	and	worsening	impact	of	PDN,	but	active	coping	was	not	correlated	with	less	impact.	
The	constituent	factors	of	active	coping	were	congruent	with	the	management	strategies	of	
traditional	PMPs.	Existing	research	(Daniel	et	al.	2015)	has	highlighted	issues	with	the	content	of	
traditional	PMPs	for	people	with	neuropathic	pain,	and	the	findings	of	the	survey	presented	in	
Chapter	6,	further	suggests	that	more	research	is	required	to	understand	the	most	appropriate	
approaches	to	helping	people	live	well	with	PDN.	For	example,	research	in	MS,	another	complex	
long-term	condition	associated	with	neuropathic	pain,	suggests	that	an	attitude	of	pain	
acceptance	was	associated	with	improved	patient	rating	of	their	quality	of	life	(Harrison	et	al.,	
2015a,	2015b).	Measures	of	pain	acceptance	have	never	been	explored	in	PDN	and	would	be	an	
avenue	for	future	work.				
There	was	consistency,	but	not	universality,	of	the	impacts	that	respondents	prioritised	for	
improved	management.	Sleep	disturbance	was	consistently	rated	the	top	priority	across	all	the	
sub-groups	analysed.	Chapter	6,	Table	29	outlined	the	various	subgroups	analysed	and	
demonstrates	that	there	were	six	most	frequently	identified	impacts.	Impacts	that	reflected	the	
subjective	pain	experience	of	PDN	were	not	prioritised.	This	suggests	that	when	presented	with	
options	developed	from	the	experience	of	people	with	PDN,	pain	reduction	is	not	necessarily	the	
most	important	priority	for	treatment.	The	clinical	implication	and	future	research	options	of	
these	impacts	were	discussed	in	detail	in	Chapter	7.	
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Recent	research	has	explored	creating	a	PDN-specific	outcome	measure	(Brod	et	al.,	
2015a).	This	research	was	partially	based	on	a	qualitative	study	using	focus	groups	and	one-to-
one	interviews	conducted	by	the	same	research	team	which	was	discussed	in	detail	in	Chapter	4	
(Brod	et	al.,	2015b).	The	outcome	measure	development	process	was	informed	by	the	existing	
literature	on	PDN	impact,	and	interviews	with	clinical	experts.	The	Diabetic	Peripheral	
Neuropathic	Pain	Impact	(DPNPI)	measure	(Brod	et	al.,	2015a)	contained	three	domains:	Physical	
mobility	(10	questions),	Sleep	(5	questions)	and	Daily	activity	(3	questions).	Clear	overlap	exists	
between	the	impacts	prioritised	in	the	Internet	survey	and	the	DPNPI	outcome	measure	produced	
(Brod	et	al.	2015a),	both	in	what	was	included	(sleep,	physical	function	and	walking)	and	what	
was	not.	Pain	severity	was	not	a	priority	in	the	survey	nor	identified	in	the	DPNPI	outcome	
measure.		
Yet	pain	reduction	is	the	primary	outcome	in	the	vast	majority	of	pharmacological	trials	
(Moore,	2013).	Secondary	outcomes	of	function	and	quality	of	life	are	usually	based	on	the	
outcome	measures	described	earlier	(Aim	2,	Chapter	4),	that	may	not	represent	the	actual	issues	
experienced	by	people	with	PDN.	
The	pilot	phase	process	for	this	survey	suggested	it	was	a	challenging,	yet	achievable	
process	to	complete.	It	was	advertised	widely	on	patient	focussed	social	media	platforms	and	by	
DUK.	Respondents	had	the	opportunity	to	add	further	impacts.	However,	despite	these	attempts	
to	gather	a	robust	sample,	the	final	sample	size	of	n=78	was	insufficient	to	allow	the	conduct	of	
PCA.	PCA	would	have	allowed	the	clustering	together	of	impacts	relating	to	similar	issues	(Floyd	
and	Widaman,	1995).	The	results	and	discussion	presented	in	Chapter	6	were	based	on	the	
individual	impact	statements,	if	PCA	had	clustered	impacts	together,	these	results	and	
consequent	discussion	may	have	been	different.		
New	knowledge	
• The	impacts	developed	in	Aim	2	(Chapter	4)	were	recognized	and	endorsed	by	survey	
respondents.	
• Passive	coping	approaches	were	strongly	correlated	with	increased	impact	load,	this	was	
consistent	with	the	wider	pain	literature	(O’Sullivan,	2005).	
• Six	impacts	were	prioritised	by	respondent	sub-groups	with	commonality,	but	not	
universality.	Sleep	was	consistently	the	top	priority,	others	were	physical	fitness,	walking,	
numb	feet,	future	prognosis	and	depression.		
• Pain	severity	was	not	prioritised	by	survey	respondents.	
	
	
Chapter	8	–	Thesis	summary	
Page	233	
Future	research	considerations	
• Clinicians	who	help	people	manage	PDN	must	ensure	they	clearly	understand	the	
expectations	and	priorities	of	their	patients.	
	
8.2	Overall	thesis	limitations	and	strengths	
8.2.1	Limitations	of	the	research	
One	limitation	of	this	thesis	was	the	White	British	profile	of	the	interview	and	survey	
samples.	This	issue	has	been	discussed	in	the	limitations	of	each	study	and	in	the	section	earlier,	
but	to	summarise,	the	experience	of	pain	is	highly	contingent	on	multiple	social	and	cultural	
variables	(Gatchel	et	al.,	2007;	Engel,	1978).	Research	has	also	found	people	from	ethnic	minority	
groups	have	additional	challenges	in	self-managing	diabetes,	including	higher	levels	of	social	
deprivation	and	reduced	health	literacy	(Claydon,	Campbell-Richards	and	Hill,	2013).	This	thesis	
has	been	based	on	the	experiences	of	participants	who	do	not	represent	the	full	range	of	cultural	
variables.	For	the	interview	study,	participants	were	located	around	the	UK,	but	no	details	of	
socioeconomic	status	were	recorded.	The	Internet	survey	was	advertised	nationally	and	on	peer-
support	web	pages,	these	webpages	were	open	to	the	worldwide	web	and	so	respondents	may	
have	been	based	outside	the	UK.	The	socio-economic	variables	of	the	study	populations	were	not	
known	in	detail	and	so	the	results	and	conclusions	cannot	be	assumed	to	translate	to	other	
populations.		
Future	research	conducted	in	the	UK	would	need	to	prioritise	recruitment	of	people	with	
PDN	from	ethnic	minority	backgrounds.	This	targeted	recruitment	would	allow	checking	whether	
the	initial	impact	codes	from	the	interview	study	were	sufficiently	encompassing	for	the	
experiences	of	PDN	in	all	social	groups,	or	whether	specific	impacts	had	been	overlooked.	The	
results	of	the	Internet	survey	also	require	validation	in	ethnic	minority	populations	with	a	
programme	of	targeted	recruitment.		
This	thesis	has	been	limited	to	the	UK	and	so	people	with	PDN	were	managed	within	the	
NHS	system.	No	interview	participant	described	management	of	diabetes	or	PDN	outside	of	the	
NHS	in	private	or	independent	sector	health	providers.	It	is	possible	that	people	who	are	managed	
within	health	insurance	systems,	such	as	the	USA,	may	have	different	experiences	and	
perspectives	on	management	of	PDN.	However,	Brod	et	al.	(2015b)	was	conducted	in	the	USA	and	
the	impacts	identified	through	their	focus	groups	were	broadly	similar	to	those	described	by	
participants	in	this	thesis.	
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A	second	limitation	was	that	many	interviewees,	both	patients	and	clinicians	not	involved	
in	pain	management,	had	little	or	no	actual	experience	of	observing	or	advising	the	strategies	
employed	in	PMPs.	Their	perspectives	were	based	only	on	the	PMP	mind-map	and	the	ability	to	
ask	clarifying	questions	of	the	researcher.	It	was	of	course	important	that	the	researcher	did	not	
express	opinions	based	on	his	own	experience	of	running	PMPs.	Similarly,	the	pain	specialist	
clinicians	did	not	share	the	detailed	knowledge	about	the	medical	complexity	of	people	with	DM,	
that	made	their	diabetes	colleagues	more	cautious	in	advocating	PMP	strategies	for	PDN.		
With	more	time	resource,	it	would	have	been	useful	to	arrange	cross-discipline	visits,	for	
pain	clinicians	to	observe	DM	clinics,	and	diabetes	clinicians	to	observe	PMPs	in	progress.	This	
may	have	altered	the	clinicians’	opinions.	
	
8.2.2	Strengths	of	the	research	
The	primary	strength	of	this	research	was	that	it	built	upon	the	experience	of	people	who	
have	lived	with	PDN	for	many	years.	Placing	the	patient	at	the	centre	of	both	clinical	services	and	
research	direction	aims	to	ensure	that	clinical	services	are	accessible	and	appropriate	for	the	
patient	cohort	(Gooberman-Hill,	2012),	and	that	research	focuses	on	their	unmet	needs	(Brett	et	
al.,	2014;	Nierse	et	al.,	2012).	
The	researcher	had	contact	with	people	living	with	PDN	in	the	context	of	interviews,	but	
this	was	furthered	with	the	help	and	advice	from	two	EPRPs	(Hewlett	et	al.,	2006).	The	ability	to	
discuss	the	wording	of	interview	questions,	developing	codes,	theme	structures	and	Internet	
survey	questions	helped	keep	the	research	grounded	and	focussed	on	the	experience	of	living	
with	PDN.		
Qualitative	research	does	not	expect	to	generate	results	that	can	be	generalised	beyond	
the	sample	population	(Polit	and	Beck,	2010).	The	limitations	in	sample	population	identified	in	
the	previous	section	could	have	been	addressed	by	devoting	project	resources	to	specific	
recruitment	and	further	qualitative	studies.	Instead,	a	decision	was	made	to	use	the	new	
knowledge,	which	had	been	acquired,	and	explore	patient	priorities.	This	decision	enabled	a	form	
of	validation	by	triangulation	(Petty,	Thomson	and	Stew,	2012b;	Yardley,	2000).	Had	many	of	the	
impacts	generated	by	the	interviews	not	been	rated	as	experienced	by	survey	respondents,	this	
would	suggest	there	was	something	unique	about	the	interview	sample.	As	the	least	frequently	
experienced	impact	(I	have	contemplated	suicide	due	to	my	PDN)	was	still	endorsed	by	29.3%	of	
the	sample,	this	suggested	the	interview	sample	were	at	least	somewhat	representative	of	other	
people	with	PDN.			
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A	further	strength	of	this	thesis	was	the	pragmatic	approach	to	the	research	process,	
retaining	a	focus	on	the	patient	experience	and	informed	by	the	clinical	experience	of	researcher	
and	supervisory	team.	The	development	of	the	survey	structure	to	allow	respondents	to	select	
their	priority	impacts	had	a	number	of	potential	solutions,	each	with	positives	and	negatives.	It	
was	important	to	make	the	process	feasible	using	the	online	programme,	but	crucially	not	to	
allow	any	imposition	from	the	researcher	to	limit	the	eventual	priorities	selected	by	respondents.	
The	options	considered	and	the	rational	for	the	approach	taken	can	be	found	in	Chapter	6,	
section	6.7.		
The	final	strength	to	highlight	was	the	nature	of	meetings	between	researcher	and	
supervisory	team,	including	Amanda,	the	main	EPRP.	These	meetings	were	always	collegiate,	with	
any	differences	of	opinion	clearly	voiced	and	discussed	openly,	so	that	all	concerned	were	clear	at	
the	end	of	the	meeting,	of	the	rationale	for	steps	taken.	The	expertise	present	in	these	meetings	
gave	confidence,	at	least	to	me,	that	the	end	results	and	conclusions	of	this	research	process	
were	appropriate	and	robust.		
8.3	Personal	reflections	
I	have	used	research	extensively	in	my	clinical	practice	and	when	teaching	pain	related	
post-graduate	courses.	In	order	to	give	back	or	contribute	to	the	body	of	pain	rehabilitation	
knowledge	I	entered	this	PhD	process	hoping	to	design	a	series	of	elegant	studies	that	would	
clearly	answer	the	specified	research	questions.	Of	course,	my	experience	did	not	match	my	pre-
conceived	expectations.	But,	the	experience	I	have	gained	of	real-world	research	will	be	
invaluable	in	my	future	clinical	career.		
I	was	fortunate	to	spend	time	observing	tertiary	care	clinics	for	PDN.	I	was	able	to	gain	a	
much	greater	understanding	of	diabetes	and	the	current	management	for	PDN	from	these	
observations.	I	entered	this	PhD	with	insufficient	attention	to	detail.	Critical	commentary	on	my	
written	work	from	the	supervisory	team,	critique	that	I	sometimes	felt	bordered	on	pedantry,	
helped	me	to	reflect	more	clearly	on	precision.	What	I	initially	felt	was	pedantic	was	actually	a	
focus	on	precision	in	understanding	the	research	paper	being	appraised,	or	precision	in	writing	a	
research	proposal.	The	time	devoted	by	the	supervisory	team	in	clinically	dissecting	my	written	
work,	has	helped	me	to	reduce	the	desire	to	write	in	academic	language,	but	rather	to	write	in	
clear	and	simple	English.	This	has	helped	me	to	recognise	and	structure	the	argument	needed	to	
support	a	conclusion.	I	started	this	PhD	as	an	experienced	clinician	and	the	culture	shock	of	being	
an	in-experienced	researcher	was	swift.	The	supervisory	team	helped	me	to	navigate	this	new	
environment	and	slowly,	gradually	managed	to	help	me	think	more	like	a	researcher.	
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The	biggest	regret	I	have	from	the	PhD	process,	was	not	striking	the	right	balance	between	
independent	study	and	asking	for	support	from	the	supervisory	team	when	required.	I	could	have	
used	the	expertise	and	enthusiasm	of	the	supervisory	team	more	effectively	and	in	a	timelier	
manner.	This	would	be	a	key	piece	of	advice	I	would	give	potential	PhD	students	in	the	future.		
Outside	of	the	studies	presented	in	this	thesis,	there	was	family	relocation	from	West	
Yorkshire	back	to	the	South	West,	moving	my	family	back	with	my	parents	for	what	became	a	
much	longer	time	period	than	initially	expected.	My	father	passed	away	last	year.	There	were	
many	times	when	I	thought	long	and	hard	about	why	I	had	started	the	PhD	process	in	the	first	
place	and	whether	it	was	worth	continuing	it	to	the	end.	But,	Dad	would	have	been	disappointed	
and	I	am	inherently	stubborn.		
I	have	been	back	in	part-time	clinical	practice	for	two	years,	and	I	am	aware	of	the	benefits	
this	PhD	process	has	had,	and	will	continue	to	into	the	future.	I	will	discuss	with	the	supervisory	
team	the	best	way	to	bring	the	key	elements	of	these	research	studies	to	publication,	but	my	
future	career	will	not	be	primarily	research	focussed.	I	will	continue	to	develop	clinical	services	
that	will	require	on-going	monitoring	and	audit.	This	PhD	has	developed	my	knowledge	of	the	
research	process	required	for	both	quantitative	and	qualitative	studies.	It	has	developed	my	
attention	to	detail	for	critical	appraisal,	argumentation	and	clarity	of	writing.		
Clinically	it	has	further	embedded	an	approach	I	endeavour	to	take	with	people	who	have	
persistent	pain	for	many	years,	that	of	open	questioning	with	as	few	preconceived	expectations	
as	possible,	of	why	they	have	sought	physiotherapy.	My	standard	opening	question	is	“What	do	
you	want	to	achieve	with	this	appointment	today?”	To	me	this	keeps	the	profession	as	patient-
centred	as	possible	from	the	first	consultation.		
These	skills	and	knowledge	will	enable	me	to	develop	further	as	a	clinical	physiotherapy	
leader	in	the	field	of	pain	rehabilitation.	
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Appendix	3	–	Patient	interview	study	PIS	
Research	Study	Title:	Qualitative	exploration	of	living	with	and	managing	painful	diabetic	
neuropathy.	
You	are	being	invited	to	take	part	in	a	study.	Before	you	decide	if	you	want	to	take	part,	it	is	
important	for	you	to	understand	why	the	study	is	being	done	and	what	it	will	involve.	Please	take	
the	time	to	read	the	following	information	carefully.	Talk	to	others	about	the	study	if	you	wish.		
Ask	us	if	there	is	anything	that	is	not	clear	or	if	you	would	like	more	information.	Take	time	to	
decide	whether	or	not	you	wish	to	take	part.	
What	is	the	purpose	of	the	study?	
This	study	is	part	of	a	series	of	studies,	aiming	to	improve	ways	of	managing	painful	diabetic	
neuropathy	(PDN).	
This	study	involves	face-to-face	interviews	with	people	who	experience	PDN.		
The	topics	of	this	interview	will	include:	
• How	the	PDN	impacts	on	your	life.	
• How	you	currently	manage	the	PDN	and	its	impact.	
• How	would	you	view	physical	activity	as	a	strategy	to	manage	the	PDN.	
• How	would	you	view	strategies	used	for	the	management	of	other	chronic	pain	problems.	
• How	you	prioritise	the	competing	demands	of	managing	diabetes	and	its	complications.	
Do	I	have	to	take	part?	
It	is	up	to	you	to	decide	if	you	want	to	take	part.	If,	once	you	have	read	this	information	sheet,	
you	are	still	interested	in	this	study	and	would	like	to	know	more	please	contact	Ben	Davies	by	
using	the	pre-paid	reply	slip	at	the	beginning	of	this	information.	If	you	do	agree	to	take	part,	you	
will	be	asked	to	sign	a	consent	form	when	you	attend	for	the	interview.	You	are	free	to	withdraw	
at	any	time,	without	giving	a	reason.	Your	usual	clinical	care	for	the	diabetes	and	for	PDN	is	
unaffected	by	your	participation	in	this	research.	
Why	have	I	received	this	information?	
The	research	is	about	diabetes	and	a	pain	condition	that	occurs	in	some	people	who	have	
diabetes	(Painful	Diabetic	Neuropathy).	Your	diabetic	clinical	team	have	diagnosed	you	with	both	
of	these	conditions	and	therefore	we	would	like	to	know	more	about	your	experiences	so	that	we	
can	design	an	intervention	to	potentially	help	people	like	you	in	the	future.	
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What	will	the	research	involve?	
If	you	have	an	initial	interest	in	being	involved	with	this	research,	please	contact	me	using	the	
pre-paid	reply	slip	at	the	beginning	of	this	information.	I	will	contact	you	to	answer	any	questions	
you	have,	and	to	discuss	being	involved	in	this	study.	If	you	are	happy	to	participate	we	will	
schedule	a	one	off	interview,	this	will	be	face	to	face	and	can	be	at	your	home,	your	local	GP	
surgery	or	at	another	place	that	is	convenient	to	you.		
The	interview	will	take	no	longer	than	90	minutes.	
Before	we	meet,	I	will	ask	you	to	look	at	a	list	of	possible	complications	that	diabetes	can	cause,	
the	list	is	at	the	end	of	this	information	sheet.	I	will	ask	you	to	identify	which	of	these	problems	
you	have	and	to	rank	the	order	in	which	they	impact	on	how	you	live	your	life.	If	you	agree	to	take	
part	in	the	research	I	will	ask	you	to	bring	this	sheet	to	the	interview.	
When	we	meet,	I	will	answer	any	further	questions	that	you	may	have.	If	you	agree	to	participate	
I	will	ask	you	to	give	written	consent	to	be	involved	and	for	me	to	record	the	interview.	
Some	basic	information	will	be	recorded	including	age,	gender,	ethnicity,	type	of	diabetes,	
duration	of	diabetes	and	pain,	and	a	list	of	the	painkillers	that	you	use.		
I	will	use	this	information	to	ensure	that	I	recruit	a	wide	range	of	people	who	experience	this	
problem.	
I	will	send	you	a	written	copy	of	the	interview	to	allow	you	to	check	the	accuracy.	
What	are	the	risks	and	benefits	of	taking	part?	
I	will	be	asking	you	to	describe	in	detail	how	your	pain	impacts	on	your	life.	This	maybe	distressing	
for	you	and	for	this	reason	you	can	choose	to	terminate	the	interview	or	take	a	break	at	any	time.	
Should	the	interview	cause	significant	distress	I	will	be	able	to	put	you	in	touch	with	Professor	
McCabe	in	order	to	plan	the	best	way	forward.	
There	are	no	immediate	benefits	to	participating,	but	in	the	long	term	this	research	will	hopefully	
lead	to	better	management	of	PDN.	
What	happens	when	the	research	study	stops?	
The	data	collected	will	be	analysed	and	a	report	will	be	written.	A	summary	report	will	be	made	
available	to	you	on	request.	This	data	will	be	used	to	define	a	pain	coping	skills	programmes	
specifically	for	PDN.	The	University	of	the	West	of	England	(UWE)	will	keep	the	anonymous	data	
for	9	years.	
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Will	my	taking	part	in	the	study	be	kept	confidential?	
Yes,	I	will	anonymise	the	interview	transcripts	and	research	data,	and	you	will	not	be	referred	to	
by	name	in	the	interview.	All	electronic	files	will	be	stored	on	secure	password	protected	servers	
at	UWE	Bristol.	All	paper	files	will	be	anonymised	and	stored	in	locked	filing	cabinets	at	UWE	
Bristol.	All	identifying	information	will	be	removed	when	the	data	is	written	up	for	publication.		
What	will	happen	if	I	don’t	want	to	carry	on	with	the	study?	
If	you	decide	you	do	not	wish	to	carry	on	with	the	study	you	may	withdraw	at	any	time.	Any	data	
that	we	have	collected	up	to	your	withdrawal	will	not	be	used	in	the	study.	Your	usual	clinical	care	
will	not	be	affected	by	taking	part	in	this	study	even	if	you	subsequently	decide	to	withdraw.	
Who	is	organising	the	study?	
This	study	forms	part	of	a	PhD	research	project	at	UWE.	
The	study	has	been	reviewed	by	UWE	Ethics	committees	and	local	NHS	Research	Ethics	
Committees.	
	
Chief	Investigator:	
Ben	Davies,	MSc,	MCSP,	PhD	candidate.	
	
PhD	supervisory	team:	
Professor	Candy	McCabe,	UWE.		
Dr	Fiona	Cramp,	UWE.		
Dr	Jeremy	Gauntlett-Gilbert,	RNHRD.	
Professor	David	Wynick,	UHBristol.	
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Appendix	4	–	Clinician	interview	study	PIS	
Research	Study	Title:	Clinicians’	perspectives	on	the	management	of	painful	diabetic	neuropathy	
You	are	being	invited	to	take	part	in	a	study.	Before	you	decide	if	you	want	to	take	part,	it	is	
important	for	you	to	understand	why	the	study	is	being	done	and	what	it	will	involve.	Please	take	
the	time	to	read	the	following	information	carefully.	Talk	to	others	about	the	study	if	you	wish.		
Ask	us	if	there	is	anything	that	is	not	clear	or	if	you	would	like	more	information.	Take	time	to	
decide	whether	or	not	you	wish	to	take	part.	
What	is	the	purpose	of	the	study?	
This	study	is	part	of	a	series,	aiming	to	enhance	management	strategies	for	painful	diabetic	
neuropathy	(PDN).	
This	study	involves	interviews	(face	to	face	or	via	telephone)	with	clinicians	who	are	involved	in	
the	management	of	diabetes	and	PDN.	The	focus	of	the	interview	will	be	to	obtain:	1)	your	views	
on	current	management	strategies	for	PDN,	and	2)	your	views	on	pain	coping	skills	programmes	
strategies	and	their	application	to	PDN.	
Do	I	have	to	take	part?	
It	is	up	to	you	to	decide	whether	you	want	to	take	part.	If,	once	you	have	read	this	information	
sheet,	you	are	still	interested	in	this	study	and	would	like	to	know	more	please	contact	Ben	Davies	
via	the	email	or	phone	number	provided	at	the	end	of	this	document.	If	you	do	agree	to	take	part,	
you	will	be	asked	to	either	sign	a	consent	form	when	you	attend	for	the	interview	appointment,	
or	give	verbal	recorded	consent	if	the	interview	is	by	telephone.	You	are	free	to	withdraw	at	any	
time,	without	giving	a	reason.		
Why	have	I	received	this	information?	
I	plan	to	interview	members	of	all	professions	who	help	manage	diabetes	and	PDN.	This	includes	a	
representative	sample	of	all	members	of	the	multi	disciplinary	teams	in	secondary	and	primary	
care.	I	hope	to	recruit	medical	staff,	specialist	nurses,	practice	nurses,	dieticians,	podiatrists,	
psychologists,	occupational	therapists	and	physiotherapists.		
You	have	received	this	study	information	because	I	believe	that	you	fulfil	these	criteria.	
What	will	the	research	involve?	
If	you	are	willing	to	participate	I	will	schedule	a	one	off	interview	appointment,	this	can	be	face	to	
face	or	via	telephone.	The	interview	will	take	no	longer	than	an	hour.	
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When	we	meet,	I	will	answer	any	further	questions	that	you	may	have.	If	you	agree	to	participate	
I	will	take	informed	consent	from	you	to	be	involved	and	to	record	the	interview.	If	the	interview	
is	by	phone,	consent	will	be	the	first	recorded	section.	
With	your	permission	the	interview	will	be	recorded	to	digital	audio	file	and	transcribed.	
The	areas	of	interest	for	this	interview	will	include:	
• Your	profession	and	duration	of	experience	with	diabetes	and	PDN.	
• How	you	currently	manage	PDN.	
• Your	views	on	physical	activity	as	a	strategy	for	the	management	of	PDN.	
• Your	views	on	strategies	from	pain	coping	skills	programmeto	manage	PDN.	
• Your	view	on	how	patients	would	respond	to	the	offer	of	a	PDN-specific	pain	coping	
programme.	
• Any	practical	suggestions	for	the	implementation	of	a	potential	PDN-specific	pain	coping	
programme.	
I	will	send	you	a	copy	of	the	transcript	following	the	interview	to	allow	you	to	comment	on	the	
accuracy.	All	the	interview	transcripts	will	be	analysed	to	look	for	themes	that	would	help	inform	
a	PDN	specific	pain	coping	skills	programme.	
What	are	the	risks	and	benefits	of	taking	part?	
There	are	no	immediate	risks	or	benefits	to	participants	taking	part	in	this	research.	You	will	
however	need	to	give	up	around	1	hour	of	your	time	in	order	to	take	part.	
What	happens	when	the	research	study	stops?	
The	data	collected	will	be	analysed	and	a	report	will	be	written.	A	summary	report	will	be	made	
available	to	you	on	request.	I	will	use	this	data	to	inform	an	intervention	specific	for	PDN.	
Will	my	taking	part	in	the	study	be	kept	confidential?	
Yes,	your	involvement	in	this	study	will	not	be	revealed	to	anyone.	Further,	the	audio	
transcriptions	will	be	anonymised	and	you	will	not	be	referred	to	by	name	in	the	interview.	All	
electronic	files	will	be	stored	on	secure	password	protected	servers	at	UWE	Bristol.	All	paper	files	
will	be	anonymised	and	stored	in	locked	filing	cabinets	at	UWE	Bristol.	All	identifying	information	
will	be	removed	prior	to	publication.		
What	will	happen	if	I	don’t	want	to	carry	on	with	the	study?	
If	you	decide	you	do	not	wish	to	carry	on	with	the	study	you	may	withdraw	at	any	time.	Any	data	
that	we	have	collected	up	to	your	withdrawal	will	not	be	used	in	the	study.	
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Who	is	organising	the	study?	
This	study	forms	part	of	a	PhD	research	project	at	UWE.		
This	study	has	been	reviewed	by	UWE	Faculty	Ethics	Committees.	
Chief	Investigator:	
Ben	Davies,	MSc,	MCSP,	PhD	candidate.	
PhD	supervisory	team:	
Professor	Candy	McCabe,	UWE.		
Dr	Fiona	Cramp,	UWE.		
Dr	Jeremy	Gauntlett-Gilbert,	RNHRD.		
Professor	David	Wynick,	UHBristol.	
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Appendix	5	–	Patient	interview	questionnaire	
If you enrol in the study, please complete this questionnaire and bring it with you to 
the interview. 
 
Diabetes can cause a range of complications. 
 
These complications are arranged on this page, in no specific order. 
 
Please circle the complications that you experience 
 
Please note next to each complication how you would rank each complication in 
terms of how much it interferes with your life, with 1 = Most interfering problem, 2 = 
Next most interfering etc. etc. 
 
 
Kidney problems 
Eye problems 
Nerve pain 
Numbness  
Heart/Vascular problems 
Memory loss 
“Frozen Shoulder” 
Foot ulcers 
High blood pressure 
“Fatty Liver” problems  
Sex life problems 
Bladder problems 
Bowel problems 
Blood sugar control problems 
Weight issues 
Mood or emotional problems 
 
Any other problems not listed? 
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Appendix	6	–	Pain	management	programme	mind-map	
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Appendix	7	–	Patient	Interview	consent	form	
Consent form date of issue: 28/5/13 
Consent form version number: v2 
REC Ref: 013/SW/0125 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project:  Patient perspectives on management of painful diabetic 
neuropathy 
Name of Researcher: Ben Davies 
Please initial all boxes  
1. I confirm that I have read and understand the information 
sheet dated 28/5/13 (version 4.3) for the above study.  I have 
had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason. 
 
3. I understand that this interview will be audio recorded  
 
4. I understand that research data, including interview 
recordings will be stored anonymously 
 
5. I agree to take part in the above study.    
 
            
Name of Participant  Date    Signature 
                                
            
Name of Person   Date    Signature  
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Appendix	8	–	Patient	demographics	form	
Patient Identification Number for this trial: 
DEMOGRAPHIC FORM 
Title of Project:  Patient perspectives on management of painful diabetic 
neuropathy 
Name of Researcher: Ben Davies 
Gender 
Age 
Ethnicity 
DM type 
Duration of DM 
Duration of PDN 
Analgesia 
Occupational status 
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Appendix	9	–	Patient	interview	schedule	
Main	root	question	 Possible	stem	questions	
Please	tell	me	about	your	life	with	
PDN?	
• Tell	me	more	about	how	it	affects	your	working	day?	
• Can	you	elaborate	on	how	it	affects	your	social	life?	
• In	what	ways	do	others	close	to	you	support	you	in	
managing	this	problem?	
How	do	you	currently	manage	this	
pain	problem?	
• Tell	me	more	about	the	benefits	of	the	medication/side	
effects	of	the	medication?	
• Tell	me	more	about	the	non-medication	ways	you	use	to	
minimise	the	impact	of	PDN	
With	other	chronic	pain	problems,	
maximising	function	through	graded	
activity	as	a	key	strategy,	how	does	
this	sound	in	relation	to	your	PDN?	
• If	pain	increases	with	activity	–	what	thoughts	do	you	
have?	
• What	images	do	you	have	when	pain	increases?	
• Can	you	explain	what	you	feel	is	happening	in	your	feet,	
when	the	pain	increases?	
Pain	coping	skills	courses	use	the	
strategies	outlined	in	this	diagram	to	
help	maximise	quality	of	life	–	can	we	
talk	through	how	they	may	relate	to	
your	PDN?	
• Tell	me	more	how	you	think	[relaxation,	challenging	
negative	thoughts,	sleep	strategies,	communication	skills	
training,	graded	activity]	may	or	may	not	be	of	benefit	to	
your	management	of	PDN?	
• What	practicalities	need	to	be	considered	for	a	PDN	
coping	skills	programme?	
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The	interview	schedule	will	be	developed	in	an	iterative	manner	across	the	first	3-5	
interviews.	The	initial	schedule	will	be	as	follows:	
1. Profession	and	years	experience	with	DM	and	PDN	(structured)	
2. When	patients	describe	that	they	have	PDN	as	a	complication	of	their	DM,	what	
management	options	do	you	currently	have?	
3. What	are	your	views	on	physical	activity	as	a	strategy	to	manage	PDN?	
4. What	are	your	views	on	pain	coping	skills	programme	strategies	to	manage	PDN?	
5. How	do	you	think	patients	would	respond	to	the	offer	of	a	PDN	specific	coping	skills	
programme?	
6. Do	you	have	any	practical	suggestions	for	the	implementation	of	a	potential	PDN	specific	
pain	coping	skills	programme?	
Questions	2-6	will	be	semi	structured,	the	interviewer	will	follow	up	points	of	interest	with	
the	participant.		
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Appendix	10	–	Patient	interview	UWE	Ethical	approval	
Faculty of Health & 
Life  
Sciences		
Glenside Campus 
         Blackberry Hill 
         Stapleton 
         Bristol    BS16 1DD 
         Tel: 0117 328 8487 
Our ref: JMA/lt 
26 April 2013 
 
Ruth Avery 
South West - Frenchay 
Bristol REC Centre 
Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol     BS1 2NT 
 
Dear Ms Avery 
Re: Qualitative	exploration	of	living	with	and	managing	PDN	
Chief	investigator:	Benjamin	Davies	
Ref No: 13/SW/0125 
 
I am writing to confirm that the University of the West of England, Bristol (“UWE”) has agreed to act 
as Research Sponsor in accordance with the Department of Health Research Governance 
Framework (2001) for the above research.  UWE’s acceptance of Research sponsorship is subject 
to ethics approval having been obtained. 
 
UWE has made the following insurance arrangements for employees, and for students working under 
the supervision of a UWE employee, and where the project is included on an authorised UWE 
research register.   
UWE has insurance cover for clinical trials up to £5m in the aggregate which includes cover for non-
negligent harm.  This cover is provided only when UWE (via Research, Business and Innovation) 
has approved projects with our insurers and they are then listed on our clinical trials register.   
For research which is not deemed a clinical trial (i.e. not on UWE’s clinical trials register):  
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• UWE’s Professional Indemnity policy provides insurance cover for indemnity against legal liability 
for damages and claimant’s costs and expenses arising out of any act, neglect, error or omission. 
 
• UWE’s Employers Liability Insurance is in place to protect UWE’s employees if they are harmed 
whilst engaged on UWE business, should UWE be held legally liable. 
 
• UWE’s Public Liability insurance policy covers legal liability for third party personal injury, death, 
disease or illness to any person or loss or damage to third party property. 
 
Details of the Employers/Public and Professional Indemnity policy covers are attached.   
 
Yours sincerely 
 
 
 
 
Prof Jennifer M. Ames 
Associate Dean (Research and Innovation) 
 
Encl 
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Appendix	12	–	NHS	REC	committee	approval	
	
 
NRES Committee South West - Frenchay 
Bristol Research Ethics Committee Centre 
Level 3, Block B 
Whitefriars 
Lewins Mead, 
Bristol 
BS1 2NT 
 
Telephone: 01173421334  
Facsimile: 01173420445 
24 May 2013 
 
Mr Ben Davies 
PhD candidate 
University of the West of England 
Blue Lodge (Post Graduate)  
Glenside Campus 
Blackberry Hill 
BS16 1DD 
 
Dear Mr Davies 
 
Study Title: Patients' perspective on the management of painful 
diabetic neuropathy 
REC reference: 13/SW/0125 
IRAS project ID: 124520 
 
The Research Ethics Committee reviewed the above application at the meeting held on 10 May 
2013.  
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
  
Document    Version    Date    
Covering Letter    29 April 2013  
Evidence of insurance or indemnity    05 February 2013  
Investigator CV       
Letter from Sponsor    29 April 2013  
Letter of invitation to participant  1  18 April 2013  
Other: Supervisor McCabe CV       
Other: Supervisor Dr Gauntlett-Gilbert CV       
Other: Supervisor Dr Cramp Cv       
Other: David Wynick CV       
Participant Consent Form  1  11 February 2013  
Participant Information Sheet  4.2  18 April 2013  
Appendix	12	–	NHS	REC	committee	approval	
Page	297	
 
Appendix	12	–	NHS	REC	committee	approval	
Page	298	
 
Appendix	13	–	REC	substantial	amendment	approval	
Page	299	
Appendix	13	–	REC	substantial	amendment		
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Appendix	14	–	Clinician	permission	letters		
North	Bristol	NHS	Foundation	Trust	
																																	
Title:	Clinicians’	perspectives	on	the	management	of	painful	diabetic	neuropathy				
CI:	Ben	Davies					
R&D	Reference:		3164	
Start	Date:	19	June	2013		
End	Date:	01	September	2013				
		
I	am	pleased	to	confirm	North	Bristol	NHS	Trust	(NBT)	NHS	permission	for	the	above	study.	
FULL	R&D	APPROVAL		
You	have	permission	to	begin	recruitment	
I	understand	that	the	University	of	the	West	of	England	will	act	as	sponsor	for	this	study.	
We	acknowledge	that	this	project	does	not	require	ethical	review	by	a	NHS	Research	Ethics	
Committee	under	the	UK	Health	Departments’	Governance	Arrangements	for	Research	Ethics	
Committees	(GAfREC),	however	it	may	be	necessary	to	contact	the	University	Research	Ethics	
Committee	(UREC).	
We	wish	you	every	success	with	your	study.	We	are	keen	to	support	good	research	at	North	
Bristol	NHS	Trust	and	are	pleased	that	you	have	decided	to	conduct	your	project	here.	
The	lead	Research	Governance	Officer	for	this	study	is	Joanna	Strickland,	who	will	remain	your	
ongoing	main	point	of	contact.	They	can	be	reached	at	the	following	email	address:	
Joanna.strickland@nbt.nhs.uk	
Approval	is	given	on	the	understanding	that	this	project	be	carried	out	according	to	Good	Clinical	
Practice	and	UK	Statutory	Instrument,	and	within	the	guidelines	of	the	NHS	Research	Governance	
Framework	for	Health	and	Social	Care,	and	NHS	Trust	policies,	procedures,	and	SOPs	which	are	
available	online	at	http://www.nbt.nhs.uk/research.	
In	particular	you	have	responsibility	for:	
-		Ensuring	that,	all	participants	sign	informed	consent	(whenever	applicable).	
-		Adhering	to	the	protocol	and	ensuring	your	co-workers	do	the	same.	
-		Ensuring	all	recruitment	figures	are	uploaded	to	the	Edge	database	on	a	weekly	basis.	
-		Providing	us	with	information	about	any	amendments	to	the	protocol,	changes	in	funding,	
personnel	or	end	date.	
-		Informing	us	of	any	research-related	adverse	events.	
-		Ensuring	that	any	staff	working	on	this	study	at	this	site	have	been	issued	with	a	contract	
with	NBT	(honorary,	substantive	or	bank)	or	a	letter	of	access	before	they	commence	work	on	the	
study	at	this	site.	
-		Maintenance	of	an	Investigator	Site	File	and/or	Trial	Master	Files.	
Researchers	who	hold	substantive	or	honorary	contracts	with	North	Bristol	NHS	Trust	(NBT)	will	
be	covered	against	claims	of	negligence	by	patients	of	NBT	under	the	Clinical	Negligence	Scheme	
for	Trusts	(CNST).	This	scheme	does	not	cover	‘no	fault’	compensation	and	the	Trust	is	precluded	
from	taking	out	separate	insurance	to	cover	this.	Any	patient	or	volunteer	taking	part	in	the	study	
is	entitled	to	know	that	if	they	suffered	injury	as	a	result	of	participating	in	the	study	they	would	
first	have	to	prove	negligence	in	a	court	of	law	before	they	could	gain	compensation.	If	the	study	
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involves	patients	of	any	other	Trust	or	healthcare	organisation,	you	will	need	to	confirm	the	
indemnity	arrangements	with	that	organisation.	
In	addition,	other	information	may	be	requested	from	time	to	time	and	lay	summary	of	the	
results	will	be	requested	from	you	at	the	end	of	the	study.	
This	full	R&D	approval	document	will	need	to	be	filed	in	your	Investigator	Site	File	and/or	Trial	
Master	Files.	
In	accordance	with	the	NBT	Research	Monitoring	and	Audit	policy,	this	study	is	subject	to	audit	by	
the	R&I	Office.	We	will	contact	the	Principal	Investigator	to	make	appropriate	arrangements	for	
this.	
	
Many	thanks	
		
Nicola	Williams	
Deputy	Director	
Research	&	Innovation	
North	Bristol	NHS	Trust	
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University	Hospital	Bristol	NHS	Foundation	Trust	
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Appendix	15	–	Patient	interviewee	details	
Identifier	 Pseudonym	 Interview		 Gender	 Age	 Ethnicity	 DM	type	 DM	duration		 PDN	duration		 Occupation	
S1P01	 Mary	 H	 F	 44	 WB	 1	 36	 7	 medically	retired	
S1P02	 Anne	 H	 F	 52	 WB	 2	 20	 15	 medically	retired	
S1P03	 John	 U	 M	 69	 WB	 1	 50	 15	 medically	retired	
S1P04	 Joan	 NHS/H	 F	 57	 WB	 2	 10	 10	 medically	retired	
S1P05	 Bob	 U	 M	 63	 WB	 2	 23	 6	 medically	retired	
S1P06	 Mike	 U	 M	 65	 WB	 2	 7	 5	 retired	
S1P07	 Sally	 H	 F	 48	 WB	 1	 24	 8	 employed	
S1P08	 Ellen	 H	 F	 63	 WB	 2	 18	 6	 medically	retired	
S1P09	 Barbara	 P	 F	 80	 WB	 2	 22	 14	 retired	
S1P10	 Neil	 P	 M	 66	 WB	 1	 34	 20	 retired	
S1P11	 Aaron	 P	 M	 75	 WI	 2	 10	 4	 retired	
S1P12	 Mark	 P	 M	 62	 WB	 2	 30	 13	 medically	retired	
S1P13	 Philip	 P	 M	 57	 WB	 1	 30	 20	 medically	retired	
S1P14	 Daniel	 P	 M	 67	 WB	 1	 38	 10	 retired	
S1P15	 Clive	 P	 M	 86	 WB	 2	 12	 3	 retired	
S1P16	 Sam	 P	 M	 53	 WB	 1	 42	 13	 volunteer		
S1P17	 Sarah	 P	 F	 24	 WB	 1	 18	 1	 employed	
S1P18	 Heather	 P	 F	 57	 WB	 2	 8	 10	 medically	retired	
S1P19	 Lisa	 H	 F	 69	 WB	 2	 20	 10	 retired	
S1P20	 Roger	 P	 M	 86	 WB	 2	 10	 1	 retired	
S1P21	 Kate	 P	 F	 58	 WB	 1	 24	 14	 medically	retired	
S1P22	 Dawn	 P	 F	 68	 WB	 1	 48	 24	 retired	
S1P23	 Jane	 P	 F	 68	 WB	 2	 7	 9	 retired	
(Interview)	Location:	H	–	home,	U	–	University	campus,	NHS	–	NHS	premises,	P	–	phone,	1	–	Type	1	diabetes,	2	–	Type	2	diabetes,	WB	–	White	British,	WI	–	West	Indian.	
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Appendix	16	–	Partial	transcript	of	patient	interview	
The	partial	transcripts	included	in	appendix	16	and	17	have	not	been	edited	from	the	verbatim	
transcripts.		
 
INTERVIEWER:	
So how did you cope then, how, you’ve had this problem now for ten years, you take 
occasional co codamol? 
LISA:	
When I have a really bad day I give in to it and don’t try and do too much, um and then 
make up for it when I’ve got a good day.  
INTERVIEWER:	
Um.  
LISA:	
Um I mean it’s never lasts all day, I mean it’s there, it’s there in the background, I mean 
my feet are hurting now, but I’ve learnt to live with it, so I just sort of basically ignore it, 
um, when it’s really bad I wouldn’t walk very far.  
INTERVIEWER:	
Uh huh.  
LISA:	
This is the biggest impact, um, I used to go, believe it or not, I used to go to exercise 
classes, or originally used to go to a gym regularly.  
INTERVIEWER:	
Um.  
LISA:	
Um and then when I started getting bad, I stopped and used to go to um a weekly, 
twice a week an exercise class, but then because they got really quite bad, I felt my 
balance wasn’t good and my stability or my feet wasn’t good, so I was afraid of falling 
over in that, in that sort of, so basically gave up doing that, so I, it’s hard to explain, 
um, because you felt un, un, insecure, er you stopped and now I sort of feel I don’t 
know what I could and couldn’t do that wouldn’t make it worse.  
INTERVIEWER:	
Um.  
LISA:	
If that sounds logical to you? 
INTERVIEWER:	
What kind of physical activity could you do? 
LISA:	
Could I do that would not make things worse? 
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INTERVIEWER:	
Yeah.  
LISA:	
Um.  
INTERVIEWER:	
And you’d also want to be safe with this? 
LISA:	
And safe that, that’s the other thing yes.  
INTERVIEWER:	
Loss of balance and sensitivity? 
LISA:	
Yes I was losing a bit of sensation on the feet, so um sort of standing up in a, in a open 
space and sort of say moving from foot to foot, you felt that you were unstable and so 
that really drove me to really stop doing that.  
INTERVIEWER:	
Uh huh.  
LISA:	
So really the only physical exercise now is I do the gardening or the housework or 
walking.  
INTERVIEWER:	
Uh huh.  
LISA:	
But I don’t do anything that would involve me sort of standing on one leg or something, 
whereas I might lose um the sort of balance.  
INTERVIEWER:	
Yeah so you’re being somewhat safe? 
LISA:	
Yes, yes, try to be safe, I mean it’s always something that, is very difficult to think about 
how you get back to doing some exercise without um somebody telling you that yes you 
should sit and do, so I mean, I do sit and do some exercising of my feet when I’m sitting 
down at times.  
INTERVIEWER:	
You sort of do like the ankle rolls and up on the toes and things? 
LISA:	
Yes, and, and try to keep the muscles going there, but I’m sure that I’m not doing all I 
should do or couldn’t do, but I don’t know what else to do.  
INTERVIEWER:	
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Um.  
LISA:	
If that makes sense [laughing].  
INTERVIEWER:	
Yeah absolutely so you said you have, you rarely take medication you just kind of get on 
with this problem? 
LISA:	
Yes, yes. 
INTERVIEWER:	
And you seem to suggest that on, you know, a day when your pain is particularly bad, 
you’ll do less? 
LISA:	
I adapt to what I’m doing for the day yes.  
INTERVIEWER:	
Your expectations for that day will drop? 
LISA:	
Yes.  
INTERVIEWER:	
But then you’ll catch up when things improve? 
LISA:	
Well being retired, I mean, if, if I don’t need to go shopping today and if my feet are 
bad, then I go shopping tomorrow.  
INTERVIEWER:	
Um.  
LISA:	
Um you know, if, if it’s a nice, if a garden needs to do a bit, and we, we feel like doing it 
fine, but if I don’t, then I don’t, um, and it’s because of the, I am now retired, obviously, 
um I’ve got that flexibility in life, um, so yes, I cope that way.  
INTERVIEWER:	
So those time pressures are different? 
LISA:	
The time pressures are different, if I was at work it would be completely different.  
INTERVIEWER:	
Um.  
LISA:	
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Um and then you’d have to be trying to go somewhere when you felt you were sort of 
crippled.  
INTERVIEWER:	
Uh huh.  
LISA:	
But it doesn’t.  
INTERVIEWER:	
Any other practical strategies you have for managing this impact? 
LISA:	
Shout a bit [laughing], I’ve got a very good husband, he’s very good [laughing].  
INTERVIEWER:	
He understands? 
LISA:	
Er yeah, yeah, I mean if they are bad, he will, you know, he helps around the house, so 
if I can’t do something, he’ll do it.  
INTERVIEWER:	
Uh huh.  
LISA:	
So um, apart from that, I just, I’m just me and just sort of try to get on with things and 
try not to let it sort of wallow in self pity and depression and um just try and be me, just 
get on with life.  
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INTERVIEWER:	
Okay	and	for	going	through	that	process	of	managing	that	patient,	other	than	the	pain	scale,	the	
kind	of	one	to	ten	scale	of	pain	…	
GP1:	
Yeah.	
INTERVIEWER:	
…	is	there	anything	else	that	you	consider	in	your	assessment	about	the	patient?	
GP1:	
Yeah,	I	mean	as	I	would	with	any	type	of	chronic	pain	whether	it	was	back	pain	or	anything	else	…	
INTERVIEWER:	
Yeah.	
GP1:	
erm,	of	course	it’s	really	important	to	look	at	the	psychological	aspects	because	two	people	can	
have	apparently	the	same	pathological	or	an	anatomical	problem	…	
INTERVIEWER:	
Yeah.	
GP1:	
but	they	will	perceive	pain	in	very	different	ways,	so	you	know	I’d	have	to	think	about	are	they	
depressed	…	
INTERVIEWER:	
Yeah.	
GP1:	
if	they’re	depressed	then	that	will	make	them,	the	chances	are	it	makes	pain	worse	and	…	
INTERVIEWER:	
Yeah.	
GP1:	
look	at	other	reasons	why	they’re,	why	they	maybe	feeling	pain.	
INTERVIEWER:	
Do	you	use	any	questionnaires	in	that	process	or	is	it	just	a	consultation,	you	know	conversation	
etcetera?	
GP1:	
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Well	if	its	depression	then	its	a	conversational	thing	and	then	if	I’m	…	
INTERVIEWER:	
Sure.	
GP1:	
suspicious	then	we,	on	a	bog	standard	thing	there’s	a	PHQ	line	…	
INTERVIEWER:	
Okay.	
GP1:	
for	depression.	Erm,	so	I’d	be	looking	at	other	psychological	explanations	and	why	they	maybe	
feeling	pain,	why	now	…	
INTERVIEWER:	
Uh-huh.	
GP1:	
looking	at	the	rest	of	their	life,	you	know	they	maybe,	their	life	maybe	painful	…	
INTERVIEWER:	
Uh-huh.	
GP1:	
and,	erm,	they	may	demonstrate	that	painful	life	through	something	else	such	as	painful	diabetic	
neuropathy.	
INTERVIEWER:	
Okay.	
GP1:	
Erm,	so	I	would	treat	that	as	I	would	with	any	kind	of	chronic	pain.	
INTERVIEWER:	
Okay	and	where	would	your	treatment	options	be	from	that	assessment?	
GP1:	
Well	sometimes	with	these	treatment	options,	with	this	sort	of	approach	part	of	the	value	is	in	at	
least	discussing	it	with	the	patient	and	drawing	their	attention	to	a	possible	association	with	their	
life	…	
INTERVIEWER:	
Yeah.	
GP1:	
and	their	pain	…	
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INTERVIEWER:	
Yeah.	
GP1:	
and	sometimes	when	they	realise	that	then	they	may	stop	thinking	so	much	about	mediation	
solutions	to	their	pain	and,	er,	sometimes	the	pain	becomes	less	of	an	issue	when	they	can	see	that	
association	because	they	become	less	worried	about	their	pain,	they	might	be	just	less	concerned	
about	it	and,	therefore	…	
INTERVIEWER:	
Okay.	
GP1:	
if	they’re	less	concerned	about	it	then	the	pain	gets	less	because	so	often	in,	you	see	people	with	
painful	syndrome,	but	their	anxiety	about	it	triggers	a	lot	of	thought	and	rumination	…	
INTERVIEWER:	
Yeah.	
GP1:	
which	makes	the	pain	appear	worse	which	makes	the	anxiety	worse	and	so	on.	So	if	you	can	help	
reduce	the	anxiety	that	they’re,	this	is	a	problem,	its	not	necessarily	going	to	get	any	worse,	its	not	
going	to	be,	not	necessarily	serious,	its	not	a	sign	of	cancer	or	something	disastrous	…	
INTERVIEWER:	
Um.	
GP1:	
erm,	then	that	can	relieve	the	anxiety	which	then	relieves	the	pain.	
INTERVIEWER:	
Yeah.	
GP1:	
So	sometimes	just	the	consultations	because	it	normally	takes	more	than	one,	erm,	talking	it	
through	is	…	
INTERVIEWER:	
Is	therapeutic	…	
GP1:	
therapeutic.	
INTERVIEWER:	
…	in	its	own	right.	
GP1:	
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Yeah.	
INTERVIEWER:	
Yeah.	
GP1:	
Sometimes	giving	people	confidence	that	they	can	exercise	okay	…	
INTERVIEWER:	
Yeah.	
GP1:	
that	by	exercising	alright	won’t	do	them	any	harm,	in	fact	it	may	well	do	them	good	both	physically	
and	psychologically,	so	empowering	people	to	live	normal	lives	…	
INTERVIEWER:	
Uh-huh.	
GP1:	
and	not	let	the	pain	take	over	their	lives.	So	that’s	a	sort	of,	probably	a	fairly	lightweight	GP	
approach	to	pain,	chronic	pain	management.	
INTERVIEWER:	
Lightweight	as	in	sort	of	psychologically	light?	
GP1:	
Lightweight	as	in	you	know	I’m	not	a	clinical	psychologist	…	
INTERVIEWER:	
Sure.	
GP1:	
and	I’m	not	sitting	down	with	them	for	forty	five	minutes	for	six	weeks	…	
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	 	 NVivo	code	 Survey	statement	 Type	of	interference	
Impact	 1	 sleep	disturbance	 My	sleep	is	disturbed	due	to	PDN	 Rest	
Impact	 2	 emotional	depression	 PDN	leads	me	to	feel	depressed	 Mood	
Impact	 3	 losing	mobility	 PDN	makes	walking	difficult	 Function	
Impact	 4	 affecting	day	to	day	activity	 PDN	affects	my	ability	to	do	every	day	jobs	 Function	
Impact	 5	 numb	feet	 PDN	causes	me	to	have	numb	feet	 Sensory	
Impact	 6	 what	other	people	think	 It	bothers	me	what	other	people	think	of	
me	due	to	the	problems	I	have	with	PDN	
Mood	
Impact	 7	 becoming	socially	isolated	 I	have	become	more	socially	isolated	due	
to	PDN	
Social	
Impact	 8	 can't	sit	for	too	long	 PDN	stops	me	from	sitting	comfortably	 Rest	
Impact	 9	 emotional	frustration	 PDN	leads	me	to	get	frustrated	 Mood	
Impact	 10	 PDN	difficult	to	cope	with	 I	don't	cope	well	with	PDN	 Coping	
Impact	 11	 a	hidden	problem	no-one	else	
sees	
It	bothers	me	that	other	people	can't	see	I	
have	this	problem	
Mood	
Impact	 12	 worries	for	the	future	 I	am	worried	that	my	PDN	will	get	worse	in	
the	future	
Mood	
Impact	 13	 affect	on	partner	 My	PDN	has	an	affect	on	my	partner	 Social	
Impact	 14	 affecting	all	aspects	of	life	 PDN	affects	a	wide	range	of	activities	that	
I	want	to	do	
Function	
Impact	 15	 emotional	anger	 PDN	leads	me	to	feel	angry		 Mood	
Impact	 16	 keeping	it	to	myself	 I	keep	my	problem	with	PDN	away	from	
my	close	family	
Mood	
Impact	 17	 life	pre-PDN	 I	am	not	the	person	I	was	before	I	
developed	PDN	
Mood	
Impact	 18	 regular	foot	checks	 I	have	to	check	my	feet	regularly	for	
possible	injury	
Function	
Impact	 19	 affecting	concentration	 PDN	affects	my	ability	to	concentrate	 Social	
Impact	 20	 losing	balance	 I	have	to	be	careful	walking	due	to	my	
balance	
Function	
Impact	 21	 not	able	to	do	my	work	 I	have	difficulty	doing	my	job	due	to	PDN	 Employment	
Impact	 22	 Stepping	back	from	physical	
activity	
I	have	reduced	my	physical	activity	due	to	
PDN	
Function	
Impact	 23	 struggling	with	social	life	 PDN	affects	my	social	life	 Social	
Impact	 24	 suicide	 I	have	contemplated	suicide	due	to	my	
PDN	
Mood	
Impact	 25	 why	me	with	PDN	 I	don’t	understand	why	I	have	PDN	 Mood	
Impact	 26	 crying	with	pain	 PDN	hurts	so	much	it	brings	tears	to	my	
eyes	
Sensory	
Impact	 27	 emotional	worry	 PDN	leads	me	to	worry	more	than	I	would	
if	I	didn’t	have	it	
Mood	
Impact	 28	 had	to	stop	driving	 PDN	makes	me	think	about	driving	
carefully	
Function	
Impact	 29	 loss	of	intimacy	 PDN	affects	my	intimate	relationships	with	
a	partner	
Social	
Impact	 30	 affect	on	family	 My	PDN	affects	my	close	family	 Social	
Impact	 31	 affecting	memory	 PDN	affects	my	memory	 Function	
Impact	 32	 can't	face	food	 PDN	affects	my	appetite	for	food	 Function	
Impact	 33	 fallen	over	 PDN	and	balance	problems	lead	me	to	fall	
over	
Function	
Impact	 34	 loss	of	independence	 PDN	stops	me	being	as	independent	as	I	
expect	to	be	
Social	
Impact	 35	 problem	with	footwear	 PDN	makes	it	difficult	to	buy	shoes	that	
are	comfortable	
Function	
Impact	 36	 restless	legs	 PDN	gives	me	a	sense	of	restless	legs	 Sensory	
Impact	 37	 skin	sensitivity	 My	skin	is	sensitive	to	the	lightest	touch	 Sensory	
Impact	 38	 am	pain	not	been	moving	 PDN	affects	me	as	soon	as	I	put	my	foot	to	
the	ground	in	the	morning	
Sensory	
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Impact	 39	 feet	look	normal	 My	feet	look	normal	but	I	have	this	severe	
pain	
Sensory	
Impact	 40	 headaches	 PDN	can	lead	me	to	have	headaches	 Sensory	
Impact	 41	 holidays	affected	 PDN	affects	our	family	holidays	 Social	
Impact	 42	 narrowing	down	life	 My	life	had	become	more	restricted	due	
to	PDN	
Function	
Impact	 43	 not	going	out	 I	don't	go	out	as	much	because	of	PDN	 Social	
Impact	 44	 struggle	to	get	up	for	work	 I	struggle	to	get	up	for	work	due	to	the	
PDN	
Employment	
Impact	 45	 worries	about	money	 I	worry	how	our	money	will	be	affected	
because	of	PDN	
Mood	
Impact	 46	 worry	about	fitness	 I	worry	about	keeping	my	physical	fitness	
due	to	PDN	
Mood	
Impact	 47	 be	on	my	own	 When	PDN	flares	up	I	just	want	to	be	on	
my	own	
Social	
Impact	 48	 become	agoraphobic	 PDN	makes	me	worried	about	going	out	of	
the	house	
Function	
Impact	 49	 considering	others	 I	always	have	to	think	about	the	needs	of	
other	people	
Mood	
Impact	 50	 embarrassed	emotion	 PDN	makes	me	feel	embarrassed	 Mood	
Impact	 51	 getting	breathless	 I	get	more	breathless	than	before	I	had	
PDN	
Function	
Impact	 52	 getting	cramp	 I	get	cramp	more	frequently	than	before	I	
has	PDN	
Sensory	
Impact	 53	 loss	of	confidence	 I	have	lost	confidence	to	be	myself	due	to	
PDN	
Function	
Impact	 54	 no	quality	of	life	 My	overall	quality	of	life	is	really	affected	
by	PDN	
Mood	
Impact	 55	 pain	makes	me	mean	 When	PDN	flares	up	I	can	be	less	tolerant	
to	those	around	me	
Mood	
Impact	 56	 self	image	 My	self-image	has	changed	due	to	PDN	 Mood	
Impact	 57	 stopped	dancing	 PDN	has	stopped	me	going	dancing	 Function	
Impact	 58	 extra	split	of	social	impact	 I	keep	my	problems	with	PDN	away	from	
my	wider	social	network	
Social	
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Appendix	19	–	Internet	survey	PIS	
Research	Study	Title:	An	Internet	survey	investigating	the	impact	of	Painful	Diabetic	
Neuropathy	(PDN)	and	patient	treatment	priorities.	
You	are	being	invited	to	take	part	in	a	study.	Before	you	decide	if	you	want	to	take	part,	it	is	
important	for	you	to	understand	why	the	study	is	being	done	and	what	it	will	involve.	Please	take	
the	time	to	read	the	following	information	carefully.	Talk	to	others	about	the	study	if	you	wish.		
Ask	us	by	e-mail	if	there	is	anything	that	is	not	clear,	or	if	you	would	like	more	information.	There	
is	an	e-mail	address	at	the	bottom	of	this	information.	Take	time	to	decide	whether	or	not	you	
wish	to	take	part.	
What	is	the	purpose	of	the	study?	
This	study	is	part	of	a	research	programme,	aiming	to	improve	ways	of	managing	painful	diabetic	
neuropathy	(PDN).	
This	study	involves	an	Internet	survey	completed	by	people	who	experience	PDN.		
This	study	aims	to	find	out	1)	more	about	the	impact	of	PDN	on	an	individual’s	life	and	2)	what	
priorities	people	have	for	managing	the	impacts	of	their	PDN.	
Do	I	have	to	take	part?	
No,	it	is	up	to	you	to	decide	if	you	want	to	take	part.	We	will	not	contact	you	directly	if	you	decide	
not	to	take	part.	
What	will	the	research	involve?	
We	are	asking	people	that	agree	to	take	part	to	complete	an	Internet	survey.	The	survey	will	take	
about	20	minutes	to	complete.	After	you	have	finished	the	survey,	you	will	have	completed	our	
study	and	you	do	not	have	to	do	anything	else.		
The	survey	involves	a	range	of	questions:		
• There	are	brief	questions	about	you	and	your	history	of	diabetes	and	PDN.		
• There	are	questions	about	coping	with	on-going	pain.		
These	questions	are	followed	by	58	brief	statements	about	the	impact	that	PDN	has	on	people’s	
lives.	These	statements	come	from	an	interview	study	we	conducted	with	people	who	experience	
PDN	and	reflect	the	personal,	social	and	mood	impacts	that	they	reported.		
• You	will	be	asked	to	identify	which	of	these	impacts	you	experience	and,	if	relevant,	how	
much	that	impact	affects	your	quality	of	life.		
• You	will	then	be	asked	to	choose	up	to	10	impacts	and	put	these	in	the	order	of	priority	
that	you	would	most	like	help	to	manage	them	better.	
• Finally,	you	will	be	asked	if	you	have	sought	help	for	PDN	from	any	health	professional.	
	
What	are	the	risks	and	benefits	of	taking	part?	
There	are	no	specific	risks	to	participating	in	this	research.		
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There	are	no	immediate	direct	benefits	to	participating.	We	hope	this	research	will	help	develop	
potential	management	strategies	for	PDN	in	the	future	that	are	matched	to	the	priorities	of	
people	with	the	condition.	
What	happens	when	the	research	study	stops?	
We	will	analyse	the	data	and	publish	a	full	report	in	the	academic	literature	so	that	other	
researchers,	as	well	as	health	care	professionals	can	use	the	findings.	A	summary	report	will	also	
be	made	available	via	the	Diabetes	UK	website	and	Internet	forums.	The	University	of	the	West	of	
England	(UWE)	will	keep	the	data	for	9	years	and	then	it	will	be	destroyed.	
Will	my	taking	part	in	the	study	be	kept	confidential?	
Yes,	the	survey	is	completely	anonymous.	The	webpage	does	not	record	any	hidden	information	
about	your	location	when	completing	the	survey	(computer	or	IP	address).	The	personal	
information	you	give	in	the	survey	cannot	be	linked	to	you	personally.	All	electronic	files	will	be	
stored	on	secure	password	protected	servers	at	UWE	Bristol.	UK	data	protection	laws	protect	the	
security	of	this	data.	
What	will	happen	if	I	don’t	want	to	carry	on	with	the	study?	
You	may	withdraw	at	any	time	by	exiting	the	survey	webpage.	Once	you	complete	the	survey,	it	
will	not	be	possible	to	remove	your	data,	as	we	will	not	know	which	data	belongs	to	you.		
Who	is	organising	the	study?	
This	study	is	organised	by	the	University	of	the	West	of	England,	the	Royal	United	Hospital	(Bath),	
and	the	University	Hospitals	Bristol	NHS	Foundation	Trust.	
This	study	forms	part	of	a	PhD	research	project	at	UWE.	
The	UWE	Health	and	Applied	Sciences	ethics	committee	has	reviewed	and	approved	this	study.	
	
Further	information	on	painful	neuropathy	
If	you	need	further	information	about	any	symptoms	you	experience,	please	speak	to	your	GP	or	
practice	nurse.	Other	sources	of	information	include	the	Diabetes	UK	
https://www.diabetes.org.uk	and	NHS	Choices	websites	http://www.nhs.uk/pages/home.aspx.		
	
Chief	Investigator:	
Ben	Davies,	MSc,	MCSP,	PhD	candidate.	
	
Access to the survey website 
You can access this survey using this link: Impact of PDN survey 
Or by using this web address: https://tinyurl.com/npv9kz7	
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PhD	supervisory	team:	
Professor	Candy	McCabe,	UWE,	Royal	United	Hospital,	Bath.		
Dr	Fiona	Cramp,	UWE.		
Dr	Jeremy	Gauntlett-Gilbert,	Royal	United	Hospital,	Bath.		
Professor	David	Wynick,	UHBristol.	
	
	
	
Appendix	20	–	Internet	survey	UWE	Ethics	approval	
Page	318	
Appendix	20	–	Internet	survey	UWE	Ethics	approval	
Faculty of Health & Applied  
Sciences		
Glenside Campus 
Blackberry Hill 
Stapleton 
Bristol   BS16 1DD 
 
         Tel: 0117 328 1170 
UWE	REC	REF	No:		HAS/15/11/038	
3rd	December	2015	
Ben	Davies	
	
Dear	Ben		
Application	title:	An	Internet	survey	investigating	the	impact	of	Painful	Diabetic	
Neuropathy	(PDN)	and	patient	treatment	priorities	Your	ethics	application	was	considered	by	the	Faculty	Research	Ethics	Committee	and,	based	on	the	information	provided,	has	been	given	ethical	approval	to	proceed	with	the	following	conditions:		
1. Although	the	survey	is	completely	anonymous	and	the	information	sheet	outlines	very	
clearly	the	data	protection	and	withdrawal	processes,	it	is	important	to	have	a	statement	
for	consent	before	the	participant	is	allowed	to	move	on	to	the	next	section	and	complete	
the	survey.	This	might	have	been	already	planned	but	it	was	not	clear	to	me	from	reading	
the	application.	Consent	form	can	be	ticked	/	approved	anonymously.		
2. Also	I	am	not	sure	if	this	will	be	provided	along	with	the	outline	of	the	study,	but	please	
provide	a	list	of	support	/information	services	that	participants	can	access	easily	on	the	
information	sheet	or	any	documentation	which	will	be	used	to	advertise	the	study.	
If	these	conditions	include	providing	further	information	please	do	not	proceed	with	your	
research	until	you	have	full	approval	from	the	committee.		You	must	notify	the	committee	in	
advance	if	you	wish	to	make	any	significant	amendments	to	the	original	application	using	the	
amendment	form	at	http://www1.uwe.ac.uk/research/researchethics/applyingforapproval.aspx.		
Please	note	that	any	information	sheets	and	consent	forms	should	have	the	UWE	logo.		
Further	guidance	is	available	on	the	web:	
http://www1.uwe.ac.uk/aboutus/departmentsandservices/professionalservices/marketingandco
mmunications/resources.aspx	
The	following	standard	conditions	also	apply	to	all	research	given	ethical	approval	by	a	UWE	
Research	Ethics	Committee:			
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1. You	must	notify	the	relevant	UWE	Research	Ethics	Committee	in	advance	if	you	wish	to	make	
significant	amendments	to	the	original	application:	these	include	any	changes	to	the	study	
protocol	which	have	an	ethical	dimension.	Please	note	that	any	changes	approved	by	an	
external	research	ethics	committee	must	also	be	communicated	to	the	relevant	UWE	
committee.		
2. You	must	notify	the	University		Research	Ethics	Committee	if	you	terminate	your	research	
before	completion;	
3. You	must	notify	the	University	Research	Ethics	Committee	if	there	are	any	serious	events	or	
developments	in	the	research	that	have	an	ethical	dimension.	
	
Please	note:	The	UREC	is	required	to	monitor	and	audit	the	ethical	conduct	of	research	
involving	human	participants,	data	and	tissue	conducted	by	academic	staff,	students	and	researchers.	
Your	project	may	be	selected	for	audit	from	the	research	projects	submitted	to	and	approved	by	the	
UREC	and	its	committees.	
Please	remember	to	populate	the	HAS	Research	Governance	Record	with	your	ethics	
outcome.	
We	wish	you	well	with	your	research.	
Yours	sincerely	
	
Dr	Julie	Woodley	
Chair	
Faculty	Research	Ethics	Committee	
c.c		Candy	McCabe	
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Appendix	21	–	Internet	pilot	survey	responses	
Internet	
survey	ID	
number	
pilot	
completed
?	
reminde
r	sent?	
25/1/16	
time	to	
complet
e	(mins)	
Comments	
1	 	 yes	 	 	
2	 	 no	 	 	
3	 	 yes	 	 	
4	 	 yes	 	 	
5	 	 yes	 	 	
6	 	 yes	 	 	
7	 yes	 yes	 26	 	
8	 	 yes	 	 	
9	 yes	 	 33	 At	the	time	my	PD	was	at	its	worst	I	received	help	with	hand	
grips	being	fitted	near	steps	and	in	the	bath	and	shower.		
Also	near	the	toilet.		These	gave	me	confidence.		When	my	
symptoms	were	at	their	worst	I	could	have	screamed	with	
the	pain,	but	I	received	a	lot	of	help	from	the	Pain	
Management	team,	and	gradually	managed	over	time	to	
reduce	the	drugs	being	taken.		They	also	explained	my	
symptoms,	which	helped	me	to	adjust.	
10	 	 yes	 	 	
11	 	 yes	 	 	
12	 yes	 	 43	 Your	survey	is	dedicated	to	PDN	and	is	well	put	together.		
Easy	to	read	and	understand.	I	may	have	missed	it	but	I	
think	a	section	on	understanding	what	the	cause	of	PDN	and	
explanation	of	the	effects	on	the	feet	and	legs.		There	are	
other	'syndromes'	that	produce	neuropathic	pain,	
numbness	etc.,	which	mimic	those	caused	by	diabetes.		
Perhaps	a	short	question	or	two	surrounding	those	
'syndromes'	Feel	free	to	e-mail	if	you	would	like	clarification	
13	 	 yes	 35	 	
14	 yes	 	 38	 It	isn`t	easy	to	"drag"	up	to	10	statements	across	
15	 	 yes	 	 	
16	 	 yes	 	 	
17	 	 yes	 	 	
18	 	 yes	 	 	
19	 yes	 	 32	 The	large	number	of	questions	on	page	7	is	still	
overwhelming.	I	personally	found	this	section	the	most	
difficult	to	answer	
20	 	 yes	 	 	
21	 	 yes	 	 	
22	 	 yes	 23	 	
23	 	 yes	 9hours	 The	link	you	gave	me	by	e-mail	enabled	easy	access	to	the	
web-site	.I	did	wonder	whether	my	difficulty	was	due	to	
having	changed	to	Windows	8?I	tried	numerous	times	to	get	
through	on	my	own	and	had	almost	given	up.	If	other	
people	experience	the	same	it	might	be	suggest	an	
unwillingness	to	take	part	whereas	the	truth	is	they	did	try	
but	couldn't	get	through.	
	 	 Average		 32		mins	 	
Appendix	22	–	PDN	impacts	based	on	experience	
Page	321	
Appendix	22	–	PDN	impacts	based	on	experience	
	 	 Impact	statement	 n=	 %	not	exp’d	
(Likert	0)	
%	Exp’d	
(Likert	1-
4)	
Impact	 18	 I	have	to	check	my	feet	regularly	for	possible	
injury	
58	 5.2	 94.8	
Impact	 12	 I	am	worried	that	my	PDN	will	get	worse	in	the	
future	
61	 6.6	 93.4	
Impact	 1	 My	sleep	is	disturbed	due	to	PDN	 61	 8.2	 91.8	
Impact	 5	 PDN	causes	me	to	have	numb	feet	 60	 8.3	 91.7	
Impact	 9	 PDN	leads	me	to	get	frustrated	 58	 10.3	 89.7	
Impact	 40	 My	feet	look	normal	but	I	have	this	severe	pain	 62	 11.3	 88.7	
Impact	 19	 PDN	affects	my	ability	to	concentrate	 60	 13.3	 86.7	
Impact	 37	 PDN	gives	me	a	sense	of	restless	legs	 60	 15.0	 85.0	
Impact	 55	 When	PDN	flares	up	I	can	be	less	tolerant	to	
those	around	me	
58	 15.5	 84.5	
Impact	 3	 PDN	makes	walking	difficult	 61	 16.4	 83.6	
Impact	 8	 PDN	stops	me	from	sitting	comfortably	 59	 16.9	 83.1	
Impact	 27	 PDN	leads	me	to	worry	more	than	I	would	if	I	
didn’t	have	it	
62	 17.7	 82.3	
Impact	 47	 I	worry	about	keeping	my	physical	fitness	due	to	
PDN	
58	 19.0	 81.0	
Impact	 20	 I	have	to	be	careful	walking	due	to	my	balance	 61	 19.7	 80.3	
Impact	 53	 I	have	lost	confidence	to	be	myself	due	to	PDN	 61	 19.7	 80.3	
Impact	 14	 PDN	affects	a	wide	range	of	activities	that	I	
want	to	do	
60	 20.0	 80.0	
Impact	 43	 My	life	had	become	more	restricted	due	to	PDN	 60	 20.0	 80.0	
Impact	 4	 PDN	affects	my	ability	to	do	every	day	jobs	 58	 20.7	 79.3	
Impact	 36	 PDN	makes	it	difficult	to	buy	shoes	that	are	
comfortable	
61	 21.3	 78.7	
Impact	 22	 I	have	reduced	my	physical	activity	due	to	PDN	 60	 21.7	 78.3	
Impact	 56	 My	self-image	has	changed	due	to	PDN	 60	 21.7	 78.3	
Impact	 39	 PDN	affects	me	as	soon	as	I	put	my	foot	to	the	
ground	in	the	morning	
60	 23.3	 76.7	
Impact	 48	 When	PDN	flares	up	I	just	want	to	be	on	my	
own	
59	 23.7	 76.3	
Impact	 17	 I	am	not	the	person	I	was	before	I	developed	
PDN	
60	 25.0	 75.0	
Impact	 23	 PDN	affects	my	social	life	 60	 25.0	 75.0	
Impact	 2	 PDN	leads	me	to	feel	depressed	 59	 25.4	 74.6	
Impact	 15	 PDN	leads	me	to	feel	angry		 60	 26.7	 73.3	
Impact	 26	 PDN	hurts	so	much	it	brings	tears	to	my	eyes	 60	 26.7	 73.3	
Impact	 10	 I	don't	cope	well	with	PDN	 59	 27.1	 72.9	
Impact	 57	 PDN	has	stopped	me	going	dancing	 58	 29.3	 70.7	
Impact	 16	 I	keep	my	problem	with	PDN	away	from	my	
close	family	
60	 31.7	 68.3	
Impact	 38	 My	skin	is	sensitive	to	the	lightest	touch	 59	 32.2	 67.8	
Impact	 42	 PDN	affects	our	family	holidays	 58	 34.5	 65.5	
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	 	 Impact	statement	 n=	 %	not	exp’d	
(Likert	0)	
%	Exp’d	
(Likert	1-
4)	
Impact	 33	 PDN	and	balance	problems	lead	me	to	fall	over	 60	 35.0	 65.0	
Impact	 35	 PDN	stops	me	being	as	independent	as	I	expect	
to	be	
60	 35.0	 65.0	
Impact	 44	 I	don't	go	out	as	much	because	of	PDN	 60	 35.0	 65.0	
Impact	 54	 My	overall	quality	of	life	is	really	affected	by	
PDN	
57	 35.1	 64.9	
Impact	 11	 It	bothers	me	that	other	people	can't	see	I	have	
this	problem	
59	 35.6	 64.4	
Impact	 58	 I	keep	my	problems	with	PDN	away	from	my	
wider	social	network	
59	 35.6	 64.4	
Impact	 7	 I	have	become	more	socially	isolated	due	to	
PDN	
60	 38.3	 61.7	
Impact	 25	 I	don’t	understand	why	I	have	PDN	 59	 39.0	 61.0	
Impact	 50	 I	always	have	to	think	about	the	needs	of	other	
people	
59	 39.0	 61.0	
Impact	 13	 My	PDN	has	an	affect	on	my	partner	 59	 40.7	 59.3	
Impact	 21	 I	have	difficulty	doing	my	job	due	to	PDN	 59	 40.7	 59.3	
Impact	 29	 PDN	affects	my	intimate	relationships	with	a	
partner	
59	 40.7	 59.3	
Impact	 28	 PDN	makes	me	think	about	driving	carefully	 58	 41.4	 58.6	
Impact	 45	 I	struggle	to	get	up	for	work	due	to	the	PDN	 58	 43.1	 56.9	
Impact	 32	 PDN	affects	my	appetite	for	food	 60	 43.3	 56.7	
Impact	 49	 PDN	makes	me	worried	about	going	out	of	the	
house	
59	 44.1	 55.9	
Impact	 50	 PDN	makes	me	feel	embarrassed	 56	 44.6	 55.4	
Impact	 30	 My	PDN	affects	my	close	family	 58	 44.8	 55.2	
Impact	 6	 It	bothers	me	what	other	people	think	of	me	
due	to	the	problems	I	have	with	PDN	
60	 45.0	 55.0	
Impact	 46	 I	worry	how	our	money	will	be	affected	because	
of	PDN	
59	 45.8	 54.2	
Impact	 51	 I	get	more	breathless	than	before	I	had	PDN	 56	 48.2	 51.8	
Impact	 52	 I	get	cramp	more	frequently	than	before	I	has	
PDN	
58	 50.0	 50.0	
Impact	 31	 PDN	affects	my	memory	 59	 50.8	 49.2	
Impact	 41	 PDN	can	lead	me	to	have	headaches	 58	 53.4	 46.6	
Impact	 24	 I	have	contemplated	suicide	due	to	my	PDN	 58	 70.7	 29.3	
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	 	 Impact	statement	 n=	for	
Likert	1-
4	
%	3	or	
4/4	
%	1	or	
2/4	
Impact	 12	 I	am	worried	that	my	PDN	will	get	worse	in	the	
future	
57	 84	 16	
Impact	 11	 It	bothers	me	that	other	people	can't	see	I	have	
this	problem	
38	 76	 24	
Impact	 52	 I	get	cramp	more	frequently	than	before	I	has	
PDN	
29	 76	 24	
Impact	 1	 My	sleep	is	disturbed	due	to	PDN	 56	 75	 25	
Impact	 9	 PDN	leads	me	to	get	frustrated	 52	 75	 25	
Impact	 14	 PDN	affects	a	wide	range	of	activities	that	I	want	
to	do	
48	 75	 25	
Impact	 5	 PDN	causes	me	to	have	numb	feet	 55	 75	 25	
Impact	 40	 PDN	can	lead	me	to	have	headaches	 55	 75	 25	
Impact	 22	 I	have	reduced	my	physical	activity	due	to	PDN	 47	 74	 26	
Impact	 23	 PDN	affects	my	social	life	 31	 74	 26	
Impact	 53	 I	have	lost	confidence	to	be	myself	due	to	PDN	 49	 73	 27	
Impact	 36	 PDN	gives	me	a	sense	of	restless	legs	 48	 73	 27	
Impact	 47	 When	PDN	flares	up	I	just	want	to	be	on	my	own	 47	 72	 28	
Impact	 21	 I	have	difficulty	doing	my	job	due	to	PDN	 35	 71	 29	
Impact	 18	 I	have	to	check	my	feet	regularly	for	possible	
injury	
55	 71	 29	
Impact	 43	 I	don't	go	out	as	much	because	of	PDN	 48	 71	 29	
Impact	 57	 PDN	has	stopped	me	going	dancing	 41	 71	 29	
Impact	 56	 My	self-image	has	changed	due	to	PDN	 47	 70	 30	
Impact	 10	 I	don't	cope	well	with	PDN	 43	 70	 30	
Impact	 55	 When	PDN	flares	up	I	can	be	less	tolerant	to	
those	around	me	
49	 69	 31	
Impact	 46	 I	worry	about	keeping	my	physical	fitness	due	to	
PDN	
32	 69	 31	
Impact	 42	 My	life	had	become	more	restricted	due	to	PDN	 38	 68	 32	
Impact	 2	 PDN	leads	me	to	feel	depressed	 44	 68	 32	
Impact	 7	 I	have	become	more	socially	isolated	due	to	PDN	 37	 68	 32	
Impact	 38	 PDN	affects	me	as	soon	as	I	put	my	foot	to	the	
ground	in	the	morning	
40	 68	 33	
Impact	 3	 PDN	makes	walking	difficult	 51	 67	 33	
Impact	 23	 I	have	contemplated	suicide	due	to	my	PDN	 45	 67	 33	
Impact	 27	 PDN	makes	me	think	about	driving	carefully	 51	 67	 33	
Impact	 35	 PDN	makes	it	difficult	to	buy	shoes	that	are	
comfortable	
39	 67	 33	
Impact	 44	 I	struggle	to	get	up	for	work	due	to	the	PDN	 39	 67	 33	
Impact	 15	 PDN	leads	me	to	feel	angry		 44	 66	 34	
Impact	 26	 PDN	leads	me	to	worry	more	than	I	would	if	I	
didn’t	have	it	
44	 66	 34	
Impact	 30	 PDN	affects	my	memory	 32	 66	 34	
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	 	 Impact	statement	 n=	for	
Likert	1-
4	
%	3	or	
4/4	
%	1	or	
2/4	
Impact	 48	 PDN	makes	me	worried	about	going	out	of	the	
house	
45	 64	 36	
Impact	 6	 It	bothers	me	what	other	people	think	of	me	due	
to	the	problems	I	have	with	PDN	
33	 64	 36	
Impact	 20	 I	have	to	be	careful	walking	due	to	my	balance	 49	 63	 37	
Impact	 58	 I	keep	my	problems	with	PDN	away	from	my	
woder	social	network	
38	 63	 37	
Impact	 4	 PDN	affects	my	ability	to	do	every	day	jobs	 46	 63	 37	
Impact	 39	 My	feet	look	normal	but	I	have	this	severe	pain	 46	 63	 37	
Impact	 13	 My	PDN	has	an	affect	on	my	partner	 35	 63	 37	
Impact	 29	 My	PDN	affects	my	close	family	 35	 63	 37	
Impact	 17	 I	am	not	the	person	I	was	before	I	developed	PDN	 45	 62	 38	
Impact	 28	 PDN	affects	my	intimate	relationships	with	a	
partner	
34	 62	 38	
Impact	 19	 PDN	affects	my	ability	to	concentrate	 52	 62	 38	
Impact	 33	 PDN	stops	me	being	as	independent	as	I	expect	to	
be	
39	 62	 38	
Impact	 8	 PDN	stops	me	from	sitting	comfortably	 49	 61	 39	
Impact	 16	 I	keep	my	problem	with	PDN	away	from	my	close	
family	
41	 61	 39	
Impact	 49	 I	always	have	to	think	about	the	needs	of	other	
people	
33	 61	 39	
Impact	 25	 PDN	hurts	so	much	it	brings	tears	to	my	eyes	 36	 58	 42	
Impact	 37	 My	skin	is	sensitive	to	the	lightest	touch	 51	 57	 43	
Impact	 50	 PDN	makes	me	feel	embarrassed	 36	 56	 44	
Impact	 31	 PDN	affects	my	appetite	for	food	 29	 55	 45	
Impact	 51	 I	get	more	breathless	than	before	I	had	PDN	 29	 55	 45	
Impact	 45	 I	worry	how	our	money	will	be	affected	because	
of	PDN	
33	 55	 45	
Impact	 24	 I	don’t	understand	why	I	have	PDN	 17	 53	 47	
Impact	 54	 My	overall	quality	of	life	is	really	affected	by	PDN	 37	 49	 51	
Impact	 41	 PDN	affects	our	family	holidays	 27	 48	 52	
Impact	 32	 PDN	and	balance	problems	lead	me	to	fall	over	 34	 47	 53	
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Appendix	24	–	Free	text	additions	
Free	text	addition	 Current	or	new	code	
It	doesn't	affect	my	life	except	when	HCPs	
assume	it	is	Diabetic	-	I	don't	believe	it	is!	-	so	
though	I	have	pain	when	the	duvet	touches	that	
exact	spot	on	the	one	big	toe,	it	has	no	other	
effect.		I	thought	the	numbness	in	my	feet	and	
the	loss	of	balance	were	caused	by	hardening	of	
the	arteries,	I	didn't	know	neuropathy	even	
caused	that?	
Code:	sleep	disturbed	
Code:	skin	sensitivity	
Code:	numb	feet	
Code:	causes	of	symptoms	
been	admitted	to	hosp	with	stomach	nerve	pain	 New	code:	autonomic	neuropathy	
Added	to	the	intermittent	claudication,	it	has	
exacerbated	the	already	worrying	concern	for	
my	longevity	and	QOL	
Code:	future	worries	
	
agonizing	pins	and	needles	that	make	me	cry	 Code:	crying	with	pain	
It's	bloody	awful	terrible	condition	 Code:	affects	all	aspects	of	life	
Self	harming	behaviour	-not	suicidal	ideation.	
Cutting	legs	and	hands	and	tying	things	around	
them	to	cut	off	circulation.	I	am	a	professional	
and	am	required	to	work	long	stressful	hours.	I	
cannot	take	the	medication	I	need	to	knock	me	
out	so	I	am	not	exausted.	I	have	this	year	had	
very	high	sickness	absence.	
Code:	suicide	
New	code:	self	harming	behaviour	
Code:	fatigue	with	PDN	
Code:	not	able	to	do	my	work	
Code:	side	effects	of	medication	
PDM	stopped	me	dancing	-	but	I've	recently	
discovered	it	helps	reduce	toe	numbness	and	
pain	intensity,	whereas	medication	didn't.	
Code:	stopped	dancing	
Code:	feeling	better	with	activity	
Code:	medication	not	working	
struggle	to	use	my	hands/make	a	fist/grip	
things....hands	go	numb.	worst	in	bed	so	have	
to	get	out	of	bed	to	shake	my	hands	standing	up	
then	struggle	to	get	back	to	sleep.	
New	code:	hand	numbness	
Code:	sleep	disturbance	
Code:	getting	up	in	the	night	
In	so	much	pain	at	times	I	just	cry	with	the	level	
of	pain	I	am	in.	Pain	so	bad	at	times	unable	to	
prepare	meals.	
Code:	crying	with	pain	
Code:	affecting	all	aspects	of	life	(or	new	code	
specific	to	meal	preparation)	
Do	you	feel	fire	in	your	feet?,	I	do	every	night	
and	first	thing	in	the	morning.	
Code:	Templar	torture	
Code:	morning	pain	
Mine	is	cramp	in	my	toes	all	the	time	 Code:	getting	cramps	
Worry	of	having	to	amputate	my	feet	 Code:	future	worries	
I	have	also	had	toes	amputated	after	a	fall	 Code:	losing	balance	
Code:	fallen	over	
fear	of	going	out	and	not	being	able	to	keep	
walking	long	enough	to	get	back	home	
Code:	not	going	out	
Code:	losing	mobility	
Code:	losing	confidence	
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Publications	
Davies	B.,	Cramp	F.,	Gauntlett-Gilbert	J.,	Wynick	D.,	McCabe	CS.	2015.	The	role	of	physical	activity	
and	psychological	coping	strategies	in	the	management	of	painful	diabetic	neuropathy	–	A	
systematic	review	of	the	literature.	Physiotherapy,	101(4),	pp.319–326.	
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Accepted	abstracts	
European	Pain	Federation	EFIC	–	Copenhagen	–	September	2017.	
04.	Pain	treatment	(conservative)	
4.06	Neuropathic	pain	
Poster	Board	
AN	INTERNET	SURVEY	EXPLORING	THE	TREATMENT	PRIORITIES	OF	PEOPLE	
WITH	PAINFUL	DIABETIC	NEUROPATHY	(PDN)	
BACKGROUND	AND	AIMS	
PDN	is	a	neuropathic	pain	condition	which	has	significant	impact	on	patients’	
quality	of	life.	Analgesia	is	the	main	management	strategy	but	recommended	
medications	are	often	ineffective	at	controlling	pain	to	manageable	severity.	
This	survey	aimed	to	understand	the	treatment	priorities	of	people	with	PDN		
METHODS	
Previous	qualitative	research	produced	a	set	of	58	impacts,	related	to	PDN.	
An	Internet	survey	was	conducted	to	explore	which	of	these	impacts	were	
peoples’	priorities	for	better	management	strategies.	Respondents	short-
listed	10	impacts,	then	ordered	these	by	priority	for	better	management.	This	
survey	was	advertised	by	DiabetesUK	and	posted	to	major	patient	forums	for	
diabetes.	
RESULTS	
There	were	n=107	responses,	with	n=78	meeting	pre-set	diagnostic	criteria	
for	PDN.	The	sample	were	55%	female,	63%	had	Type	2	diabetes,	aged	mean	
57(SD13)	years.	Respondents	had	diabetes	for	mean	17.8(13.7)	years	and	
PDN	for	mean	7.3(6.3)	years.	The	priorities	of	subgroups	(gender,	type	of	
diabetes,	high/low	pain	and	whether	they	had	sought	help	for	PDN)	were	
analysed.	Sleep	disturbance	was	consistently	the	top	priority	amongst	
subgroups.	Physical	fitness,	walking,	numb	feet,	anxiety	and	depression	were	
consistently	prioritised	by	at	least	half	the	subgroups	analysed	(see	table	1).	
Impacts	describing	pain	experience	were	not	prioritised	by	respondents.	
CONCLUSIONS	
People	with	PDN	may	have	other	priorities	than	pain	reduction.	Clinicians	
need	to	ensure	that	advice	and	treatment	are	focussed	on	the	patients’	
impacts	of	most	importance.	
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British	Pain	Society	ASM	Birmingham	2017	parallel	workshop	
Title	of	Session		 Physiotherapy	and	Physical	Activity	Approaches	in	Persistent	
Pain	
	
Session	Organiser	 Dr	Jane	Hall,	Senior	Clinical	Research	Physiotherapist	
Organisers	
contact	details	
	 CRPS	Service,	Bath	Centre	for	Pain	Services,	Royal	
National	Hospital	for	Rheumatic	Diseases,	Upper	Borough	Walls,	
Bath,	BA1	1RL	
	
Session	summary	 This	session	will	consider	patient	and	health	professional	
understanding	and	approaches	to	physical	activity	within	the	context	
of	three	long	term	conditions	(Peripheral	Diabetic	Neuropathy,	
Osteoarthritis	and	Complex	Regional	Pain	Syndrome).		The	safety	and	
effectiveness	of	regular	physical	activity	and	exercise	will	be	
considered	via	patients’	concerns	of	condition	exacerbation.	A	
neurocognitive	therapeutic	model	which	changes	the	associations	
and	perception	about	pain	will	be	described	in	terms	of	application	in	
a	rehabilitation	context.	Attendees	will	gain	insight	into	emerging	
treatment	paradigms	and	barriers	to	patient	engagement	and	
discussion	will	stimulate	consideration	of	different	perspectives	in	
long-term	rehabilitation	and	physical	activity	strategies	
	
Speaker	1	 Ben	Davies,	Clinical	Specialist	Physiotherapist	in	Pain	
Management				
Presentation	Title	 Considering	physical	activity	for	people	who	have	painful	
diabetic	neuropathy.	
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World	Congress	of	Physical	Therapy	–	European	Region,	Liverpool	2016.	
Should	pain	management	programmes	strategies	be	part	of	managing	painful	diabetic	
neuropathy	(PDN)?	(Poster)	
Ben	Davies1,	Fiona	Cramp1,	Jeremy	Gauntlett-Gilbert1,2,	Candida	McCabe1,2	
1	Faculty	of	Health	and	Applied	Sciences,	University	of	the	West	of	England,	Bristol	UK.	
2	Royal	United	Hospital,	Bath,	UK	
Abstract	body	
Relevance.	Diabetes	is	increasing	in	prevalence	and	globally	ranks	14th	for	its	impact	on	quality	
adjusted	life	years.	PDN	is	a	distressing	and	disabling	condition	occurring	in	6-34%	of	people	with	
diabetes.	Despite	extensive	involvement	in	managing	a	wide	range	of	patients	with	chronic	pain,	
physiotherapists	do	not	routinely	manage	people	with	PDN.		
Purpose.	Analgesic	medications	are	the	predominant	treatment	for	PDN	yet	they	are	often	
reported	as	inadequate.	Multidisciplinary	pain	management	programme	may	be	beneficial	for	
people	with	PDN.	The	key	management	strategies	for	these	programme	are	graded	physical	
activity	(PA)	and	psychological	coping	skills	(PsyCS).	The	objectives	of	this	study	were	to:	(1)	
interview	people	with	PDN	to	explore	the	impact	of	PDN,	management	strategies	for	PDN	and	
perspectives	on	PA	and	PsyCS;	(2)	interview	diabetes	and	pain	management	clinicians	to	explore	
their	perspectives	on	pain	management	strategies.	
Methods/Analysis.	Semi-structured	interviews	were	conducted	with	people	who	experience	PDN.	
Recruitment	was	through	local	PDN	clinics	and	a	nationwide	advert.	All	participants	had	PDN	and	
could	communicate	in	English	without	the	need	of	an	interpreter.	No	other	exclusion	criteria	were	
applied.	Clinicians	with	appropriate	expertise	were	identified	and	approached	to	participate.	At	
least	two	representatives	from	key	professions	were	sought.	Interviews	were	conducted	face-to-
face	or	by	telephone,	audio	recorded,	transcribed	and	analyzed	using	Inductive	Thematic	Analysis.	
University	and	NHS	Ethics	Committees	(Frenchay	13/SW/0125)	granted	ethical	approval.	
Results.	Twenty-three	people	with	PDN	were	interviewed	(mean	age	62yrs,	range	24-86,	12	
women,	10	Type	1	diabetes,	22	White	British).	In	total	58	impacts	of	PDN	were	identified.	A	wide	
range	of	management	techniques	had	been	tried.	People	were	concerned	about	future	health	
and	fitness	and	wanted	advice	about	PA	from	professionals,	but	did	not	want	their	pain	to	be	
exacerbated.	Few	people	had	accessed	PsyCS,	but	those	who	had,	reported	benefits.	A	strong	
theme	developed	that	psychology	played	no	part	in	peoples’	experiences,	and	hence	PsyCS	were	
not	appropriate.		
Nineteen	clinicians	from	primary	and	secondary	care	were	interviewed.	Diabetes	specialists	often	
felt	clinically	impotent	when	analgesic	strategies	failed.	The	majority	were	unaware	of,	or	did	not	
consider	referral	to	PMPs.	Podiatrists	expressed	concern	that	PA	could	damage	insensate	feet.	
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Pain	management	specialists	suggested	that	programme	were	person,	not	pathology	specific	and	
could	be	adapted	for	people	with	PDN.		
Discussions	and	conclusions.	It	may	be	possible	to	adapt	pain	programme	to	meet	the	needs	of	
people	with	PDN.	Consideration	would	need	to	be	given	to	the	multiple	co-morbidities	and	
complications	that	people	with	PDN	experience.	
Patient	uncertainty	regarding	the	appropriateness	of	PA	and	PsyCS	would	also	need	to	be	
addressed.	The	findings	from	this	study	need	to	be	explored	in	a	wider	population	to	determine	
the	management	priorities	of	people	with	PDN.			
Impact	and	Implications.	PDN	is	a	significant	and	disabling	pain	condition,	with	significant	costs.	
There	are	differing	perspectives	from	patients	and	specialist	clinicians,	whether	PA	and	PsyCS	
should	become	part	of	a	broader	approach	to	management	of	PDN.	The	findings	from	this	
research	have	informed	an	internet	survey	that	is	currently	being	carried	out	to	determine	
patients’	priorities	for	PDN	management.	
	
 
Appendix	25	–	Publications	and	accepted	abstracts	
Page	331	
Health and Applied Sciences postgraduate research conference, UWE 2015. 
How	does	painful	diabetic	neuropathy	affect	peoples’	lives,	and	how	might	pain	management	
strategies	be	an	acceptable	management	pathway?	(Presentation)	
Ben	Davies1,	Fiona	Cramp1,	Jeremy	Gauntlett-Gilbert1,2,	Candida	McCabe1,2	
1	Faculty	of	Health	and	Applied	Sciences,	University	of	the	West	of	England,	Bristol	UK.	
2	Royal	United	Hospital,	Bath,	UK	
Abstract	body:	
Background.	Painful	diabetic	neuropathy	(PDN)	is	a	significant	complication	of	diabetes	that	is	
associated	with:	unpredictable	pain,	difficulty	with	everyday	tasks,	sleep	disturbance	and	
emotional	distress.	Existing	drug	management	is	only	partially	successful.	Pain	management	
program,	consisting	of	physical	rehabilitation	and	psychological	coping	skills	may	have	potential	in	
PDN	management.	Prior	to	investigating	these	programme	it	was	important	to	explore	the	impact	
that	PDN	has	on	an	individual	and	the	acceptability	of	such	program.	
Method.	Semi-structured	1:1	interviews	were	conducted	with	people	who	experience	PDN;	they	
were	recruited	from	a	national	sample.	These	interviews	were	analysed	using	thematic	analysis.		
Results.	Interviews	were	conducted	with	23	participants.	Some	themes	reflected	the	existing	
knowledge	of	PDN	–	the	impact	PDN	has	on	sleep,	walking	and	employment.	Other	themes	were	
new	–	increasingly	on	my	own,	a	shrinking	world	and	a	very	personal	problem.	Participants	had	
received	drug	management	from	the	NHS	and	had	experimented	with	many	strategies	to	try	and	
cope	with	PDN.	Participants	were	worried	about	maintaining	physical	activity	for	health	reasons	
and	were	open	to	advice	from	a	health	professional	for	exercise	that	would	not	worsen	their	PDN.	
There	were	mixed	opinions	about	the	acceptability	of	psychologically	based	coping	skills.		
Implications.	The	impact	of	PDN	is	more	multi-faceted	than	the	existing	literature	suggests.	Some	
of	these	impacts	would	appear	suitable	for	management	with	existing	pain	management	
strategies.	Further	research	is	required	to	identify	which	of	these	impacts	patients	would	
prioritise	for	management	and	explore	if	these	priorities	match	to	existing	evidenced	treatments.	
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Physiotherapy	UK	conference	2014	
The	patient’s	experience	of	managing	painful	diabetic	neuropathy	(Presentation).	
Ben	Davies1,	Fiona	Cramp1,	Jeremy	Gauntlett-Gilbert1,2,	Candida	McCabe1,2	
1	Faculty	of	Health	and	Applied	Sciences,	University	of	the	West	of	England,	Bristol	UK.	
2	Royal	United	Hospital,	Bath,	UK	
Abstract	body	
Purpose.	People	with	painful	diabetic	neuropathy	(PDN)	are	primarily	managed	with	medication	
with	variable	outcomes.	
This	research	explored	the	experiences	of	people	with	PDN	including	impact	on	daily	living,	
personal	management	strategies	and	views	relating	to	multidisciplinary	pain	management	
programme	strategies.	
Relevance.	A	purposive	sample	was	recruited	from	local	secondary	care	diabetes/podiatry	clinics	
and	nationwide	recipients	of	Balance	magazine	(DiabetesUK).	All	adults	with	PDN	with	
conversational	level	English	were	eligible.	Targeted	selection	of	respondents	was	used	to	capture	
a	breadth	of	demographic	variables.	Twelve	participants	(5	male,	4	Type	1,	11	white	British,	1	
West	Indian,	mean	age	60.7(SD10.7)	years,	mean	diabetes	duration	24.4(12.7)	years,	mean	PDN	
duration	10.6(5.1)	years)	were	interviewed.		
Methods.	Semi-structured	interviews	were	conducted,	either	face	to	face	or	via	telephone.	
Interviews	were	transcribed	verbatim	and	anonymised.		
Analysis.	Data	were	analysed	using	inductive	thematic	analysis.	Expert	patient	research	partners	
were	engaged	in	the	review	of	themes	produced.		
Results.	PDN	impacts	on	all	aspects	of	personal,	social	and	emotional	life.	Management	is	nearly	
entirely	pharmacological,	only	two	participants	had	experienced	psychological	coping	
interventions.	Participants	had	tried	numerous	self-management	strategies	including	relaxation,	
cannabis	and	walking	on	stinging	nettles.	Participants	reported	distress	due	to	PDN	and	the	
majority	were	open	to	pain	coping	strategies.	Some	participants	were	however	unable	to	
reconcile	psychological	processes	with	pain	attributed	to	nerve	damage.	
Conclusions.	Pharmacological	management	of	PDN	does	not	fully	address	the	impact	of	PDN	on	
daily	living.	The	principles	of	multi-disciplinary	pain	management	programme	appear	to	be	
acceptable	to	a	majority	of	patients	and	may	have	the	potential	to	improve	coping	strategies.			
Implications.	Research	is	needed	to	develop	and	test	a	PDN	specific	pain	coping	programme.		
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British	Pain	Society	conference	2014	
Painful	diabetic	neuropathy.	Patient	and	clinician	perspectives	on	current	management	and	
multidisciplinary	pain	management	strategies.	(Poster).	
Ben	Davies1,	Fiona	Cramp1,	Jeremy	Gauntlett-Gilbert1,2,	Candida	McCabe1,2	
1	Faculty	of	Health	and	Applied	Sciences,	University	of	the	West	of	England,	Bristol	UK.	
2	Royal	United	Hospital,	Bath,	UK	
Abstract	body:	
Background.	Painful	diabetic	neuropathy	(PDN)	affects	20%	of	people	with	diabetes	(Daousi	et	al.,	
2004).	Diabetes	is	increasing	in	prevalence,	so	is	the	number	of	people	experiencing	the	burning	
pain,	associated	cognitive	distress	and	functional	limitations	of	PDN	(Alberti	&	Zimmet,	2013).	
PDN	is	managed	primarily	with	neuropathic	pain	medications,	there	is	a	range	of	evidenced	
pharmacological	guidance	(Spallone,	2012),	however	analgesic	failure	is	common	(Moore	et	al.,	
2013)	and	people	remain	in	pain	and	distress	(Gore	et	al.,	2006).	People	with	PDN	are	rarely	
referred	to	multidisciplinary	pain	programme	where	the	key	approaches	are	physical	and	
psychological	rehabilitation	strategies.	It	is	unclear	if	the	design	of	these	programme	is	
appropriate	for	a	purely	neuropathic	pain	problem.	A	qualitative	study	was	designed	to	answer	
the	questions:	1)	how	do	patients	experience	management	of	PDN	and	2)	what	are	the	
perspectives	and	attitudes	of	clinicians	and	patients	to	multidisciplinary	pain	management	
strategies?	
Methods.	This	study	used	semi-structured	interviews	with	clinicians	and	patients.	Clinicians	were	
purposively	sampled	from	the	primary	and	secondary	care	multidisciplinary	team,	who	help	
people	to	manage	diabetes	and	PDN.	Clinicians	included	Consultants,	Primary	and	Secondary	care	
nurses,	Podiatrists,	Psychologists	and	Physiotherapists.	Patients	with	PDN	were	recruited	from	
secondary	care	diabetes	clinics	and	a	tertiary	care	PDN	clinic.	One-to-one	interviews	were	
conducted	and	transcribed	verbatim.	The	data	was	coded	using	a	Thematic	Analysis	approach	
(Braun	&	Clarke,	2012)	and	analysis	was	completed	in	collaboration	with	an	Expert	Patient	
Research	Partner	(EPRP).	Thematic	analysis	is	a	flexible	methodology	that	is	appropriate	for	
seeking	patterns	across	a	dataset.	From	these	codes,	themes	were	developed	that	addressed	the	
research	questions.	
Results.	Data	analysis	is	ongoing	but	four	early	themes	are	present.	1)	Patients’	experience	of	
PDN;	patients	frequently	do	not	associate	pain	with	diabetes	and	do	not	raise	it	with	diabetes	
clinicians.	2)	Clinicians	considering	PDN;	clinicians	describe	not	asking	about	pain,	through	
oversight	or	because	they	have	limited	therapeutic	options.	3)	Early	diagnosis	and	management	
of	PDN;	patients	can	experience	symptoms	for	years	before	accessing	treatment,	they	feel	passed	
from	pillar	to	post,	they	can	be	recommended	inappropriate	analgesia	(NSAIDs),	or	appropriate	
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analgesia	(Amitriptyline)	without	appropriate	review.	Finally,	4)	Access	to	specialist	opinion;	
clinicians	and	patients	alike	describe	being	at	a	loss	for	the	next	step	in	a	pathway,	medication	
optimisation	is	not	clear,	all	clinicians	describe	patients	with	significant	depression	and	anxiety.	All	
participants	consider	pain	management	strategies	could	be	useful.	There	is	uncertainty	what	form	
the	physical	rehabilitation	should	take	and	this	is	the	focus	of	another	study.	
Conclusions.	PDN	is	a	significant	problem	to	those	that	experience	it,	analgesia	helps	but	has	
minimal	impact	on	patients’s	functioning	and	levels	of	distress.	Clinicians	and	patients	are	open	to	
the	option	of	multidimensional	rehabilitation.	Such	rehabilitation	is	not	highlighted	in	guidance	
documents	or	care	pathways.	Some	uncertainty	remains	over	the	exact	nature	of	the	physical	
activity	indicated	for	painful	neuropathy	and	this	is	the	focus	of	another	study.	The	inclusion	of	
multidisciplinary	pain	management	strategies	appears	appropriate	in	guidelines	for	PDN	
management.	
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Bristol	Research	in	practice	symposium,	2014	
Painful	diabetic	neuropathy:	A	systematic	review	of	physical	activity	and	psychological	coping	
strategies.	(Presentation).	
Ben	Davies1,	Fiona	Cramp1,	Jeremy	Gauntlett-Gilbert1,2,	Candida	McCabe1,2	
1	Faculty	of	Health	and	Applied	Sciences,	University	of	the	West	of	England,	Bristol	UK.	
2	Royal	United	Hospital,	Bath,	UK	
Abstract	body:	
Background.	The	prevalence	of	diabetes	is	rising.	Painful	diabetic	neuropathy	(PDN)	is	a	
microvascular	complication	affecting	16-20%	of	people	with	diabetes.	It	is	a	burning	pain	that	is	
significantly	associated	with	impairments	to	mobility,	sleep	quality,	and	life	capacity.	PDN	is	
currently	managed	with	medication	but	its	effectiveness	is	variable.	People	with	PDN	are	rarely	
referred	to	pain	management	programme	that	use	physical	rehabilitation	and	psychological	
coping	strategies	to	maximise	quality	of	life.			
Aim.	To	perform	a	systematic	review	of	literature	relating	to	physical	activity	and	psychological	
coping	strategies	for	the	management	of	PDN.		
Methods.	A	keyword	search	was	applied	to	ten	databases.	Studies	were	included	if	they	used	
controlled	methods	to	investigate	physical	activity	or	psychological	coping	strategies	for	the	
management	of	pain	and/or	pain	related	distress	due	to	PDN.	Studies	were	assessed	for	bias	and	
critically	appraised.			
Results.	Four	studies,	of	variable	quality,	were	identified	for	inclusion.	One	non-randomised	study	
investigated	Tai	Chi	and	reported	improvements	in	SF36	domains	including	bodily	pain	(Ahn	and	
Song,	2012).	Three	randomised	controlled	studies	investigated	psychological	interventions.	
mindfulness	meditation	was	reported	to	have	no	effect	on	pain	or	quality	of	life	(Teixeira,	2010),	
although	the	required	sample	size	was	not	obtained.	Solution	focussed	therapy	was	reported	to	
impact	on	self-reported	problems,	but	these	were	not	necessarily	related	to	pain	(Didjurgeit	et	al.,	
2002).	Finally,	a	pilot	study	of	cognitive	behavioural	therapy	reported	a	decline	in	pain	severity	
and	interference	in	the	intervention	group	(Otis	et	al.,	2013).	
Discussion.	Four	studies	have	investigated	the	impact	of	physical	activity	or	psychological	
strategies	on	pain	and	distress	experienced	by	people	with	PDN.	Clear	conclusions	of	treatment	
efficacy	cannot	be	drawn	from	the	literature	and	it	is	not	currently	possible	to	make	
recommendations	for	practice.	Further	high	quality	studies	using	clearly	defined	physical	and/or	
psychological	rehabilitation	strategies	and	measuring	subjective	pain	and	related	distress	
outcomes	are	required.	
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Allied	Health	Professions	conference,	Bristol,	2014.	
Clinician	and	patient	perspectives	on	multidisciplinary	rehabilitation	for	painful	diabetic	
neuropathy	(PDN).	(Commended	poster).	
Ben	Davies1,	Fiona	Cramp1,	Jeremy	Gauntlett-Gilbert1,2,	Candida	McCabe1,2	
1	Faculty	of	Health	and	Applied	Sciences,	University	of	the	West	of	England,	Bristol	UK.	
2	Royal	United	Hospital,	Bath,	UK	
Abstract	body:	
Aim:	A	qualitative	study	was	designed	to	answer	the	questions:	1)	how	do	patients	experience	
management	of	PDN	and	2)	what	are	the	perspectives	of	clinicians	and	patients	to	
multidisciplinary	pain	management	strategies?	
Method:	Semi-structured	interviews	were	conducted	with	clinicians	and	patients.	Clinicians	were	
purposively	sampled	from	the	primary	and	secondary	care	multidisciplinary	teams,	who	manage	
diabetes	and	PDN.	Patients	with	PDN	were	recruited	from	secondary	care	diabetes	and	PDN	
clinics.	One-to-one	interviews	were	conducted	and	transcribed	verbatim.	Data	was	coded	and	
analysed	using	a	Thematic	Analysis	approach	(Braun	&	Clarke,	2012)	in	collaboration	with	an	
Expert	Patient	Research	Partner	(EPRP).	Thematic	analysis	is	a	flexible	methodology	that	is	
appropriate	for	seeking	patterns	across	a	dataset.	From	these	codes,	themes	were	developed	that	
addressed	the	research	question.	
Results:	Analysis	is	ongoing	but	four	early	themes	are	present.	1)	Patients’	experience	of	PDN;	
patients	may	not	associate	pain	with	diabetes	and	do	not	raise	it	with	clinicians.	2)	Clinicians	
considering	PDN;	clinicians	do	not	consistently	inquire	about	pain,	through	oversight	or	due	to	
limited	therapeutic	options.	3)	Early	diagnosis	and	management	of	PDN;	patients	experience	
symptoms	for	significant	duration	before	accessing	treatment,	they	feel	bounced	between	clinics,	
they	may	be	recommended	inappropriate	analgesia	(NSAIDs),	or	appropriate	analgesia	
(Amitriptyline)	without	appropriate	review.	Finally,	4)	Access	to	specialist	opinion;	clinicians	
describe	patients	in	pain	with	cognitive	distress	where	analgesic	options	have	failed.	All	
participants	consider	pain	management	strategies	could	be	beneficial.	
Conclusion:	PDN	is	a	significant	personal	and	medical	problem.	Analgesia	is	the	mainstay	of	
treatment	but	can	be	ineffectual.	Clinicians	and	patients	are	open	to	the	option	of	
multidimensional	rehabilitation.	Such	rehabilitation	is	not	highlighted	in	guidance	documents	or	
care	pathways.	Uncertainty	remains	over	the	nature	of	the	physical	activity	indicated	for	painful	
neuropathy	and	this	is	the	focus	of	another	study.	The	inclusion	of	multidisciplinary	pain	
management	strategies	warrants	further	research.	
	
